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This book is a very provocative and interesting addition to the literature on Epilepsy. It 
offers a lot of appealing and stimulating work to offer food of thought to the readers 
from different disciplines. Around 5% of the total world population have seizures 
but only 0.9% is diagnosed with epilepsy, so it is very important to understand the 
differences between seizures and epilepsy, and also to identify the factors responsible 
for its etiology so as to have more effective therapeutic regime. In this book we have 
twenty chapters ranging from causes and underlying mechanisms to the treatment and 
side effects of epilepsy. This book contains a variety of chapters which will stimulate 
the readers to think about the complex interplay of epigenetics and epilepsy.
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Approximately 1 out of 120 people have epilepsy and 2 out of every 3 new cases are 
found in developing countries. Young children and people over the age of 65 are more 
susceptible to epilepsy; however, it can occur to any one at any time in life. Although 
around 5% of the total world population have seizures, only 0.9% are diagnosed with 
epilepsy so it is very important to understand the differences between seizures and 
epilepsy and also to identify the factors responsible for its etiology in order to have 
more effective therapeutic regime. This book presents twenty chapters ranging from 
causes and underlying mechanisms to treatment and side effects of epilepsy. This 
introductory part offers merely a brief skim through some of these quite interesting 
multidisciplinary chapters. 
The chapter entitled “Histopathological Changes in Temporal Epilepsy” is an 
interesting review on the etiology of drug resistant epilepsy. In this paper, authors 
discuss the dual pathology of epilepsy in association with other alterations due to 
neuronal injury and loss.  Authors offer a hypothesis that the presence of an 
epileptogenic foci provokes a process of progressive damage of the nervous tissue and 
result in drug resistant epilepsy. 
Next chapter, entitled “The Role of Astrocytes in Epileptogenesis” is a review about 
how astrocytes modulate different types of partial seizure. Authors discuss the pivotal 
role of astrocytes in epilepsy and their involvement in: managing the trafficking of 
substances between capillary vessels and neurons, homeostasis of ions, principally 
potassium (K+), and their role in the metabolism of the brain through the degradation 
of both glucose and glutamate. In addition, they discuss the release of gliotransmitters, 
and multiple contacts of cortical astrocytes. They also debate on how astrocytic 
integration can affect the function of several groups of neurons or synapses, thus 
working in a more coherent model. Any change in astrocytic physiology changes the 
equilibrium between neuronal excitation and inhibition leading to epileptogenesis. 
Further on, the chapter “START proteins in Epilepsy” is based on the observations that 
the release of neuroactive steroids impairs neuronal survival in the hippocampus. In 
this chapter, various molecules including steroidogenic acute regulatory protein 
(StAR)-related lipid transfer domain-containing proteins (START proteins) and their 
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(StAR)-related lipid transfer domain-containing proteins (START proteins) and their 
relationship with neurosteroidogenesis were reviewed for further understanding of 
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their role in epilepsy. The START domain that operates as a lipid exchange unit is 
suggested for further studies as to elucidate the exact nuclear roles of StarD6 on 
neurosteroidogenesis with StAR in the nervous system. 
“Introduction of a novel molecular mechanism on epilepsy progression: roles of 
growth hormone signaling in a mouse model of temporal lobe epilepsy” is a chapter 
on epilepsy with foci and the candidate molecules involved in refractory epilepsy. Up-
regulation of growth hormones found to have occurred during the process, and 
metabolic regulation by GH-signaling appears to be responsible for initiating the after 
discharge threshold during epileptogenesis. 
“Role of gap junctions and connexion proteins in the mechanism of seizures” is a 
paper with reference to the connexion proteins, resultant hemichannels, and the 
association of two hemichannels on neighboring cells to form a gap junction. 
Literature suggested a deep and multifaceted relationship between gap junction 
regulation and seizure susceptibility. In this chapter authors have sought to bring 
together research from a wide range of disciplines encompassing electrophysiology, 
molecular biology and mathematical modeling, with the aim of addressing the role of 
gap junctions in the mechanism of seizures. 
Chapter “Recombinant Laforin for Structural Studies” is about autosomal recessive 
Lafora disease, also known as progressive myoclonic epilepsy. This type of epilepsy is 
caused by the mutations in two genes: EPM2A gene, coding for the protein laforin, 
and NHLRC1 gene, for the protein malin. Focusing on Laforin and its involvement in 
Lafora disease, authors reported it as therapeutic contender for myoclonic epilepsy as 
well as a novel candidate for biotechnological applications of carbohydrate binding 
proteins. 
“The Cross-talk between Mitochondria and the Nucleus in the Response to Oxidative 
Stress Associated with Mitochondrial Dysfunction in Mitochondrial 
Encephalomyopathies” is an interesting review combined with author’s own work. In 
this review authors discussed the biochemical consequences of mitochondrial 
dysfunction-elicited oxidative stress, mitochondrial retrograde signaling and 
regulation of Ca2+ homoeostasis in neuronal excitability and resultant epileptic 
seizures.  They also discussed the role of stress responsive gene, Sirt1, in the signaling 
pathway of the cross-talk between mitochondria and the nucleus. 
“Temporal Lobe Epilepsy (TLE): molecular targets and cell death” is about TLE and 
other molecular mechanisms involved in the process of cell death.   Authors also 
explored Bcl-2 gene family and their levels in the hippocampus of patients with 
intractable seizures. In this paper authors have nicely demonstrated that Caspase-
mediated inflammatory process could be a potential mechanism for the pathogenesis 
of TLE and Caspase inhibitors may act as novel therapeutic agents. 
“Ghrelin regulation in epilepsy” is a review discussing whether hormonal changes in 
relation to epilepsy are due to seizures activity per se or to consequential effects of 
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antiepileptic drugs.  Authors re-evaluate the hormones involved in epilepsy focusing 
on ghrelin, a 28 amino acid peptide produced by stomach. Increasing evidence 
indicated that ghrelin plays a role in anxiety and stress, though in vitro and in vivo 
experiments are still controversial. However, it is confirmed that ghrelin has 
anticonvulsant properties and blood ghrelin levels were shown to be decreased both in 
experimental epileptic rodents and in humans. Literature indicated that ghrelin can act 
as a neuroprotective agent due to its antiepileptic and anti-inflammatory effects on 
neuronal brain cells. A better understanding of ghrelin’s activities may help to develop 
new therapeutic approaches to epilepsy. 
“Regulation of GluR6-PSD95-MLK3 signalling in KA-induced rat seizure models” is a 
short review about the beneficial effects of the co-application of muscimol and 
baclofen against Kainic acid induced seizures. An experimental model based on Kainic 
acid (KA) injections replicates many phenomenological features of human temporal 
lobe epilepsy. Moreover some details are present in the article explaining how both 
ionotropic and metabotropic GABA agonists can inhibit the assembly of the GluR6-
PSD95-MLK3 signaling responsible for KA-induced seizures. 
“Biophysical Aspects of the non synaptic epileptiform Activity” is a very nicely 
written chapter, which demonstrates the conjoint actuation of non-synaptic 
mechanisms and connections, able to induce and sustain seizures. Focusing on 
different regions of the hippocampus, and their ability to generate or sustain non-
synaptic epileptiform activities authors found them to be directly related with the 
reduced levels of calcium and increased level of potassium in the extracellular fluid. 
Authors postulated that these epileptiform activities of non-synaptic origin could be 
mediated by gap-junctions, ionic fluctuations, or field effect. They described the 
cellular mechanisms regarding epilepsy using computational simulations for 
membrane ionic currents, Na+/K+-ATPase, co-transporters, and exchangers.  
“The Complex Interplay Of Epigenetics And Epilepsy” is a very well written and 
interesting review about the pharmacological manipulation of epigenetic factors and 
development of subtype-specific HDAC (Histone deacetylases) inhibitors. Evidence is 
emerging that epileptogenesis involves changes in the expression patterns of several 
classes of functionally or genomically-grouped genes that coordinate neural 
development, homeostasis and stress responses, and neural network formation. 
Abnormal activity of epigenetic mediators including DNMTs, MBDs, HDACs and 
repressor complexes could result in altered neuro- and gliogenesis, aberrant migration 
of newly born cells, and improper integration of these cells into circuits, thereby 
causing hyper-excitable circuits and seizures. 
“Mechanisms Involved in the Pathophysiological Progression of Epilepsy” is a review 
about pharmacological and genetic importance in molecular signaling mechanisms 
underlying epileptogenesis. Authors discuss a number of ionotropic and metabotropic 
glutamate receptors, neurotrophin receptors, calcium regulated enzymes and non-
receptor tyrosine kinases which are involved in orchestrating various biochemical 
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events in brain, finally leading to precipitation of a multitude of severe epileptic 
condition. The chapter is designed to contribute novel concepts for antiepileptic drug. 
“The Gingival Fibromatoses (GF)” is a review with personal observations in which 
authors suggested that GF can be apparent within a systemic disease, and 
anticonvulsant drug therapy is one of the most common causes of isolated GF. They 
discuss the prevalence of GF secondary to drug treatment following long term 
phenytoin therapy. They talk about the clinical heterogeneity and reflected genetic 
heterogeneity. Then they discuss different conditions which extends from the 
association of GF with hypertrichosis up to the multi-systemic syndromes of 
Zimmermann-Laband and Ramon. In addition to reviewing the literature they discuss 
patients with GH, tonic clonic seizures and GF unrelated to antiepileptic treatment.  
“Experimental Epilepsy Models and Morphological Alterations” is a review about the 
different chemically and electrically induced epilepsy models. Authors conclude that 
there is no model for answering all questions regarding epilepsy and the studies 
performed by using experimental models can only explore the basic mechanisms of 
that particular type of epilepsy. Some chemicals can induce more than one type of 
epilepsy model. For example crystallized penicillin can induce simple partial, 
generalized myoclonic, generalized tonic-clonic and generalized absence epilepsy 
when given using different routes of administration. Therefore, EEG and behavioral 
studies should be used for analyzing the induced model. 
“Two types of epilepsy models and processes of cognition” is a review in which 
author presents literature and her own data for the comparison of two types of 
epileptic activities that is the convulsive epilepsy induced by pentilenetetrazole (PTZ) 
kindling in Wister rats and non-convulsive absence epilepsy in WAG/Rij rats. The 
main difference between these two types of epilepsy was described.   
Oxcarbazepine (OXC) is an antiepileptic drug (AED) of the second generation, with a 
chemical structure similar to carbamazepine, but with different metabolism OXC is 
used for the treatment of partial seizures as monotherapy or adjunctive therapy in 
adults, and in children aged 4 to 16 years. OXC is also sometimes used to treat acute 
mania in adults, bipolar disorder, and manic-depressive disorder. The neurobiological 
interaction between epilepsy and sleep is receiving enhanced attention. A key role for 
limbic monoamines in epilepsy has been established and recently some studies 
showed the importance of hippocampal monoamines in limbic seizures control 
Medicinal herbs are a two edged sword, as discussed in the following chapter. Some 
herbs are often used in the treatment of the disease, including epilepsy; however,   
they could also induce or worsen epileptic activity.  Effects of an Ethanolic extract and 
essential oil of Artemisia dracunculus L. (Tarragon) were explored before and after the 
induction of epileptiform activity in snail neurons, using intracellular recording 
technique. Ethanolic extract and essential oil of Tarragon produce different 
electrophysiological changes in Pentylenetetrazole (PTZ)-induced epilepsy model.  
Preface      XIII 
 
Tarragon extract results in the complete disappearance of paroxysmal depolarization 
shift (PDS)-induced by PTZ, while its essential oil potentiate the epileptic activities in 
the presence of PTZ.  Based on their electrophysiological findings, authors suggested 
that a certain caution is needed when medicinal herbs are used for treating patients 
suffering from epilepsy. 
“In situ release of anti epileptic drugs from nanostructure reservoirs” is a very 
informative chapter about novel drug delivery system. Author’s exhibited how 
anticonvulsant drug phenytoin encapsulated into the sol-gel biocompatible Titania 
and can be successfully implanted into the temporal lobe of the brain by low invasion 
stereotactic surgery. The implantation process is such that the damage of the 
surrounding tissue is minimal. The drug release from the implants is controlled by the 
parameters of the matrix such as its morphology, drug-matrix interaction strength, etc. 
Depending on the parameters of the synthesis, the release profile may be designed 
according to the necessities in terms of release rate and the amount of the released 
drug. One of the main prospects of the study is to achieve better protection ’in vivo’ 
for longer time. Also, one needs to find a correlation between the drug release ’in 
vitro’ and its effect and release profile ’in vivo’.  
In short, this book contains a range of proposals regarding causes mechanisms and 
treatment options of epilepsy which will be of interest to a number of scientists and 
scholars from different disciplines. 
 
Prof. Dr. Fatima Shad Kaneez 
Human Physiology, PAP RSB Institute of Health Sciences 
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Histopathological Changes in  
Temporal Epilepsy 
Assaad Fawaz and Al Khani Raydeh 
 Damascus University/Faculty of medicine 
Syria  
1. Introduction 
A wide variety of lesions have been reported in the different studies of epilepsy in the 
literature; though the question is still raised if these observed lesions are the cause or the 
consequence of seizures. The lesions that might play a role in the onset, maintenance and 
progression of pharmacoresistance of epileptic seizures, as well as the lesions that might 
results in are not yet well predicted and comprehensible.  
2. Histopathological findings  
A confusing array of histopathological findings was reported in the studies of temporal lobe 
and hippocampus in chronic pharmacoresistant temporal epilepsy, in the literature. We 
would like to suggest that these findings could be grouped in certain categories: 
2.1 Malformations  
Many types of malformations were reported in epileptic series; these included the following: 
(Wolf et al, 1993-1995; Prayson et al, 1996; Volk et al, 1997; Armstrong et al, 2007; Al Khani & 
Assaad, 2008): 
2.1.1 Subependymal nodular cortical heterotopias and band heterotopias [double 
cortex]  
Congenital lesions composed of heterotopic cortical tissue in a periventricular 
subependymal location; they are closely associated with epilepsy (d’Orsi, 2004; Armstrong 
et al, 2007) (see fig. 1-2) 
2.1.2 Cortical malformations  
They include lissencephaly (smooth or nearly smooth cortical surface), hemimegalencephaly 
(enlarged hemisphere) and pachygyria-polymicrogyria (Sisodiya et al, 2004; Armstrong et 
al, 2007). Gyral fusion and abnormal elongation of a sulcus are other reported findings (see 
fig.3) (Al Khani & Assaad, 2008). 
It is suggested that cortical malformations can both form epileptogenic foci and alter brain 
development in a manner that causes a diffuse hyperexcitability of the cortical network 
(chevaussus et al, 1999).  
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2.1.3 Neuronal and glioneuronal malformations  
These malformations are composed of foci of havardous atypical neurons and Glioneuronal 
tissue. They overlap with neuronal and neuronal-glial tumors (Wolf et al, 1993-1995; 
prayson et al, 1996; Volk et al, 1997; Al Khani & Assaad, 2008), (see paragraph 2.4)  
2.1.4 Microdysgenesis  
This includes the following lesions of abnormal migration (Armstrong et al, 2007): 
1. Ectopic neurons in the white matter in greater than normal numbers 
2. Gray matter heterotopias: foci of displaced “gray matter” composed of neurons, glia, 
and neuropil characteristics. 
3. Hamartia that are microscopic collections of small, round “oligodendroglia-like” cells. 
They may be observed in the cortex or in the white matter and have some staining 
characteristics of immature neurons 
4. Perivascular glial nuclei refer to the presence of chains of bare glial nuclei in the white 
matter 
5. Neuronal clusters   
2.1.5 Vascular malformations  
Vascular malformations are known to cause seizures; notably arteriovenous malformations. 
All vascular tumors of the central nervous system are considered as malformative lesions 
(Louis et al, 2007).  
2.2 Cortical dysplasia/dysgenesis  
The histopathology of “cortical dysplasia” or “cortical dysgenesis” as described by the 
authors (Taylor et al, 1971; Prayson et al, 1995-1996; Frater et al, 2000; Wang et al, 2006; 
Armstrong et al, 2007; Bernasconi et al, 2011) includes a variety of structural changes which 
could be focal, multifocal, or diffuse, resulting in changes in the neuronal network inciting 
seizures attacks: neuronal migration abnormalities, diffuse architectural disorganization of 
the cortex with cortical laminar disruption, gyral fusion, clusters of atypical neurons and 
glial cells within the cortex, malalignment of neurons, neuronal cytomegaly, increased 
numbers of molecular layer neurons,  the presence of large neurons displaying a pyramidal 
or round shape, ballooned cells, and a high concentration of neurofilaments in giant neurons 
and of glial intermediate filaments in ballooned cells, evoking disruption of cell 
differentiation and maturation and an impairment of synaptogenesis (Garbelli et al, 1999). 
The term “cortical dysgenesis or disorganization” might be more appropriate.  
Classification schemes were described; the widely adopted is that described by palmini et al. 
This classification distinguished two types of cortical dysplasia based of the presence or 
absence of dysmorphic neurons or balloon cells, as follows (palmini et al, 2004): 
Type I: 
IA: Isolated architectural abnormalities, usually laminar or columnar disorganization, but 
no dysmorphic neurons 
IB: Architectural abnormalities, giant cells or immature neurons can be found 
Type II: 
IIA: Architectural abnormalities with dysmorphic cells are found, but no balloon cells 
IIB: Architectural abnormalities with both dysmorphic cells and balloon cells 
Changes of the above described “cortical dysplasia” are observed in all cases of epilepsy in 
some studied series (Al Khani & Assaad, 2008) (fig 3&4). Irregular brain surface and  
 
 




Fig. 1. Subependymal nodular cortical heterotopia observed at the left side of the figure. The 
columnar ependymal cells are clearly seen (HE stain).   
irregular cortical thickness were also described; that might be the consequence of neuronal 
reorganization associated with glial cell reaction.  
Cortical dysgenesis might begin as an in utero migrational abnormality (Sprifeafico et al, 
1998) so some authors put these lesions under the category of malformations (Armstrong et 
al, 2007), or as an acquired cortical dysplasia in response to perinatal brain damage (Marin-
Padilla et al, 1999). This alteration becomes an ongoing process that affects the structural 
and functional differentiation of neurons, synaptic profiles, fiber distribution, glial elements, 
and vasculature. Cortical dysplasia/disorganization becomes worse with the recurrence of 
seizures and exacerbates neuronal damage. 
2.3 Signs of neuronal injury, neuronal lysis, apoptosis and neuronal loss  
Neuronal damage and loss have been well documented in studies of epilepsy. Neuron loss 
is mainly observed in CA2& CA1 sectors of ammon horn (fig 5) and it might be observed in 
the other sectors in the advanced cases; it is found to be followed by axonal and mossy 
fibers sprouting and reorganizing (El Bahh et al, 1999; Armsrong et al, 2007).  Neuron injury 
and loss was evident in many series, affecting especially the pyramidal cells in the cortex 
and the granular cells in the dentate gyrus (dentate nucleus) (Proper et al, 2000; Al Khani 
and Assaad, 2008) (fig.6-9). The survived cells showed variability in size and shape, edema 
and vacuolization, and disorganization. Unexplained PAS+ material was also described in 
some observations in the cytoplasm of the injured neurons. Neuronal lysis and apoptosis 
were noted in our study adjacent to injured neurons. Neuronal damage especially affecting 
these neurons was well documented in animal experimental models.(Bouilleret et al, 2000)  
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Fig. 2. Subependymal nodular cortical heterotopia showing cluster of atypical neurons at the 
left lower side (HE stain). 
 
 
Fig. 3. Gyral fusion in the temporal lobe showing focal complete adhesion of the nervous 
tissue in “slits-shape”(HE stain). Cortical dysplasia is also noted at both sides of the sulcus 
(HE stain). 
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The loss of a critical number of interneurons in the dentate gyrus was suggested as a 
possible cause of seizure initiation (Fritschy et al, 1999) It was suggested that childhood 
seizures can damage or alter the postnatally developing granule cells of the human 
hippocampus, and that early neuron loss and aberrant axon circuits may contribute to 
chronic hippocampal seizures (Mathern et al, 1996). The role of apoptosis-related genes and 
the activation of the programmed death pathway were well documented by some authors, 
explaining that neuronal loss (Uysal et al, 2003; d’Orsi et al, 2004; Niquet et al, 2004; ). 
Apoptotic neurons were noted beside neuron lysis; these two forms of cell death in 
histopathological findings might contribute to neuron loss (Becker et al, 1999; Al Khani & 
Assaad 2008) (fig 7). 
 
 
Fig. 4. Cortical dysplasia showing architectural abnormalities (HE stain). Note the subpial 
gliosis in this figure. 
2.4 Tumors and hamartomatous tumors 
Some tumors are known to be frequently associated with epilepsy, such as 
dysembryoplastic neuroepithelial tumors (DNETs), ganglioneuromas and gangliogliomas, 
which can be either bilateral or multifocal (Barbosa et al, 1999; Whittle et al, 1999; 
Rosemberg et al, 1998; Al Khani and Assaad, 2008; Louis et al, 2007) (fig. 10). The 
hamartomatous origin of these tumors is suggested by some authors, as they are composed 
of mature multiple cell types (Gyure et al, 2000; Louis et al, 2007) Other low-grade tumors 
were reported in some cases of pharmacoresistant temporal epilepsy, such as 
xanthoastrocytomas (fig.11), low-grade astrocytomas, oligodendrogliomas, 
oligoastrocytomas, vascular tumors (Oda et al, 1998) and mixed or composite tumors 
(Hirose et al, 1998) Their incidences varies widely from one series to another; they were 
found with high percentages in some series, where most of the glioneuronal tumors were  
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Fig. 5. The dentate gyrus and the four sectors of ammon’s horn (cresyl violet stain; 
Armstrong et al, 2007). 
 
 
Fig. 6. Cluster of injured vacuolated neurons (HE stain).  
 




Fig. 7. Cluster of injured neurons revealing variation in sizes, vacuolization, shrinking, 






Fig. 8. Quasi complete loss of pyramidal cells in CA1 sector, with signs of neuron injury in 
the dentate gyrus (CA2 sector) with vacuolization, balloonization and loss of the granular 
neurons (HE stain).  
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Fig. 7. Cluster of injured neurons revealing variation in sizes, vacuolization, shrinking, 
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Fig. 9. Neuronal injury in the granular cells of the dentate gyrus (CA2 sector) with atypical 
and giant pyramidal neurons in CA1 sector. Abnormal intracytoplasmic inclusions are also 
noted (HE stain).    
bifocal, multifocal, or associated with each other, with transitional zones or “composite 
tumors” as described by some other authors (Prayson et al, 1999; Al Khani & Assaad, 2008) 
(fig.12). The juxtaposition of these tumors, and the transition between DNETs, 
gangliogliomas, or hamartomatous glioneuronal lesions might support the hypothesis that 
all these tumors are of hamartomatous origin. The relationship and the transition between 
these lesions have also been reported other authors (Hirose et al, 1998; Moreno et al, 2001).  
2.5 Inflammation 
Different causes of inflammatory changes are described in the cases of epilepsy; the most 
famous is Rasmussen’s encephalitis that is frequently reported in series of epilepsy (Frater et 
al, 2000; Prayson et al, 1999; Al Khani & Assaad, 2008) It is defined by lymphoid infiltration 
of the cerebrocortical perivascular compartment and neuropil, microglial nodule formation, 
astrogliosis, and variable neuronal loss. Cytomegalovirus and herpes virus HSV1 are found 
in some cases.(Jay et al, 1995). 
Inflammation caused by protozoan, parasites, and brain abscess was sometimes 
accompanied by seizures (Armstrong et al, 2007). Chronic encephalitis without evidence of 
pathogenic agent is sometimes reported (Prayson et al, 1999; Al Khani & Assaad, 2008) .  
2.6 Ischemic and hemorrhagic disorders 
Ischemic changes and infarct were reported in some series; this might results in severe 
atrophy (fig. 13).  Abnormal blood supply was noted by some authors (Al Khani & Assaad, 
2008; Fratel et al, 2000; Li et al, 1999; Prayson et al, 1999; Bernhardt et al, 2009). Hematomas 
were associated in some series with chronic epilepsy (Hisada et al, 1999; Al Khani & Assad, 
2008). 
 











Fig. 11. Xanthoastrocytoma is a rare low-grade glial tumor that can constitute an 
epileptogenic focus. 
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Fig. 11. Xanthoastrocytoma is a rare low-grade glial tumor that can constitute an 
epileptogenic focus. 
 




Fig. 12. Dysembryoplastic neuroepithelial tumor at the upper side of the figure, showing 
transition to ganglioglioma; reinforcing the malformative nature of these tumors.  
 
 
Fig. 13. Severe atrophy of the temporal lobe and the hippocampus due to atypical 
vascularization. Focal calcification is noted at the middle upper part of the figure (HE stain). 
2.7 Metabolic disorders, vacuolization, and cystic changes  
This was represented by vacuolar degeneration of neurons and glial cells (fig. 14), and cystic 
changes of the cortical, subcortical or glial tissue, reaching many centimeters in some cases 
where they could be detected on the macroscopic examination of the cut section; otherwise, 
they were microscopic findings. Cystic changes of the nervous tissue were constant 
observations in some refractory epilepsy series; thought they are considered as non-specific 
findings. These cysts were not alcianophilic, PAS stain was also negative (Al Khani & 
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Assaad, 2008). Progressive metabolic changes were noted, occurring during the  
development of hippocampal sclerosis in a model of mesial temporal lobe epilepsy 
(Bouilleret et al, 2000) The progress of metabolic or pathologic abnormalities of temporal 
lobe epilepsy may not be altered by adequate seizure control, as the presence of an 
epileptogenic focus might be associated with progressive neuronal injury even in clinically 
well-controlled patients (Spanaki et al, 2000) This might explain the exacerbation of 
neuronal damage and nervous tissue injuries with all the pathological changes constantly 
observed. Some authors found that hippocampal cell loss results in decreased efferent 
synaptic activity and neuronal activity in the thalamus and basal ganglia, and subcortical 
hypometabolism, which may reinforce the epileptogenic potential of the mesial temporal 
lobe discharge (Dlugos et al, 1999).  In a studied series of refractory epilepsy, signs of 
metabolic disorders were noted in all of the cases (Al Khani & Assaad, 2008). 
 
 
Fig. 14. Vacuolization of the glial cells in the temporal lobe and hippocampus (HE stain). 
2.8 Northern epilepsy 
Other authors found intraneuronal accumulation of cytoplasmic autofluorescent granules in 
which is called as northern epilepsy (Herva et al, 2000). 
2.9 Sclerosis/gliosis 
Gliosis is noted in all of the reported series of epilepsy with various degrees. Some 
investigators view hippocampal sclerosis as the primary cause of temporal lobe epilepsy, 
whereas others interpret the changes to be the result of chronic seizure activity. The 
macroscopic and radiological term of hippocampal sclerosis is interpreted, on 
histopathological examination, as astrogliosis associated with neuronal loss (Rushing et al, 
1997; Prayson et al, 1999). Astrogliosis or oligoastrogliosis (fig 15) was observed, in varying 
degrees, in the temporal lobe and hippocampus in all cases of drug resistant epilepsy in some 
series (Al Khani & Assaad, 2008), even in patients with no remarkable abnormalities on MRI in 
the temporal lobe, but with an irregular hippocampal signal on MRI. Cortical gliosis, 
especially subpial gliosis (fig 4) was always accompanied by advanced cortical dysplasia; this 
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leads to believe that progressive gliosis might be a reactive process induced by neuronal injury 
and loss, seizure attacks, and metabolic disorders. Sclerosis/gliosis might be considered as the 
end-stage of the all modifications. Focal oligogliosis is sometimes noted (fig 16). 
 
 
Fig. 15. Oligoastrogliosis in the white matter (HE stain). 
 
 
Fig. 16. Focal oligogliosis in a heterotopic subependymal cortical nodule (HE stain). 
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3. Combinations of lesions: “Dual pathology” 
Some authors mentioned that seizure attacks require dual pathology, as several 
observations revealed combinations of lesions (Jay et al, 1994; Oda et al, 1998; Juhsz et al, 
1999; Li et al, 1999; Prayson et al, 2010); for example, the coexistence of brain tumors and 
cortical dysplasia, neuronal migration disorders and low grade gliomas, lesions having both 
neoplastic and malformed foci, extrahippocampal lesion plus hippocampal atrophy, and 
coexistence of hippocampal sclerosis and a potentially epileptogenic cortical lesion. It was 
also reported that bilateral hippocampal atrophy was found frequently in patients with 
temporal lobe developmental malformations, and that the presence of bilateral amygdala or 
amygdalo-hippocampal atrophy was associated with a higher risk of seizure recurrence 
(Kuzniescky et al, 1999). The multifocality of malformative lesions was well reported by 
some authors (Wolf et al, 1995; Moreno et al, 2001; Armstrong et al, 2007). In our series (Al 
Khani & Assaad, 2008) dual pathology was well documented as tumors were always present 
in association with other changes, that were almost always seen: cortical dysplasia, 
astrogliosis, cystic changes, and neuron injury and loss.  The presence of bifocal or 
multifocal tumors and/or hamartomas was another observation to be noted. 
4. Conclusion 
A wide variety of lesions is documented in histopathological study of the temporal lobe and 
the hippocampus in temporal epilepsy, especially pharmacoresistant epilepsy. Some lesions 
were constantly present; cortical disorganization, neuron injury and loss, and gliosis. A 
presumable epileptogenic focus as hamartoma or tumoral lesion is frequently observed.  
Multiplicity and multifocality of lesions are well documented, reinforcing the hypothesis 
that the presence of an epileptogenic focus provokes a process of progressive damage of the 
nervous tissue. The good understanding of these processes and their sequencing, especially 
those leading to neuron death and loss, might contribute in the prevention of progression of 
epileptic seizure and the damage of nervous tissue in previously susceptible patients. 
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1. Introduction  
Epilepsy is a major neurological disorder that affects 0.5-2.0% of the global population 
(Hauser, 1998; Picot et al.; 2008). The term “epilepsy” likely encompasses a number of 
various etiological and pathophysiological processes. The International League Against 
Epilepsy (ILAE) has classified the epilepsies as being either focal or generalized. In all 
likelihood, this classification implies different causes and anatomical/functional substrates. 
Epileptogenesis (the processes by which epilepsy develops within an otherwise normal 
brain) probably differs for the various types of epilepsy (Lüders, 2008). In this sense, 
epileptogenesis of (for example) temporal lobe epilepsy (TLE) with hippocampal sclerosis 
(HS), would be different from that observed in patients with cortical dysplasia; this would 
hold true for other cryptogenic or idiopathic focal epilepsies as well. Therefore, to date, it 
has not been possible to establish a unique underlying cause or mechanism that is involved 
in the transition from normal to epileptic cortical tissue, although there are several 
hypotheses to explain the different types of seizures and epilepsies. 
From a therapeutic point of view, the epilepsies in humans can be divided into pharmaco 
sensitive and pharmaco resistant. In the former, the patient is successfully treated by one or 
more anti-epileptic drugs (AED). Nearly two-thirds of patients respond to anticonvulsant 
therapy. However, in a significant percentage of patients, the seizures cannot be controlled 
by drugs, despite verifying both maximal dosage and an adequate treatment duration. The 
percentages of medical intractability among epileptic patients are: focal epilepsy, 24%; 
idiopathic epilepsy, 9.3%; and catastrophic epilepsy, 66.7% (Lardizabal, 2008). In some cases, a 
viable therapeutic option is surgery. Generally, the candidates for this treatment are patients 
who suffer from focal or partial epilepsy. In these patients, it is possible—at least in theory—to 
identify a well-defined area of the cortex that is responsible for the seizures; this is known as 
the epileptic zone (EZ). From an operational point of view, the EZ is defined as the region in 
which excision or disconnection relieves the patient from seizures. This option frequently 
involves removing the brain section where the EZ is located, and this possibility offers a 
unique opportunity to gain access to the real processes (the neural networks, membrane 
properties and synaptic dynamics) underlying partial epilepsy in human patients.  
TLE is the most common form of partial epilepsy in adults and is usually drug-resistant 
(Engel 2001; Wieser, 2004). This type of pathology is frequently associated with a salient 
pathological condition called hippocampal sclerosis (see Figure 1 -Kuzniecky et al.; 1987). 
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pathological condition called hippocampal sclerosis (see Figure 1 -Kuzniecky et al.; 1987). 
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For several decades, HS has been considered the source of the electrical events that cause 
spontaneous seizures (Falconer, 1974; Spencer 1998). However, HS is found in 
approximately 40-65% of patients who undergo surgery for TLE (de Lanerolle et al.; 2003), 
and whether hippocampal sclerosis is the cause or the consequence of repeated seizures is 
still a matter of debate (Jefferys, 1999; Boison, 2008). The progression of epileptogenesis to 
chronic epilepsy often leads to pharmacoresistance and affects up to 30% of all patients with 
epilepsy, particularly those with TLE (Engel, 2001). 
A wide range of brain injuries and brain lesions are associated with an increased risk of 
epilepsy. In fact, such symptomatic etiologies account for 30-49% of all unprovoked seizures 
and epilepsy (Herman, 2002). The most common risk factors are cerebrovascular disease 
(21%), tumor (11%) and traumatic brain injury (7%) (Forsgren, 1990). A feature that is 
common to all of these conditions is the compromised permeability of the blood-brain 
barrier (BBB). Although idiopathic epilepsy accounts for up to 65% of cases, these patients 
likely share some pathophysiological mechanisms with injury-induced epilepsies. 
Much is known regarding neuronal electrophysiology in epileptic tissues (Avoli et al.; 2005; 
Pastor et al.; 2006); however, there is little information regarding the transition from a 
normal brain to an epileptic brain. Recently, it was shown in both rats and humans that 
astrocytes could be involved in some types of partial seizure (de Lanerolle et al.; 2010). 
Astrocytes are situated in key pivotal places that may play a role in epilepsy in several 
ways. Indeed, astrocytes control the trafficking of substances between capillary vessels and 
neurons. Another important function is in the homeostasis of extracellular ions, principally 
potassium (K+), which is directly involved in neuronal excitability. Finally, astrocytes are 
mediators of the neuron–to-neuron synapse through the tripartite synapse. In addition to 
astrocytes, another important factor is a change in the permeability of the BBB, which is 
formed by endothelial cells, although glial cells contribute yet to its function. 
 
 
Fig. 1. Microphotograph of a Nissl-stained hippocampus obtained from a patient who 
underwent surgery for TLE. A loss of cells is evident in the CA1, CA3 and hilus regions. 
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Albumin, the most abundant protein in blood, has also been implicated in epileptogenesis 
(Seiffert et al.; 2004; Herrera-Peco et al.; 2008) together with changes in BBB permeability or 
the inflammatory cascade, although the role of these mechanisms in epilepsy are still poorly 
understood (de Lanerolle et al.; 2010). Although not conclusive, different results point to 
astrocytes as being important mediators of the mechanisms involved in epileptogenesis and 
the origin and spreading of seizures. In this chapter, we review some of the recent theories 
and results concerning these topics, with a special emphasis on results obtained from 
human patients. We shall analyze the role of BBB permeability in the leakage of albumin 
into the brain’s extracellular space and the possible role of this protein in the activation of 
astrocytes. Although other reviews have focused on the role of the TGF-β receptor (TGF-βR) 
in the action of albumin, we shall review a putative role for a different albumin receptor that 
is currently not well characterized but clearly has different properties than TGF-βR. 
2. A brief introduction to astrocyte physiology  
Glial cells outnumber neurons by approximately 10-50:1. Glial cells can be divided into two 
major classes called microglia and macroglia. 
• Microglia are phagocytes that mobilize in response to brain injury (for example, 
infection or disease). From a physiological and embryological point of view, they are 
unrelated to the others cells of the nervous system. Microglia are activated and 
recruited during infection, seizure and injury or disease, including multiple sclerosis, 
stroke, acquired immunodeficiency syndrome (AIDS)-related dementia and Parkinson’s 
disease. In this regard, microglia serve as major antigen-presenting cells. 
• Macroglia comprise three different types of cells: 
• Oligodendrocytes and Schwann cells are located in the Central Nervous System 
(CNS) and Peripheral Nervous System (PNS), respectively. Both cell types provide 
insulation for neuronal axons. Each oligodendrocyte envelops an average of 15 
axonal internodes. However, each Schwann cell envelops only one internode on a 
single axon. The insulation provided by these cells is necessary for saltatory nerve 
conduction (Donaldson & Mia-Sin Wu, 2001). 
• Astrocytes are the most numerous glial cells and tend to have long processes, some 
of which terminate as end-feet on the surface of neurons and, among other things, 
supply nutrients. Some astrocytes project their end-feet to capillaries, where they 
help endothelial cells form the BBB. However, their exact definition and the types 
of astrocytes that exist remain incompletely understood (Haydon & Carmignoto, 
2006; de Lanerolle et al.; 2010). 
Traditionally, the main role of astrocytes has been considered to be to provide support to 
neurons (Barres, 1991). However, over the previous decades, astrocytes have been found to 
play several roles other than supportive. Seminal works showed that astrocytes express 
receptors for neurotransmitters (Porter & McCarthy, 1997) and can respond to a local 
application of glutamate with a calcium elevation that travels as a wave through a 
syncytium (Corner-Bell et al.; 1990). Together, these data suggest that astrocytes possess the 
capacity to signal using spike-like calcium transients. In fact, these calcium spikes can travel 
over long distances and serve as a tool for communication.  
Astrocytes are normally identified by their expression of glial fibrillary acidic protein 
(GFAP). However, glial cells can be further categorized according to their functional 
properties as follows (Matthias et al.; 2003, Wallraff et al.; 2004; Jabs et al.; 2008):  
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• Cells with large outward K+ current and attenuated inward K+ current (IKir). The resting 
potential (Vr) of these cells is therefore relatively depolarized (∼-31 mV). Most of these 
cells contain TTX-sensitive Na+ currents but are unable to generate action potentials. 
These cells express alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) type receptors (GluR), but not glutamate transporter currents. Finally, these 
cells completely lack gap junction coupling but receive spontaneous synaptic input 
from glutamatergic and γ-aminobutyric acid neurons (GABAergic).  
• Cells that resemble protoplasmic astrocytes. These cells have a more negative Vr (∼-70 
mV), and IKir is present. These cells express glutamate transporter currents (GluT) but 
not GluR currents. Finally, these cells are extensively coupled via gap junctions. 
• A third cell type closely resembles the GluR cell type described above. These are 
considered a third class of macroglia and have various names, including neuron glia-2 
(NG2) cells, oligodendrocyte precursor cells, polydendrocytes, synantocytes and 
complex cells (Pauker & Bergles, 2006). These cells express chondroitin sulfate 
proteoglycan, do not express GFAP and lack GluT currents and gap junctions. As with 
GluR astrocytes, they express AMPA receptors as well as GABA receptors; moreover, 
they receive synaptic terminals. Current injection into these cells elicits action potentials 
that are reversibly blocked by TTX. To complicate matters further, two classes of NG2 
cells have been recently identified (Káradóttir et al.; 2008): one class expresses voltage-
gated Na+ currents together with voltage-gated K+ currents, whereas the other does not 
express Na+ currents. Presumably, both of these cell classes additionally express 
voltage-gated Ca2+ currents. 
2.1 Plasma membrane properties of astrocytes 
Some astrocytes exhibit a high resting K+ conductance and possess gap junction coupling; 
thus, the first major function that was assigned to these cells was the clearance of 
extracellular K+ following neuronal activity. However, glial cells express a set of receptors 
that is similar to neurons, but at different relative densities. This suggests that astrocytes 
perform other functions than buffering K+. Among their intrinsic membrane proteins are 
metabotropic glutamate receptors (mGluR) (Zur Nieden and Deitmer, 2006), purinergic 
receptors (Jeremic et al.; 2001) and GABA type-B receptors. Other ionotropic receptors, such 
as AMPA, are also present. An elevated amount of GluR1 in the AMPA receptors of reactive 
astrocytes has been reported, which suggests an increased responsiveness of these astrocytes 
to glutamate (Seifert et al.; 2004). This change has been observed in astrocytes that were 
obtained from sclerotic tissue. Moreover, in animal models, mGluR3, mGluR5 and mGluR8 
up-regulation has been reported in the hippocampus (Steinhäuser & Seifert, 2002). These 
receptors are involved in the astrocyte’s response to glial and neurotransmitter. During 
normal brain function activity, astrocytes play a major role in the clearance of glutamate that 
is released from the nerve terminal into the extracellular space.  
Astrocytes achieve this through the activity of two glutamate transporter molecules, namely 
the excitatory amino acid transporter (EAAT) subtypes EAAT1 and EAAT2 (de Lanerolle et 
al.; 2010). The GABA transporter GAT3 is usually only weakly expressed (if at all) in 
astrocytes. Aquaporin 4 (AQP4) is a water transporter molecule that is found on astrocytes. 
The distribution of these transporter molecules is asymmetric, being more densely 
expressed on the perivascular astrocytic end-feet than on the membrane that faces the 
neuropil (de Lanerolle et al.; 2010). 
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Several studies demonstrated the presence of voltage-dependent ionic channels, including 
Na+, K+ and Ca2+ channels (Barres et al.; 1990; Sontheimer et al.; 1991; Sontheimer & 
Waxman, 1993). Voltage-gated Na+ channels are present in astrocytes in various brain 
regions. It has been postulated that this might serve to regulate [Na+]i and thereby control 
the activity of the Na+/glutamate transporter or Na+/K+ ATPase exchanger (Sontheimer et 
al.; 1994). Calcium channels have also been identified in both cultured astrocytes and acute 
astrocyte preparations (Verkhratsky & Steinhäuser, 2000). Astrocytes play a major role in K+ 
homeostasis in the central nervous system. During neuronal activity, [K+]o is temporally 
increased, which depolarizes nearby membranes. Astrocytes help move K+ away from 
regions of high concentration to restore the normal extracellular concentration (Steinhäuser 
& Seifert, 2002). Inwardly rectifying potassium (Kir) channels in astrocytes play a major role 
in removing K+ from the extracellular space.  
2.2 Calcium signaling in astrocytes 
Glial cells respond with changing [Ca2+]i to various neurotransmitters, the most important of 
which are glutamate, ATP, adenosine and GABA (Haydon & Carmignoto, 2006). These 
transmitters activate metabotropic receptors that are coupled to second messenger systems.  
Astrocytes not only exhibit changes in [Ca2+]i after extracellular neurotransmitter release, 
but spontaneous calcium oscillations can also occur in the absence of neuronal activity (Nett 
et al.; 2002; Parri & Crunelli 2003; Zur Nieden & Deitmer, 2006). It has been established that 
both evoked and spontaneous astrocyte calcium increases depend on calcium release from 
internal stores (Fiacco & McCarthy, 2006). A neurotransmitter-induced increase in astrocytic 
calcium activates astrocytic metabotropic Gq-coupled receptors that drive the release of 
calcium from the endoplasmic reticulum (ER) upon activation of phospholipase C (PLC) 
and conversion of phosphotidylinositol bisphosphate to inositol triphosphate (IP3) (Nadal et 
al.; 1995; Porter & McCarthy, 1996; Araque et al.; 1998a, Newman 2005; Pastor et al.; 2010). 
Spontaneous [Ca2+]i changes are not completely understood, but some theories that are 
supported by various experimental data have been postulated. These include a mechanism 
involving voltage-gated calcium channels and calcium induced-calcium release (Parri & 
Crunelli, 2003), activation of mGluR by the quantal release of small amounts of glio or 
neurotransmitters (possibly spillover from synaptic region) (Zur Neider & Deitmer, 2006) 
and a “switch” in the intrinsic activity of metabotropic receptors (Pasti et al.; 1997). 
Although the ryanodine receptor has been implicated in calcium changes in epilepsy 
(Tashiro et al.; 2002), its role has not yet been clarified because several studies failed to show 
any significant contribution in astrocytes that were obtained from epileptic patients (see 
Figure 2 and reference Pastor et al.; 2010). 
In astrocytes, a local calcium increase following IP3 receptor activation often propagates as a 
‘‘calcium wave’’ some distance from its point of origin (Nadal et al.; 1997). The propagation 
of calcium waves is believed to occur via calcium diffusing locally (after its initial release) to 
neighboring IP3 receptors, where it acts as a co-agonist with IP3 to release stored calcium 
from adjacent compartments (Fiacco & McCarthy, 2006). 
Upon stimulation, astrocytes in culture display a calcium wave that propagates 
intercellularly through thousands of cells (Cornell-Bell et al.; 1990). The mechanisms that are 
involved in the propagation of intercellular calcium waves in cultured astroglia include: (1) 
gap junctions between astrocytes that allow the intercellular diffusion of second messengers 
such as IP3, and (2) the calcium-induced release of ATP that diffuses extracellularly to 
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as AMPA, are also present. An elevated amount of GluR1 in the AMPA receptors of reactive 
astrocytes has been reported, which suggests an increased responsiveness of these astrocytes 
to glutamate (Seifert et al.; 2004). This change has been observed in astrocytes that were 
obtained from sclerotic tissue. Moreover, in animal models, mGluR3, mGluR5 and mGluR8 
up-regulation has been reported in the hippocampus (Steinhäuser & Seifert, 2002). These 
receptors are involved in the astrocyte’s response to glial and neurotransmitter. During 
normal brain function activity, astrocytes play a major role in the clearance of glutamate that 
is released from the nerve terminal into the extracellular space.  
Astrocytes achieve this through the activity of two glutamate transporter molecules, namely 
the excitatory amino acid transporter (EAAT) subtypes EAAT1 and EAAT2 (de Lanerolle et 
al.; 2010). The GABA transporter GAT3 is usually only weakly expressed (if at all) in 
astrocytes. Aquaporin 4 (AQP4) is a water transporter molecule that is found on astrocytes. 
The distribution of these transporter molecules is asymmetric, being more densely 
expressed on the perivascular astrocytic end-feet than on the membrane that faces the 
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Although the ryanodine receptor has been implicated in calcium changes in epilepsy 
(Tashiro et al.; 2002), its role has not yet been clarified because several studies failed to show 
any significant contribution in astrocytes that were obtained from epileptic patients (see 
Figure 2 and reference Pastor et al.; 2010). 
In astrocytes, a local calcium increase following IP3 receptor activation often propagates as a 
‘‘calcium wave’’ some distance from its point of origin (Nadal et al.; 1997). The propagation 
of calcium waves is believed to occur via calcium diffusing locally (after its initial release) to 
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gap junctions between astrocytes that allow the intercellular diffusion of second messengers 
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neighboring astrocytes to activate purinergic receptors that are coupled to internal calcium 
stores (Cotrina et al.; 2000; Suadicani et al.; 2004). There is no evidence of the existence of 
intercellular astrocyte calcium waves in intact tissue, suggesting that long-range glial 
signaling may be an artifact of cultured astroglia; however, it has been proposed that this 
process might occur in pathological conditions such as epilepsy (Peters et al.; 2003). In 
general, these observations suggest that widespread intercellular calcium waves are not 
likely to occur between astrocytes under physiological conditions in situ. However, a recent 
in vivo study showed that “Ca2+ signals (…) can propagate through the cell and couple to 
adjacent astrocytes in the form of a Ca2+ wave” (Ding et al.; 2007). 
These changes in [Ca2+]i can act as a second messenger in various cellular process, including 
the release of gliotransmitters or the modification of gene expression patterns. 
 
 
Fig. 2. Ryanodine fails to block the response to bovine plasma albumin (Alb; 20 mg/ml) in 
astrocytes obtained from epileptic patients (unpublished data). 
2.3 Interactions between astrocytes and neurons 
Astrocytes were initially considered to be supportive cells. However, during the last years 
of the past century, it became clear that glial cells can also contribute to information 
processing by neurons. Various studies have led to the proposal of the “tripartite 
synapse”, in which the astrocyte monitors synaptic activity and provides feedback by 
modulating the strength of the synaptic connection (Araque et al.; 1999; 2001). This 
concept is based on studies showing that glial cells respond to neuronal activity with an 
[Ca2+]i increase, which in turn triggers the release of gliotransmitters that can cause 
feedback regulation of neuronal activity. 
Calcium increases in astrocytes are coupled to the regulated release of neuroactive 
molecules and classic neurotransmitters that include ATP, inflammatory cytokines, 
vasoactive compounds, D-serine and glutamate (Parpura et al.; 1994 ; Coco et al.; 2003 ; 
Zonta et al.; 2003; Mothet et al.; 2005). 
Other modes of glutamate release by astrocytes are calcium-independent and include 
release through large pores, including gap junction hemi-channels and purinergic P2X7 
receptors (Ye et al.; 2003; Fellin et al.; 2006), a reversal of glutamate transport (Anderson & 
Swanson, 2000) and by volume-sensitive anion channels (Takano et al.; 2005). However, 
calcium-independent modes of astrocytic glutamate release have only been observed under 
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pathological conditions, such as severe energy depletion, highly increased external K+ and 
in divalent cation-free extracellular solutions. Therefore, a considerable body of data 
suggests that the calcium-dependent release of glutamate from astrocytes occurs via a 
regulated exocytotic vesicular mechanism. 
It has been shown that synaptotagmin 4 is essential for Ca2+-dependent glutamate release. 
Presumably, an excess of the synaptotagmin isoform 4 in place of isoform 1 suggests that the 
kiss-and-run release mechanism prevails over full vesicle fusion (Wang et al.; 2001). 
Moreover, several studies demonstrated the presence and participation of SNARE proteins 
in exocytosis (Araque et al.; 2000). 
Glutamate release likely acts through NMDA receptors (NMDARs) that are composed of 
NR1/NR2B subunits. These receptors are located extrasynaptically, whereas in the synaptic 
membrane, the NR1/NR2A configuration is found (Haydon & Carmignoto, 2006).  
This situation of NMDAR can account for the high amplitude and slow kinetics of the slow 
inward currents (SIC; see Figure 3) that are recorded after astrocytic glutamate release  
(∼100 pA), whereas synaptic currents are only around 2-3 pA in amplitude. In addition to 
exerting kinetic differences, synaptic and extrasynaptic NMDA receptors may accomplish 
different—and to some degree opposing—functional roles (Krapivinsky et al.; 2003). 
It has been suggested that the release of glutamate from a single astrocyte has the potential 
to act synchronously on several different dendrites. Indeed, this mechanism may underlie 
the generation of paroxysmal depolarization shifts (PDS) that can be induced in several 
neurons in a rat model of epilepsy. Besides NMDARs, AMPA receptors (AMPARs) may also 
be activated by astrocytic glutamate release. These receptors are also present at 
extrasynaptic locations, and their activation may serve as a type of coincidence detector with 
synaptic NMDARs (Haydon & Carmignoto, 2006). 
 
 
Fig. 3. Astrocytes can activate neurons by gliotransmitter release. A) Infrared differential 
interface contrast (DIC) image showing the stratum radiatum (SR) and the recorded neuron 
in the stratum pyramidale (SP) of a rat hippocampal slice. B) Whole-cell currents from a 
CA1 pyramidal neuron showing a neuronal slow inward current (SIC, expanded in the 
bottom trace). Courtesy of Dr. Alfonso Araque, Consejo Superior de Investigaciones 
Científicas, Madrid. 
Glutamate is not the only molecule that is released from astrocytes to modulate the activity 
of neurons. Other molecules are functionally important as well. In fact, in addition to 
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neighboring astrocytes to activate purinergic receptors that are coupled to internal calcium 
stores (Cotrina et al.; 2000; Suadicani et al.; 2004). There is no evidence of the existence of 
intercellular astrocyte calcium waves in intact tissue, suggesting that long-range glial 
signaling may be an artifact of cultured astroglia; however, it has been proposed that this 
process might occur in pathological conditions such as epilepsy (Peters et al.; 2003). In 
general, these observations suggest that widespread intercellular calcium waves are not 
likely to occur between astrocytes under physiological conditions in situ. However, a recent 
in vivo study showed that “Ca2+ signals (…) can propagate through the cell and couple to 
adjacent astrocytes in the form of a Ca2+ wave” (Ding et al.; 2007). 
These changes in [Ca2+]i can act as a second messenger in various cellular process, including 
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requiring glutamate for NMDAR activation, the co-agonist D-serine may also be important. 
Astrocytes are the only cells that express the enzyme serine racemase, making glial cells the 
only source for this molecule in the brain (Wolosker et al.; 1999). It has been suggested that 
vesicles might contain both D-serine and glutamate, thereby allowing their simultaneous 
release upon increased [Ca2+]i (Haydon & Carmignoto, 2006). 
Another important gliotransmitter that is released by astrocytes is ATP, and the mechanisms 
that are involved are the subject of debate. There is evidence that the release of both ATP 
and glutamate involve phospholipase C, but it has been suggested that ATP release depends 
on the diacylglycerol pathway (Wang et al.; 2000), although this hypothesis is still under 
debate. Released at micromolar concentrations ATP has powerful effects on adjacent 
neurons acting through purinergic receptors (P2). ATP can activate P2 presynaptic receptors. 
In fact, the activation of P2Y1 receptors in CA1 interneurons—most likely after the release of 
ATP from both neurons and astrocytes—may induce action potentials in these neurons and 
lead to increased GABAergic synaptic inhibition of pyramidal neurons (Bowser & Khakh, 
2004). However, an excitatory effect of ATP has been described in which glutamate-
mediated miniature end-plate synaptic currents are increased (Gordon et al.; 2005). Once 
ATP has been released into the extracellular space, a variety of ectonucleotidases degrade 
ATP into adenosine. Adenosine is a ubiquitous modulator of synaptic transmission and 
neuronal activity and acts through specific receptors. Indeed, there are high-affinity 
inhibitory adenosine A1 and excitatory A2A receptors that are activated by nanomolar 
concentrations of adenosine as well as low-affinity or low-abundance A2B and A3 receptors. 
The most relevant function of adenosine is to induce presynaptic inhibition of transmitter 
release and therefore has potent anticonvulsant and neuroprotective functions (Boison, 
2008). It is important to note that adenosine—either released or produced by ATP 
degradation—can diffuse from the synaptic cleft and act laterally to regulate the strength of 
neighboring synapses in a mechanism named heterosynaptic suppression, which is 
mediated by the accumulation of adenosine acting through A1 receptors (Zhang et al.; 2003). 
We will see below in detail the effect of adenosine on seizure threshold (see 4.5 The role of 
adenosine kinase in epileptogenesis); however, suffice it to say that adenosine acting 
through A1 receptors has a potent anticonvulsant effect. 
In addition to the release of gliotransmitters, it is important to consider that one cortical 
astrocyte makes contacts with approximately 300-600 neuronal dendrites. These “local 
modules” of astrocytic integration can affect the function of several groups of neurons or 
synapsis, thus working in a more coherent mode (Halassa et al.; 2007). 
Astrocytes play an important role in the metabolism of the brain through their exclusive role 
in the degradation of both glucose and glutamate. The importance of astrocytes in these 
processes lies in their expression of key enzymes that are not normally found in neurons. Of 
course, these processes are extremely important for appropriate brain function but are 
beyond the scope of this review. The reader is referred to Hertz et al. (1999) and Herrera-
Peco et al. (2008). 
2.4 Astrocytes are activated by albumin 
Albumin (C123H193N35O37) is the most abundant protein in blood, representing more than 
50% of all proteins. Its molecular weight is 2754.06 g/mol, and its concentration in plasma is 
around 35-55 mg/ml (Nadal et al.; 2001). Among its functions is the binding of several polar 
lipids, particularly lysophosphatidic acid (LPA), other fatty acids and sphingomyelins that 
are derived from platelet activation (Fuentes, E.t al.; 1999). Albumin is also the main 
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component in maintaining osmotic plasma pressure. Thus far, albumin has been shown to 
activate various cell types, including rat astrocytes in culture (Nadal et al.; 1995; 1997) and in 
brain slices (Ivens et al.; 2007; Nadal et al.; 1998).  
Depending on its concentration, plasma albumin—that is, albumin obtained from non-
clotted blood—can have a dual effect on astrocytic [Ca2+]i. A low albumin concentration can 
induce a decrease in calcium, whereas higher doses increase [Ca2+]i in a dose-dependent 
manner (Figure 4). These effects, which were initially studied in astrocytes obtained from rat 
pups, were recently demonstrated in humans (Pastor et al.; 2010).  
The dual effect on cytosolic calcium in astrocytes depends on two different components of 
native plasma albumin that can be separated by methanol extraction (Nadal et al.; 1994; 
1995). The protein component of albumin causes a reduction in [Ca2+]i, whereas native 
albumin—to which the lipid factor is normally attached—induces repetitive calcium spiking 
and DNA synthesis in addition to decreased [Ca2+]i. This factor cannot be a protein 
contaminant such as a growth factor because its activity can be extracted by methanol 
through a dialysis membrane, is sensitive to lipases but not boiling and can be reconstituted 
with extracted albumin to restore the full activity of native albumin. The preferential 
extraction by methanol suggests that the factor is a polar lipid such as a phospholipid or 
ganglioside (Nadal et al.; 1995). This polar lipid has not yet been identified, but it has been 
suggested that it might be the same substance that binds to glia cell stimulating factor (GSF) 
(Nuñez & García-Sancho, 1996). 
 
 
Fig. 4. Changes in [Ca2+]i in human astrocytes induced by bovine plasma albumin (BPA). 
The bars indicate the application of glutamate (Glu 500 mM) or BPA at the indicated 
concentrations (in mg/ml). Note that 0.1 mg/ml BPA induced a decrease in fluorescence. 
The microphotographs show the changes in [Ca2+]i of one human astrocyte (arrow) to BPA. 
The numbers at left indicate the albumin concentration. The cells were loaded with Fura-2 
AM (10-6 mol/L). Unpublished data. 
As is the case with other neurotransmitters, the change in [Ca2+]i depends on the release of 
IP3 after G-protein-mediated activation of PLC (Nadal et al.; 1995; 1997; Pastor et al.; 2010). 
The albumin receptor has not yet been identified. 
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requiring glutamate for NMDAR activation, the co-agonist D-serine may also be important. 
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only source for this molecule in the brain (Wolosker et al.; 1999). It has been suggested that 
vesicles might contain both D-serine and glutamate, thereby allowing their simultaneous 
release upon increased [Ca2+]i (Haydon & Carmignoto, 2006). 
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The most relevant function of adenosine is to induce presynaptic inhibition of transmitter 
release and therefore has potent anticonvulsant and neuroprotective functions (Boison, 
2008). It is important to note that adenosine—either released or produced by ATP 
degradation—can diffuse from the synaptic cleft and act laterally to regulate the strength of 
neighboring synapses in a mechanism named heterosynaptic suppression, which is 
mediated by the accumulation of adenosine acting through A1 receptors (Zhang et al.; 2003). 
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adenosine kinase in epileptogenesis); however, suffice it to say that adenosine acting 
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modules” of astrocytic integration can affect the function of several groups of neurons or 
synapsis, thus working in a more coherent mode (Halassa et al.; 2007). 
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in the degradation of both glucose and glutamate. The importance of astrocytes in these 
processes lies in their expression of key enzymes that are not normally found in neurons. Of 
course, these processes are extremely important for appropriate brain function but are 
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component in maintaining osmotic plasma pressure. Thus far, albumin has been shown to 
activate various cell types, including rat astrocytes in culture (Nadal et al.; 1995; 1997) and in 
brain slices (Ivens et al.; 2007; Nadal et al.; 1998).  
Depending on its concentration, plasma albumin—that is, albumin obtained from non-
clotted blood—can have a dual effect on astrocytic [Ca2+]i. A low albumin concentration can 
induce a decrease in calcium, whereas higher doses increase [Ca2+]i in a dose-dependent 
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(Nuñez & García-Sancho, 1996). 
 
 
Fig. 4. Changes in [Ca2+]i in human astrocytes induced by bovine plasma albumin (BPA). 
The bars indicate the application of glutamate (Glu 500 mM) or BPA at the indicated 
concentrations (in mg/ml). Note that 0.1 mg/ml BPA induced a decrease in fluorescence. 
The microphotographs show the changes in [Ca2+]i of one human astrocyte (arrow) to BPA. 
The numbers at left indicate the albumin concentration. The cells were loaded with Fura-2 
AM (10-6 mol/L). Unpublished data. 
As is the case with other neurotransmitters, the change in [Ca2+]i depends on the release of 
IP3 after G-protein-mediated activation of PLC (Nadal et al.; 1995; 1997; Pastor et al.; 2010). 
The albumin receptor has not yet been identified. 
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In addition to its effects on cytosolic calcium, plasma albumin can also induce the synthesis 
of DNA. This process of synthesis is the normal precursor to mitosis, which implies that 
albumin can act as a mitogen in astrocytes. 
In addition to the calcium pathway that is activated by albumin, this protein is also taken 
up by astrocytes, neurons and microglia (albeit to a lesser extent) (Ivens et al.; 2007; van 
Vliet et al.; 2007). This effect of albumin on glial cells is mediated by the TGF-βR (TGF-βR; 
Figure 5), which activates the Smad signaling pathway (Cacheux et al.; 2009). This 
mechanism of activation has been extensively studied in a rat model of epilepsy and is 
discussed below in detail. 
An important question regarding the type of albumin (either plasmatic or serum) remains 
unanswered. In fact, both models, the albumin-receptor activated and the TGF-βR, have 
been described with plasma albumin (Nadal et al.; 1995; Pastor et al.; 2010) and serum 
albumin (Seiffert et al.; 2004; Ivens et al.; 2007) respectively. In the latter case, albumin 
carries different lipids that are derived from the coagulation cascade, including 
lysophosphatidic acid (LPA), lysophosphatidylcholine, sphingomyelin and platelet-
activating factor. All of these lipids can elicit calcium signals of varying magnitude in 
cortical astrocytes, although only LPA-induced calcium signals are comparable in amplitude 
to those induced by the active physiological lipid that is bound to plasma albumin. None of 
these lipids, however, was found to cause cell division in astrocytes (Fuentes et al.; 1999). 
There is therefore no direct invariable relationship between the ability of lipids to induce 
calcium signals and mitogenic activity. Perhaps under pathologic conditions, coagulation 
plays an important role in the effect of albumin on astrocytes; nevertheless, albumin would 
be attached to a polar lipid that has an effect distinct from LPA. 
 
 
Fig. 5. Mechanisms of action of albumin in astrocytes. Depicted is the IP3-cytosolic calcium 
pathway with its proposed effect on gene transcription, indicated by the asterisk. TGF-βR 
signaling pathway is also shown. Both of these pathways are present in cultured human 
astrocytes. * Hypothesized action. See text for more details. 
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3. The structure and function of the blood-brain barrier  
The BBB is a diffusion barrier that impedes the influx of most compounds between the 
blood and the brain, thereby isolating the brain from the external environment. Three 
cellular elements of the brain’s microvasculature comprise the BBB and are responsible for 
its properties. These components are:  
• Endothelial cells. Tight junctions (TJs) are special transmembrane proteins that are 
located between cerebral endothelial cells, where they form a diffusion barrier that 
selectively excludes most blood-borne substances from entering the brain. There is 
some evidence of cross-talk with astrocytes. Indeed, endothelial cells seem to be the 
primary source of leukemia inhibitory factor (LIF), which helps induce astrocyte 
differentiation (Mi et al.; 2001). Other molecules that are presumably released by 
endothelial cells to affect astrocytes include bradykinin and glutamate. Moreover, 
endothelial cells are involved in neurogenesis, primarily via vascular endothelial 
growth factor (VEGF) (Loussaint et al.; 2002). 
• Astrocyte end-feet. These structures tightly ensheath the vessel wall and appear to be 
critical for the induction and maintenance of the TJ barrier, although astrocytes are not 
believed to have a role in the mammalian BBB. However, astrocytes are important 
because they help induce the generation of BBB structures in endothelial cells. Astrocytes 
can act on endothelial cells by releasing cytokines such as TGF-β and glial cell-derived 
neurotrophic factor (GDNF) (Utsumi et al.; 2000, Ramsauer et al.; 2002). Intracellular 
calcium waves mediate bidirectional astrocyte-endothelial interactions. In co-culture 
models, two signaling mechanisms are presumably involved: 1) astrocytes and 
endothelial cells can exchange calcium signals via a pathway that is dependent on 
intracellular IP3 and gap junctions; and 2) diffusion of a purinergic messenger. However, 
in vivo, astrocytes and endothelial cells are not in contact, and therefore, these findings 
need to be confirmed. Nevertheless, the dilation of arterioles triggered by neuronal activity 
depends on glutamate-mediated [Ca2+]i oscillations in astrocytes (Zonta et al.; 2003). 
• Pericytes are undifferentiated cells that wrap around the endothelial cells of 
microvessels, including capillaries, venules and arterioles. Pericytes are believed to 
provide structural support and vasodynamic capacity to the microvasculature (Ballabh 
et al.; 2004). Pericytes can also help to stabilize capillaries that are recently formed by 
endothelial cells, thereby regulating angiogenesis (Balabanov & Dore-Duffy, 1998). 
The BBB differs from endothelial cells in the rest of the body by the absence of fenestrations, 
extensive tight junctions (TJs) and bare pinocytic vesicular transport. The building blocks of 
the BBB are comprised of several molecules and subcellular structures that confer its unique 
properties, the most important of which are: 
• Complex junctions in the BBB are formed by TJs and adherens junctions. Tight junctions 
are sites of apparent fusion between leaflets of the plasma membranes of adjacent cells, 
whereas adherens junctions are composed of cadherin-catenin complexes and their 
associated proteins (Matter & Balda, 2003). Cytoplasmic proteins link membrane 
proteins to actin, which is the principal protein of the cytoskeleton. 
• Tight-junction–associated membrane proteins, including occludins, claudins and 
junctional adhesion molecules (Furuse et al.; 1993; Martin-Pardura et al.; 1998; Morita et 
al.; 1999). These proteins form the extracellular component of TJs.  
• Cytoplasmic accessory proteins, including zonula occludens (ZO) proteins, cingulin 
and several others (Itoh et al.; 1999). Actin binds to ZO proteins, thereby providing 
structural support to the endothelial cells (Haskins et al.; 1998). 
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Dysfunction of the BBB exacerbates a number of neurologic diseases, including stroke and 
neuroinflammatory disorders. Under pathological conditions, different chemical mediators 
that increase BBB permeability are released. Among these mediators are glutamate, 
aspartate, taurine, ATP, endothelin-I, tumor necrosis factor (TNF)-α and interleukin-1β  
(IL-1β), all of which are produced by astrocytes (Kutsova et al.; 1999; Abbot 2000; 2002). 
Moreover, endothelial cells can release bradykinin, 5-HT, histamine, substance P, platelet 
activating factor and free radicals (Abbot, 2002; St’astný et al.; 2000). 
The function of the BBB is to control the traffic of substances between the blood and the 
brain. This is achieved in three ways: 
• Diffusion of lipid-soluble substances. The BBB permits the rapid exchange of lipid-
soluble gases such as O2 and CO2, an exchange that is limited only by the surface area of 
the blood vessel and cerebral blood flow. Barrier vessels are impermeable to molecules 
that are poorly soluble in lipids. The permeability coefficient of the BBB for many 
substances is directly proportional to the lipid solubility of the substance, which is 
measured as its oil-water partition coefficient (Laterra & Goldstein, 2000). 
• Facilitated and energy-dependent receptor-mediated transport of specific water-soluble 
substances. Most substances that must cross the BBB are not lipid soluble and therefore 
need a specific carrier-mediated transport system. One of the most important 
substances is glucose, which is transported by the glucose transporter isotype-1, or 
Glut1 (Guerin et al.; 1999). Amino acids are also transported by three distinct carrier 
systems. Another transport system is related to the multidrug resistance to 
chemotherapy (MDR) transporter (Schinkel et al.; 1994).  
• Ion channels. Various studies support the existence of a nonselective luminal ion 
channel that is inhibited by both amiloride and atrial natriuretic peptide. The existence 
of luminal Na+/H+ and Cl-/HCO3- exchangers has also been suggested. The external 
membrane of brain endothelial cells contains a relatively high density of Na+/K+-
ATPase pump. In conjunction with K+ channels in astrocytes, this abluminal endothelial 
pump may play an important role in removing extracellular K+ that is released during 
intense neuronal activity. In addition, the nonselective luminal ion channel, a distinct 
abluminal K+ channel and the abluminal Na+/K+-ATPase may work together to tightly 
regulate the entry of Na+ and the release or recycling of K+ (Haydon & Carmignoto, 
2006). Aquaporin-4 is the major water channel expressed in brain perivascular 
astrocytic processes and is the principal system for regulating the traffic of water 
between the brain and blood. Thus, its role in cerebral edema is very important.  
4. The role of astrocytes in epileptogenesis 
Until recently, little was known regarding the process by which a normal brain becomes 
epileptic following an external or internal insult, for example following traumatic brain 
injury or seizures that are induced by fever or infectious disease. These symptomatic 
epilepsies account for a significant number of patients; however, for patients with idiopathic 
or cryptogenic epilepsy, the antecedents remain unknown. In general, except for well-
defined etiologies (e.g.; cortical dysplasia), the brain’s transition from normal to epileptic—
namely, epileptogenesis—remains obscure. 
However, several lines of evidence involving astrocytes have begun to emerge during the 
last decade, providing a somewhat coherent framework. These lines of evidence can be 
grouped according to the different structures that are involved. 
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4.1 Modification of astrocyte membrane proteins 
Diverse changes have been described for the expression of intrinsic plasma membrane 
proteins in astrocytes at the epileptic seizure foci. 
In sclerotic hippocampi, reactive astrocytes express mGluR2/3, mGluR4 and mGluR8. 
Similarly, mGluR3, mGluR5 and mGluR8 are up-regulated in the hippocampus in 
experimental animal models of TLE. Activation of these receptors may lead to an increase in 
[Ca2+]i and Ca2+ wave propagation, thereby leading to the release of glutamate from 
astrocytes (Volterra & Meldolesi, 2005). 
Using microdialysis, increased levels of in situ extracellular glutamate have been found in 
sclerotic seizure foci (During & Spencer, 1993; Cavus et al.; 2002). Moreover, the down-
regulation of EAAT1 and EAAT2 has also been reported (Proper et al.; 2002). However, other 
groups were unable to confirm this observation (Tessler et al.; 1998).  
In sclerotic astrocytes, the GABA transporter GAT3 is up-regulated. In the same vein, 
microdialysis in epileptic patients has revealed decreased levels of extracellular GABA in 
the epileptic foci during the ictal state (During & Spencer 1993). The increased expression of 
the transporter would help to reduce extracellular GABA levels, thereby decreasing 
inhibitory tone during the ictal state. 
Expression of the protein AQP4 is reduced on the perivascular membrane of the astrocyte in 
sclerotic hippocampi, whereas its expression is unchanged on the membrane that faces the 
neuropil. This change may cause a decrease in water extrusion from the neuropil to the 
vessel (Eid et al.; 2005). 
In addition to changes in the expression of transport proteins in epileptic foci, ion channels 
in astrocytes are also modified. Cultured astrocytes obtained from patient hippocampus and 
entorhinal cortex1 displayed much larger tetrodotoxin (TTX)-sensitive Na+ currents than 
astrocytes from non-sclerotic hippocampi (O’connor et al.; 1998). However, as with other 
results, there are discrepancies regarding the increased Na+ current (Hinterkeuser et al.; 
2000). Changes in the differential expression of calcium channels have been reported in the 
sclerotic hippocampus, but the functional significance of this change remains unclear (de 
Lanerolle et al.; 2010). 
Impaired K+ buffering has been detected in sclerotic patient hippocampi, suggesting that 
there are defective channels in the sclerotic region, particularly in CA1 (Gabriel et al.; 1998). 
The buffering of K+, which is likely performed by the GFAP+ subset of Glu-like astrocytes 
(and carried out by the Kir channels), depends on a parallel flux of water through the 
plasma membrane to avoid hyperosmolarity. Water molecules and K+ are taken up by the 
astrocytic membrane of the neuropil and pushed into the blood and cerebrospinal fluid 
(CSF) through the end-food pole. A loss of AQP4 would impede the movement of water and 
contribute to increased [K+]o. Concomitantly, the down-regulation of Kir4.1 channels during 
a critical time window has been described in a rat model of epilepsy (Ivens et al.; 2007), as 
we discuss in detail below. Clearly, this process can contribute to further increase the 
concentration of extracellular K+. 
4.2 Changes in genes expression and metabolism 
In the sclerotic hippocampus, changes in various enzymes that are involved in the 
metabolism of astrocytes and the interaction between astrocytes and neurons have been 
                                                                 
1The entorhinal cortex is part of the parahippocampal gyrus and is the main source of input to the 
hippocampus through the perforant pathway and the collaterals of the temporoammonic pathway. 
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described (Herrera-Peco et al.; 2008). In this regard, a loss of glutamine synthetase in CA1 
and CA3, an increase in the activity of glutamate dehydrogenase and/or a decrease in the 
activity of lactate dehydrogenase have all been reported. Besides, extracellular levels of 
lactate are elevated in the sclerotic hippocampus (de Lanerolle et al.; 2010). 
On the other hand, several astrocyte-related genes are up-regulated in sclerotic regions. 
These changes in the pattern of gene expression are consistent with increased gliosis or 
immune and inflammatory responses (Lee et al.; 2007). This is discussed in detail below. 
It is likely that much of these changes are a consequence of epilepsy rather than a cause. 
Therefore, more data are needed before we can formulate an exact picture of the genetic 
changes that are related to epileptogenesis. 
4.3 Changes in BBB permeability 
It has long been recognized that there is a proliferation of the microvasculature in the sclerotic 
hippocampus, an observation that has been recently confirmed (Rigau et al.; 2007). However, 
on the contrary, there are recent reports showing a significant loss of microvessels in the CA1 
region of sclerotic hippocampi (Kastanauskaite et al.; 2009). In any case, most groups agree on 
the presence of blood vessel changes in TLE-associated hippocampal sclerosis.  
Several molecules that are located in the perivascular end-feet exhibit changes in sclerotic 
regions. AQP4 and dystrophin are reduced, whereas CD44 and plectin 1 are increased. 
Other molecules such as the chemokines CCL2 and CCL3 are up-regulated, as are the 
chemokine receptors CCR1 and CCR2 (de Lanerolle, 2010).  
It is believed that these glial-derived chemokines can guide circulating leukocytes through 
endothelial junctions and into the brain’s extracellular space. These chemokines can also help 
mediate the extravasation of albumin (de Lanerolle et al.; 2010). Therefore, these changes can 
alter the permeability of the BBB, thereby allowing molecules that normally are excluded to 
access the brain. Indeed, it has been shown that the BBB is leakier during seizures (de 
Lanerolle et al.; 2010). Furthermore, immunohistochemical localization of albumin in resected 
hippocampi from TLE patients showed strong albumin immunoreactivity in the parenchyma 
throughout the hippocampus next to the blood vessels. Neurons and astrocytes located 
around the vessels were also albumin-positive, thus demonstrating an increase in BBB 
permeability. Such extravasations of albumin were not observed in control hippocampi (van 
Vliet et al.; 2007). In an animal model, the extravasation of serum albumin to the brain’s 
extracellular space was associated with a prominent activation of astrocytes, but no 
inflammatory response or marked cell loss. This activation was associated with the 
development of epileptiform discharges within 4–7 days (Seiffert et al.; 2004).  
Changes other than permeability have been reported in the BBB. The erythropoietin receptor 
is strongly expressed in the capillaries of sclerotic hippocampi, which suggests an increased 
uptake of erythropoietin into the hippocampus (Eid et al.; 2004). 
4.4 Inflammatory and immune responses in the brain 
Astrocytes contribute to the inflammatory response in the CNS. Glial cells can produce a 
range of immunologically relevant molecules, including class II major histocompatibility 
complex antigens, cytokines and chemokines. Studies have shown that glial cells—including 
both astrocytes and microglia—express high levels of pro-inflammatory cytokines in regions 
that are recruited in the generation and propagation of seizures. In astrocytes and microglia 
of patients with TLE and hippocampal sclerosis, the IL-1β system is activated, particularly in 
end-feet perivascular regions and in endothelial cells in sclerotic brain regions (Ravizza et 
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al.; 2007). These changes can affect the permeability of the BBB, perhaps by disrupting tight-
junction organization (Del Machio et al.; 1996). It has been showed that IL-1β has a pro-
ictogenic role that is mediated by the receptor IL-1R1 (Vezzani et al.; 2002). Exposure to IL-
1β or TNF-α exacerbates the excitotoxic neuronal damage that is induced by NMDA or 
AMPA, thus suggesting that cell survival depends on the tissue concentration and duration 
of action of cytokines. This deleterious effect is mediated by the induction of toxic mediators 
to affect neuronal excitability. 
The damage in the brain that is induced by IL-1β can be mediated by an increase in the 
function of NMDA receptors or by an increase in extracellular glutamate. In this sense, IL-1β 
increases NMDA-mediated Ca2+ influx into neurons, thereby promoting excitotoxicity 
(Vezzani et al.; 2008). Other well-established mechanisms include the inhibition of 
glutamate uptake by glial cells and an increase in glutamate release via TNF-α production 
(Bezzi et al.; 2001). Additionally, IL-1β activates nitric oxide (NO) synthase, increasing the 
glutamate release. Presumably, all of these mechanisms lead to increased glutamatergic 
transmission and toxicity. However, GABAergic transmission is also affected by 
inflammation. Indeed, IL-1β has been shown to inhibit GABAA receptors, thereby 
contributing to hyperexcitability (Wang et al.; 2000). 
Other cytokines that are produced by glial cells—such as IL-6, TNF-α and prostaglandins—
have been shown to have either pro-ictogenic or inhibitory effects on seizures in a 
concentration-dependent manner, and this depends on the type of receptors involved and 
the origin of the cells (Vezzani et al.; 2008). It has been reported that TNF-α activates the 
rapid recruitment AMPA receptors that lack the GluR2 subunit to the neuronal membrane; 
this molecular conformation is permissive for Ca2+ influx, thereby increasing neurotoxicity. 
Moreover, in the sclerotic hippocampus, there is an up-regulation of the p65 subunit of the 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) (Crespel et al.; 2002), 
a protein complex that control DNA transcription and is involved in the cellular responses 
to stress. In the sclerotic hippocampus, immunoreactivity of complement proteins was 
increased in regions of neuronal loss (including CA1, CA3 and the hylus of the dentate 
gyrus). All of these data imply a direct participation of the inflammatory pathway in 
epilepsy. 
4.5 The participation of albumin in the activation of astrocytes 
Albumin is usually not in contact with astrocytes or neurons. Indeed, its concentration in the 
extracellular space of the CNS (∼35 ng/ml) is three orders of magnitude lower than in blood 
(Nadal et al.; 2001). The effect of albumin on glial cells depends on both the protein itself 
and the lipids to which it is attached (Nadal et al.; 1995; 1997). 
Recently, it was elegantly demonstrated in rats that albumin can act directly on astrocytes, 
thereby facilitating epileptogenesis (Seiffert et al.; 2004, Ivens et al.; 2007; Van Vliet et al.; 
2007). It has been shown that direct brain exposure to serum albumin is associated with 
albumin uptake into astrocytes that is mediated by TGF-βR. This uptake is followed by the 
down-regulation of Kir4.1 channels in astrocytes, which results in reduced buffering of 
extracellular potassium. This in turn leads to an increased activity-dependent accumulation 
of extracellular potassium, which results in facilitated NMDAR–mediated neuronal 
hyperexcitability and ultimately epileptiform activity (Ivens et al.; 2007). Presumably, these 
effects are mediated by GFAP+/GluT astrocytes. On the other hand, albumin can act on 
NG2/GluR astrocytes; in these cells, TGF-βR can induce the transcription factor NF-κB, 
which can modify the expression of cyclooxygenase 2 (COX-2).  
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described (Herrera-Peco et al.; 2008). In this regard, a loss of glutamine synthetase in CA1 
and CA3, an increase in the activity of glutamate dehydrogenase and/or a decrease in the 
activity of lactate dehydrogenase have all been reported. Besides, extracellular levels of 
lactate are elevated in the sclerotic hippocampus (de Lanerolle et al.; 2010). 
On the other hand, several astrocyte-related genes are up-regulated in sclerotic regions. 
These changes in the pattern of gene expression are consistent with increased gliosis or 
immune and inflammatory responses (Lee et al.; 2007). This is discussed in detail below. 
It is likely that much of these changes are a consequence of epilepsy rather than a cause. 
Therefore, more data are needed before we can formulate an exact picture of the genetic 
changes that are related to epileptogenesis. 
4.3 Changes in BBB permeability 
It has long been recognized that there is a proliferation of the microvasculature in the sclerotic 
hippocampus, an observation that has been recently confirmed (Rigau et al.; 2007). However, 
on the contrary, there are recent reports showing a significant loss of microvessels in the CA1 
region of sclerotic hippocampi (Kastanauskaite et al.; 2009). In any case, most groups agree on 
the presence of blood vessel changes in TLE-associated hippocampal sclerosis.  
Several molecules that are located in the perivascular end-feet exhibit changes in sclerotic 
regions. AQP4 and dystrophin are reduced, whereas CD44 and plectin 1 are increased. 
Other molecules such as the chemokines CCL2 and CCL3 are up-regulated, as are the 
chemokine receptors CCR1 and CCR2 (de Lanerolle, 2010).  
It is believed that these glial-derived chemokines can guide circulating leukocytes through 
endothelial junctions and into the brain’s extracellular space. These chemokines can also help 
mediate the extravasation of albumin (de Lanerolle et al.; 2010). Therefore, these changes can 
alter the permeability of the BBB, thereby allowing molecules that normally are excluded to 
access the brain. Indeed, it has been shown that the BBB is leakier during seizures (de 
Lanerolle et al.; 2010). Furthermore, immunohistochemical localization of albumin in resected 
hippocampi from TLE patients showed strong albumin immunoreactivity in the parenchyma 
throughout the hippocampus next to the blood vessels. Neurons and astrocytes located 
around the vessels were also albumin-positive, thus demonstrating an increase in BBB 
permeability. Such extravasations of albumin were not observed in control hippocampi (van 
Vliet et al.; 2007). In an animal model, the extravasation of serum albumin to the brain’s 
extracellular space was associated with a prominent activation of astrocytes, but no 
inflammatory response or marked cell loss. This activation was associated with the 
development of epileptiform discharges within 4–7 days (Seiffert et al.; 2004).  
Changes other than permeability have been reported in the BBB. The erythropoietin receptor 
is strongly expressed in the capillaries of sclerotic hippocampi, which suggests an increased 
uptake of erythropoietin into the hippocampus (Eid et al.; 2004). 
4.4 Inflammatory and immune responses in the brain 
Astrocytes contribute to the inflammatory response in the CNS. Glial cells can produce a 
range of immunologically relevant molecules, including class II major histocompatibility 
complex antigens, cytokines and chemokines. Studies have shown that glial cells—including 
both astrocytes and microglia—express high levels of pro-inflammatory cytokines in regions 
that are recruited in the generation and propagation of seizures. In astrocytes and microglia 
of patients with TLE and hippocampal sclerosis, the IL-1β system is activated, particularly in 
end-feet perivascular regions and in endothelial cells in sclerotic brain regions (Ravizza et 
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al.; 2007). These changes can affect the permeability of the BBB, perhaps by disrupting tight-
junction organization (Del Machio et al.; 1996). It has been showed that IL-1β has a pro-
ictogenic role that is mediated by the receptor IL-1R1 (Vezzani et al.; 2002). Exposure to IL-
1β or TNF-α exacerbates the excitotoxic neuronal damage that is induced by NMDA or 
AMPA, thus suggesting that cell survival depends on the tissue concentration and duration 
of action of cytokines. This deleterious effect is mediated by the induction of toxic mediators 
to affect neuronal excitability. 
The damage in the brain that is induced by IL-1β can be mediated by an increase in the 
function of NMDA receptors or by an increase in extracellular glutamate. In this sense, IL-1β 
increases NMDA-mediated Ca2+ influx into neurons, thereby promoting excitotoxicity 
(Vezzani et al.; 2008). Other well-established mechanisms include the inhibition of 
glutamate uptake by glial cells and an increase in glutamate release via TNF-α production 
(Bezzi et al.; 2001). Additionally, IL-1β activates nitric oxide (NO) synthase, increasing the 
glutamate release. Presumably, all of these mechanisms lead to increased glutamatergic 
transmission and toxicity. However, GABAergic transmission is also affected by 
inflammation. Indeed, IL-1β has been shown to inhibit GABAA receptors, thereby 
contributing to hyperexcitability (Wang et al.; 2000). 
Other cytokines that are produced by glial cells—such as IL-6, TNF-α and prostaglandins—
have been shown to have either pro-ictogenic or inhibitory effects on seizures in a 
concentration-dependent manner, and this depends on the type of receptors involved and 
the origin of the cells (Vezzani et al.; 2008). It has been reported that TNF-α activates the 
rapid recruitment AMPA receptors that lack the GluR2 subunit to the neuronal membrane; 
this molecular conformation is permissive for Ca2+ influx, thereby increasing neurotoxicity. 
Moreover, in the sclerotic hippocampus, there is an up-regulation of the p65 subunit of the 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) (Crespel et al.; 2002), 
a protein complex that control DNA transcription and is involved in the cellular responses 
to stress. In the sclerotic hippocampus, immunoreactivity of complement proteins was 
increased in regions of neuronal loss (including CA1, CA3 and the hylus of the dentate 
gyrus). All of these data imply a direct participation of the inflammatory pathway in 
epilepsy. 
4.5 The participation of albumin in the activation of astrocytes 
Albumin is usually not in contact with astrocytes or neurons. Indeed, its concentration in the 
extracellular space of the CNS (∼35 ng/ml) is three orders of magnitude lower than in blood 
(Nadal et al.; 2001). The effect of albumin on glial cells depends on both the protein itself 
and the lipids to which it is attached (Nadal et al.; 1995; 1997). 
Recently, it was elegantly demonstrated in rats that albumin can act directly on astrocytes, 
thereby facilitating epileptogenesis (Seiffert et al.; 2004, Ivens et al.; 2007; Van Vliet et al.; 
2007). It has been shown that direct brain exposure to serum albumin is associated with 
albumin uptake into astrocytes that is mediated by TGF-βR. This uptake is followed by the 
down-regulation of Kir4.1 channels in astrocytes, which results in reduced buffering of 
extracellular potassium. This in turn leads to an increased activity-dependent accumulation 
of extracellular potassium, which results in facilitated NMDAR–mediated neuronal 
hyperexcitability and ultimately epileptiform activity (Ivens et al.; 2007). Presumably, these 
effects are mediated by GFAP+/GluT astrocytes. On the other hand, albumin can act on 
NG2/GluR astrocytes; in these cells, TGF-βR can induce the transcription factor NF-κB, 
which can modify the expression of cyclooxygenase 2 (COX-2).  
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However, albumin can act on astrocytes through a pathway that is distinct from TGF-βR. 
This pathway has not been extensively explored; however, changes in [Ca2+]i can induce 
new DNA synthesis in cultured astrocytes (Pastor et al.; 2010). It is therefore reasonable to 
speculate that changes in gene expression that are observed during epileptogenesis in rats 
are induced by the calcium-dependent pathway and not only through the action of TGF-βR. 
4.6 The role of adenosine kinase in epileptogenesis 
Inhibitory neuromodulation by adenosine is primarily mediated by the activation of A1 
receptors that are coupled to inhibitory Gi and Go G-proteins. As a result, the release of 
glutamate and others neurotransmitters is inhibited. In addition, A1 receptor activation can 
decrease brain metabolism and alter astrocytic function, thereby conferring beneficial effects 
(Haberg et al.; 2000; van Claker & Biber, 2005). In contrast to A1 receptors, A2A receptors are 
coupled to excitatory Gs and Golf G-proteins and both excitatory and inhibitory responses 
have been reported (Boison, 2008). The activity of this type of receptor is restricted to active 
synapses. Stimulating nerve terminals at a high frequency can release ATP, which can be 
degraded to adenosine, which in turn acts by binding to A2A receptors. Subsequent 
activation of A2A can lead to the down-regulation of A1 receptors. With respect to the low-
affinity A2B and low-density A3 receptors, it appears that these receptors may only be 
relevant under pathological conditions, for example following traumatic brain injury or 
during cerebral ischemia (Pearson et al.; 2006). In summary, the extracellular level of 
adenosine has an important role in seizure threshold. 
Astrocytes play a key role in regulating the levels of extracellular adenosine (Boison 2006; 
Haydon & Carmignoto, 2006); this is presumably via an adenosine cycle that involves the 
vesicular release of ATP, extracellular degradation to adenosine, uptake of adenosine via 
nucleoside transporters and intracellular phosphorylation of AMP (Boison, 2008). It is 
known that astrocytes are the primary source of ATP under physiological conditions, thus 
favoring a relative tone of inhibition within the neural network. 
Extracellular levels of adenosine can be regulated by reuptake through nucleoside 
transporters, which can be divided into three isoforms of concentrative nucleoside 
transporters (CNT1, 2 and 3) that are coupled to the Na+ gradient and into four isoforms of 
equilibrative nucleoside transporters (ENT1 through ENT4) (Smith et al.; 2007). Under 
physiological conditions, ENTs appear to play a central role in controlling the extracellular 
level of adenosine in the brain. 
Once adenosine is transported into the astrocyte, it is phosphorylated by adenosine kinase 
(ADK), an enzyme that is almost exclusively expressed in these glial cells in the adult brain 
(Studer et al.; 2006).  
Adenosine kinase has a biphasic response to stress after a brain injury (Boison, 2008): 
• First, ADK is rapidly down-regulated, leading to an elevated level of adenosine. This 
enhancement serves as a protective factor via the activation of A1 receptors. This 
increase in extracellular adenosine might be a general astrocyte-based mechanism to 
protect the brain after stroke, ischemia, status epilepticus, or a similar condition. 
• In the second phase, there is an up-regulation of ADK that leads to a significant 
decrease in the level of extracellular adenosine, thereby reducing the tone of the A1 
receptors. This up-regulation of ADK is accompanied by parallel changes in G-protein–
coupled receptors, for example, down-regulation of A2 receptors or increased 
expression of GABAB receptors. 
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It has been shown that increased levels of adenosine may induce or trigger astrogliosis by 
effect that appears to be largely mediated by A2A receptors. Thus, activation of this receptor 
type potentiates the synaptic action of brain-derived neurotrophic factor (BDNF) in the 
hippocampus (Diogenes et al.; 2007), stimulates glutamate outflow and leads to excessive 
glial activation, ultimately inducing astrocytosis. Indeed, it has been shown that stimulating 
A2A receptors during brain injury (e.g.; hypoxia or inflammation) directly leads to gliosis 
(Cunha, 2005). Thus, it can be stated that astrogliosis is a consequence of acute ADK down-
regulation. This state can be chronically maintained, allowing the development and 
persistence of chronic epilepsy and ultimately drug resistance. In summary, a common 
consequence of brain injury is astrogliosis, which can be considered the most prominent 
astroglial response to CNS damage (Pekny & Nilsson, 2005) and a hallmark of the epileptic 
brain, being present in up to 90% of surgically resected hippocampi (Thom et al.; 2002), and 
it has been proposed to be an important factor both in the development of seizures and in 
the persistency of seizure disorders. Moreover, neuronal cell loss and astrogliosis can 
propagate to other parts of the limbic system, including the amygdala and perirhinal cortex 
(Wieser, 2004). However, this causal relationship between astrogliosis, ADK up-regulation 
and epilepsy was recently discussed. A recent report presented evidence that the global 
expression levels of ADK are more closely related to epilepsy than to astrogliosis, per se (Li 
et al.; 2008). 
4.7 A global portrait of the process 
All of these data can be summarized as follows. Various types of injury, including bleeding, 
ischemia, infectious disease and traumatic injury, can alter the permeability of the BBB. In 
inflammatory or infectious disease, activation of leukocytes can induce the release of 
chemokines, thereby changing permeability. In other cases (for example, after brain trauma), 
the anatomical dysfunction of capillaries is the first step. As a consequence, albumin, which 
is physiologically excluded from the brain, might efflux from the vessels. In the processes 
that are associated with coagulation (e.g.; intracranial bleeding), albumin can bind to LPA or 
other platelet-derived lipids. However, at least in the initial steps, other processes such as 
mechanical disruption of the BBB are not associated with coagulation; in this case, albumin 
would not need to be attached to lipids that are produced after platelet activation. As a 
consequence of BBB breakdown, albumin will enter the extracellular space of the brain, 
where it can interact with cells that normally do not have contact. The interaction with 
NG2/GluR astrocytes will modify the expression of COX2 and subsequently PGE2, thereby 
inducing glutamate release through a Ca2+-dependent mechanism. NG2 cells are present 
and accumulate in the sclerotic hippocampus. Neuronal activity, however, can depolarize 
NG2 cells, thereby allowing the influx of Ca2+, thereby increasing [Ca2+]i and glutamate 
release. Thus, it has been suggested that the presence of NG2/GluR cells in the sclerotic 
hippocampus can help to increase excitability and/or facilitate the propagation of a 
depolarization wave. 
On the other hand, albumin will bind to either TGF-βR or albumin receptors in 
GFAP+/GluT astrocytes. In the former case, albumin will be taken into the astrocyte and 
transported to the nucleus, where it will induce various modifications in gene expression. 
We can speculate, in the second case, that albumin acting through the albumin receptor will 
increase [Ca2+]i, which in turn would act as a second messenger in affecting gene expression, 
including down-regulation of AQP4 in the BBB lumen, glutamine synthetase and Kir4.1 
channels. As a consequence of these changes, extracellular glutamate and [K+]o would 
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However, albumin can act on astrocytes through a pathway that is distinct from TGF-βR. 
This pathway has not been extensively explored; however, changes in [Ca2+]i can induce 
new DNA synthesis in cultured astrocytes (Pastor et al.; 2010). It is therefore reasonable to 
speculate that changes in gene expression that are observed during epileptogenesis in rats 
are induced by the calcium-dependent pathway and not only through the action of TGF-βR. 
4.6 The role of adenosine kinase in epileptogenesis 
Inhibitory neuromodulation by adenosine is primarily mediated by the activation of A1 
receptors that are coupled to inhibitory Gi and Go G-proteins. As a result, the release of 
glutamate and others neurotransmitters is inhibited. In addition, A1 receptor activation can 
decrease brain metabolism and alter astrocytic function, thereby conferring beneficial effects 
(Haberg et al.; 2000; van Claker & Biber, 2005). In contrast to A1 receptors, A2A receptors are 
coupled to excitatory Gs and Golf G-proteins and both excitatory and inhibitory responses 
have been reported (Boison, 2008). The activity of this type of receptor is restricted to active 
synapses. Stimulating nerve terminals at a high frequency can release ATP, which can be 
degraded to adenosine, which in turn acts by binding to A2A receptors. Subsequent 
activation of A2A can lead to the down-regulation of A1 receptors. With respect to the low-
affinity A2B and low-density A3 receptors, it appears that these receptors may only be 
relevant under pathological conditions, for example following traumatic brain injury or 
during cerebral ischemia (Pearson et al.; 2006). In summary, the extracellular level of 
adenosine has an important role in seizure threshold. 
Astrocytes play a key role in regulating the levels of extracellular adenosine (Boison 2006; 
Haydon & Carmignoto, 2006); this is presumably via an adenosine cycle that involves the 
vesicular release of ATP, extracellular degradation to adenosine, uptake of adenosine via 
nucleoside transporters and intracellular phosphorylation of AMP (Boison, 2008). It is 
known that astrocytes are the primary source of ATP under physiological conditions, thus 
favoring a relative tone of inhibition within the neural network. 
Extracellular levels of adenosine can be regulated by reuptake through nucleoside 
transporters, which can be divided into three isoforms of concentrative nucleoside 
transporters (CNT1, 2 and 3) that are coupled to the Na+ gradient and into four isoforms of 
equilibrative nucleoside transporters (ENT1 through ENT4) (Smith et al.; 2007). Under 
physiological conditions, ENTs appear to play a central role in controlling the extracellular 
level of adenosine in the brain. 
Once adenosine is transported into the astrocyte, it is phosphorylated by adenosine kinase 
(ADK), an enzyme that is almost exclusively expressed in these glial cells in the adult brain 
(Studer et al.; 2006).  
Adenosine kinase has a biphasic response to stress after a brain injury (Boison, 2008): 
• First, ADK is rapidly down-regulated, leading to an elevated level of adenosine. This 
enhancement serves as a protective factor via the activation of A1 receptors. This 
increase in extracellular adenosine might be a general astrocyte-based mechanism to 
protect the brain after stroke, ischemia, status epilepticus, or a similar condition. 
• In the second phase, there is an up-regulation of ADK that leads to a significant 
decrease in the level of extracellular adenosine, thereby reducing the tone of the A1 
receptors. This up-regulation of ADK is accompanied by parallel changes in G-protein–
coupled receptors, for example, down-regulation of A2 receptors or increased 
expression of GABAB receptors. 
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It has been shown that increased levels of adenosine may induce or trigger astrogliosis by 
effect that appears to be largely mediated by A2A receptors. Thus, activation of this receptor 
type potentiates the synaptic action of brain-derived neurotrophic factor (BDNF) in the 
hippocampus (Diogenes et al.; 2007), stimulates glutamate outflow and leads to excessive 
glial activation, ultimately inducing astrocytosis. Indeed, it has been shown that stimulating 
A2A receptors during brain injury (e.g.; hypoxia or inflammation) directly leads to gliosis 
(Cunha, 2005). Thus, it can be stated that astrogliosis is a consequence of acute ADK down-
regulation. This state can be chronically maintained, allowing the development and 
persistence of chronic epilepsy and ultimately drug resistance. In summary, a common 
consequence of brain injury is astrogliosis, which can be considered the most prominent 
astroglial response to CNS damage (Pekny & Nilsson, 2005) and a hallmark of the epileptic 
brain, being present in up to 90% of surgically resected hippocampi (Thom et al.; 2002), and 
it has been proposed to be an important factor both in the development of seizures and in 
the persistency of seizure disorders. Moreover, neuronal cell loss and astrogliosis can 
propagate to other parts of the limbic system, including the amygdala and perirhinal cortex 
(Wieser, 2004). However, this causal relationship between astrogliosis, ADK up-regulation 
and epilepsy was recently discussed. A recent report presented evidence that the global 
expression levels of ADK are more closely related to epilepsy than to astrogliosis, per se (Li 
et al.; 2008). 
4.7 A global portrait of the process 
All of these data can be summarized as follows. Various types of injury, including bleeding, 
ischemia, infectious disease and traumatic injury, can alter the permeability of the BBB. In 
inflammatory or infectious disease, activation of leukocytes can induce the release of 
chemokines, thereby changing permeability. In other cases (for example, after brain trauma), 
the anatomical dysfunction of capillaries is the first step. As a consequence, albumin, which 
is physiologically excluded from the brain, might efflux from the vessels. In the processes 
that are associated with coagulation (e.g.; intracranial bleeding), albumin can bind to LPA or 
other platelet-derived lipids. However, at least in the initial steps, other processes such as 
mechanical disruption of the BBB are not associated with coagulation; in this case, albumin 
would not need to be attached to lipids that are produced after platelet activation. As a 
consequence of BBB breakdown, albumin will enter the extracellular space of the brain, 
where it can interact with cells that normally do not have contact. The interaction with 
NG2/GluR astrocytes will modify the expression of COX2 and subsequently PGE2, thereby 
inducing glutamate release through a Ca2+-dependent mechanism. NG2 cells are present 
and accumulate in the sclerotic hippocampus. Neuronal activity, however, can depolarize 
NG2 cells, thereby allowing the influx of Ca2+, thereby increasing [Ca2+]i and glutamate 
release. Thus, it has been suggested that the presence of NG2/GluR cells in the sclerotic 
hippocampus can help to increase excitability and/or facilitate the propagation of a 
depolarization wave. 
On the other hand, albumin will bind to either TGF-βR or albumin receptors in 
GFAP+/GluT astrocytes. In the former case, albumin will be taken into the astrocyte and 
transported to the nucleus, where it will induce various modifications in gene expression. 
We can speculate, in the second case, that albumin acting through the albumin receptor will 
increase [Ca2+]i, which in turn would act as a second messenger in affecting gene expression, 
including down-regulation of AQP4 in the BBB lumen, glutamine synthetase and Kir4.1 
channels. As a consequence of these changes, extracellular glutamate and [K+]o would 
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increase These modifications in the external milieu will lead to changes in the excitability of 
neurons, presumably by modifying NMDA function. 
In addition to changing extracellular albumin concentration, the primary injury can lead 
to a general protective reaction that consists of ADK down-regulation. If the injure is not 
too severe, general homeostatic mechanisms might control and reverse this process. 
However, if the damage is severe enough, the down-regulation will be followed by an up-
regulation of ADK, thereby decreasing the anticonvulsant effect of adenosine and 
triggering the appearance of astrogliosis, followed by recurrent seizures and resistance to 
drugs. 
5. Discussion and conclusions 
We have revisited some diverse aspects related to epilepsy and astrocytes, including 
changes in gene expression patterns, integral membrane proteins and vasculature 
permeability in the brain. Presently, one cannot be certain which of these changes are causal 
or consequential to the epileptic process is. However, there cannot be doubt with regard to 
the participation of these changes in the disease.  
The ultimate cause of epilepsy is most likely multifactorial and is both intrinsic (e.g.; 
genetics) and extrinsic (e.g.; stroke, inflammation, infection); however, for the first time we 
can now present an overview of many of the processes that lead from a normal brain to an 
epileptic brain. 
There can be no doubt that considering this process is extremely important. Properly 
understanding the process of epileptogenesis might lead to the development of new 
approaches directed at preventing the appearance of a first seizure or recurrent seizures 
after a window period, addressing the increased permeability in the BBB or the efflux of 
albumin into the brain and perhaps blocking of the astrocytes with agents directed against 
either the TGF-β or calcium-dependent pathway. In this same vein— but perhaps a bit more 
delayed in the therapy cascade—new pharmacological approaches for increasing the 
anticonvulsant effects of adenosine can be studied. 
However, therapeutics is not the only potential benefit of the emergence of this theory. 
Diagnosis can be improved by measuring the levels of molecules in the brain by PET or 
SPECT scanning. For example, the levels of adenosine or TGF-β receptors in patients may be 
measured in the future, which could be valuable in identifying the epileptic zone in patients 
who are being evaluated for epilepsy surgery. 
A large body of data has been gleaned from animal models. However, animal models and 
the human pathology are not exactly equivalent; therefore, most of these hypothesis must be 
tested in humans, where the actual illness occurs. It is important to keep this point in mind if 
we wish to provide relief to epileptic patients. In this sense, it has been shown in humans 
that cortical slowing is a typical finding after a mild traumatic brain injury, and this may be 
associated with persistently increased BBB permeability and a regional cerebral blood flow 
(rCBF) deficit (Korn et al.; 2005). 
The general portrait that has been outlined in this chapter likely raises as many questions as 
it answers. For example: 
• Is this model correct in human patients? Obviously, this is the most important question. 
Several lines of evidence suggest that this model— or a modified model—could be 
responsible for partial epilepsies in humans. However, this hypothesis needs to be 
demonstrated definitively. 
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• Is there any difference between plasma and serum albumin? It is likely that not all CNS 
injuries will be associated with coagulation. Therefore, it is important to discern which 
mechanism of astrocyte activation (TGF-βR or calcium-dependent) is acting in a given 
pathological condition. 
• Which of these pathways (TGF-βR or calcium-dependent), if any, act in humans? Do 
both pathways act in all epileptogenic processes, or do they act differentially depending 
on the etiology? 
• What is the role of astrogliosis in epilepsy? Is it merely a finding or a causal process? 
To summarize, we can affirm that astrocytes are undoubtedly very important players in the 
process of epileptogenesis, although their true role still needs to be completely uncovered. 
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increase These modifications in the external milieu will lead to changes in the excitability of 
neurons, presumably by modifying NMDA function. 
In addition to changing extracellular albumin concentration, the primary injury can lead 
to a general protective reaction that consists of ADK down-regulation. If the injure is not 
too severe, general homeostatic mechanisms might control and reverse this process. 
However, if the damage is severe enough, the down-regulation will be followed by an up-
regulation of ADK, thereby decreasing the anticonvulsant effect of adenosine and 
triggering the appearance of astrogliosis, followed by recurrent seizures and resistance to 
drugs. 
5. Discussion and conclusions 
We have revisited some diverse aspects related to epilepsy and astrocytes, including 
changes in gene expression patterns, integral membrane proteins and vasculature 
permeability in the brain. Presently, one cannot be certain which of these changes are causal 
or consequential to the epileptic process is. However, there cannot be doubt with regard to 
the participation of these changes in the disease.  
The ultimate cause of epilepsy is most likely multifactorial and is both intrinsic (e.g.; 
genetics) and extrinsic (e.g.; stroke, inflammation, infection); however, for the first time we 
can now present an overview of many of the processes that lead from a normal brain to an 
epileptic brain. 
There can be no doubt that considering this process is extremely important. Properly 
understanding the process of epileptogenesis might lead to the development of new 
approaches directed at preventing the appearance of a first seizure or recurrent seizures 
after a window period, addressing the increased permeability in the BBB or the efflux of 
albumin into the brain and perhaps blocking of the astrocytes with agents directed against 
either the TGF-β or calcium-dependent pathway. In this same vein— but perhaps a bit more 
delayed in the therapy cascade—new pharmacological approaches for increasing the 
anticonvulsant effects of adenosine can be studied. 
However, therapeutics is not the only potential benefit of the emergence of this theory. 
Diagnosis can be improved by measuring the levels of molecules in the brain by PET or 
SPECT scanning. For example, the levels of adenosine or TGF-β receptors in patients may be 
measured in the future, which could be valuable in identifying the epileptic zone in patients 
who are being evaluated for epilepsy surgery. 
A large body of data has been gleaned from animal models. However, animal models and 
the human pathology are not exactly equivalent; therefore, most of these hypothesis must be 
tested in humans, where the actual illness occurs. It is important to keep this point in mind if 
we wish to provide relief to epileptic patients. In this sense, it has been shown in humans 
that cortical slowing is a typical finding after a mild traumatic brain injury, and this may be 
associated with persistently increased BBB permeability and a regional cerebral blood flow 
(rCBF) deficit (Korn et al.; 2005). 
The general portrait that has been outlined in this chapter likely raises as many questions as 
it answers. For example: 
• Is this model correct in human patients? Obviously, this is the most important question. 
Several lines of evidence suggest that this model— or a modified model—could be 
responsible for partial epilepsies in humans. However, this hypothesis needs to be 
demonstrated definitively. 
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• Is there any difference between plasma and serum albumin? It is likely that not all CNS 
injuries will be associated with coagulation. Therefore, it is important to discern which 
mechanism of astrocyte activation (TGF-βR or calcium-dependent) is acting in a given 
pathological condition. 
• Which of these pathways (TGF-βR or calcium-dependent), if any, act in humans? Do 
both pathways act in all epileptogenic processes, or do they act differentially depending 
on the etiology? 
• What is the role of astrogliosis in epilepsy? Is it merely a finding or a causal process? 
To summarize, we can affirm that astrocytes are undoubtedly very important players in the 
process of epileptogenesis, although their true role still needs to be completely uncovered. 
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1. Introduction 
Epilepsy is a condition with seizures by abnormal, recurrent, and excessive discharges from 
neurons. Observations in experimental models of epilepsy are providing a better 
understanding of the mechanisms of seizure-induced excitotoxicity, neuroprotective 
responses and neurogenesis (Naegele, 2007). Excitotoxic neurodegeneration can be 
investigated in epilepsy models employing kainic acid or pilocarpine. Each model results in 
distinctive patterns of degeneration within the hippocampus through kainate subclass of 
glutamate receptors or cholinergic receptors, respectively. Kainic acid triggers neuronal 
injury directly by binding to kainate receptors on mossy fiber endings and on the principal 
neurons of the hippocampus. Pilocarpine causes cell death of a majority of the nonprincipal 
neurons of the hilus and CA1 pyramidal cells.  
Intensive researches have shown that some steroids display neuroprotective properties in 
various diseases including epilepsy (Wojtal et al., 2006; Biagini et al., 2010). The steroids can 
be classified into ‘neuroactive steroids’ and ‘neurosteroids’. The term ‘neuroactive steroids’ 
may be synthesized both in the nervous system and in the endocrine glands such as gonads, 
adrenal glands and placenta, and exert their effects on neural tissue. ‘Neurosteroids’, the 
concept derived from Baulieu (1997), are a family of steroid hormones including 
pregnenolone, dehydroepiandrosterone, progesterone and their derivatives. Neurosteroids 
are synthesized in the nervous system de novo from cholesterol and accumulated in the 
nervous system independently of classical steroidogenic gland secretion rates.  
Neurosteroids act in the nervous system in an autocrine/paracrine configuration (Plassart-
Schiees & Baulieu, 2001). They may regulate gene expression by binding to nuclear receptors 
or affect neurotransmission through action at membrane ion-gated and other neurotransmitter 
receptors. In addition, they affect neuronal growth, survival and differentiation, cause 
regression of neuritic extensions before they have established contact with other neurons or 
glia and protect neurons from death. Modulatory roles of neurosteroids include γ-amino-
butyric acid (GABA), N-methyl-D-aspartate, nicotinic/muscarinic cholinergic, serotonin, 
kainite and glycine receptor functions. 
Neuroprotective properties of neurosteroids have been revealed and gained particular 
attention in the treatment of diseases where neurodegeneration is predominant, including 
epilepsy (Naegele, 2007; Biagini et al., 2010). Seizures not only cause cell death, but also elicit 
neuroprotective responses in injured neurons and glia. Seizures trigger the release of 
neuroactive steroids that impair hippocampal neuron survival in excitotoxicity. Increased 
neurosteroid synthesis, presumably occurring in glial cells during epileptogenesis, delays 
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the appearance of recurrent spontaneous seizures in temporal lobe epilepsy. In this chapter, 
various molecules connected with neurosteroidogenesis are reviewed in order to provide 
further understanding on epilepsy.  
2. Neurosteroids and lipid/cholesterol 
Lipids have broad information carrying function in the central nervous system (CNS) as 
both ligands and substrates for proteins (Adibhatla & Hatcher, 2008). Lipid metabolism may 
be important for the CNS, as this organ has the highest concentration of lipids next to 
adipose tissue. The crucial role of lipids in tissue physiology and cell signaling is 
demonstrated by the many neurological disorders, and altered lipid metabolism is also 
believed to be a key event which contributes to CNS injuries. Lipids serve not only 
structural components of the cell membrane but also precursors for various second 
messengers. Especially, cholesterol is an important regulator of lipid organization and the 
precursor for steroid biosynthesis. 
The first step in the biosynthesis of neurosteroids is the conversion of cholesterol to 
pregnenolone (Wojtal et al., 2006; Biagini et al., 2010). This reaction is catalyzed by the 
cytochrome P450 cholesterol side-chain cleavage (p450scc) in successive chemical reactions. 
First and foremost, transport of cholesterol to the mitochondria is a prerequisite for 
neurosteroidogenesis. Cholesterol is not only needed for the growth and remodeling of 
neuronal and glial membranes, but also is an important regulator of lipid organization and the 
precursor for steroid biosynthesis (Adibhatla & Hatcher, 2008). The majority of cholesterol in 
the brain is derived from de novo synthesis in the neurons, astrocytes predominantly, and 
oligodendrocytes. Cholesterol is then secreted via transport molecules, taken up by lipoprotein 
receptors on neurons and internalized to the endosome/lysosome system. 
Cholesterol is transported to mitochondria by Niemann-Pick C1 (NPC1) protein where the 
neurosteroids are synthesized via the rate limiting intermediate, pregnenolone (Adibhatla & 
Hatcher, 2008). NPC1 protein is involved in transport of lipids, particularly cholesterol, from 
the late endosome/lysosome. Deficiency in the protein results in lysosomal accumulation of 
cholesterol and other lipids. Then, proteins located in the mitochondrial membranes, such as 
peripheral benzodiazepine receptor (PBR) and steroidogenic acute regulatory protein 
(StAR), allow cholesterol to cross the hydrophilic intermembrane space (Lavaque et al., 
2006). In the mitochondria, the neurosteroids are synthesized from the cholesterol via the 
rate limiting intermediate pregnenolone.  
Observations are providing a better understanding of the transport of cholesterol by NPC1, 
PBR or StAR (Adibhatla & Hatcher, 2008). Niemann-Pick disease type C is due to mutations 
in either the NPC1 or NPC2 genes, resulting in defective cholesterol transport and 
cholesterol accumulation. The PBR, which might function as a cholesterol channel, is 
essential for the delivery of cholesterol to the inner mitochondrial membrane and the 
synthesis of steroids. However, it should be noted that these molecules are not the only 
molecules implicated in the metabolism of cholesterol and little attention has been paid to 
StAR-related lipid transfer (START) domain-containing proteins (START proteins).  
3. START proteins 
START domain is an evolutionary conserved protein module of approximately 210 amino 
acids (Soccio & Breslow, 2003; Alpy & Tomasetto, 2005; Lavigne et al., 2010). START domain 
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is conserved through in plants and animals and serves as a versatile binding interface for 
lipids. The crystal structures of solved START domain reveal a conserved ‘helix-grip’ fold, 
in which a central antiparallel β-sheet is gripped by N-terminal and C-terminal α-helices, the 
latter being closely packed above the nine-strand curved β-sheet.  
In humans, START domains are found in 15 distinct proteins and can be classified by 6 
subfamilies (Table 1). Mammalian START proteins have diverse expression patterns and can 
be found free in the cytoplasm, attached to membranes or in the nucleus. START proteins 
implicate in intracellular lipid transport, lipid metabolism, and cell signaling events. 
Mutation or mis-expression of START proteins is linked to pathological processes, including 
genetic disorders, autoimmune diseases and cancer. Nevertheless, START proteins have not 
been extensively studied in the nervous system except 2 proteins, StAR and StarD6. 
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Table 1. Phylogenetic group and 15 human START proteins quoted from Alpy & Tomasetto 
(2005) with slight modification. BFIT, brown fat-inducible thioesterase; CACH, cytoplasmic 
acetyl-CoA hydrolase; CERT, Goodpasture-antigen-binding protein Δ 26; DLC, deleted in 
liver cancer; MLN64, metastatic lymph node 64; PCTP, phosphatidylchoine transfer protein; 
RhoGAP; Rho-GTPase-activating-protein-domain.  
3.1 Subcellular characteristics of StAR and StarD6 
StAR, the prototype of START proteins, is first characterized in murine MA-10 Leydig 
tumor cells that luteinizing hormone induces the expression of StAR and ultimately results 
in increased synthesis of pregnenolone (Clark et al., 1994). Its function has been extensively 
studied in classical steroidogenic tissue such as adrenal gland and ovary, and it has been 
shown to be involved in the intramitochondrial trafficking of cholesterol (Stocco, 2001). In 
steroidogenic cells, StAR-mediated delivery of cholesterol to inner mitochondrial membrane 
is a hormonally regulated step and StAR expression is tightly regulated (Stocco, 2001; Stocco 
et al., 2005).  
StarD6 is originally reported in male germ cell–specific protein of StarD4 group of START 
proteins (Soccio et al., 2002; Gomes et al., 2005). It is immunolocalized only in the nuclei of 
germ cells, not in the interstitial cells of Leydig, and may have a pivotal role in 
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spermatogenesis rather than in steroidogenesis. StarD6 is detected in the nucleus of mature 
sperm cells, where it could interact with transcriptional machinery in a lipid-dependent 
manner. Since lipids play an important role in sperm capacitation and function, StarD6 might 
regulate lipid movement within the sperm cell membrane.  
StarD6 in the Leydig cells has also been reported under perinatal hypothyroidism while 
germ cell-specific immunoreactivity is delayed (Chang et al., 2007a), which means that 
StarD6 also might play a role in the steroidogenesis under certain conditions such as 
testosterone deficiency. In this context, StarD6 might interact with mitochondrial membranes 
just similar to that of StAR (Bose et al., 2008). StarD6 has a protease-sensitive C-terminus 
similar to that of StAR and exhibits a steroidogenic activity equal to StAR. Recently, this 
question is ascertained in the nervous system by morphometry (Chang et al., 2010). 
 
 
Fig. 1. Micrographs of StAR and StarD6 in cultured dopaminergic neurons (SK-N-SH cell 
line). StAR is localized in the cytoplasm (arrows) but StarD6 loses the localization in nucleus 
(open arrow) according to maturation. Original magnification X40. (quoted from Chang et 
al., 2010)  
Morphological aspects of StarD6 are significantly different from those of StAR in cultured 
neuronal and glial cells. Cultured cells are dopaminergic neuronal cells (SK-N-SH) and glioma 
cells, M059-K and M059-J, which M059-J lack DNA-dependent protein kinase (DNA-PK) 
activity while M059-J express normal levels of DNA-PK. StAR tends to localize in the 
cytoplasm but StarD6 showed a weak intensity in the nucleus according to neuronal 
maturation (Fig. 1), while both are immunolocalized in the nuclei as well as the cytoplasm in 
glioma cells. The number of StAR and StarD6 immunopositive cells is significantly different in 
SK-N-SH and M059-K and M059-J, respectively. Especially, the immunoreactivities of StarD6 
in glioma cells are considerably changed by the presence of DNA-PK, while there is no 
significance in StAR (Fig. 2). 
The morphometric results with StarD6 in glioma cells have meaning, since oxidative DNA 
damage by excitotoxicity may activate DNA repair proteins in affected neurons (Naegele, 
2007). The number of StarD6 is significantly decreased in the glioma cell line which lacks 
DNA-PK activity. DNA-PK plays a role in nonhomologous end joining (NHEJ) against DNA 
damage, which comprises of catalytic subunit of the DNA-PK (DNA-PKcs), Ku70, and Ku80 
(Martin, 2008). NHEJ system is activated by severe forms of DNA damage, DNA double-
stand breaks. Increasing evidences implicate DNA-PK in neuroprotective properties. 
Experimental DNA-PK null mice show increased excitotoxicity and result in augmented 
StAR StarD6 
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apoptosis (Culmsee et al., 2001; Neema et al., 2005). It suggests that the activity of StarD6 in 
the nucleus might depend on the DNA repair system in preventing DNA damage.  
 
 
Fig. 2. Histographs of StAR and StarD6 in cultured glioma cell lines. M059-J cells lack DNA-
dependent protein kinase (DNA-PK) activity, while M059-K cells express normal levels of 
DNA-PK (acquired from American Type Culture Collection, ATCC, Rockville, MD, USA). 
The number of immunopositive cells was significantly different by StAR or StarD6 in the 
M059-K and M059-J, respectively (*p<0.05). Unlike StAR, the immunoreactivities of StarD6 
were considerably changed by the presence of DNA-PK (§p<0.05), and it was also 
demonstrated by Western blot analysis. Data are quoted from Chang et al., 2010 (left) and 
unpublished data (right). 
3.2 Distribution of StAR and StarD6 in the nervous system 
StAR appears to be widely distributed throughout the brain, although different levels of 
expression have been detected between different brain areas including human (Furukawa et 
al., 1998; King et al., 2002; Sierra et al., 2003; Sierra, 2004; Lavaque et al., 2006). High levels of 
StAR mRNA expression have been detected in the cerebral cortex, hippocampus proper, 
dentate gyrus, olfactory bulb, and cerebellar cortex. In general, there is a good agreement 
between those from in situ mRNA localization and data from immunohistochemical studies. 
This may implicate that steroidogenesis is a generalized process in the nervous system.  
StAR immunoreactivity has been detected in several neuronal populations, in ependymocytes 
and in some astrogial cells in the brain (Lavaque et al., 2006). StAR expression, however, seems 
to be restricted to very specific neuronal and astroglial populations in each brain area. Strong 
StAR immunoreactivity is observed in the soma of large neurons, which are characterized by 
high mitochondrial content. Although StAR is predominantly expressed by neurons in the 
CNS, astrocytes also express STAR and is known to synthesize neurosteroids from cholesterol.  
StAR may contribute to the regulation of cell proliferation in the nervous system, since steroids 
are known to affect neuronal and glial differentiation (Lavaque et al., 2006). Important changes 
in the pattern and/or level of expression of StAR occur in different brain areas during 
postnatal development (Kim et al., 2002; Sierra et al., 2003). For instance, in the cerebellar 
cortex Purkinje cells express StAR as well as have an active steroidogenic activity, in particular 
during the developmental period (Tsutsui et al., 2003). Changes of StAR in the developing 
cerebellar cortex may therefore be related with the differentiation of Purkinje cells. Important 
changes in the expression of StAR occur as well during brain aging. In 24-month-old rats StAR 
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DNA-PK (acquired from American Type Culture Collection, ATCC, Rockville, MD, USA). 
The number of immunopositive cells was significantly different by StAR or StarD6 in the 
M059-K and M059-J, respectively (*p<0.05). Unlike StAR, the immunoreactivities of StarD6 
were considerably changed by the presence of DNA-PK (§p<0.05), and it was also 
demonstrated by Western blot analysis. Data are quoted from Chang et al., 2010 (left) and 
unpublished data (right). 
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immunoreactivity is increased in hippocampal and cortical neurons compared with young 
animals (Sierra et al., 2003), while decreased in the aged cerebellum (Lavaque et al., 2006). It is 
unknown what is the physiological significance of these changes in StAR expression in the 
brain and whether they are associated with differences in steroidogenesis. 
Furthermore, StAR is colocalized in the same neural cells with p450scc and with other 
steroidogenic enzymes (Furukawa et al., 1998; King et al., 2002). It may implicate that StAR 
as a transport protein may participate in neurosteroidogenesis in the CNS. Strikingly, no 
deficiency in brain function or structure was reported either in StAR knockout mice or in 
congenital adrenal hyperplasia patients (Sierra, 2004). The brain may have StAR-
independent mechanisms of mitochondrial cholesterol transport. It should be noted that 
other proteins that contain the START domain might be involved in steroidogenesis and 
that their regional patterns of expression in the brain remain to be determined.  
 
 StAR StarD6 
Cerebrum Neuron (layers V-VI) >>glia Neuron (layers V-VI) >glia 
Hippocampus 
   Cornu ammonis 
   Dentate gyrus 
 
Strata oriens/radiatum 




Cerebellum Purkinje cell (+) Purkinje cell (±) 
Table 2. Distribution of StAR and StarD6 in the nervous system. Although StAR and StarD6 
can be detected in neurons and glia, they are primarily immunolocalized in the neurons of 
rodents. Unlike the cerebral cortex, they have compensatory distribution in the 
hippocampus and cerebellum. (According to Furukawa et al., 1998; King et al., 2002; Sierra 
et al., 2003; Sierra, 2004; Chang et al., 2007b, 2009, 2010) 
Not much is known on the distribution, development and aging of StarD6 in the CNS  
(Table 2). StarD6 is seen in the cerebral cortex, cerebellum, hippocampus, spinal cord and 
dorsal root ganglia (Chang et al., 2007b, 2009), where the highest expression of StAR is 
reported (Sierra, 2004; Lavaque et al., 2006). Strong StarD6 immunoreactivity is observed in 
deeper layers of cerebral cortex, principal cell layers of hippocampus and substantia gelatinosa 
of spinal cord, but devoid in Purkinje cell layer of cerebellum and lower motor neurons of 
spinal cord. From morphological point of view StarD6 also immunolocalized in glial cells, but 
the characteristics are not determined properly.  
StarD6 immunolocalization was mainly restricted to the nucleus, but cytoplasmic 
immunostaining frequently appeared in the principal neurons of hippocampus and spinal 
cord. This subcellular localization pattern is a distinctive feature of StarD4 group (Alpy & 
Tomasetto, 2005; Soccio et al., 2005). But the characteristics of the immunostaining of the 
StarD6 in the cytoplasm and the nucleus remain largely undetermined. The existing data 
(Gomes et al., 2005; Chang et al., 2007a,2007b,2009,2010; unpublished data) are obtained 
with the rat-specific polyclonal anti-StarD6 antibody (raised from Dr. Soh’s laboratory, 
Chonnam National University, Republic of Korea), and it should be confirmed by the 
monoclonal antibody. 
3.3 Changes of StAR and StarD6 in epilepsy 
3.3.1 Generalized changes of StAR and StarD6 in epileptic hippocampus 
Neurosteroids can interact with various neurotransmitters (Joëls, 2009; Biagini et al., 2010). 
In particular, neurosteroids are well known to potentiate the actions of GABA via GABAA 
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receptors against stress. Neurosteroids not only facilitate inhibitory responses, but also 
reduce the slope of the field excitatory postsynaptic potential in the dentate gyrus toward 
more inhibition. Various neurotrophic factors, including hormones, alter cellular activity in 
all hippocampal subfields in a region-specific way (Joëls, 2009).  
StAR has been related to neuroprotection (Sierra et al., 2003; Sierra, 2004). StAR mRNA and 
protein levels are transitorily increased following excitotoxic brain injury induced by the 
administration of kainic acid (Sierra et al., 2003). A fast and transient increase in StAR 
mRNA levels in the hippocampus was detected in the first 12 hours after injury. This was 
accompanied by an increase in StAR immunoreactivity in granular and hilar hippocampal 
neurons in the first 12-24 hours after the administration of kainic acid. 
In addition, StAR immunostaining is more intense in neurons located in the strata oriens 
and radiatum of normal hippocampus. The pattern of distribution changed in the 
pilocarpine-induced epileptic hippocampus (Chang et al., 2010). StAR was immunolocalized 
in the stratum pyramidale as well as the strata oriens and radiatum 3 hours after pilocarpine 
treatment, while changed immunoreactivity in the dentate gyrus was not remarkable. But, 
the changes in distribution in the hippocampus proper did not discussed in kainic acid-
induced epilepsy model (Sierra et al., 2003).  
A strong increase in StAR immunoreactivity was observed in layers II and III of the 
pyriform cortex of kainic acid-injected animals (Sierra et al., 2003). However, in deeper 
cortical layers the cellular mortality was very high. Therefore, a large increment of StAR 
expression of hippocampal granular neurons after brain injury is especially resistant to the 
toxicity of kainic acid. The expression in dentate gyrus is related to neuroprotection in status 
epilepticus. Moreover, subgranular neurons have mitotic activity and increased StAR might 
affect on neurogenesis and differentiation in epileptic hippocampus. 
StarD6 is acutely and transiently increased after excitotoxic brain injury also (Chang et al., 
2009, 2010). The changes are seen in the granular and polymorphic layers of the dentate gyrus 
and the CA subfields of the hippocampus 3 hours after pilocarpine treatment. In the CA1-2 
areas, StarD6 immunoreactivity was increased in the strata lacunosum-moleculare as well as 
stratum oriens and stratum radiatum after the lesion. This increase in immunolocalization 
remained until 12 hours after experiencing epilepsy, and then slightly decreased up to  
24 hours after epilepsy. StarD6 immunoreactivity remained in the pyramidal layer of the  
CA subfields, whereas the granular layer of dentate gyrus was not very intensely stained.  
In agreement with the distributional changes, a significant increase in StarD6 protein is 
detected 3 hour after brain injury with respect to the untreated animals and 24 hours after 
epilepsy.  
Similar results in distribution and Western blot analysis are obtained in domoic acid-induced 
epilepsy model (unpublished data). Domoic acid is a kainic acid analogue and 
characteristically damages the hippocampus since hippocampus has well developed 
glutamate receptors (Coulter et al., 2002; Naegele 2007). Western analysis revealed significant 
change in the level of StarD6 in response to domoic acid, an increase being observed 4 hours 
after the epilepsy compared with normal hippocampus.  
3.3.2 Time-course of StAR and StarD6 after epileptic injury 
Neurosteroids are potent trophic and survival factors for the nervous system and the 
synthesis is related to the extent of p450scc induction. The p450scc enzyme is found in 
neurons, astrocytes, oligodendrocytes, and in activated microglial cells (Biagini et al., 2010).  
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Fig. 3. Compensatory distribution of StAR and StarD6 in normal and epileptic 
hippocampus. StAR immunolocalization was seen in the strata oriens and radiatum while 
StarD6 in the stratum pyramidale in normal hippocampus. Augmented immunolocalization 
of StAR was observed in the stratum pyramidale and StarD6 in the strata lacunosum-
moleculare after pilocarpine-induced epilepsy. Figures are aligned by stratum pyramidale. 
Original magnification X20.  
Neurosteroid levels can be altered as consequence of neuronal damage as well as of glial cell 
activation. A significant increase in p450scc both in neurons and glial cells is reported, but 
the neuron-specific changes were limited to the first few days after status epilepticus 
whereas those in glial cells were long-lasting. Therefore, neurosteroidogenesis is related to 
the extent of p450scc induction in glial cells consequent to status epilepticus.  
Activation of various molecules connected with steroidogenesis after brain injury results in 
a significantly increased synthesis of neurosteroids. Interestingly the increase in StAR and 
StarD6 was restricted to neurons in epileptic hippocampus. An urgent increase of StarD6, 
even compared with StAR, after excitotoxic brain injury may be the first attempt to respond 
to primary neurodegeneration (Figure 4). Early induction of StarD6 as well as StAR is 
followed by later increase in the expression of various steroidogenic enzymes including 
p450scc (Furukawa et al., 1998; Garcia-Ovejero et al., 2002; Biagini et al., 2006). 
The induction of StAR in neurons under neurodegenerative conditions is followed by the 
increase in the expression of PBR in glial cells (Lavaque et al., 2006). The induction of 
StAR and PBR has a different time course. StAR expression is increased within the first 
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day after lesion while the increase in PBR expression is observed from 1 to 5 weeks after 
lesion. Therefore, StAR and PBR may participate in different phases of steroidogenesis 
after brain injury. The increased expression of these molecules may be the cause of the 
increase in the production of neurosteroids, such as pregnenolone. Changes in the 
expression of StAR and PBR may also result in the production of other neuroprotective 
steroids.  
Meanwhile, the results with StarD6 suggest another aspect on neurosteroidogenesis. On  
the assumption that StarD6 participate in the regulation of the production of 
neuroprotective steroids, the responses of StarD6 might be coincided with the hypothesis 
that it is the first attempt to respond to epilepsy in accordance with brain injury resulting in 
a significant increased synthesis of neurosteroids (Di Michele et al., 2000). As a result, 
nuclear immunostaining and early response of StarD6 may regulate gene expression by 
binding to nuclear receptors (Mellon et al., 2001; Plassart-Schiess & Baulieu, 2001). StarD6 
can act as transcriptional machinery in a lipid-dependent manner and thus stimulate 
neurosteroidogenesis by activating StAR and other steroidogenic enzymes. But, direct 
relationship between StAR and StarD6 is not confirmed yet in the nervous system.  
 
 
Fig. 4. Representative changes in StAR and StarD6 in the hippocampus after excitotoxic 
insult. The histogram shows relative densitometric values of StAR mRNA (Sierra et al., 
2003) and StarD6 protein (Chang et al., 2009; unpublished data). The animals killed 12 h 
after kainic acid (KA) administration showed a significant increase in StAR mRNA levels. 
Considerable changes in StarD6 level in response to domoic acid (DA) or pilocarpine (Pilo) 
observed 3-4 hours after the epilepsy. (The densitometric results are modified from original 
manuscript)  
3.3.3 Area-specific changes of StAR and StarD6 in epileptic hippocampus 
Epilepsy could cause widespread neurodegeneration in CA1-3 pyramidal layers of the 
hippocampus (Naegele, 2007), but there is enough ground for controversy on the area-
specific degeneration of hippocampus. Epilepsy-related neurodegeneration is mainly 
limited to CA3 area of the hippocampus (Neema et al., 2005; Kajitani et al., 2006; Ma et al., 
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various animal models (Marti et al., 2002; Dinocourt et al., 2003; Cavazos et al., 2004; Sanon 
et al., 2005; Wittner et al., 2005). 
When rats are treated with kainic acid, a rapid and transient increase in StAR mRNA and 
protein was detected 12 hours after brain injury in the hippocampus (Sierra et al., 2003). A 
strong increase in StAR immunostaining was observed in the granular layer of dentate gyrus 
while the control hippocampus was not very intensely stained. The results do not provide 
effective involvement of StAR for steroidogenesis, but possible role in neuroprotection in 
neurons against excitotoxic injury. In this context, distribution of StAR changed in the 
pilocarpine-induced epileptic hippocampus (Chang et al., 2010). StAR immunostaining is 
localized in the strata oriens and radiatum of normal hippocampus, and in the stratum 
pyramidale as well in epileptic hippocampus. The changes in immunolocalization are reported 
in CA1-2 areas, not in the dentate gyrus.  
Similar results on area-specific changes are reported with StarD6 in epileptic hippocampus 
(Chang et al., 2009, 2010; unpublished data). The StarD6 immunolocalizations are seen in the 
strata lacunosum-moleculare as well as strata oriens and radiatum after excitotoxic injury 
with pilocarpine and domoic acid, respectively. The changes in the strata correspond with 
distribution of steroidogenic enzymes such as p450scc (Furukawa et al., 1998; Garcia-
Ovejero et al., 2002; Biagini et al., 2006). As a result, StarD6, StAR and p450scc might act in 
consecutive order following excitotoxic brain injury, result in neurosteroidogenesis. 
In addition, the morphometric data (Chang et al., 2010) with StarD6 in DNA-PK deficient 
cells are in accord with the previous reports that lack of DNA-PK promotes apoptosis 
(Culmsee et al., 2001; Neema et al., 2005). It can be interpreted that the activity of StarD6 in 
the nucleus might depend on the DNA repair proteins. To investigate whether StarD6 is 
related with DNA repair system in nervous system, epilepsy model was established by 
domoic acid (unpublished data, Fig. 5). Contrary to the hypothesis based on previous 
reports, there was negative correlation between StarD6 and NHEJ (data not shown).  
But the levels of apurinic/apyrimidinic endonuclease (APE, also called redox factor-1) and 
8-oxoguanine DNA glycosylase (Ogg1) increased considerably at 4 hours after domoic acid 
injection. The responses are quite similar to previous reports with kainic acid (Quach et al., 
2005; Jarrett et al., 2008) and that of StarD6 (Fig. 4). The results support the notion that 
oxidative DNA damage in neurons is primarily removed by base excision repair (BER) 
pathway rather than by NHEJ (Fishel et al., 2007). Despite activation of DNA repair systems 
after excitotoxic injury, the repair responses may not sufficient to overcome for extensive 
DNA damage.  
The distribution of BER proteins revealed that transient increase of APE in strata radiatum 
and lacunosum-moleculare and Ogg1 in stratum pyramidale. Increased immunoreactivities 
of APE and Ogg1 diminished in the pyramidal cells of CA3 area 24 hours after domoic acid 
injection compared to CA1. In case of StarD6, the immunostaining was induced in the strata 
radiatum and lacunosum-moleculare after epilepsy and then normalized in the stratum 
pyramidale in CA3 as well as CA1. Neurodegeneration in CA3 pyramidal cells may be 
caused by the decreased BER activity after seizure since there was no area-specific change in 
StarD6 especially in CA3. StarD6 in the nucleus did not respond on DNA repair system after 
epilepsy, but immunolocalization of StarD6 as well as APE in the strata lacunosum-
moleculare may have significance where localized various steroidogenic enzymes 
(Furukawa et al., 1998; Patte-Mensah et al., 2003; Biagini et al., 2006; Wojtal et al., 2006; Chia 
et al., 2008).  
 




Fig. 5. Area-specific changes of StarD6 and APE in epileptic hippocampus. 
Immunoreactivities of StarD6 and APE increased in the strata radiatum and lacunosum-
moleculare (*) 3 hours after epilepsy (C and D) compared with control hippocampus (A and 
B) or 5 days after epilepsy (E and F). Note the changes in stratum pyramidale. Although 
StarD6 immunoreactivity remained in all subfields, the intensities diminished in CA3 
(arrow) while those in CA1 were maintained. Scale bar = 1mm. 
3.3.4 Functional aspects of StAR and StarD6 in epileptic hippocampus 
StAR has been shown to be involved in the intramitochondrial trafficking of cholesterol 
(Alpy & Tomasetto, 2005; Lavigne et al., 2010). Then, cholesterol is made available to the 
first enzyme of the steroidogenic pathway, p450scc, which transforms cholesterol into 
pregnenolone, the precursor for glucocorticoids, mineralocorticoids and sex steroids. StAR-
mediated delivery of cholesterol to the inner mitochondrial membrane, where p450scc is 
located, is a hormonally regulated step, which is rate limiting in steroidogenesis.  
The up-regulation of StAR expression after excitotoxic injury suggests that this protein may 
play a role in the adaptation of neural tissue to neurodegenerative conditions (Sierra et al., 
2003; Sierra, 2004; Lavaque et al., 2006; Chang et al., 2010). That is, StAR in the dentate gyrus 
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Fig. 5. Area-specific changes of StarD6 and APE in epileptic hippocampus. 
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StarD6 immunoreactivity remained in all subfields, the intensities diminished in CA3 
(arrow) while those in CA1 were maintained. Scale bar = 1mm. 
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respectively. Strikingly, no deficiency in brain function or structure was reported either in 
StAR knockout mice or in congenital adrenal hyperplasia patients (Sierra, 2004). The brain 
may have StAR-independent mechanisms of mitochondrial cholesterol transport.  
It should be noted that StAR is not the only molecule implicated in the mitochondrial 
transport of cholesterol. PBR, which might function as a cholesterol channel, is essential for 
the delivery of cholesterol to the inner mitochondrial membrane and the synthesis of 
steroids. NPC1 is also involved in transport of lipids from the late endosome to 
mitochondria. Furthermore, there has been described a family of proteins which contain the 
START domain. These START domain proteins, such as StarD6, are related to 
steroidogenesis.  
In some START proteins, the START domain probably functions in lipid sensing rather than 
in lipid transfer (Alpy and Tomasetto, 2005; Lavigne et al., 2010). StarD2/PCTP, StarD4, 
StarD5 and StarD10 are detected in the cytoplasm and nucleus, and StarD6 only in the 
nucleus. It is therefore possible that some START-containing proteins have nuclear roles and 
may even regulate transcription in a lipid-dependent manner. Structurally, the START 
domain contains a lipid-binding domain specific for diacylglycerol/phorbol-ester, the C1 
domain (Brose and Rosenmund, 2002) and functions as a lipid-sensing domain providing a 
rapid way of regulating the catalytic activity, and thus modulates lipid metabolism.  
 
 
Fig. 6. Schematic representation of various molecules participating in neurosteroidogenesis. 
StAR and PBR is mainly localized in the outer mitochondrial membrane of neuron and glia, 
respectively, while p450scc acts in the inner mitochondrial membrane. Note StarD6 in the 
nucleus, which may interact with StAR for neurosteroidogenesis. Stimulus-dependent up-
regulation of START proteins appears as follows; StarD6 in a few hours and StAR in a day, 
while PBR and p450scc in a few weeks.  
The changed immunolocalization of StarD6 in the strata lacunosum-moleculare might 
suggest a role of this protein as a regulator of transcription related to the cholesterol 
metabolism (Chang et al., 2009, 2010, unpublished data). Although StAR is a well known 
protein implicated in the steroidogenesis, StarD6 changed the localization from stratum 
pyramidale to the strata lacunosum-moleculare after excitotoxic injury. Another important 
change is the time course of responsiveness after epilepsy. The response of StarD6 arises 
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from the nucleus with DNA repair proteins to respond to excitotoxic stimuli. StarD6 can 
function as a lipid-sensing domain and modulate neurosteroid synthesis.  
There is growing evidence that cholesterol is of particular importance in development of 
Alzheimer’s disease (Wojtal et al., 2006; Adibhatla & Hatcher, 2008). In the patients’ brains 
of Alzheimer’s disease, a general trend was observed towards decreased levels of all 
steroids. The lower levels correlated with increased amounts of β-amyloid peptides and 
phosphorylated tau proteins. Increased level of StAR is reported in aged rats (Sierra et al., 
2003) and in patients with Alzheimer’s disease (Webber et al., 2006) compared with young 
animals and age-matched patients without dementia, respectively. It means that the 
expression of StAR hormonally regulated by the level of neurosteroids in the nervous 
system. Although the existing knowledge on StarD6 is still incomplete, it can be expected 
that StarD6 is also regulated by the levels of neurosteroids, cholesterol and lipid. 
Furthermore, StarD6 is localized in the nucleus and appears early response than StAR in 
epilepsy (Chang et al., 2009, 2010, unpublished data), results in stimulus-dependent 
expression of StAR follows after StarD6.  
4. Conclusion 
The START domain operates as a lipid exchange and/or a lipid-sensing domain. There are 
15 mammalian proteins that possess a START domain, an evolutionary conserved protein 
module and they are involved in several different biological processes: lipid transfer, lipid 
metabolism and signal transduction. While the role of StAR in steroid hormone production 
has been demonstrated, StarD6 remain largely uncharacterized. Much less is understood 
about how its START domain specifically recognizes cholesterol and how it affects on other 
molecules participating in neurosteroidogenesis. StarD6 can take precedence over other 
molecules such as StAR, PBR and p450scc in excitotoxic brain injury and they might be 
hormonally regulated. There are no reports on the brain function or structure in StarD6 
knockout animal model or in patients’ brain and the brain may have StarD6-independent 
mechanisms of lipid/cholesterol sensing. Therefore, further studies are needed to elucidate 
the exact nuclear roles of StarD6 on neurosteroidogenesis with StAR in the nervous system. 
It could suggest new therapeutic strategy for epilepsy since neurosteroids act as autocrine or 
paracrine neuromodulators and the regulation of neurosteroidogenesis may have profound 
influences in the nervous system. 
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1. Introduction 
Epilepsy is a chronic neurological disease involving recurring behavioral seizures, and 
affects approximately 1% of the worldwide population of humans and cats, and 2-3% of 
dogs. Epilepsy causes recurring behavioral seizures, which are transient behavioral changes 
caused by disordered, synchronized, and rhythmic firings of populations of neurons in the 
brain that propagate to regions connected with the first insult on the neural circuits, induced 
by abnormal neural plasticity (Browne and Holmes 2000). The seizure expression is induced 
by idiopathic/cryptogenic and remote symptomatic causes, as concrete examples, febrile 
illness in children younger than 16 years (Besli et al., 2010) and cerebrovascular and 
ethanol/drug-related accidents in adults. When the seizures are prolonged, or occur in a 
series, there is an increased risk of status epilepticus. About 15 % of persons with epilepsy 
experience status epilepticus, which induces more brain damage. It is known that large 
populations of epilepsy patients express status epilepticus due to medication changes in 
both children and adults. Hence, improving the compliance of patients to take medicine 
appropriately is very helpful to prevent the expression of status epilepticus.  
Despite the importance of medication, more than one third of patients with epilepsy are 
estimated to have pharmacoresistant epilepsy (Browne and Holmes 2000). Half of patients 
with refractory epilepsy are characterized as having mesial temporal lobe epilepsy (TLE) 
with foci in the amygdaloid complex, hippocampus, and surrounding cortex. To solve the 
problem of pharmacoresistance, it is important to clarify the molecular mechanisms 
involved in the development of pharmacoresistant seizures. Additionally, patients with 
epilepsy are at high risk of developing anxiety, depression, learning disorders, and sudden 
death (Dodrill, 1986; Franks, 2003; Motamedi and Meador, 2003; Sillanpää and Shinnar, 
2010). To improve the quality of life of patients, it is useful to clarify the comorbidity 
between seizures and other neuropsychiatry disorders. Depression and anxiety have the 
highest incidence in patients with TLE (Perini, et al., 1996). Hence, it should be clarified how 
the molecular signaling system regulates the development of pharmacoresistant abnormal 
neural plasticity and, as a result, recurring prolonged seizures that are induced by 
symptomatic causes. New drugs that can respond to seizures that known drugs fail to cure 
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should be developed based on the newly found signaling machinery. Many researchers 
have found molecular candidates responsible for seizure progression and the molecular 
mechanisms have been clarified little by little (Jia et al., 2011; Pitkänen and Lukasiuk, 2011). 
On the other hand, we have focused on clarification of the molecular mechanisms of 
epilepsy progression using a mesial TLE mouse model, amygdale kindled mice, showing 
epileptic seizures induced due to the development of abnormal neural plasticity in TLE 
regions. So far we have found three molecules responsible for epileptogenesis, a growth 
hormone, a sialyltransferase, and ganglioside GQ1b (Matsuhashi et al., 2003; Kato et al., 
2008; Kato et al., 2009). The clarification of signaling mechanisms with these molecules will 
resolve the pharmacoresistancy and open a path for therapeutic intervention for cases of 
anxiety and depression in the near future. 
2. Experimental animals 
2.1 Introduction of experimental animal models 
Several chronic models showing recurrent seizures have been developed as shown in Table 1.  
 
Stimulant   Chronic recurrent seizures References 
Physical  kindling  Goddard et al., 1969; Racine et al., 1972; Kato et al., 2001 
Chemical 
(metal)  alumina cream  Heinemann et al., 1986 
  cobalt Chang et al., 2004 




schedule) Schallier et al., 2009 
  kainate Antonucci et al., 2009 
  pilocarpine  Pitkänen et al., 2011 
Inherited  EL mice  Fueta et al., 1983 
  DBA/2 mice (audiogenic) Seyfried and Glaser, 1981 
  SER rat Hanaya et al., 2010 
  Mongolian gerbil  Buchhalter 1993 
  targeted gene-deficient mice Puranam and McNamara, 1999; Meisleret al., 2001 
Table 1. Species of epileptic model animals (especially rodents). 
Physical (electro-stimulation): Kindling consists of the repeated administration of 
subconvulsive electrical stimulus to any of several brain regions, resulting in the 
development of EEG seizures (afterdischarges) and progressive behavioral seizures. When 
repeated stimuli are administrated into the amygdaloid complex and hippocampus, mesial 
temporal lobe epilepsy (MTLE), which is the cause in one-half patients with refractory 
epilepsy, is induced as eventual secondary generalized grand mal seizures. The kindling 
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model provides better insights into how abnormal neural plasticity is altered and newly 
acquired during epileptogenesis. Furthermore, when the number of grand mal seizures 
increases, status epilepticus is also caused in kindled mice. We therefore focused on kindling 
to clarify the molecular mechanisms of epileptogenesis and the occurrence of status 
epilepticus. 
Chemical (metal): When alumina cream is applied to the cerebral cortex of monkeys and 
cats, chronic spontaneous seizures are induced, however, the seizures subside after several 
months to years (Heinemann et al., 1986). Investigating the mechanisms of the termination 
of seizure expressions might provide clues to end refractory epilepsy. Implantation of cobalt 
into the cerebral cortex easy induces focal and secondarily generalized seizures in rodents, 
however, cobalt metal causes a large area of cortex to be lost, while the hippocampus 
containing the dentate gyrus appears intact (Chang et al., 2004). Microinjection of ferric ions 
into the rodent brain results in chronic recurrent seizures, which are brain injury responses 
induced by hemorrhage and free radical reactions observed in human posttraumatic 
epilepsy (Willmore and Ueda, 2009). 
Chemical (drug): Status epilepticus model mice are prepared with pentylenetetrazol (PTZ), 
kainate, and pirocarpin. PTZ-induced seizures: injection of PTZ (43 mg/kg) into the 
peritoneal cavity of 4-week-old mice 3 times per week for 4 weeks induced stereotyped 
spontaneous seizures (unpublished procedure). Kainate-induced seizures: an infusion of 
kainate (1 nmol/0.5  μl) into the hippocampus of 8-week-old mice induces status epilepticus 
about 20 days after infusion (unpublished procedure; Antonucci et al., 2009). Pirocapine-
induced seizures: pirocarpine (100 mg/kg) is injected into the peritoneal cavity every 20 min 
until onset of status epilepticus (Elliott et al., 2003). SE induced with kainate and pirocarpine 
accompanies hippocampal damage, which seems to mimic human hippocampal atrophy. 
Additionally, the concentration of each drug should not be over the adequate dosage, as 
mice die immediately following the appearance of seizures. 
Spontaneous and genetic manipulation: EL mouse: tonic-chronic seizures appear when a 
mouse is tossed to height of 10 cm 10 times a day for 2-3 weeks (unpublished procedure; 
Fueta et al., 1983). Audiogenic seizure model of DBA/2: audiogenic seizures appear when a 
3-week-old mouse receives one 60-sec exposure to a pure tone sound (120 db) (Seyfried and 
Glaser, 1981). SER rat: rats homozygous for both zitter (zi) and tremor (tm) autosomal 
recessive mutations shows spontaneous epileptic seizures involving hippocampal atrophy 
in the CA3 subfield, in addition to many vacuoles in the brain (Hanaya et al., 2010). Gerbils 
with hypoplasia of the basilar artery circle suffer chronic seizures by a sudden change of 
circumstances (Buchhalter 1993). On the other hand, many one-gene-deficient mice have 
been produced with epileptic seizures, in which it is suggested that several channel gene 
deficient-dependent seizures mimic idiopathic seizures (Puranam and McNamara, 1999; 
Meisleret al., 2001). 
2.2 Preparation of kindled mice 
Figure 1 shows the dorsal side of the head (B) and the coronal section of the brain (C) in 
kindled mice with a microinjection cannula. All procedures were performed according to 
the guidelines for animal welfare of Osaka Prefecture University and Kyoto Sangyo 
University, and approved protocols. Surgical procedures were conducted under anesthesia 
with isoflurane (Dainippon Sumitomo Pharma Co. Ltd., Osaka, Japan) and Escain (Mylan 
Inc., Osaka, Japan) as described previously (Kato et al., 2001). Positions of brain regions 
were determined according to the stereotaxic coordinates shown by Paxinos and Franklin  
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should be developed based on the newly found signaling machinery. Many researchers 
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schedule) Schallier et al., 2009 
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Fig. 1. Photos show free-moving mice receiving kindling stimulation, E.E.G. recording, and 
microinjection (A) and views showing positions of electrodes and microinjection cannula (B 
and C). Views showing the dorsal side of the head (left) and a coronal section of the brain 
(right) in kindled mice with a microinjection cannula (A). In (A), Stim., stimulation; E.E.G., 
electroencephalographic; cannula, microinjection cannula transplanted into the 
hippocampus.  
(2001). Unipolar cathode electrode; made of tungsten steel and 0.1 mm in width (Inter 
Medical Co. Ltd., Nagoya, Japan), and an anode electrode; made of a screw and 1.0 mm in 
width and 3.0 mm in length (Biotex Kyoto, Japan), were implanted on the right side of the 
basolateral amygdaloid complex (A -2.0, L 3.0, V 4.5 mm from bregma; a) and on the left 
side of the subdural space (A 2.0, L 1.5 mm from bregma; b), respectively. Ten days after 
surgery, unrestrained conscious mice received a biphasic square wave pulse [480 μA; 60 Hz, 
200 μs duration, for 2 sec] using an electrical stimulator (SEN-3301; Nihon Kohden, Tokyo, 
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Japan) and isolator (SS-202J) once a day. Electroencephalographic (EEG) recordings were 
carried out with bilateral electrodes of the subdural space (b and c) prior to and after 
stimulation using PreAmp and Head Amp (BEMCT-21 and BH-3, Low cut = 0.5, High cut = 
30; Biotex, Kyoto, Japan) and the data acquisition program SleepSign ver.2.0 (Kissei Comtec 
Co. Ltd., Nagano, Japan). Seizures were monitored with a modified classification of Racine's 
criteria (Racine 1972) and the duration of afterdischarge and freezing was added to the 
behavioral criteria as described previously (Kato et al., 2001): stage 1, plus mouth and facial 
movement; stage 2, plus forelimb clonus and duration of afterdischarge greater than 5 sec; 
stage 3, plus forelimb clonus and duration of freezing greater than 15 sec; stage 4, plus tonic 
clonic seizures and tail up; stage 5, plus falling over. After reaching stage 5, mice were used 
in experiments as fully kindled mice following more stimulation for only 3 days. The brains 
of the mice were removed after decapitation within 2 hrs of the last kindling stimulation. 
The sham-operated mice were not stimulated but otherwise treated identically in all 
respects. 
2.3 Microinjection of drugs into the brains 
To observe the effect of drugs during epileptogenesis, a microinjection cannula (ID=0.2 mm; 
Eicom Corp., Kyoto, Japan) with a guide cannula (ID = 0.4 mm, OD = 0.5mm; Eicom Corp.) 
was also implanted on the left side of the hippocampus (A –2.0, L 1.5, V 2.5 mm; d in Fig. 1B 
and C) at the time of surgery to prepare kindled mice (Kato et al., 2009). 
One microliter of genotropin (1 μl of 540 pmol/μl; Faizer, Tokyo, Japan), pegvisomant (90 
pmol/μl, antagonist, Faizer) and buffer (40 mg/ml D-mannitol, 2 mg/ml glycine, and 0.02 
mM sodium phosphate, pH 6.85); and 1 μl octreotide acetate (1 μl of 90 pmol/μl; Novartis, 
Tokyo, Japan) and buffer (45 mg/ml D-mannitol, 3.4 mg/ml lactic acid in NaHCO3, pH 4.5) 
were injected into the hippocampus of unrestrained conscious mice (d in Fig. 1B) at a flow 
rate of 0.5 μl /min using a microsyringe pump (KDS 200 series; KD Scientific) according to 
the schedule described in Fig. 3A, in which we administered drugs every other day 7 times 
in total before and during epileptogenesis, respectively. Concentrations of the drugs applied 
to mice were determined based on the weight of drugs per weight of human patients. Mice 
received a biphasic square wave pulse 30 min following the microinjection. Statistical tests 
were mainly performed using a combination of Excel and Statview-J 5.0. Additionally, one 
microliter each of genotropin octreotide acetate, and pegvisomant (antagonist, recombinant 
protein, 12 mg/ml; Pfizer) was injected into the hippocampus of respective mice without 
kindling stimulation. Pegvisomant was used to investigate whether it affected the functions 
of endogenous GH in the brain. 
3. Differential expressions during epilepsy progression and following status 
epilepticus 
Reports have indicated gene expression patterns during and following epileptogenesis and 
the development of status epilepticus induced in rodents with drugs and electro-stimulation 
(Nedivi et al., 1993; Tang et al., 2002; Becker et al., 2003; Elliott et al., 2003; Lukasiuk et al., 
2003; Gorter et al., 2006). They have found several promising new anti-epileptogenic targets, 
for example, previous studies have indicated common immediate early genes including 
SER-regulated genes (Becker et al., 2003; Gorter et al., 2006) and prostaglandin-endoperoxide 
synthase 2 (Ptgs2, Cox-2) (Gorter et al. 2006; Ristori et al. 2008) as candidates for genes 
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causative of epileptogenesis. While inhibition of Cox-2 reduces epileptiform bursting in the 
hippocampus slice (Ristori et al., 2008), the inhibitor had no effect on epileptogenesis or 
spontaneous seizures in vivo (Holtman et al., 2009). This contradiction suggests that the roles 
of Cox-2 should also be studied in epilepsy. It was also reported that the expressions of 
hormone genes, such as galanin (Lerner et al., 2008; Mitsukawa et al., 2008), neuropeptide Y 
(Shannon and Yang, 2004; El Bahh et al., 2005; Silva et al., 2005), leptin (Shanley et al., 2002), 
and somatostatin (Monno et al., 1993; Buckmaster et al., 2002) were up-regulated in the brain 
following epileptogenesis and showed anti-epileptic effects. On the other hand, candidate 
genes associated with human epilepsy have been nominated in the HuGE database (Jia et 
al., 2011). More recent experimental research has shown the effect of antiepileptic drugs on 
differential gene expressions and antiepileptogenic behaviors (Pitkänen and Lukasiuk, 
2011). 
In the present review, we introduce growth hormone signaling as a candidate molecular 
system associated with epileptogenesis. We have screened differential gene expressions in 
the brain regions during kindling epileptogenesis by genechip array. As a result, we have 
identified growth hormone (GH), increasing the gene expression in the brain regions that 
kindling stimuli propagate from the basolateral amygdala during epileptogenesis (Fig. 2). 
On the other hand, the present amygdala kindled mice also indicated up-regulated 
expressions of SER-regulated genes (Kato et al., 2009) and the Cox-2 transcript (Fig. 4) 
following kindled seizures. 
4. Research 
4.1 Growth hormone signaling system 
Differential expressions of the GH transcript that increases in the brain during and 
following kindling epileptogenesis (Fig. 2) have been confirmed using a quantitative real-
time polymerase chain reaction-based analysis of mRNA (qRT-PCR) and Western blot 
analysis (Kato et al., 2009). Next, we investigated the distribution of the GH transcript in the 
brain to know whether the transcript is expressed in regions where the kindling-stimuli 
propagate in amygdala-kindled mice using in situ hybridization (Kato et al., 2009). Neuronal 
cells were typically oval with cRNA signals of GH in the regions, in which GH mRNA was 
expressed moderately in the brain, particularly around the limbic area containing the 
piriform cortex, the anterior thalamic nucleus, and the hippocampus. Previous studies of 
neural connections have already clarified that amygdala kindling leads more easily to the 
propagation of stimuli to the hippocampus→anterior thalamus→apical cortex involving the 
cingulate through neural connections (Meibach and Siegel 1977; Amaral and Witter 1995; 
Price 1995; Gemmell and O'Mara 2002). Thus, it was suggested that regions of the brain that 
express GH could be involved in the propagation of stimuli in neural circuits during 
epileptogenesis. 
To compare mRNA levels, total RNA was prepared from the apical part of the cerebral 
cortex (yellow circle), thalamus, (green circle), and the caudal part of the cerebral cortex 
[which includes posterior hippocampus, amygdaloid complex, temporal lobe] (red circle) of 
kindled, intermediate stage 3, and sham-operated mice. GeneChip array shows up-
regulation of GH transcript during epileptogenesis (A). Means and S.E.M. were calculated 
based on raw signal intensities (MG430_Scal_Signal) compensated by signal intensity with 
GAPDH control probes on the Mouse Genome 430 2.0 Array of the Affymetrix Genechip. 
There were significant differences of GH expression using Kruskal-Wallis tests of Kyplot 4.0: 
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in the apical cortex (x70.6, **p<0.01), the thalamus (x54.4, **p<0.01) and caudal cortex (x23.2, 
*<0.05) between sham-operated and full-kindled mice. 
 
 
Fig. 2. Comparisons of expression levels of Gh between full-kindled, intermediate stage 3, 
and sham-operated mice using genechip array. To compare mRNA levels, total RNA  
was prepared from the apical part of the cerebral cortex (yellow circle), thalamus,  
(green circle), and the caudal part of the cerebral cortex [which includes posterior 
hippocampus, amygdaloid complex, temporal lobe] (red circle) of kindled, intermediate 
stage 3, and sham-operated mice. GeneChip array shows up-regulation of GH  
transcript during epileptogenesis (A). Means and S.E.M. were calculated based  
on raw signal intensities (MG430_Scal_Signal) compensated by signal intensity  
with GAPDH control probes on the Mouse Genome 430 2.0 Array of the Affymetrix 
Genechip. There were significant differences of GH expression using Kruskal-Wallis  
tests of Kyplot 4.0: in the apical cortex (x70.6, **p<0.01), thalamus (x54.4,  
**p<0.01), and caudal cortex (x23.2, *<0.05) between sham-operated and full-kindled  
mice.  
To investigate whether GH has distinct roles in epileptogenesis, we injected genotropin 
(human GH recombinant, rGH) and octreotide, which is a somatostatin analog reducing 
secretion of GH (Lamberts 1987) into the hippocampus according to the schedule described 
in Fig. 3A. First, the administration of rGH resulted in a significant enhancement of 
epileptogenesis compared to the control as a whole (two-way factorial ANOVAs in Fig. 3C) 
and an increased number of spikes in afterdischarge following epileptic seizures (two-way 
factorial ANOVAs in Fig. 3B). Second, the progression of behavioral changes during 
epileptogenesis was attenuated (two-way factorial ANOVA in Fig. 3E); however, there were 
no differences in the number of spikes and duration of afterdischarges (Fig. 3D). This 
suggests that growth hormone causes the afterdischarge threshold to decrease during 
epileptogenesis. 
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Fig. 3. Effect of genotropin and octreotide on epileptogenesis (adapted from Kato et al., 
2009). Schedules of injection (A) of genotropin (1 ml of 540 pmol/ml, red circles in B and 
4C), octreotide acetate (1 ml of 90 pmol/ml, blue circles in D and E), and their buffer (1 ml, 
black circles in B-E) or kindling stimulation are shown. Stimulation was started from 
number 1 and continued to the 17th day. The number of spikes in afterdischarges on 
electroencephalograms (EEGs) are shown (B and D). Transition of stages (C and D). Means 
and S.E.M. for the two characteristics of mice with or without drugs following stimulation 
on each day were evaluated with two-way factorial ANOVA, which showed differences in 
mice with or without in B to E (Kato et al., 2009). The data for days when mice received 
stimulation were compared between injections of drugs and the buffer (Mann-Whitney U-
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hippocampus was exposed to rGH for 24 hrs without kindling stimulation, rGH induced 
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in the caudal cortex containing the hippocampus and amygdaloid complex (Fig. 4, result 
experimented by Mr. M. Suzuki). Both Egr1 and Cox-2 mRNAs were seizure-responsive 
genes in our kindling system. These relative results show that exogenous rGH induced an 
increase of Egr1 mRNA directly at least downstream of GH signaling, while Cox-2 
transcripts were not regulated by GH signaling. It has been reported that Cox-2 inhibitor  
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has little effects on epileptogenesis or spontaneous seizures (Holtman et al., 2009), which 
also suggests that Cox-2 does not function under GH signaling. 
GH regulates physiological processes, including carbohydrate and lipid metabolism as well 
as somatic growth and development, therefore, it is possible that epileptogenesis is 
correlated with the differential expression of carbohydrates and lipids. Next, we screened 
the differential expression of gangliosides during epileptogenesis.  
4.2 Effect of ganglioside expressions 
A crude ganglioside mixture was prepared with extracts of the hippocampus dissected from 
adult mice following kindled seizures, and high performance thin-layer chromatography 
(HPTLC) analysis was performed according to previous reports (Iwamori and Nagai, 1981). 
The signal intensity of each ganglioside developed on the HPTLC plate was calculated in 
individual mice (6 kindled and 6 sham-operated mice) using PDquest software (Bio-
rad,Tokyo, Japan) and analyzed using a combination of Excel and Statview-J 5.0. The analysis 
demonstrated a decrease of GM1 and increase of GQ1b following kindled seizures (Kato et al., 
2008). The increase of GQ1b in the hippocampus following kindled seizures was confirmed by 
immunofluorescence with anti-GQ1b antibody. Taken together, the level of endogenous GQ1b 
increased following seizures in amygdaloid kindled mice, suggesting that the contents of 
GQ1b in the hippocampus are subject to epileptogenesis regulated by GH signaling. 
5. Conclusion 
We first found that GH plays distinct roles in epileptogenesis in the limbic system of the 
brain via GH signaling. While it was reported that GH is involved in lipolysis and has an 
effect that opposes that of insulin in the peripheral tissues (Scacchi et al., 2003), the present 
kindled seizures up-regulated the expressions of GQ1b in the brain. Given that 2-deoxy-D-
glucose (2DG) increases the afterdischarge threshold (Garriga-Canut et al. 2006) and the 
present kindled-seizures cause up-regulation of the expressions of an enzyme related to 
carbohydrate transition, α2,3-sialyltransferase (ST3Gal IV), in the hippocampus and 
thalamus (Okabe et al., 2001; Matsuhashi et al., 2003). Hence, we propose that metabolic 
regulation by GH signaling adjusts the afterdischarge threshold during epileptogenesis. We 
have developed ST3Gal IV gene-deficient mice and are studying the involvement of ST3Gal 
IV in epileptogenesis. The relevance of GH signaling, sialylation, and lipid metabolism in 
the progress of epilepsy should be clarified in the near future. 
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1. Introduction 
Epilepsy is a major cause of ongoing disability and a significant cause of hospital admission. 
According to the World Health Organisation, the disease affects approximately 50 million 
people worldwide and current pharmacological treatment regimes are ineffective in 
approximately 30% of cases (http://www.who.int/mediacentre/factsheets/fs999/en/ 
index.html). Clearly, there is a need for more effective and targeted pharmacological 
epilepsy treatments.  
In simplistic terms, seizures are said to result from an imbalance in the regulation of brain 
activity, such that too much excitation or too little inhibition tips the balance towards 
hyperexcitability (seizure). The reality is almost certainly more complicated, as evidenced by 
common reports of low efficacy of some currently used antiepileptic drugs, whose primary 
mechanisms of action are either depression or enhancement of brain excitatory and 
inhibitory pathways, respectively. The complexity of this area of neurobiology is further 
highlighted by the observation that seizures can be triggered by anaesthetic drugs, many of 
which are themselves effective anticonvulsants. Clearly, there are subtleties to the 
mechanisms of seizure generation and regulation, the complexity of which we are only 
beginning to understand. A greater understanding of these underlying mechanisms will 
inevitably lead to more targeted and effective treatment options. 
One area that has become the focus of considerable amounts of research in the last 10 years 
is the role of gap junctions in seizure mechanisms. Gap junctions form direct cytoplasmic 
connections between cells, providing electrical continuity and allowing passage of low 
molecular weight molecules from one cell to another. Gap junctions are created from the 
assembly of six connexin proteins in the cell membrane into a hemichannel; and the 
association of two hemichannels on neighbouring cells forms a mature gap junction. Acting 
as electrical synapses, it has been hypothesised that gap junctions could promote seizure 
activity by facilitating the spread and synchronisation of electrical activity in the brain. In 
support of this, there are a growing number of experimental studies showing a reduction in 
seizure severity following pharmacological gap junction blockade (Bostanci and Bagirici 
2007; Nassiri-Asl et al. 2009). Intriguingly, several studies point to gap junction blockade 
having the opposite effect (Voss et al. 2009; Jacobson et al. 2010), suggesting that the 
relationship between gap junction regulation and seizure propensity is multifaceted. 
The apparent discrepancies in the literature surrounding the role of gap junctions in 
seizurogenesis probably reflect two main complicating factors. Firstly, there are no known 
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drugs that selectively regulate gap junctions; all have off-target effects which could 
confound experiments utilising these agents (Juszczak and Swiergiel 2009). Secondly, the 
effect of gap junction regulation on seizure activity will almost certainly depend on the 
specific gap junction subtype manipulated. The reason for this is that gap junctions of a 
given subtype tend to be restricted to a particular class of cells; meaning that targeted 
modulation of a specific gap junction subtype effectively restricts the effect to a specific cell 
population. It should not be surprising therefore, that blockade of gap junctions linking 
inhibitory interneurons for example, will have a different effect to blockade of those 
between excitatory pyramidal cells.  
The central tenet of this chapter is that we cannot begin to fully understand the role that gap 
junctions play in seizure mechanisms until we appreciate the need for a targeted approach 
to gap junction modulation; in terms of both off-target, non-gap junctional side-effects and 
gap junction subtype specificity. These ideas are also important for the development of more 
effective epilepsy treatment options based on gap junction modulation, which will depend 
upon the targeted modulation of gap junction subtypes (Song and Tanouye 2006). Achieving 
targeted gap junction modulation is a major challenge for experimental biologists; however, 
there are new techniques and approaches that offer some hope for future research. For 
example, mimetic peptides (short polymers of amino acids) have shown promise as a tool 
for blocking gap junction formation (Evans and Boitano 2001). The specificity of effect of 
mimetic peptides comes from the sequence of amino acids, which are chosen to mimic a 
portion of the extracellularly exposed gap junction connexin protein. The introduced 
peptide binds to the native protein and interferes with the cell-cell docking process required 
for mature gap junction formation. In this way, formation of new gap junctions of the 
targeted subtype is prevented. Experimental approaches can also be supplemented by 
mathematical modelling studies, which have the enviable advantage that model parameters 
can be manipulated with absolute specificity. Clearly, no computer model developed to date 
comes close to representing the brain in all its complexity or functionality; but when aligned 
with (and refined by) experimental data, computer models can provide an informative 
adjunct to experimental biology. 
In this chapter, we provide a detailed review of the current knowledge around the 
aforementioned topics. Our discussion focuses on the relationship between gap junctions 
and seizurogenesis in the mature, adult brain. Gap junction expression is highly dynamic 
early in development and understanding the contribution of changing levels of different gap 
junction subtypes to seizures is beyond the scope of this discussion. To this end, the chapter 
will be structured into three sections. Firstly, we will review the neurobiology of gap 
junctions and the distribution of gap junction subtypes across cell populations and cerebral 
locations in the adult brain. Our focus will be on brain regions known to be involved in 
seizurogenesis; principally the hippocampus and the cerebral cortex. We will then give an 
overview of recent as well as potential novel approaches to manipulating gap junctions that 
may provide more specificity of effect, such as mimetic peptides and siRNA technologies; 
and may also provide the basis of new therapeutic approaches to treating epilepsy. Finally, 
we will discuss how differentiation between gap junction-linked astrocytic, interneuronal 
and pyramidal cell networks may help us to understand the nature of gap junction 
regulation of seizure processes. This research is in its infancy, but there are clues from recent 
experimental and mathematical modelling studies that provide a solid foundation from 
which to explore this topic.  
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2. Gap junction structure and subtype distribution 
Gap junctions are proteinaceous structures that form connections between adjacent cells, 
directly linking the cytoplasm of one cell to another. The basic structural unit is the connexin 
protein, of which there are 21 known subtypes in the human (Sohl and Willecke 2004). 
Connexins associate within the cytoplasmic membrane into a hexameric structure known as 
a connexon, or hemichannel; the association of two hemichannels on adjacent cells forms a 
mature, functional gap junction (see Fig 1). The junction so-formed allows direct electrical 
communication between cells and the passage of small molecular weight chemicals; and 
also serve intracellular signalling roles independent of their channel-forming function (see 
(Goodenough and Paul 2003; Jiang and Gu 2005) for reviews).  
 
 
Fig. 1. Schematic representation of gap junction structural organisation 
Gap junctions are found in most animal tissues and are widely expressed throughout the 
mammalian brain (Condorelli et al. 2003). However, expression patterns are not uniform 
and the distribution of different gap junction subtypes is dependent upon location and 
developmental maturity. For simplicity and in order to focus on the regions of greatest 
clinical relevance for human epilepsy (Hauser and Kurland 1975; Wiebe 2000), we will limit 
our discussion to the distribution of gap junction subtypes within the mature cerebral cortex 
and hippocampus.  
2.1 Cortical and hippocampal gap junction expression 
Only a limited number of connexins have been shown unequivocally to be expressed in the 
mature cerebral cortex. Connexin30, 32, 43, 45 and 47 gap junctions are expressed by cortical 
glial cells (Dermietzel et al. 1991; Dermietzel et al. 1997; Condorelli et al. 2002; Condorelli et 
al. 2003). The most common of these are connexin30 and connexin43, which are expressed 
by astrocytes (Dermietzel et al. 1991; Condorelli et al. 2002). Oligodendrocytes express 
connexin32 and connexin45 (Dermietzel et al. 1997), but constitute a small fraction of glial 
cells in the CNS (5-10% compared to 50-60% for actrocytes (Singh et al. 2003)). Connexin32 
expression has also been localised to CNS neurons, but only in subcortical structures 
(thalamus and basal ganglia) (Dermietzel et al. 1989). Central nervous system neurons 
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express connexin36, 45 and 57, with the latter restricted to horizontal cells of the retina 
(Hombach et al. 2004). Connexin36 is the most common neuronal gap junction in the mature 
cerebral cortex, and its expression is restricted primarily to inhibitory interneurons (Deans et 
al. 2001). Connexin45 is expressed neuronally (Condorelli et al. 2003; Maxeiner et al. 2003), 
however adult cortical expression of connexin45 is low and restricted to parieto-occipital 
and entorhinal cortical regions (Maxeiner et al. 2003). Thus, in the mature cerebral cortex, 
the most prominent gap junctions are those between inhibitory neurons (connexin36) and 
those between astrocytes (connexin30 and 43). 
Connexin distribution patterns in the hippocampus are similar to those in the cerebral 
cortex; astrocytic gap junctions are formed predominantly by connexin30 (Condorelli et al. 
2002; Rouach et al. 2008), and connexin43 (Rouach et al. 2008) and GABAergic interneuronal 
junctions by connexin36 (Deans et al. 2001). There is evidence that connexin36 may also be 
sparsely expressed by pyramidal cells in the hippocampus where they are thought to form 
axo-axonal junctions (Schmitz et al. 2001; Hamzei-Sichani et al. 2007). 
3. Genetic experimental techniques for targeting gap junction subtypes 
Determining the exact role of gap junctions in seizurogenesis has been challenging because 
all known gap junction blocking drugs lack specificity (for an excellent review see (Juszczak 
and Swiergiel 2009)). For example, the gap junction blockers quinine and mefloquine have 
anti- and pro-seizurogenic properties independent of their gap junction-blocking effects. 
Quinine, at modest concentrations (~20µM), is well known to block a variety of neuronal ion 
channels; in particular quinine’s use-dependent blockade of sodium channels is a very 
similar action to the antiepileptic drug phenytoin (Lin et al. 1998). In vitro, quinine is 
convulsive at an intraperitoneal dose of 250 mg/kg (Amabeoku and Chikuni 1992) and 
mefloquine at 150mg/kg (Amabeoku and Farmer 2005) in mice. This effect is via a GABAA 
antagonist action (Thompson and Lummis 2008) and is seen in in vitro slices at 100µM and 
400 µM for mefloquine and quinine, respectively (Thompson and Lummis 2008). Mefloquine 
may also enhance neuronal excitability in cultures via a disruption to calcium homeostasis 
at greater than 30µM (Dow et al. 2003). Mefloquine also inhibits 5-HT3 receptors at 10µM 
(Thompson and Lummis 2008). 5-HT3 receptors are a ligand-gated Na/K channel and 
blockade would tend to have an inhibitory effect on neuronal excitability.  
The lack of specificity of pharmacological gap junction blockers has made it very difficult to 
interpret studies utilising these agents. Not only do they have non-gap-junctional off-target 
effects, they also affect multiple gap junction subtypes. Perhaps the exception to this is 
mefloquin (Cruikshank et al. 2004), which is reasonably specific for connexin36 gap 
junctions when delivered at an appropriately low dose (this is particularly so for cell 
cultures, where low doses that are more specific for connexin36 can be utilised (Cruikshank 
et al. 2004)). To fully understand the role of gap junctions in seizure processes, it is 
imperative to differentiate between gap junction subtypes. That is, it would be naïve to 
assume that blocking connexin43 gap junctions linking astrocytes would have the same 
functional effect as blocking connexin36 gap junctions linking inhibitory interneurons.  
Genetic approaches to controlling connexin subtype expression and function (reviewed 
recently by Giaume and Theis (2010)) have potential to greatly increase our understanding 
of gap junction function. By targeting the subtype-specific connexin sequences at either the 
DNA, RNA or protein level, it may be possible to regulate gap junction function with 
unparalleled precision. In the section that follows we will outline the genetic techniques that 
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offer the greatest promise as experimental tools in this regard, including mimetic peptides, 
transgenic manipulation and DNA/RNA interference. In section four we will look at 
functional studies that have utilised some of these techniques for the purpose of 
understanding gap junction regulation of seizure activity. 
3.1 Mimetic peptides 
Connexin mimetic peptides are short amino acid polymers corresponding to extracellular 
regions of the connexin protein. These molecules have shown promise as specific blockers of 
gap junction activity (Evans and Boitano 2001; Herve and Dhein 2010). It is thought that by 
binding to the connexin protein, connexin mimetics prevent connexon docking and block 
formation of the fully functional gap junction (Evans and Boitano 2001). In theory it should 
be possible to effect blockade of a specific gap junction subtype by designing mimetic 
peptide sequences specific to the connexin subtype in question. While promising in 
principle, there are some obstacles to the use of mimetics to effectively block gap junctions.  
Firstly, there is considerable overlap in the amino acid sequences in the extracellular 
domains of connexin proteins. For example, GAP27 is a mimetic peptide that was developed 
to target the second extracellular loop of the connexin43 protein. The amino acid sequence 
SRPTEK within GAP27 is also present in the extracellular domains of most other connexin 
subtypes; thus, GAP27 may block gap junctions universally (Evans and Boitano 2001). 
Specificity to connexin43 can be enhanced by restricting the age range of animals used. 
Cortical grey matter expression of connexin30 does not develop until three weeks after birth, 
peaks at four weeks and remains high into adulthood (Kunzelmann et al. 1999). In contrast, 
connexin43 is already expressed in neonatal tissue and also remains high into adulthood 
(Kunzelmann et al. 1999). Thus, in one to three week old rodents, connexin43 is the 
predominant astrocytic gap junction. Expression of the other main cortical connexin 
subtype, interneuronal connexin36, develops between that of connexin43 and connexin30, 
peaking at two weeks after birth and declining during the third week (Belluardo et al. 2000). 
Expression of connexin43 and connexin30 in astrocytic cultures show similar developmental 
time-courses, with connexin43 present in the first days of culture and connexin30 expression 
not detected until the cultures are five to six weeks old (Kunzelmann et al. 1999). 
Secondly, connexin mimetic peptides also block connexin hemichannels, albeit at different 
concentrations and over a different time course compared to their effect on gap junctions. 
Hemichannel effects occur at lower concentrations (5µM compared to 500-1000µM) 
(O'Carroll et al. 2008; Samoilova et al. 2008) and more rapidly (<30mins compared to >10 
hours, cultures and hippocampal slices, respectively) (Leybaert et al. 2003; Samoilova et al. 
2008). Although under normal physiological conditions the open probability of connexon 
hemichannels is low due to the blocking effect of divalent extracellular ions (magnesium 
and calcium) (Ebihara 2003; Ebihara et al. 2003), the open probability can be enhanced when 
extracellular magnesium and/or calcium levels are reduced (Ebihara et al. 2003). Thus, a 
possible effect of mimetic peptides on hemichannels must be considered likely when 
utilising the low-magnesium seizure model and at the higher mimetic concentrations 
required for gap junction blockade.  
Thirdly, the brain also expresses channels formed from pannexins, a group of proteins 
that share basic structural similarities to the connexin family at the level of the mature 
protein but are otherwise unrelated. Pannexins are expressed by inhibitory neurons in the 
hippocampaus (Bruzzone et al. 2003); however, the specific cellular expression in the 
cerebral cortex is not known. Pannexins form hemichannels in vivo, not complete cell-cell 
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express connexin36, 45 and 57, with the latter restricted to horizontal cells of the retina 
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offer the greatest promise as experimental tools in this regard, including mimetic peptides, 
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gap junctions (MacVicar and Thompson 2009). Because pannexins do not share sequence 
homology with connexins (Baranova et al. 2004; Locovei et al. 2006), in theory they should 
not be blocked by connexin mimetic peptides. However, there is evidence showing that 
pannexin hemichannels are blocked by connexin mimetic peptides via a physical steric 
hindrance mechanism (Dahl 2007; Wang et al. 2007). Also, unlike connexon hemichannels, 
pannexin channels can be activated under normal physiological conditions (Bao et al. 
2004). Thus, a possible effect of mimetic peptides on pannexin channels cannot be 
overlooked. Furthermore, pannexins themselves may be involved in seizurogenic 
processes, as shown by mimetic peptide blockade of Pannexin-1 in hippocampal slices 
(Thompson et al. 2008).  
3.2 Connexin transgenic knockout animals 
Gene knockout is a widely used technique for studying the function of a gene by removing 
that gene in an otherwise normal animal. This prevents the expression of the gene and its 
protein product. With conventional knockout techniques, embryonic stem cells are 
genetically manipulated by recombining a DNA cassette in place of the gene of interest to 
disrupt that locus. The manipulated stem cells are transferred into a developing embryo at 
the blastocyst stage and offspring homozygous for the altered loci are produced through a 
series of breeding crosses. Thus, the knockout animals develop in the absence of the gene 
under investigation. While this can be a powerful tool for investigating the function of the 
absent gene, it suffers from the limitation that developmental compensation can confound 
functional studies. Furthermore, because the gene is rendered non-functional in all tissues 
from which it would normally be expressed, it can be difficult to isolate any functional 
effects observed to a specific tissue or organ. 
To circumvent these problems, these techniques have been refined to allow for conditional 
knockout of a gene of interest in a site- and time-specific manner. The most common of these 
techniques utilises the viral-derived Cre/loxP recombinase system (see Kuhn and Torres 
(2002) for review). Cre is a recombinase enzyme that catalyses the removal of DNA 
segments flanked by loxP; which are specific 34 base-pair DNA sequences. The technique 
involves crossing two transgenic strains of animals, one expressing Cre and the other 
engineered with LoxP sites flanking a gene of interest (i.e. a floxed allele) to create a new 
strain in which Cre-mediated recombination removes the floxed gene. Tissue-specific gene 
knockout is achieved by restricting Cre expression to a particular tissue, for example by 
placing the enzyme under the control of a tissue-specific promoter (Kuhn et al. 1995). Time-
specific gene knockout can be achieved by using an inducible Cre promoter to control the 
expression of the Cre recombinase transgene (Kuhn et al. 1995).  This conditional knockout 
approach thereby theoretically allows any gene of interest to be deleted in a tissue- and 
time-specific manner during development. An example of an application of this approach is 
the conditional removal of connexin36 in neurons by crossing NESTIN-Cre animals with 
connexin36 floxed animals (Wellershaus et al. 2008). 
Deletion of various members of the connexin family has revealed some detail of the role of 
these proteins in regulating normal brain behaviour and thereby points to the 
contribution that these proteins may make to various normal and pathological 
neurological states. Examples include observations that Connexin36 knockout mice have 
reduced frequency hippocampal gamma oscillations (Buhl et al. 2003) and display an 
increased sensitivity to the seizures induced by the proconvulsant drug pentylenetetrazol 
(Jacobson et al. 2010).  
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3.3 Antisense oligodeoxynucleotide (AsODN) 
Antisense oligonucleotide (AsODN) directed destruction of messenger RNA (mRNA) 
molecules is a method by which to reduce gene expression at the level of the expressed 
transcript. AsODNs are short DNA sequences that are complementary to a targeted single 
stranded mRNA. For association of an AsODN with its target sequence, mRNA binding 
must occur. This involves binding of matched nucleotides along the length of both the 
AsODN and targeted mRNA sequence - with purine bases (guanine or adenine) associating 
with pyrimidine bases (cytosine or thymine or uracil); accordingly, very specific binding to a 
matched target sequence can be achieved. The AsODN-mRNA hybrid molecule formed by 
this association is digested by the endogenous enzyme RNase H1, effectively eliminating the 
targeted AsODN-transcript hybrid and reducing levels of the associated mature protein due 
to lower levels of translation. There are a number of reports of AsODNs being used to 
experimentally reduce levels of connexin protein (e.g. Moore and Burt (1994); Law et al. 
(2006)) although none of these studies have addressed the effects of connexin depletion on 
seizure phenotype. 
3.4 Small interfering RNA (siRNA) targeting of connexin gene expression 
Another approach to studying the function of a protein is to reduce levels (knockdown) of 
its messenger RNA (mRNA) transcripts by the use of small interfering RNA. The effect on 
phenotype (the physical manifestation) of such a knockdown provides clues as to the role of 
the targeted transcript, and thereby its protein product, in normal physiology. 
Small interfering RNA are short RNA duplexes (i.e. double stranded) molecules 21-28 
nucleotides long, which can recruit cellular protein machinery – i.e. the RNAi silencing 
complex or RISC – to detect a specific transcript and to degrade it in the cytoplasm. As a 
result, the mRNA transcript is no longer available to the translation protein machinery, 
thereby reducing levels of the mature protein (reviewed in (Karkare et al. 2004)). They can 
be introduced in vitro to cells in culture, in vivo into various target tissues by injection (e.g. 
intrathecally) and by viral transfection.     
There are a number of reports of successful application of siRNA to knockdown connexin 
levels (e.g. (Nakano et al. 2008; Schock et al. 2008)) although, similarly to the AsODN 
approach, to date this methodology has not been used in vivo to study the effect of depletion 
of any of the connexin protein family on seizures. 
3.5 Other methods for reduction of connexin based cell-to-cell connectivity 
Other methods for selective reduction or elimination of cell-to-cell connectivity via gap 
junctions is via the use of antibodies directed to regions of the connexon extracellular loop. 
This approach was used by Lin and colleagues (2002) to study the effect of connexin43 
blockade on glioma cells. In that study the authors raised an antibody (namely EL1-46) to an 
epitope (peptide) corresponding to amino acid positions 46-76 in the first external loop (EL1) 
of the mature protein. The resultant antibodies were shown to produce up to 70% blockade 
of gap junctions when used at 60mg/mL against cultured astrocytes.  In another study, 
antibodies (EL2-186) raised to an epitope corresponding to amino acids 186-206 in the 
second extracellular loop of connexin43 were shown to give up to 50% reduction in cell-to-
cell coupling in cultured astrocytes (Hofer and Dermietzel 1998). 
While antibodies have not been widely used to study seizure by in vivo application, the 
rapid turnover of the connexin family of proteins would likely make them good targets for 
such an approach.   
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4. Do gap junctions promote or hinder seizure activity? 
Interest in the subject of gap junction involvement in the generation of seizure activity has 
been driven largely from two complementary ideas: that seizures result from 
hypersynchronous activation of neuronal populations within the central nervous system; 
and that direct electrical communication between neurons (via open gap junctions) ought to 
promote hypersynchronous activity because of the near instantaneous propagation of 
electrical activity between gap junction-linked cells. The idea that open gap junctions 
promote seizure activity has been fuelled by a large number of studies showing that gap 
junction blockade with pharmacological agents is almost universally anticonvulsant (Xiong 
et al. 2000; Kohling et al. 2001; Bostanci and Bagirici 2007a; Bostanci and Bagirici 2007b; 
Medina-Ceja et al. 2008; Nassiri-Asl et al. 2008; Nassiri-Asl et al. 2009). However, taking 
these studies at face value belies the complexity of the nervous system and underestimates 
the bluntness of many of the tools with which it has been examined.  
As we have already proposed, we do not believe it is possible to approach the question of 
gap junction involvement in seizure mechanisms without considering the distribution of 
gap junction subtypes within specific cell populations. In the following section we will 
review the theoretical and experimental basis for pro- and/or anti-convulsant effects of gap 
junction subtypes on seizures. Because connexin36 and connexin43 subtypes have been most 
extensively studied, the discussion which follows will focus separately on the role of 
connexin36-linked neuronal and connexin43-linked astrocytic populations. This does not 
preclude the possibility that other less well studied gap junction subtypes may also be 
important. 
4.1 Gap junction-linked interneuronal networks 
In the mature brain, neuronal gap junction expression is restricted largely to inhibitory 
interneurons and are almost exclusively of the connexin36 subtype. Connexin36 gap 
junctions are not expressed uniformly across all interneuron classes. Rather, two main 
expression patterns predominate: that between same-class parvalbumin-containing 
multipolar-bursting (MB) cells (Deans et al. 2001; Liu and Jones 2003; Markram et al. 2004; 
Baude et al. 2007), which synapse onto pyramidal cells in the region of the soma or proximal 
dendrites (Deans et al. 2001; Liu and Jones 2003; Markram et al. 2004); and that between 
multipolar calretinin-positive (MCR) and MB interneurons (see Fig 2).  
The effect on global brain dynamics of a disruption to gap junction connectivity within these 
inhibitory networks is not intuitively obvious. Figure 2 is a simplified wiring diagram 
showing the main synaptic and gap junction connections within the cerebral cortex. 
According to this schema, blockade of direct electrical communication between inhibitory 
cells could have excitatory effects at the level of pyramidal cell activity via two mechanisms. 
Firstly, blocking gap junctions between same-class MB interneurons (I2 in figure 2) will 
result in a reduction in synchronous firing within this population (Deans et al. 2001) and 
cause a disruption to inhibitory timing at the pyramidal cell soma. Inhibitory timing is a 
critical element in maintaining stability in pyramidal cell networks and small inhibitory 
delays provide a powerful seizurogenic stimulus (Steyn-Ross et al. 2004). Secondly, open 
gap junctions between MCR and MG cells (I1 and I2, respectively in figure 2) provide an 
“excitation” path between MCR and MB cells, effectively enhancing the inhibitory effect of 
MB cells at the pyramidal cell soma. Thus, closing these gaps will effectively reduce MB 
activity and release MB inhibition of the pyramidal cell population.  
 




Fig. 2. Schematic showing possible connections involved in seizure spread. Two excitatory 
(triangles, E1 and E2) and two inhibitory (circles, I1 and I2) neurons are shown. Chemical 
synaptic pathways are shown in solid lines and gap-junction mediated pathways are shown in 
dashed lines. Excitatory pathways are indicated by a “+” and inhibitory pathways by a “-“. 
The prediction is that connexin36 gap junction blockade will tend to have a pro-seizure 
effect and there is accumulating experimental evidence to support this hypothesis. Yang and 
Ling (2007) have shown an increase in excitatory post synaptic potential amplitude 
following uncoupling of (GABAergic) inhibitory interneurons with carbenoxolone. 
Carbenoxolone is a broad spectrum gap junction blocker (Gajda et al. 2005; Nilsen et al. 
2006) and would have likely blocked all gap junctions in this study. Enhancement of 
seizure-like event (SLE) frequency has been shown in hippocampal slices following 
application of carbenoxolone and quinine (Kraglund et al. 2010). The seizure models used in 
this study (Cs+-induced SLE and low-Ca SLE activity) are non-synaptic in origin, 
confirming that the excitation effect is not via a synaptic mechanism. Similar excitatory 
effects have been observed in neocortical slices with mefloquin, which blocks connexin36 
gap junctions with greater specificity than carbenoxolone (Voss et al. 2009). This effect is 
eliminated in connexin36 knockout animals (Voss et al. 2009). Furthermore, connexin36 
knockout mice have a greatly enhanced propensity for pentylenetetrazol seizures (Jacobson 
et al. 2010) and increased hippocampal inter-ictal discharges (Pais et al. 2003) compared to 
wild-type animals.  
Interestingly, connexin32 knockout mice also exhibit neocortical neuronal excitability (Sutor 
et al. 2000). One of the explanations for this given by the authors is a desynchronisation of 
inhibitory interneuronal networks; although this is based on the speculation that connexin32 
gaps are expressed by interneurons in the cerebral cortex. Currently, there is no evidence 
that cortical neurons express connexin32 gaps (Dermietzel et al. 1989), although neurons 
from subcortical nuclei such as the thalamus and basal ganglia show a low level of neuronal 
expression (Dermietzel et al. 1989). 
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Fig. 2. Schematic showing possible connections involved in seizure spread. Two excitatory 
(triangles, E1 and E2) and two inhibitory (circles, I1 and I2) neurons are shown. Chemical 
synaptic pathways are shown in solid lines and gap-junction mediated pathways are shown in 
dashed lines. Excitatory pathways are indicated by a “+” and inhibitory pathways by a “-“. 
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Contrary to the above findings, hippocampal slices from connexin36 knockout mice show a 
reduction in ongoing seizure-like activity in response to the convulsant 4-aminopyridine 
(Maier et al. 2002) and a reduction in fast “ripple” (100-200Hz) oscillations (Maier et al. 
2002). Ripples are partly of inhibitory origin (Grenier et al. 2001) and have been implicated 
in the initiation of seizures (Grenier et al. 2003). The implication is that connexin36 blockade 
inhibits seizure initiation by disrupting ripple formation.  
The discrepancies in experimental findings clearly illustrates that the role of connexin36 gap 
junctions in seizureogenesis remains to be unequivocally resolved. Many of the studies 
mentioned above suffer from the limitations already discussed, particularly in terms of non-
specificity of pharmacological drug action. In those studies where connexin36 knockout 
animals have been studied, compensatory effects may also confound the interpretation of 
results (Voss et al. 2010). Furthermore, the utilisation of different seizure models, analysis 
methods and choice of tissue between research groups adds further complexity that may 
account for the apparent contradictions in some results.  
4.2 Mathematical models of gap junction effects 
A further avenue of investigation that may help to untangle some of this complexity is 
computer-aided mathematical modelling. Modelling studies have the enviable advantage 
that selected parameters can be manipulated with absolute specificity. As mentioned in the 
introduction, no computer model developed to date comes close to representing the brain in 
all its complexity or functionality; but when aligned with (and refined by) experimental 
data, computer models can provide an informative adjunct to experimental biology. 
Clearly a generalised seizure is the manifestation of a dramatic change in the mode of 
activity of neuronal populations. It can be most accurately described as a change in the 
dynamics of a neural mass. The most important conclusion from modelling studies is that 
the seizure state is principally a transition from a stable steady mode of operation to an 
oscillatory mode. We would emphasize that the dynamic signature of a seizure is oscillation, 
rather than simple hyperexcitation – although often hyperexcitation (manifest clinically as the 
tonic phase of a generalised seizure) will precipitate a secondary oscillation (manifest 
clinically as the clonic phase of a generalised seizure). The tendency for this transition to 
occur depends on both the intrinsic properties of each of the neurons, and also on how they 
are connected together into networks. The strength and time-course of the interneuronal 
connections are critical in whether the behaviour of the system will be stable or unstable 
(oscillatory). The synapses may be chemical or electrical, and are modulated by a variety of 
glial activities (as mentioned previously). We emphasize that the electrical connections 
between neurons differ from the chemical synapses in three critical ways:  
i. a chemical synapse between inhibitory neurons is inhibitory – i.e. it effectively reduces 
the activity of the downstream neuron, thus allowing downstream excitatory neuronal 
activation. In contrast an electrical synapse between inhibitory neurons has similar 
dynamic effects as an excitatory glutamatergic synapse – i.e. increasing the activity of the 
second neuron, which in turn dampens the excitatory cells and the system as a whole 
(see fig 2). Dynamically this is equivalent to an increase in the strength of the basket 
cells, which tend to control seizure spread. 
ii. if the interneuronal gap junctions are open, the inhibitory neurons become a form of 
syncitium, which supports spatial demarcation of areas of high-firing in the neocortex 
and reduces the tendency of the cortex to become oscillatory. 
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iii. open gap junctions will reduce input resistance of the neuron, and hence act to shunt 
both excitatory and inhibitory synaptic input, which effectively results in a weakening 
of chemical synaptic connectivity. 
Quantitative modelling of the influences of electrotonic synapses is still at an early stage. 
There are a number of papers which model the effects of gap junctions on other oscillatory 
behavior in the brain (gamma rhythms); and quite a few papers that model seizures of 
various types – but relatively few papers that look at both seizures and gap junctions. 
Broadly, there are two approaches to quantitative modelling of gap junctions and their 
modulation of neural dynamics. One is to model, in detail, modest (typically ~ 4 000) 
numbers of inhibitory and excitatory neurons. We refer to these as “neuron-by-neuron” 
models. These models try to include the various multicompartmental ion channel 
conductances within neurons, and chemical and electrotonic synaptic connections between 
different neuronal subtypes. Whilst these approaches present a seductive verisimilitude 
with real brain connections, they have significant, and under-appreciated, disadvantages. 
They are computationally very expensive, and – whilst it is easy to replicate experimentally-
derived EEG or ECoG signals in the model output – it is difficult to generalise the results 
beyond the immediate outputs; and thus achieve some sort of broader analytic 
understanding of the dynamics of the neuronal populations. The other approach is to use 
some form of “mean-field” or “neural mass” model. These models quantify the behavior of 
a ‘typical’ neuron, and are unable to distinguish individual neurons. Therefore the accurate 
correspondence of the parameters in the model with neurobiological measurements is more 
difficult – but the mean-field models are computationally very tractable, and allow a more 
general understanding of processes that influence the dynamics of the brain. They also 
allow the full mathematical arsenal of statistical physics to be applied to neurobiology. The 
seizure state is usually identified as an extreme oscillation in neuronal dynamics. This being 
the case, the problem of whether the brain will enter a seizure can be rephrased in the 
language of dynamical systems theory as: “whether the state of the various parameters that 
control the brain dynamics is such that the brain can enter a region of instability?” If the 
problem is linearised it simplifies to the question of: “whether the largest real eigenvalue in 
the system is greater than zero?” We can look at ranges of values for various parameters, 
that we have deemed to be important in controlling the behaviour of the model system. 
Certain combinations of parameter ranges will result in a stable neuronal activity (the 
system will evolve towards a fixed point); and at other ranges the system will be unstable (it 
will oscillate or undergo irregular chaotic behaviour). The boundary between these two 
modes of behavior is called a “basin boundary”. If the system is close to a basin boundary 
that encloses an unstable state, minor noise-induced changes in parameter values are more 
likely to precipitate the neuronal population into a seizure. Typically the choice of 
parameter values are constrained by experimental estimates from different neuronal 
populations of such factors as the number of neuronal connections, neuronal membrane 
potential, and synaptic gain.  
4.2.1 Neuron-by-neuron models 
Using very detailed neuron-by-neuron models, Traub and co-workers (Traub 2003) have 
published a number of papers in which they investigate various aspects of the effects of both 
inhibitory-inhibitory gap junctions and excitatory-excitatory axonal gap junctions. They found 
that inhibitory-inhibitory gap junctions were not necessary for the presence of gamma 
oscillations, but that the presence of open gap junctions increased the strength and precision of 
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these oscillations. This has been a recurring theme in almost all experimental and modelling 
studies of the contribution of gap junctions to neural activity. Namely, that the role of the gap 
junctions is a secondary one; in which they interact with chemical synaptic function to 
sculpture and augment existing neuronal rhythms. In these papers this group were primarily 
interested in testing whether pyramidal cell axo-axonal gap junctions were necessary for the 
expression of very fast oscillations – which are believed to be important in the process of 
seizure development (see section 4.3 below). The role of the much more common inhibitory-
inhibitory gap junctions was relegated to a few sentences in which they stated “in addition to 
gamma oscillations, synchronized epileptiform bursts also occur in the connexin36 knockout 
(but not wild-type) in the presence of kainate (Pais et al. 2003).” (Traub 2005). 
The other important attempts at neuron-by-neuron modelling of interneuronal gap junction 
effects were by van Drongelen (2004) and Di Garbo (2004). Both papers had similar results. 
They found that inhibitory-inhibitory gap junctions acted to synchronize the inhibitory cell 
populations, but the actual effects depended strongly on pre-existing activity. If this activity 
was already strongly synchronous, then whether gaps junctions were open or closed had 
little influence.  
4.2.2 Mean-field models 
In mean-field models seizures are usually conceived of as the result of a so-called “Hopf 
bifurcation” in the dynamics of the brain (Breakspear et al. 2006). There is mathematical 
precision and complexity behind this statement, but in simple descriptive terms, the 
dynamics of the brain change from a fixed point to a widespread oscillation between zero 
firing and high firing states. To date there are no publications of mean field models of the 
effects of gap junctions in seizure generation, but preliminary communication by Steyn-Ross 
et al. in general agree with experimental results and the neuron-by-neuron models – i.e. that 
open inhibitory-inhibitory gap junctions tend to stabilise the brain, whereas excitatory-
excitatory gap junctions have the opposite effect. The effects are not very large but may be 
clinically important. As an example of the sort of output from the mean-field approach, 
figure 3 shows the regions that are associated with oscillatory behaviour in the presence of 
open or closed inhibitory-inhibitory gap junctions. The white area is the region of seizure 
behavior if the gap junctions are open, and the grey area is the increased area of oscillation if 
the gap junctions are closed. It can be seen that closure of these gap junctions increases the 
size of the basin boundary by about 20%. This means that the range over which 
combinations of the magnitude of the inhibitory post-synaptic potential and the degree of 
resting membrane depolarisation result in seizures is modestly greater if the inhibitory- 
inhibitory gap junctions are closed.  
4.3 Gap junction-linked pyramidal axo-axonal networks 
A discussion on neuronal gap junctions and seizures would not be complete without 
considering pyramidal cell axoaxonal junctions. Axoaxonal gap junctions have been 
demonstrated between pyramidal cells in the hippocampus (Schmitz et al. 2001; Hamzei-
Sichani et al. 2007) and are probably of the connexin36 subtype (Hamzei-Sichani et al. 2007). 
Modeling studies have implicated these junctions in the generation of fast ripple oscillations 
(Traub et al. 2001) and epileptogenesis (Traub et al. 2002); and blockade is theorised to have 
an anticonvulsant effect. The finding that neither pharmacological nor genetic connexin36 
blockade has an anticonvulsant effect in neocortical slices (Voss et al. 2010) suggest that 
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either these gap junctions are not present in the cortex or are so few as to have minimal 
impact on seizure processes. If initial findings that axoaxonal gap junctions are composed of 
connexin36 subunits (Hamzei-Sichani et al. 2007) prove to be correct, this may explain some 
of the discrepancy in connexin36 gap junction blocking studies. That is, it would provide a 
rational basis for connexin36 blockade potentially having both pro- or anti-convulsant 




Fig. 3. Size of areas where the model shows seizure-like oscillatory behavior. We have 
chosen a parameter space with axes of synaptic gain (Inhibitory Postsynaptic Potential 
(IPSP)) and intrinsic neuronal excitability (change in resting membrane potential (δVrest)). 
The white area is the region of parameter space in which the model cortex is unstable 
(positive real eigenvalues) when the inhibitory-inhibitory gap junctions are open. The grey 
area is the region of instability with closed inhibitory-inhibitory gap junctions. The black 
area is the region of stable cortical dynamics. 
4.4 Gap junction-linked astrocytic networks 
Increasingly important and diverse roles for glial cells in cortical neurophysiological 
function and dysfunction are being reported. In particular, the role of astrocytes in epilepsy 
has been (Penfield 1929) and remains a subject of considerable interest (see Steinhauser and 
Seifert (2002) for review). Astrocytes are extensively linked by gap junctions (primarily 
connexin43 and connexin30) and connexin43 is upregulated at epileptic foci in vivo (Fonseca 
et al. 2002), implicating a role for this gap junction in the seizure process. The nature of this 
role however is not clearly understood. Two divergent possibilities present themselves from 
the literature.  
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Firstly, gap junction-linked astrocytic networks could contribute to seizure genesis by 
facilitating the spread of neuronal activity via propagating calcium waves (Nedergaard 
1994) and glutamate release. Astrocytes produce spontaneous slow calcium transients 
during seizure-like activity in many in vitro models of epilepsy (Tashiro et al. 2002; Stout 
and Charles 2003; Tian et al. 2005); these events occur independent of neuronal activity 
(Parri et al. 2001; Wang et al. 2006) and are causally linked to astrocytic release  
of glutamate (Parpura et al. 1994; Tian et al. 2005) and an increase in neuronal excitability 
(Fellin et al. 2006) and synchronicity (Fellin et al. 2004). Furthermore, astrocytic release  
of glutamate can induce epileptiform activity in pyramidal cells independent of synaptic 
activity (Kang et al. 2005; Tian et al. 2005) and can enhance synaptically driven seizure-
like events (Fellin et al. 2006). There is also evidence that gap junction-coupled astrocytes 
may support epileptiform activity by supplying glucose to neuronal networks (Rouach  
et al. 2008). Together, these data build a strong case for an important function for  
gap-junction-linked astrocytes in promoting seizure activity. There is experimental 
support for this from hippocampal slice studies, where connexin43 gap junction blockade 
with GAP27 has been shown to attenuate seizure-like activity (Samoilova et al. 2008). An 
important caveat is that this study may be confounded by effects of the mimetic peptide 
on pannexin and hemichannels. Indeed, pannexin1 hemichannel blockade with “panx” 
(100µM, sequence WRQAAFVDSY) has antiepileptic effects in hippocampal slices 
(Thompson et al. 2008). Pannexin1 hemichannels augment synaptic function by providing 
an NMDA-linked depolarizing current during intense synaptic activity (Thompson et  
al. 2008). 
Alternatively, gap junction-linked astrocytic networks could limit seizure activity by 
acting as a sink for extracellular potassium ions (Orkand 1986) and/or excitatory 
neurotransmitters such as glutamate. The effect of an elevation in extracellular potassium 
is to shift the equilibrium potential for potassium to a more depolarised level; the flow-on 
effect of which is resting membrane depolarisation and enhanced cell excitability. A 
similar sequestering role for gap-junction-linked astrocytic networks has been proposed 
for the excitatory neurotransmitter glutamate (Tanaka et al. 2008). Uncoupling astrocytic 
connexin43 gap junctions has also been shown to directly reduce the expression of the 
glutamate transporter GLT-1, resulting in reduced glutamate uptake by astrocytes (Figiel 
et al. 2007). Astrocytic networks could also limit seizure activity through the coordinated 
release of ATP (see Halassa and Haydon (2010) for review), the conversion of which to 
adenosine has an inhibitory effect on neuronal activity. Experimental support for seizure-
limiting effects of astrocytic coupling comes from hippocampal slice studies showing that 
conditional deletion of astrocytic connexin43 and unrestricted deletion of connexin30 
results in impaired potassium clearance and reduced seizure threshold (Wallraff et al. 
2006). While this study has the advantage of targeted genetic manipulation, one cannot 
rule out the possibility of confounding compensatory developmental effects in the 
transgenic animals.  
Connexin30 is the other main connexin subtype expressed by astrocytes in the mature CNS. 
Functional effects of targeted manipulation of connexin30 gap junctions have not been 
investigated. However, connexin30 has been shown to be up-regulated following kainate-
induced seizures in rats (Condorelli et al. 2002). While this implicates connexin30 in the 
seizure process, an inherent problem with this and similar studies is that changes in 
connexin or gap junction expression do not necessarily indicate whether these modifications 
are a cause or a consequence of the seizure process. Thus, while there are a growing number 
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of papers documenting alterations in connexin subtype expression (including connexin43 
(Fonseca et al. 2002)) during or after seizures (see (Rouach et al. 2002) and tables 2 and 3), 
studies such as these are generally not helpful in determining the functional role of the 
subtype in question. 
In summary, the role of astrocytic gap junctions in seizureogenesis has not been 
unequivocally resolved; with theoretical and experimental grounds for both pro- and 
anticonvulsant effects. It may be that both hypotheses will hold true and that the functional 
expression of astrocytic gap junction manipulation will be shown to depend upon secondary 
factors such as the genetic background of the animals (Wiencken-Barger et al. 2007) and/or 
physiological factors underlying the regulation of astrocytic function. 
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5. Conclusion 
In this chapter we have sought to bring together research from a wide range of disciplines 
encompassing electrophysiology, molecular biology and mathematical modelling, with the 
aim of addressing the role of gap junctions in the mechanism of seizures. The prevailing 
notion that open gap junctions promote seizure activity is overly simplistic and does not do 
justice to a growing body of literature showing that the opposite may be true in certain 
situations. There is also no evidence to support the idea that gap junctions either cause or 
ablate seizures per se; rather, they perform a modulatory role that is dependent upon the 
prior activity of the system and upon gap junction subtype. In any discussion it is essential 
to be precise about the type of experimental manipulation used, and exactly which gap 
junction subtype is under consideration. Thus, excitatory effects may be expected when 
pyramidal cell axo-axonal gap junctions are opened, while the opposite is likely with 
opening of inhibitory interneuronal gap junctions. Electrophysiological and modelling 
studies support this delineation. However, there is still some way to go before we will fully 
understand this complex area of neurobiology. The role of astrocytic gap junctions in 
particular remains an open question. Astrocytes are increasingly being recognised for their 
complex neuroregulatory functions and gap junctions are well suited for this role. Whether 
astrocytic gap junctions promote or hinder seizure activity is likely to depend upon 
prevailing neurophysiological factors governing the state of ongoing neuronal activity. 
Furthermore, many gap junction subtypes have been poorly studied to date and their 
possible role in seizure processes is undetermined. Greater understanding of these matters 
rests upon development and application of experimental techniques and pharmacological 
tools for targeted modulation of specific gap junction subtypes.  
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1. Introduction 
Lafora disease or Lafora progressive myoclonic epilepsy was first described in 1911 by 
Gonzalo Lafora (Lafora, 1911; Lafora & Glueck, 1911). The disease belongs 
phenomenologically to the progressive myoclonic epilepsies (Monaghan & Delanty, 2010) 
and is the most prevalent of such conditions, which include myoclonic epilepsy with 
ragged-red fibers, action myoclonus-renal failure syndrome, Kuf’s disease, infantile 
neuroaxonal dystrophy, the sialidoses and Unverricht-Lundborg disease (Baltic myoclonus) 
(Monaghan & Delanty, 2010). These diseases afflict initially healthy children with ever-
worsening and soon intractable myoclonus and epilepsy, usually associated with 
neurodegeneration, eventual dementia and early death (Ramachandran et al., 2009). 
The first symptoms of Lafora disease appear between the ages of 8 and 18 years. There is an 
insidious, near-simultaneous or rapidly successive onset of headaches, difficulties in school 
work, myoclonic jerks, generalized seizures and in many cases, visual hallucinations of both 
epileptic and psychotic origin. The myoclonus, seizures and hallucinations gradually 
worsen and become intractable. For many years, the patient struggles to maintain normal 
contact and communication, interrupted by extremely frequent myoclonic absence seizures. 
Gradually, dementia sets in, and by 10 years after onset, the patient is in near continuous 
myoclonus with absences, frequent generalized seizures, and profound dementia or a 
vegetative state (Minassian, 2001; Ramachandran et al., 2009; Striano et al., 2008). 
A distinctive pathology characterizes Lafora disease. Cells of various types exhibit dense 
accumulations of malformed and insoluble glycogen molecules, termed polyglucosans, 
which lack the symmetric branching that allows glycogen to be soluble. These polyglucosan 
accumulations are called Lafora bodies, and in the central nervous system, they are present 
profusely in all brain regions and in the majority of neurons, specifically in the cell bodies 
and dendrites (Minassian, 2001; Ramachandran et al., 2009; Striano et al., 2008). 
Genetically, Lafora disease is an autosomal recessive disease caused by mutations in two 
genes: (1) the EPM2A gene, located on chromosome 6 at 6q24, coding for the protein laforin, 
a dual-specificity phosphatase (DSP), accounting for the largest group of patients (Minassian 
et al., 1998) and (2) the EPM2B (NHLRC1) gene, located on chromosome 6 at 6p22, coding 
for the protein malin, an E3 ubiquitin ligase that interacts with laforin (Chan et al., 2003a; 
Chan et al., 2003b). About 20% of cases are not explained by abnormalities in genes coding 
for laforin or malin (Singh & Ganesh, 2009); it is postulated that the mutations involved in 
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these cases involve either an unknown third gene or a regulatory sequence for the EPM2A 
or EPM2B genes (Monaghan & Delanty, 2010; Singh & Ganesh, 2009). 
Laforin is the only human DSP known to have a carbohydrate binding module (CBM) 
responsible for targeting the phosphatase towards glycogen (Wang et al., 2002). CBMs are 
typically found in glucosyl hydrolases and glucotransferases in bacterial, fungal or plant 
genomes (Boraston et al., 2000; Boraston et al., 2004; Gentry & Pace, 2009; Hashimoto, 2006; 
Shoseyov et al., 2006). The vast majority of enzymes containing CBMs utilize the domain to 
bind a specific glucan and enzymatically act on the sugar, as in the case of α-amylase 
(Boraston et al., 2004). Accordingly, it has been demonstrated that laforin and starch excess 4 
protein (SEX4), an Arabidopsis thaliana protein with laforin-like properties (Gentry et al., 
2007), bind and dephosphorylate glucans, such as glycogen and starch (Gentry et al., 2007; 
Gentry et al., 2005; Tagliabracci et al., 2007; Tagliabracci et al., 2008; Tagliabracci et al., 2011; 
Worby et al., 2006). While laforin and SEX4 bind similar types of glucans, they utilize 
distinct CBMs (Boraston et al., 2004). CBMs are classified into 62 evolutionarily distinct 
families, based on their primary sequence, secondary and tertiary structure predictions, and 
crystal structures (Boraston et al., 2004; Hashimoto, 2006; Shoseyov et al., 2006). In 2004, 
laforin was included in the CBM20 family, formerly known as the starch-binding domain of 
family 4 – SBD4 (CAZy database - http://www.cazy.org/Carbohydrate-Binding-
Modules.html) (Coutinho & Henrissat, 1999). At that time, CBM20 family members were 
only known to be associated with amylases and glucanotransferases in bacteria, fungi and 
plants (Coutinho & Henrissat, 1999). The degree of homology of laforin and other members 
of the CBM20 family is very low. Furthermore, the laforin CBM secondary structure does 
not correlate very well with the other members of the CBM20 family (Girard et al., 2006). 
Nevertheless, the conservation of three tryptophans is of particular significance. They are 
invariant both in the few available laforin sequences from other species, as well as in most 
other CBM20 sequences (Girard et al., 2006). 
The phosphatase domain of laforin has been characterized and shown to act as a DSP, based 
on the differential kinetic parameters of dephosphorylation of the substrates p-nitrophenyl 
phosphate (pNPP) and 3-O-methylfluoresceinyl phosphate (OMFP). For DSPs, the kcat/KM 
values are typically more than two orders of magnitude higher with OMFP than with pNPP, 
whereas they are in the same order of magnitude for protein tyrosine phosphatases (Girard 
et al., 2006). 
The pNPPase activity of laforin has been shown to be inhibited by glycogen and related 
polysaccharides such as amylopectin and amylose, with inhibition potencies increasing with 
the decrease in polymer branching (Wang & Roach, 2004). Later, it was observed that laforin 
can dephosphorylate such polysaccharides (Tagliabracci et al., 2007). 
Laforin activity was also shown to be dependent on laforin dimerization via its CBM (Liu et 
al., 2006) and to interact with proteins involved in glycogen metabolism, such as glycogen 
synthase (GS) (Worby et al., 2006), and with the glycogen-targeting regulatory subunit R5 of 
protein phosphatase 1 (PP1) (Fernández-Sánchez et al., 2003). Laforin was also shown to 
interact with two ubiquitous proteins with unknown functions, EPM2AIP1 (Ianzano, 2003) 
and HIRIP5, a cytosolic protein predicted to be involved in iron homeostasis (Ganesh et al., 
2003). Laforin also interacts with malin, a single subunit E3 ubiquitin ligase containing a RING 
domain and six NHL domains (Gentry et al., 2005). Malin was shown to interact and to 
regulate laforin levels by mediating its ubiquitination, and the malin RING domain was 
necessary and sufficient to mediate laforin polyubiquitination leading to its proteosomal 
degradation (Gentry et al., 2005). Additionally, laforin was shown to recruit specific substrates 
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to be ubiquitinated by malin (Lohi et al., 2005; Solaz-Fuster et al., 2008). GS and R5 
ubiquitination promote the proteasomal degradation of both proteins (Lohi et al., 2005; Solaz-
Fuster et al., 2008), and K63-linked ubiquitination of AMP-activated protein kinase (AMPK, a 
serine/threonine protein kinase that acts as a sensor of the cellular energy status) which 
extends the protein lifetime (Moreno et al., 2010). Laforin also promotes the dephosphorylation 
of glycogen synthase kinase 3 (GSK3) at Ser9, activating this enzyme and leading to the GS 
phosphorylation at multiple sites with subsequent inhibition (Lohi et al., 2005). 
Therefore, laforin seems to be involved in glycogen metabolism as a sensor of poorly 
branched glycogen resulting from GS overactivity relative to glycogen-branching enzyme 
activity by modulating GS, either via GSK3 dephosphorylation resulting in GS inhibition, or 
via malin interaction, resulting in GS ubiquitination and subsequent degradation and 
inhibition of R5-induced glycogen synthesis. 
The laforin/malin complex has also been recently implicated in autophagy, acting as a 
cellular toxicity suppressor by clearing misfolded proteins through the proteasome system 
(Aguado et al., 2010; Garyali et al., 2009; Knecht et al., 2010). A putative role for laforin in 
Tau hyperphosphorylation (one of the distinctive hallmarks of Alzheimer’s disease) via 
GSK3 dephosphorylation has also been reported (Puri et al., 2009). 
Despite the solid evidence for laforin’s involvement in glycogen metabolism and Lafora 
disease, little is known about the structural mechanism of the glycogen interaction. This is due 
to the lack of a solid protocol for producing the large amounts of protein needed for structural 
studies. In this work we report the expression, purification and characterization of both laforin 
and its CBM, with appropriate yields for future structural and biophysical studies. 
2. Heterologous protein expression and purification 
In order to produce enough protein to perform structural studies, heterologous systems 
must be used. E. coli is by far the most widely employed host for heterologous protein 
expression (Rai & Padh, 2001). Its popularity is due to the vast body of knowledge about its 
genetics, physiology and complete genomic sequence, which greatly facilitates gene cloning 
and cultivation (Rai & Padh, 2001). High growth rates combined with the ability to express 
high levels of heterologous proteins, i.e., strains producing up to 30% of their total protein as 
the expressed gene product, result in high volumetric productivity. Furthermore, E. coli can 
grow rapidly to high densities in simple and inexpensive media (Rai & Padh, 2001).  
Laforin cDNA, coding for full-length laforin with a hexahistidine tag at its C-terminus, 
was cloned into the vector pET21a by Dr. Jack Dixon’s laboratory (Gentry et al., 2005). 
Previously, this tag was associated with problems in laforin purification and stability 
(Girard et al., 2006; Liu et al., 2006; Wang & Roach, 2004). Therefore, the hexahistidine tag 
was removed by using site-directed mutagenesis to introduce a stop codon at the end of 
the full-length laforin coding sequence. This was achieved using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene) according to the manufacturer’s instructions and 
using the oligonucleotide primers Laf_ΔHis-for and Laf_ΔHis-rev, whose sequences are 
presented in Table 1. 
The isolated CBM of laforin (Fig. 1, bold sequence) was also produced in order to study 
the biophysical interaction between the laforin CBM and carbohydrates and for future 
biotechnology applications. The cDNA sequence of the CBM domain was PCR amplified 
from the construct provided by Dr. Jack Dixon, using the oligonucleotides Laf_CBM-for 
and Laf_CBM-rev (Table 1), containing the restriction endonuclease recognition sites for 
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NcoI and XhoI, respectively, and ligated into NcoI/XhoI linearized pET29a. The 
Laf_CBM-rev primer introduced a RGD motif followed by a hexahistidine tag at the C-
terminus of the CBM. The RGD motif is found in the extracellular matrix and blood 
proteins, such as fibronectin, vitronectin, osteopontin, collagens, thrombospondin, 
fibrinogen, and von Willebrand factor and has been described as the major functional 
group responsible for cellular adhesion (Hwang et al., 2007; Ruoslahti & Pierschbacher, 
1987). The inclusion of a RGD motif at the C-terminus of the laforin CBM was intended to 
be a cell attachment motif in starch-based biomaterial functionalized with the CBM-RGD 
protein (Moreira et al., 2010). 
 





Table 1. Oligonucleotide primers used for laforin site-directed mutagenesis and for CBM 
cloning. The stop codon sequence introduced by site-directed mutagenesis is highlighted in 
bold. Underlined nucleotides indicate the restriction endonuclease recognition sequences 
used for cloning. 
Full-length Laforin and its CBM were expressed by transforming competent E. coli BL21 star 
strain (Invitrogen; a bacterial strain that is suited for high-level recombinant protein 
expression, due to improved stability of mRNA and the absence of lon and ompT proteases) 
with the constructs described above. After transformation, cells were plated onto Luria 
Broth (LB)-agar plates containing the appropriate antibiotic for positive clone selection, and 
positive colonies were then grown overnight in liquid LB/antibiotic media. These cultures 
were used to seed typically 1-2 liters of LB/antibiotic and grown at 37 ºC until the bacterial 
culture reached a cell density corresponding to an OD600 of 0.6. At that point, protein 
expression was induced for 3 h by the addition of isopropyl β-D-1-thiogalactopyranoside 
(IPTG) to a final concentration of 0.5 mM.  
As previously reported, laforin expression in E. coli is associated with the appearance of 
inclusion bodies (Girard et al., 2006), with the CBM behaving in a similar way (Moreira et 
al., 2010). Our expertise in refolding proteins expressed in the form of inclusion bodies was 
crucial for the successful production of high amounts of correctly folded protein 
(Castanheira et al., 2005; Turner et al., 2001; Simões et al., 2007). After cell pellet disruption, 
the inclusion bodies were washed in 50 mM Tris–HCl, 50 mM NaCl, pH 7.4, followed by a 
second washing step in 50 mM Tris–HCl, 50 mM NaCl, pH 7.4, 0.1% Triton X-100 (v/v). 
These washing steps were needed to remove membrane proteins and other contaminants 
that are released upon cell disruption (Clark, 2001). Purified inclusion bodies were dissolved 
in 8 M urea buffer (8 M urea, 0.1 M Tris, 1 mM glycine, 1 mM EDTA, pH 10.5) with 100 mM 
β-mercaptoethanol. 
Protein refolding was promoted by rapid dilution (20x) of the dissolved protein into 1 L of 
20 mM Tris base, 0.5 mM oxidized/1.25 mM reduced glutathione, 0.5 mM DTT; the pH was 
then slowly adjusted to pH 8.0 with 6 M HCl solution, and the protein was kept at 4 ºC until 
purification. After 3-7 days in a cold room, the refolded proteins were purified by two 
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 1  atgcgcttccgctttggggtggtggtgccacccgccgtggccggcgcccggccggagctg 
   M R F R F G V V V P P A V A G A R P E L  
 61  ctggtggtggggtcgcggcccgagctggggcgttgggagccgcgcggtgccgtccgcctg 
   L V V G S R P E L G R W E P R G A V R L  
 121 aggccggccggcaccgcggcgggcgacggggccctggccctgcaggagccgggcctgtgg 
   R P A G T A A G D G A L A L Q E P G L W  
 181 ctcggggaggtggagctggcggccgaggaggcggcgcaggacggggcggagccgggccgc 
   L G E V E L A A E E A A Q D G A E P G R  
 241 gtggacacgttctggtacaagttcctgaagcgggagccgggaggagagctctcctgggaa 
   V D T F W Y K F L K R E P G G E L S W E  
 301 ggcaatggacctcatcatgaccgttgctgtacttacaatgaaaacaacttggtggatggt 
   G N G P H H D R C C T Y N E N N L V D G  
 361 gtgtattgtctcccaataggacactggattgaggccactgggcacaccaatgaaatgaag 
   V Y C L P I G H W I E A T G H T N E M K  
 421 cacacaacagacttctattttaatattgcaggccaccaagccatgcattattcaagaatt 
   H T T D F Y F N I A G H Q A M H Y S R I  
 481 ctaccaaatatctggctgggtagctgccctcgtcaggtggaacatgtaaccatcaaactg 
   L P N I W L G S C P R Q V E H V T I K L  
 541 aagcatgaattggggattacagctgtaatgaatttccagactgaatgggatattgtacag 
   K H E L G I T A V M N F Q T E W D I V Q  
 601 aattcctcaggctgtaaccgctacccagagcccatgactccagacactatgattaaacta 
   N S S G C N R Y P E P M T P D T M I K L  
 661 tatagggaagaaggcttggcctacatctggatgccaacaccagatatgagcaccgaaggc 
   Y R E E G L A Y I W M P T P D M S T E G  
 721 cgagtacagatgctgccccaggcggtgtgcctgctgcatgcgctgctggagaagggacac 
   R V Q M L P Q A V C L L H A L L E K G H  
 781 atcgtgtacgtgcactgcaacgctggggtgggccgctccaccgcggctgtctgcggctgg 
   I V Y V H C N A G V G R S T A A V C G W   
 841 ctccagtatgtgatgggctggaatctgaggaaggtgcagtatttcctcatggccaagagg 
   L Q Y V M G W N L R K V Q Y F L M A K R  
 901 ccggctgtctacattgacgaagaggccttggcccgggcacaagaagattttttccagaaa 
   P A V Y I D E E A L A R A Q E D F F Q K  
 961 tttgggaaggttcgttcttctgtgtgtagcctgtga 
   F G K V R S S V C S L -  
Fig. 1. Laforin cDNA sequence (lower case letters) and translated protein sequence (upper 
case letters). The amino acids corresponding to the carbohydrate-binding module (CBM) are 
in bold.  
consecutive chromatographic steps. Each refolded protein was first concentrated to 150 mL 
by tangential flow ultrafiltration (Sartocon Slice, Sartorius), followed by concentration to 12-
15 mL with a N2-pressurized stirred-cell concentrator (Amicon 8200, Millipore). The protein 
solution was then clarified by ultracentrifugation (100,000x g, 20 min, 4 ºC), and the 
supernatant was applied to a size-exclusion chromatography column (HiLoad 26/60 
Superdex 200 prep grade, GE Healthcare), which was previously equilibrated in 20 mM Tris, 
0.4 M urea, pH 8.0, at 2 mL/min in order to separate the aggregated forms from the non-
aggregated forms of each protein (Fig. 2A and D). Full-length laforin (Fig. 2A) was shown to 
elute in two separate peaks. The first peak eluted at the expected column void volume 
(around 115 mL) and corresponded to soluble protein aggregates, and the second peak 
eluted at around 188 mL, which according to the column calibration should correspond to a 
globular protein with a molecular weight of 74 kDa, the expected value for the full-length 
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NcoI and XhoI, respectively, and ligated into NcoI/XhoI linearized pET29a. The 
Laf_CBM-rev primer introduced a RGD motif followed by a hexahistidine tag at the C-
terminus of the CBM. The RGD motif is found in the extracellular matrix and blood 
proteins, such as fibronectin, vitronectin, osteopontin, collagens, thrombospondin, 
fibrinogen, and von Willebrand factor and has been described as the major functional 
group responsible for cellular adhesion (Hwang et al., 2007; Ruoslahti & Pierschbacher, 
1987). The inclusion of a RGD motif at the C-terminus of the laforin CBM was intended to 
be a cell attachment motif in starch-based biomaterial functionalized with the CBM-RGD 
protein (Moreira et al., 2010). 
 





Table 1. Oligonucleotide primers used for laforin site-directed mutagenesis and for CBM 
cloning. The stop codon sequence introduced by site-directed mutagenesis is highlighted in 
bold. Underlined nucleotides indicate the restriction endonuclease recognition sequences 
used for cloning. 
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with the constructs described above. After transformation, cells were plated onto Luria 
Broth (LB)-agar plates containing the appropriate antibiotic for positive clone selection, and 
positive colonies were then grown overnight in liquid LB/antibiotic media. These cultures 
were used to seed typically 1-2 liters of LB/antibiotic and grown at 37 ºC until the bacterial 
culture reached a cell density corresponding to an OD600 of 0.6. At that point, protein 
expression was induced for 3 h by the addition of isopropyl β-D-1-thiogalactopyranoside 
(IPTG) to a final concentration of 0.5 mM.  
As previously reported, laforin expression in E. coli is associated with the appearance of 
inclusion bodies (Girard et al., 2006), with the CBM behaving in a similar way (Moreira et 
al., 2010). Our expertise in refolding proteins expressed in the form of inclusion bodies was 
crucial for the successful production of high amounts of correctly folded protein 
(Castanheira et al., 2005; Turner et al., 2001; Simões et al., 2007). After cell pellet disruption, 
the inclusion bodies were washed in 50 mM Tris–HCl, 50 mM NaCl, pH 7.4, followed by a 
second washing step in 50 mM Tris–HCl, 50 mM NaCl, pH 7.4, 0.1% Triton X-100 (v/v). 
These washing steps were needed to remove membrane proteins and other contaminants 
that are released upon cell disruption (Clark, 2001). Purified inclusion bodies were dissolved 
in 8 M urea buffer (8 M urea, 0.1 M Tris, 1 mM glycine, 1 mM EDTA, pH 10.5) with 100 mM 
β-mercaptoethanol. 
Protein refolding was promoted by rapid dilution (20x) of the dissolved protein into 1 L of 
20 mM Tris base, 0.5 mM oxidized/1.25 mM reduced glutathione, 0.5 mM DTT; the pH was 
then slowly adjusted to pH 8.0 with 6 M HCl solution, and the protein was kept at 4 ºC until 
purification. After 3-7 days in a cold room, the refolded proteins were purified by two 
 
 
Recombinant Laforin for Structural Studies 
 
105 
 1  atgcgcttccgctttggggtggtggtgccacccgccgtggccggcgcccggccggagctg 
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Fig. 1. Laforin cDNA sequence (lower case letters) and translated protein sequence (upper 
case letters). The amino acids corresponding to the carbohydrate-binding module (CBM) are 
in bold.  
consecutive chromatographic steps. Each refolded protein was first concentrated to 150 mL 
by tangential flow ultrafiltration (Sartocon Slice, Sartorius), followed by concentration to 12-
15 mL with a N2-pressurized stirred-cell concentrator (Amicon 8200, Millipore). The protein 
solution was then clarified by ultracentrifugation (100,000x g, 20 min, 4 ºC), and the 
supernatant was applied to a size-exclusion chromatography column (HiLoad 26/60 
Superdex 200 prep grade, GE Healthcare), which was previously equilibrated in 20 mM Tris, 
0.4 M urea, pH 8.0, at 2 mL/min in order to separate the aggregated forms from the non-
aggregated forms of each protein (Fig. 2A and D). Full-length laforin (Fig. 2A) was shown to 
elute in two separate peaks. The first peak eluted at the expected column void volume 
(around 115 mL) and corresponded to soluble protein aggregates, and the second peak 
eluted at around 188 mL, which according to the column calibration should correspond to a 
globular protein with a molecular weight of 74 kDa, the expected value for the full-length 
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laforin dimer (2 x 37 kDa). The fractions obtained during size-exclusion purification were 
analyzed for phosphatase activity in 50 mM Tris/HCl buffer, pH 7.2 at 30 ºC using 10 mM 
pNPP as the substrate by spectrophotometrically following the increase of absorbance at 410 
nm induced by the release of p-nitrophenol (ε410nm = 18.3 mM_1 cm_1) (Girard et al., 2006). 
The second peak from the size-exclusion was active. The active fractions were combined, 
and the protein was further purified by anion-exchange chromatography on a Mono Q 5/50 
GL (GE Healthcare) (Fig. 2B).  
 
 
Fig. 2. Protein purification. (A) Full-length laforin size-exclusion chromatogram; (B) 
Anion-exchange chromatogram of full-length laforin; (C) SDS-PAGE analysis of full-
length laforin purification: (1) E. coli cells before induction; (2) E. coli cells after a 3 h 
induction, soluble fraction; (3) cells after a 3 h induction, insoluble fraction; (4) 
concentrated protein applied to a size-exclusion column; (5) second peak from the size 
exclusion column applied to an anion-exchange column; (6) Anion-exchange major peak; 
(7) molecular weight standard. The gel was stained with Coomassie brilliant blue. (D) 
Laforin’s CBM size-exclusion chromatogram; (E) Anion-exchange chromatogram of 
laforin’s CBM; (F) SDS–PAGE analysis of laforin’s CBM purification: (1) sample applied to 
a size-exclusion column; (2) second peak (eluted at about 150–200 mL) from the size-
exclusion column; (3) highest peak (eluted at about 20 mL) from the anion-exchange 
column; (4) molecular weight standard. The gel was stained with Coomassie brilliant 
blue. 
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Refolded 7 7250 39 186 100  
Superdex 38 5524 22 251 56 1.3 
Mono Q 6.5 3400 7 486 47 2.6 
Table 2. Full-length laforin purification table. One unit of activity was defined as the activity 
corresponding to the consumption of 1 μM substrate (pNPP) in one minute at 30 ºC. 
Most of the protein was eluted in the major peak with a NaCl concentration of 
approximately 250 mM, which was also the peak where most of the pNPPase activity was 
found, indicating that most of the protein was correctly folded and relatively homogeneous. 
At the end of the purification process from several expression batches, we obtained between 
5 and 7 mg of purified laforin per liter of expression media. The purification table (Table 2) 
shows that the starting material after refolding was already relatively pure, as the 
purification factor was only 2.6, which is again consistent with the lack of contaminant 







amount of total 
CBM (mg) 
Yield (%) Purity (%) 
Cell extract 306 85.7 100 28 
Refolded protein 106 72.1 84 68 
Applied to size 
exclusion 43.4 34.7 40 80 
Applied to ion 
exchange 33 29.7 35 90 
Mono Q (major peak) 12.8 11.5 13 90 
Table 3. Laforin CBM purification table. Purity was determined by analysis of SDS–PAGE 
band intensities using the Quantity One software, version 4.6 (BioRad). 
For the CBM of laforin, a similar procedure was adopted. The first purification step, by size-
exclusion chromatography (HiLoad 26/60 Superdex 200 prep grade, GE Healthcare), was 
run with the same conditions as for the full-length protein and revealed no significant 
aggregates. Most of the protein eluted at 173 mL, which corresponds to tetrameric laforin 
CBM, and a minor fraction that eluted at 198 mL corresponds to dimerized protein (Fig. 2D). 
The fractions corresponding to the major peak were combined and applied to the anion 
exchange column (Mono Q 5/50 GL, GE Healthcare), with most of the protein eluted at 400 
mM NaCl (Fig. 2E). The SDS-PAGE analysis of the purified protein revealed an intense band 
with a molecular weight close to the expected value (22 kDa), and even under denaturing 
conditions, a band corresponding to the dimeric form of the protein was observed (Fig. 2F). 
This result is in agreement with the previously described resistance of laforin to dimer 
separation, prior to SDS–PAGE (Liu et al., 2006). 
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exclusion column; (3) highest peak (eluted at about 20 mL) from the anion-exchange 
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For the CBM of laforin, a similar procedure was adopted. The first purification step, by size-
exclusion chromatography (HiLoad 26/60 Superdex 200 prep grade, GE Healthcare), was 
run with the same conditions as for the full-length protein and revealed no significant 
aggregates. Most of the protein eluted at 173 mL, which corresponds to tetrameric laforin 
CBM, and a minor fraction that eluted at 198 mL corresponds to dimerized protein (Fig. 2D). 
The fractions corresponding to the major peak were combined and applied to the anion 
exchange column (Mono Q 5/50 GL, GE Healthcare), with most of the protein eluted at 400 
mM NaCl (Fig. 2E). The SDS-PAGE analysis of the purified protein revealed an intense band 
with a molecular weight close to the expected value (22 kDa), and even under denaturing 
conditions, a band corresponding to the dimeric form of the protein was observed (Fig. 2F). 
This result is in agreement with the previously described resistance of laforin to dimer 
separation, prior to SDS–PAGE (Liu et al., 2006). 
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The purification table of laforin CBM purification shows a yield of more than 12 mg of 
purified protein per liter of expression media. This protein expression and purification 
method is the first successful strategy to obtain the laforin CBM and will thus allow its study 
and characterization as an independent unit, as well as its use in biotechnology applications 
(Moreira et al., 2010).  
3. Heterologous protein characterization 
3.1 Protein oligomerization state 
Laforin has been shown to exist in a dimeric state; the CBM is responsible for this 
dimerization because its deletion completely abolishes the dimerization and phosphatase 
activity of laforin (Liu et al., 2006). The oligomerization state of both laforin and its CBM 
were analyzed by two distinct methods: analytical size-exclusion chromatography and 
dynamic light scattering (DLS) (Fig. 3). 
 
 
Fig. 3. Protein oligomerization analysis. (A) Analytical size-exclusion chromatography of 
purified full-length laforin with a Superose 12 10/300 GL column (GE Healthcare); (B) 
Dynamic Light Scattering analysis of purified full-length laforin; (C) Analytical size-
exclusion chromatography of purified laforin CBM with a Superdex 200 10/300 GL column 
(GE Healthcare); (D) Dynamic Light Scattering analysis of purified laforin CBM. 
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The analysis of full-length laforin by analytical size-exclusion chromatography on Superose 
12 10/300 GL confirmed that laforin is highly homogeneous, eluting with an elution volume 
corresponding to a globular protein of 64 kDa, based on the column calibration (Fig. 3A, 
grey box). This result is consistent with the dimer state of full-length laforin (2 x 37 kDa). 
This result was later confirmed by DLS. The protein was analyzed in both the anion-
exchange elution buffer (20 mM Tris, 0.4 M urea, 250 mM NaCl, pH 8.0) and in 50 mM Tris, 
50 mM NaCl, pH 7.4, with similar results. The particles detected had a hydrodynamic radius 
corresponding to a globular protein with a mass of 76 kDa, again consistent with the 
presence of a dimer. 
The analysis of the oligomerization state of the CBM of laforin by analytical size-exclusion 
chromatography using a Superdex 200 10/300 GL showed that the protein is also in a 
dimeric state, with a calculated molecular weight of 44 kDa. The differences observed 
between the preparative size-exclusion chromatography used during protein purification, 
where the protein eluted as a tetramer, and the analytical size-exclusion chromatography, 
where the protein eluted as a dimer, are due to the presence of 150 mM NaCl in the 
analytical size-exclusion chromatography buffer, which was absent from the preparative 
size exclusion chromatography buffer. The DLS analysis confirmed this result; the protein 
eluting in the highest peak from the anion-exchange column (Fig. 2E) revealed a 
hydrodynamic radius corresponding to a 44 kDa protein, thus confirming the dimerization 
of the isolated protein. 
3.2 Protein – carbohydrate interaction assay 
The functionality of the CBM, i.e., its ability to bind starch, was evaluated using an 
adsorption assay, for both the full-length laforin and for the CBM. The purified protein 
samples were centrifuged (13,000 rpm, 10 min, 4 ºC) to remove any precipitated protein, and 
the protein was then mixed with 50 mg of starch (previously washed with 50 mM Tris–HCl, 
150 mM NaCl, pH 7.4 buffer) for 1 h at 4 ºC. The mixture was centrifuged (13,000 rpm, 10 
min, 4 ºC), and the supernatant was analyzed by SDS–PAGE. The starch was washed with 
buffer (3 x 0.3 mL), and the recombinant protein was eluted from the starch with a 5 mg/mL 
glycogen solution (0.3 mL, at 4 ºC for 1 h). The starch was then treated with buffer 
containing 2% SDS (0.3 mL, at 95 ºC for 5 min) in order to analyze the protein that remained 
adsorbed after glycogen elution. 
The results showed that both full-length laforin and its CBM are able to bind starch and are 
specifically desorbed from starch when incubated with glycogen. For the full-length laforin, 
the SDS-PAGE analysis (Fig. 4A) revealed that most of the protein binds to the starch moiety 
because the protein solution supernatant after starch incubation (Fig. 4A lanes 2) showed a 
significant decrease in protein levels. This is not due to precipitated protein in the sample 
because the protein sample was centrifuged prior to the starch incubation. The subsequent 
washing steps revealed no washed protein (Fig. 4A lanes 3), and after the incubation with 
glycogen, laforin was effectively eluted from starch (Fig. 4A, lane 4). From the differences in 
band intensities between the initial protein and the supernatant after incubation, one would 
expect a stronger band from the glycogen elution, but the relatively faint band resulting 
from the glycogen elution can be attributed to a stronger binding of laforin to starch rather 
than glycogen, as previously reported (Chan et al., 2004). The results obtained with the CBM 
are in line with this assumption because a stronger protein band is observed in the starch 
pellet after glycogen elution (Fig. 4B, lane 4) than the one resulting from the glycogen 
elution (Fig. 4B, lane 3). 
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The analysis of full-length laforin by analytical size-exclusion chromatography on Superose 
12 10/300 GL confirmed that laforin is highly homogeneous, eluting with an elution volume 
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corresponding to a globular protein with a mass of 76 kDa, again consistent with the 
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where the protein eluted as a dimer, are due to the presence of 150 mM NaCl in the 
analytical size-exclusion chromatography buffer, which was absent from the preparative 
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The functionality of the CBM, i.e., its ability to bind starch, was evaluated using an 
adsorption assay, for both the full-length laforin and for the CBM. The purified protein 
samples were centrifuged (13,000 rpm, 10 min, 4 ºC) to remove any precipitated protein, and 
the protein was then mixed with 50 mg of starch (previously washed with 50 mM Tris–HCl, 
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The results showed that both full-length laforin and its CBM are able to bind starch and are 
specifically desorbed from starch when incubated with glycogen. For the full-length laforin, 
the SDS-PAGE analysis (Fig. 4A) revealed that most of the protein binds to the starch moiety 
because the protein solution supernatant after starch incubation (Fig. 4A lanes 2) showed a 
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expect a stronger band from the glycogen elution, but the relatively faint band resulting 
from the glycogen elution can be attributed to a stronger binding of laforin to starch rather 
than glycogen, as previously reported (Chan et al., 2004). The results obtained with the CBM 
are in line with this assumption because a stronger protein band is observed in the starch 
pellet after glycogen elution (Fig. 4B, lane 4) than the one resulting from the glycogen 
elution (Fig. 4B, lane 3). 
 





Fig. 4. Protein–starch-binding assay. (A) Full-length laforin starch-binding assay: (1) laforin 
supernatant before starch incubation; (2) supernatant after starch incubation; (3) starch-
washing supernatant; (4) supernatant after glycogen elution. All steps were performed in 
duplicate. Gel was silver stained. (B) CBM starch-binding assay: (1) CBM supernatant before 
starch incubation; (2) starch-washing supernatant; (3) supernatant after glycogen elution; (4) 
starch pellet after glycogen elution. All steps were performed in duplicate. The gel was 
Coomasie stained. 
Together, these results confirmed the starch binding activity of both laforin and its CBM. 
3.3 Laforin phosphatase activity characterization 
The laforin phosphatase activity was characterized using both pNPP (Montalibet et al., 2005) 
and OMFP, previously reported to be a better substrate for dual-specificity phosphatases 
than pNPP (Girard et al., 2006; Gottlin et al., 1996). The kinetic parameters for pNPP as a 
substrate were measured in a total volume of 1 mL by incubation of the enzyme with 
various amounts of substrate in 50 mM Tris-HCl buffer, pH 7.2 in a Varian Cary 100 UV/Vis 
spectrophotometer with the temperature control set to 30 ºC by following the absorbance 
increase at 410 nm induced by the release of p-nitrophenol (ε410nm = 18.3 mM-1 cm-1) (Girard 
et al., 2006). For OMFP, the kinetic parameters were obtained by a fluorescence-based assay, 
using conditions similar to the ones used for pNPP. The assay was performed using a 
Horiba Jobin Yvon Fluoromax-3 fluorometer by following the fluorescence emission of the 
product formed with excitation at 485 nm and emission measured at 530 nm. The data were 
fit to the Michaelis-Menten equation (Eq. 1) using the software Enzyme Kinetics Module 
v.1.2 – Sigmaplot v 9.01 (Systat Software, Inc.).  
 V = kcat [S] / (KM + [S])       (1) 
The kinetic parameters (Table 4) show that the recombinant laforin produced in this study 
has similar properties when compared to the previously published kinetic parameters for 
GST- and His-tagged versions of laforin (Girard et al., 2006), confirming the behavior of 
laforin as a dual-specificity phosphatase with OMFP better as the substrate than pNPP 
(Castanheira et al., 2010).  
The pH profile of laforin phosphatase activity was also evaluated using OMFP as a 
substrate. The results presented in Fig. 5A are in agreement with the results published 
earlier for tagged versions of laforin (Girard et al., 2006; Peters et al., 2003; Wang et al., 2002; 
Wang & Roach, 2004), with maximal activity at the acidic pH of 6.0. The capability of 
 
Recombinant Laforin for Structural Studies 
 
111 
glycogen to inhibit the phosphatase activity of laforin was also evaluated by including 
increasing amounts of glycogen in the phosphatase activity assay. The results presented in 
Fig. 5B show that laforin, in agreement with previously published reports (Girard et al., 




pNPP  OMFP  
kcat (s-1) KM (mM)
kcat/KM 




Laforin 0.56 ± 0.07 8.4 ± 0.7 0.07 ± 0.01  7.6 ± 1.5 0.21 ± 0.05 36 ± 11 
GST-pG 
laforin 1.1 ± 0.1 11.4 ± 3.0 0.10 ± 0.03  9.5 ± 2.0 0.26 ± 0.04 36 ± 13 
His-laforin 1.7 ± 0.2 33 ± 3 0.051 ± 0.004  6.5 ± 1.3 0.75 ± 0.29 8.7 ± 5.1 
Table 4. Steady-state kinetic parameters for laforin phosphatase activity. Comparison with 
published data for tagged versions of laforin, obtained from Girard (2006). 
 
 
Fig. 5. Laforin phosphatase activity characterization: Optimum pH (A) and inhibition by 
glycogen (B).  
4. Conclusion 
In this work, we have shown that both full-length laforin and its CBM can be produced in E. 
coli expression systems in high amounts and purified without the use of fusion tags. The 
characterization of the purified protein showed that in both cases, the protein is dimerized 
and has a functional CBM. For full-length laforin, the phosphatase activity was 
characterized and shown to have similar characteristics to the various forms of laforin 
previously described. The protein expression methodology used in this study proved to be 
suited for the production of high amounts of protein. This will enable the structural 
characterization and determination of the three-dimensional structure of laforin, which will 
contribute to the understanding of the molecular mechanism of action of laforin. The 
 





Fig. 4. Protein–starch-binding assay. (A) Full-length laforin starch-binding assay: (1) laforin 
supernatant before starch incubation; (2) supernatant after starch incubation; (3) starch-
washing supernatant; (4) supernatant after glycogen elution. All steps were performed in 
duplicate. Gel was silver stained. (B) CBM starch-binding assay: (1) CBM supernatant before 
starch incubation; (2) starch-washing supernatant; (3) supernatant after glycogen elution; (4) 
starch pellet after glycogen elution. All steps were performed in duplicate. The gel was 
Coomasie stained. 
Together, these results confirmed the starch binding activity of both laforin and its CBM. 
3.3 Laforin phosphatase activity characterization 
The laforin phosphatase activity was characterized using both pNPP (Montalibet et al., 2005) 
and OMFP, previously reported to be a better substrate for dual-specificity phosphatases 
than pNPP (Girard et al., 2006; Gottlin et al., 1996). The kinetic parameters for pNPP as a 
substrate were measured in a total volume of 1 mL by incubation of the enzyme with 
various amounts of substrate in 50 mM Tris-HCl buffer, pH 7.2 in a Varian Cary 100 UV/Vis 
spectrophotometer with the temperature control set to 30 ºC by following the absorbance 
increase at 410 nm induced by the release of p-nitrophenol (ε410nm = 18.3 mM-1 cm-1) (Girard 
et al., 2006). For OMFP, the kinetic parameters were obtained by a fluorescence-based assay, 
using conditions similar to the ones used for pNPP. The assay was performed using a 
Horiba Jobin Yvon Fluoromax-3 fluorometer by following the fluorescence emission of the 
product formed with excitation at 485 nm and emission measured at 530 nm. The data were 
fit to the Michaelis-Menten equation (Eq. 1) using the software Enzyme Kinetics Module 
v.1.2 – Sigmaplot v 9.01 (Systat Software, Inc.).  
 V = kcat [S] / (KM + [S])       (1) 
The kinetic parameters (Table 4) show that the recombinant laforin produced in this study 
has similar properties when compared to the previously published kinetic parameters for 
GST- and His-tagged versions of laforin (Girard et al., 2006), confirming the behavior of 
laforin as a dual-specificity phosphatase with OMFP better as the substrate than pNPP 
(Castanheira et al., 2010).  
The pH profile of laforin phosphatase activity was also evaluated using OMFP as a 
substrate. The results presented in Fig. 5A are in agreement with the results published 
earlier for tagged versions of laforin (Girard et al., 2006; Peters et al., 2003; Wang et al., 2002; 
Wang & Roach, 2004), with maximal activity at the acidic pH of 6.0. The capability of 
 
Recombinant Laforin for Structural Studies 
 
111 
glycogen to inhibit the phosphatase activity of laforin was also evaluated by including 
increasing amounts of glycogen in the phosphatase activity assay. The results presented in 
Fig. 5B show that laforin, in agreement with previously published reports (Girard et al., 




pNPP  OMFP  
kcat (s-1) KM (mM)
kcat/KM 




Laforin 0.56 ± 0.07 8.4 ± 0.7 0.07 ± 0.01  7.6 ± 1.5 0.21 ± 0.05 36 ± 11 
GST-pG 
laforin 1.1 ± 0.1 11.4 ± 3.0 0.10 ± 0.03  9.5 ± 2.0 0.26 ± 0.04 36 ± 13 
His-laforin 1.7 ± 0.2 33 ± 3 0.051 ± 0.004  6.5 ± 1.3 0.75 ± 0.29 8.7 ± 5.1 
Table 4. Steady-state kinetic parameters for laforin phosphatase activity. Comparison with 
published data for tagged versions of laforin, obtained from Girard (2006). 
 
 
Fig. 5. Laforin phosphatase activity characterization: Optimum pH (A) and inhibition by 
glycogen (B).  
4. Conclusion 
In this work, we have shown that both full-length laforin and its CBM can be produced in E. 
coli expression systems in high amounts and purified without the use of fusion tags. The 
characterization of the purified protein showed that in both cases, the protein is dimerized 
and has a functional CBM. For full-length laforin, the phosphatase activity was 
characterized and shown to have similar characteristics to the various forms of laforin 
previously described. The protein expression methodology used in this study proved to be 
suited for the production of high amounts of protein. This will enable the structural 
characterization and determination of the three-dimensional structure of laforin, which will 
contribute to the understanding of the molecular mechanism of action of laforin. The 
 
Underlying Mechanisms of Epilepsy 
 
112 
understanding of both the mechanism of the laforin-laforin or laforin-malin interactions is 
important for the development of Lafora disease therapies. The protein-protein and protein-
carbohydrate interfaces represent targets for the design of new drugs that promote or 
stabilize laforin’s dimerization or its interaction with binding partners (Veselovsky et al., 
2002).  
5. Future perspectives 
The work presented in this chapter paves the way for the structural studies needed to 
understand the molecular mechanism of protein-carbohydrate interaction. These studies 
will be performed using techniques such as NMR that will provide site-specific information 
on the architecture, binding selectivity and plasticity of the carbohydrate-binding sites of 
laforin. Other biophysical techniques such as Trp fluorescence have been used to address 
the chemical polarity shifts associated with protein-carbohydrate interactions. Protein-
carbohydrate interactions will also be studied by surface plasmon resonance in order to 
obtain the kinetic parameters of carbohydrate-ligand binding with wild-type and mutant 
proteins. Finally, X-ray crystallography and solution NMR will be used to obtain the three 
dimensional structure of laforin and its CBM, respectively. 
These studies will most likely provide new insights into the molecular mechanism of 
protein-carbohydrate binding and into the structural determinants involved in laforin 
dimerization, which will create new opportunities for the design of Lafora disease therapies 
and novel biotechnology applications for carbohydrate-binding proteins. 
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1. Introduction 
According to data from the World Health Organization (WHO), epilepsy is a common 
chronic brain disorder affecting approximately 50 million people worldwide. The hallmark 
of epilepsy is the recurrence of seizures, which on a cellular level is characterized by 
synchronized discharges of large groups of neurons that interrupt normal function. TLE is 
the most frequent type of human epilepsy (Engel, 2001; Willianson et al., 1993). In about 40% 
of patients, the seizures are refractory to medical therapy (De Lanerolle & Lee, 2005). The 
majority of these patients suffer from symptomatic focal epilepsies, which are frequently a 
consequence of brain trauma, complicated febrile convulsions, prolonged seizures (status 
epilepticus; SE), ischemic lesions and brain tumors (French et al., 1993; Mathern et al., 1995).  
Neuroimaging and cognitive testing of patients with refractory epilepsy also suggest 
detrimental effects as a result of repeated seizures over time, including volume reduction 
within the involved brain structures. TLE syndrome is characterized by partial seizures that 
may or may not be secondarily generalized. The common symptoms include abdominal 
sensations and fear in patients with mesial temporal sclerosis (Devinski, 2004).  
Neuropathological studies indicate that TLE is frequently associated with hippocampal 
sclerosis that is routinely detected by imaging studies during the presurgical evaluation of 
patients with an intractable TLE (Mathern et al., 1995). In a review, de Lenarolle and Lee 
(2005) cited that about 70% of hippocampi removed surgically from patients with TLE 
showed hippocampal sclerosis, and 30% did not show sclerosis, known as paradoxical TLE. 
The etiology and the pathogenesis of this type of medial temporal lobe damage are not 
known. Several studies have shown a correlation between severe childhood illness 
(infection, febrile convulsions, prolonged seizure and hippocampal atrophy in TLE 
(Cavanagh & Meyer 1956; Mathern et al., 1995). However, not all TLE patients exhibiting 
hippocampal damage have a history of an initial insult. Some experimental and human data 
suggest that recurrent seizures may cause progressive damage to the hippocampus 
(Sloviter, 1983; Mathern et al., 1995). Until recently, it was unknown whether the damage 
found in the hippocampus was the cause or the consequence of TLE. However, the surgical 
 
Underlying Mechanisms of Epilepsy 
 
116 
a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of 
glycogen in vivo. P. Natl. Acad. Sci. USA, 104(49), 19262-6. ISSN: 1091-6490. 
Tagliabracci, V.S., Girard, J.M., Segvich, D., Meyer, C., Turnbull, Julie, Zhao, X., Minassian, 
B.A., DePaoli-Roach, A.A. & Roach, P.J. (2008). Abnormal metabolism of glycogen 
phosphate as a cause for Lafora disease. J. Biol. Chem., 283(49), 33816-25. ISSN:1083-
351X. 
Tagliabracci, V. S., Heiss, C., Karthik, C., Contreras, C. J., Glushka, J., Ishihara, M., Azadi, P., 
Hurley, T.D., DePaoli-Roach, A.A. & Roach, P.J. (2011). Phosphate Incorporation 
during Glycogen Synthesis and Lafora Disease. Cell Metab., 13(3), 274-82. ISSN: 
1550-4131. 
Veselovsky, A.V., Ivanov, Y.D., Ivanov, A.S., Archakov, A.I., Lewi, P. & Janssen, P. (2002). 
Protein-protein interactions: mechanisms and modifications by drugs. J. Mol. 
Recognit. 15(6):405-422. ISSN:1099-1352. 
Wang, J., Stuckey, J.A., Wishart, M.J., & Dixon, J.E. (2002). A unique carbohydrate binding 
domain targets the lafora disease phosphatase to glycogen. J. Biol. Chem., 277(4), 
2377-80. ISSN:1083-351X. 
Wang, W. & Roach, P.J. (2004). Glycogen and related polysaccharides inhibit the laforin 
dual-specificity protein phosphatase. Biochem Bioph. Res. Co., 325(3), 726-30. ISSN: 
0006-291X. 
Worby, C.A., Gentry, M.S., & Dixon, J.E. (2006). Laforin, a dual specificity phosphatase that 
dephosphorylates complex carbohydrates. J. Biol. Chem., 281(41), 30412-8. 
ISSN:1083-351X. 
7 
Temporal Lobe Epilepsy:  
Cell Death and Molecular Targets 
Maria José da Silva Fernandes1, Esper Abrão Cavalheiro1, 
 João Pereira Leite2 and Daniele Suzete Persike1 
1Disciplina de Neurologia Experimental, Departamento de Neurologia e Neurocirurgia 
 Universidade Federal de São Paulo, UNIFESP, São Paulo 
2Disciplina de Neurologia, Departamento de Neurociências e Ciências do Comportamento 
 Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo – USP, São Paulo 
Brasil 
1. Introduction 
According to data from the World Health Organization (WHO), epilepsy is a common 
chronic brain disorder affecting approximately 50 million people worldwide. The hallmark 
of epilepsy is the recurrence of seizures, which on a cellular level is characterized by 
synchronized discharges of large groups of neurons that interrupt normal function. TLE is 
the most frequent type of human epilepsy (Engel, 2001; Willianson et al., 1993). In about 40% 
of patients, the seizures are refractory to medical therapy (De Lanerolle & Lee, 2005). The 
majority of these patients suffer from symptomatic focal epilepsies, which are frequently a 
consequence of brain trauma, complicated febrile convulsions, prolonged seizures (status 
epilepticus; SE), ischemic lesions and brain tumors (French et al., 1993; Mathern et al., 1995).  
Neuroimaging and cognitive testing of patients with refractory epilepsy also suggest 
detrimental effects as a result of repeated seizures over time, including volume reduction 
within the involved brain structures. TLE syndrome is characterized by partial seizures that 
may or may not be secondarily generalized. The common symptoms include abdominal 
sensations and fear in patients with mesial temporal sclerosis (Devinski, 2004).  
Neuropathological studies indicate that TLE is frequently associated with hippocampal 
sclerosis that is routinely detected by imaging studies during the presurgical evaluation of 
patients with an intractable TLE (Mathern et al., 1995). In a review, de Lenarolle and Lee 
(2005) cited that about 70% of hippocampi removed surgically from patients with TLE 
showed hippocampal sclerosis, and 30% did not show sclerosis, known as paradoxical TLE. 
The etiology and the pathogenesis of this type of medial temporal lobe damage are not 
known. Several studies have shown a correlation between severe childhood illness 
(infection, febrile convulsions, prolonged seizure and hippocampal atrophy in TLE 
(Cavanagh & Meyer 1956; Mathern et al., 1995). However, not all TLE patients exhibiting 
hippocampal damage have a history of an initial insult. Some experimental and human data 
suggest that recurrent seizures may cause progressive damage to the hippocampus 
(Sloviter, 1983; Mathern et al., 1995). Until recently, it was unknown whether the damage 
found in the hippocampus was the cause or the consequence of TLE. However, the surgical 
 
Underlying Mechanisms of Epilepsy 
 
118 
removal of the sclerotic hippocampus results in the best seizure-free outcome (De Lanerolle 
& Lee, 2005).  
2. Neuropathological findings in temporal lobe epilepsy 
The hippocampus or Ammon’s horn is one of the most vulnerable areas in the temporal lobe 
to develop cell loss following seizures. The histological pattern of hippocampal sclerosis in 
TLE patients is characterized by the loss of pyramidal cells in the prosubiculum and the 
CA1 of the hippocampus (Mathern et al., 1995). These findings also include neuronal loss in 
the hilus of the dentate gyrus and the adjacent CA3 region of the hippocampus (Mouritzen, 
1982; Babb & Lieb 1984). In many cases, the hippocampal damage in TLE was accompanied 
by aberrant mossy fiber reorganization. Mossy fibers from the dentate granule cells, which 
normally innervate the hilar mossy cells and the CA3 pyramidal cells and interneurons, 
reorganize and project into the inner third of the molecular layer of the dentate gyrus 
(Sutula et al., 1989; Babb et al., 1991; Szabadics & Soltesz, 2009). The term "mesial temporal 
sclerosis" has been introduced to describe cellular damage in the hippocampus, amygdala 
and entorhinal cortex (De Lanerolle & Lee, 2005). 
3. Epileptogenesis 
The development of an epileptic disorder involves a cascade of events that become activated 
by an initial insult to the brain. Based on studies using animal models (Turski et al., 1983; 
Leite et al., 1990) or human patients, there is a period so that events triggered by an initial 
insult (trauma or SE) can generate an active epileptic focus. It is believed that this latency 
period (weeks in animal models or years in patients) reflects a reaction mechanism resulting 
from cellular loss and is required for the synaptic reorganization to occur, which leads to an 
increased excitability and to changes in synchronization that establishes the chronic 
epileptic disorder. Figure 1 is a schematic diagram showing the events activated at different 
time points following an insult in human and in animal epilepsy models, which could be 
involved with the development of spontaneous seizures.  
Thus, epilepsy can be considered an active process that results in both ictal phenomena and 
permanent interictal functional and structural changes in the brain (Mathern et al., 1995). 
Patients who develop TLE demonstrate a progression in both the number of seizures and in 
the neurological symptoms related to the seizure, such as cognitive and behavioral disorders 
(Engel et al., 1991, French et al., 2004). The long latency before the usual complex partial 
seizures form in TLE offers a potential time window for therapeutic interventions, which 
may be a good alternative to prevent the appearance of seizures. 
4. Experimental animal models of TLE  
The experimental animal models provide a useful approach to assess the mechanisms 
involved in the epileptogenesis. The damage precedes the appearance of spontaneous 
seizures in several animal models of partial epilepsies. SE induced by systemic injection of 
pilocarpine or kainic acid caused structural brain damage in rats. Cell loss was observed in 
the hilus and the CA3 region of the hippocampus as well as in the amygdala, entorhinal 
cortex, thalamus and cerebral cortex (Turski et al., 1983). Moreover, prominent mossy fiber 
sprouting occurred (Mello et al., 1993). According to Olney et al. (1974), kainic acid and 
 
 




Fig. 1. A schematic diagram of epileptogenesis in patients and an experimental model of 
TLE. An initial precipitant insult can cause lesioning or functional changes. During a latent 
period, which can take years (5-10 years) in patients or weeks (2-3 weeks) in animal models, 
the insult initiates the reorganization of the brain and becomes prone to generate 
spontaneous motor seizures. Epileptogenesis includes changes that involve cell death, 
inflammation, neurogenesis, gliosis, sprouting, dendritic plasticity, and blood-brain barrier 
damage (Pitkanen & Lukasiuk, 2011). The short time frame for the development of the main 
features of the pathogenesis of TLE in animals encourages use in this study.  
other glutamate analogues are toxic because they activate glutamate receptors on neuronal 
membranes, resulting in prolonged depolarization, neuronal swelling and death. By 
activating M1 muscarinic receptors, pilocarpine activates phospholipase C, which in turn 
produces diacylglycerol (DG) and inositol triphosphate (IP3), which results in alterations in 
calcium and potassium concentrations that lead to enhanced excitability (Raza et al., 2004; 
Smolders et al., 1997, Smolders et al., 1996).  
The increased excitability in the hippocampus resulted in the decreased activity of ATPases 
that were unable to repolarize the membrane or promote calcium extrusion (Fernandes et 
al., 1996; Funke et al., 1998). High intracellular calcium can promote glutamate release, 
which by activating glutamate receptors allows the influx of additional calcium to induce 
SE, excitotoxicity and cell death (Smolders et al., 1997; Fernandes et al., 1996). In these 
experimental models, the recurrent spontaneous seizures occurred after a latent period, 
which is reminiscent of the human TLE (Mello et al., 1993). Inflammatory mediators have 
been described in the hippocampus of rats treated with pilocarpine, and molecules, such as 
kinins and prostaglandins, and also participate in the pathophysiology of TLE (Naffah-
Mazzacoratti et al., 1995; Argañaraz et al., 2003; Perosa et al., 2007).  
Kindling is an animal model of TLE where increasingly stronger seizures are induced by 
electrically stimulating brain areas (Goddard et al., 1969). Repeated seizures induce 
progressive cellular alterations, not only in the hippocampus, but also in the amygdala and 
the entorhinal cortex (Cavazos et al., 1994). Furthermore, studies have demonstrated that the 
neuronal loss is accompanied by aberrant mossy fiber axonal growth of the dentate granule 
cells in the hippocampus (Cavazos et al., 1991). 
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SE, excitotoxicity and cell death (Smolders et al., 1997; Fernandes et al., 1996). In these 
experimental models, the recurrent spontaneous seizures occurred after a latent period, 
which is reminiscent of the human TLE (Mello et al., 1993). Inflammatory mediators have 
been described in the hippocampus of rats treated with pilocarpine, and molecules, such as 
kinins and prostaglandins, and also participate in the pathophysiology of TLE (Naffah-
Mazzacoratti et al., 1995; Argañaraz et al., 2003; Perosa et al., 2007).  
Kindling is an animal model of TLE where increasingly stronger seizures are induced by 
electrically stimulating brain areas (Goddard et al., 1969). Repeated seizures induce 
progressive cellular alterations, not only in the hippocampus, but also in the amygdala and 
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5. Molecular changes in epileptogenesis 
Significant cell death and reorganization occurs in the CA1 region, and studies have shown 
an intense synaptic reorganization of calbindin and parvalbumin-positive neurons, which 
are presumably GABAergic neurons, that results in the inhibition of inhibitory neurons 
leading to abnormal synchrony and seizure activity (Wittner et al., 2002). This suggests that 
hyperexcitability is not due to the loss of γ-aminobutyric acid (GABA) but involves other 
mechanisms that are related to increased excitatory neurotransmission. In addition, there is 
evidence that mossy cells in the hilus and pyramidal neurons in the CA3 region show 
increased expression of GluR1 that promotes the excitation of granule cells (Eid et al., 2002). 
To date, studies have focused on the increased astrogliosis in this region, which could also 
contribute to the hyperexcitability. There is evidence that astrocytes contribute to the high 
levels of glutamate in hippocampal areas where neurons are sparse (De Lanerolle & Lee, 
2005). Some changes in astrocytes, such as high sodium channels expression, reduced 
inward rectifying potassium channels, elevated expression of GluR1 and downregulation of 
glutamine synthetase, an enzyme responsible for the conversion of glutamate to glutamine, 
represent potential mechanisms by which astrocytes can release glutamate (O'Connor et al., 
1998; Schroder et al., 2000; Eid et al., 2004, van der Hel et al., 2005).  
Astrocytes can modulate the inflammatory reactions through the expression of the 
transcription factor nuclear factor kB (NF-kB) and activation of prostaglandin E2 (PGE2) in 
response to interleukin-1β (IL-1β) (Dong & Benveniste, 2001). PGE2 increases calcium levels 
within astrocytes and contributes to glutamate release (Bezzi et al., 1998).  
In addition to IL-1β, astrocytes can also produce other immunological agents, such as 
interleukins (IL-1, IL10 and IL-6), interferon-alpha and beta (IFN-α and β), tumor necrosis 
factor-alpha (TNF-α) and transforming growth factor-beta (TGF-β) (Dong & Benveniste, 
2001; John et al., 2005). Studies have shown that IL-1β is upregulated in the sclerotic 
hippocampus from patients with TLE and can exacerbate seizures through glutamate 
release (John et al., 2005). The genes regulated by IL-1β are upregulated in sclerotic 
hippocampi from TLE patients (John et al., 2005). 
Growing evidence indicates that purines are widely involved in the molecular mechanisms 
underlying the various functions of astrocytes, either by modulating intracellular molecules 
involved in energy metabolism and nucleic acid synthesis or by activating a variety of 
membrane receptors (Neary et al., 1996; Abbrachio & Burnstock, 1998). By activating P2 
receptors, purines can also modulate calcium influx, and there is substantial evidence that 
cellular cascades initiated by calcium influx and perturbed intracellular calcium homeostasis 
are involved in the status epilepticus-induced excitotoxic cell death. Other studies have 
indicated that large amounts of ATP released from dying cells after the insult might induce 
reactive astrogliosis, microglia proliferation and act as a powerful chemoattractant at the site 
of injury (Davalos et al., 2005). Both astrocytes and activated microglia are able to induce the 
release of cytokines, such as IL-1β, TNF-α, and IL-6, which could influence the 
neuroinflammatory processes during neurodegeneration (Sanz & Di Virgilio, 2000). The 
activation of microglial P2X7 receptors by ATP induces TNF-α release, and this effect is 
regulated by extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein 
(MAP) kinase (Suzuki et al., 2004). 
It is not known whether microglia protect or damage neurons or whether TNF is beneficial 
or toxic. However, recent studies have demonstrated that P2X7 receptors were able to 
modulate the immune response of glial cells, and the expression of P2X7 receptors was 
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increased in the rat hippocampus following pilocarpine-induced SE (Dona et al., 2009; 
Fernandes et al., 2010). Several authors have reported that the neuroinflammation is an 
injury-induced glial activation that can contribute to the pathology of epilepsy (Naffah-
Mazzacoratti et al., 1995; Rappold et al., 2006; Vezzani & Granata, 2005). 
6. Cell death secondary to seizures  
The mechanism by which seizures cause neuronal death is understood based on studies that 
examined glutamatergic neurotransmission. The glutamatergic neurotransmission induced 
by excitotoxicity leads to the over-activation of glutamate receptors, which causes an 
excessive influx of Na+ and Ca2+ that induces osmolytic stress, cell swelling/rupturing, free 
radical production, which damages DNA, and protease activation leading to the proteolysis 
of cell and organelle membranes. This ultimately culminates with cell necrosis (Fujikawa, 
2005, 2006). The glutamate-mediated excitotoxicity and necrosis are primary contributing 
factors, but seizures also activate programmed cell death pathways, such as apoptosis 
(Henshall 2007, 2008).  
7. Apoptosis  
Apoptosis is the physiological process of programmed cell death (Strasser et al., 2000). 
Apoptotic signals through a highly ordered molecular cascade that is energy-dependent and 
may involve new gene transcription. Several studies have identified key genes in the 
nematode worm, Caenorhabditis elegans, that promoted (ced-3, ced-4) or inhibited (ced-9) 
apoptosis (Ellis and Horvitz, 1986; Hengartner et al., 1992). Further, the mammalian 
homologues of these genes allowed for the characterization of two classes of proteins 
involved in apoptosis: caspases and Bcl-2 (Hengartner and Horvitz, 1994; Yuan et al., 1993).  
8. Caspases and Bcl-2 
Caspases are aspartate-specific cysteine proteases present in cells as zymogens. A 
proteolytic cleavage is required for the enzymes to become active. In mammals, fourteen 
types of caspases have been identified and were divided into the inflammatory/cytokine-
processing caspases that include -1, -4, -5, -11, and -12. The apoptosis-regulatory caspases 
were divided into initiators of apoptosis that include -8, -9, and -10, and the apoptotic 
executioners are caspases -3, -6, and -7 (Thornberry and Lazebnik, 1998; Henshall & Simon, 
2005). The activation of cell death signaling is initiated by a caspase, which will then activate 
specific executioner caspases. The executioner caspases will cleave key structural and 
functional proteins within the cell, such as actin and the inhibitor of caspase-activated 
DNase (ICAD), as well as providing feedback loops for further processing of caspases 
(Mashima et al., 1997; Sakahira et al., 1998; Thornberry and Lazebnik, 1998; Henshall and 
Simon, 2005). 
The Bcl-2 gene family is comprised of more than 20 different members that regulate 
apoptosis positively, pro-apoptotic, or negatively, anti-apoptotic, primarily by affecting the 
mitochondria (Henshall and Simon, 2005; Kroemer et al., 2007). Many efforts have been 
made to elucidate the role of Bcl-2 proteins in apoptosis (Henshall & Simon, 2005; Kim et al., 
2006). The pro-apoptotic Bcl2 family protein, Bax, becomes active by binding to tBid and 
can trigger the formation of pores in the mitochondrial membrane, which allows the 
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release of the apoptogenic factor, cytochrome c. The Bcl-2 pro-apoptotic proteins, Bim and 
Puma, neutralize the anti-apoptotic protein Bcl2. The proteins Bcl-2 and Bcl-xl confer 
protection by promoting oligomerization with pro-apoptotic members, by maintaining the 
integrity of the mitochondria, by mobilizing calcium and by acting as an antioxidant 
(Henshall & Simon, 2005). 
The high level of intracellular calcium (Ca2+) that results from the activation of glutamate 
can trigger mitochondrial dysfunction directly or activate calcium phosphatases (e.g., PP2B 
and calcineurin) or regulatory molecules responsible for the release of Bad from the anti-
apoptotic protein, 14-3-3 (for details see Henshall & Simon, 2005). The transcription factor, 
Fox-O, is involved as a second regulatory step, is activated by dephosphorylation and 
upregulates Bim, whereas p53 upregulates Puma. These BH3-only proteins may promote 
Bax/Bak by inactivating the anti-apoptotic Bcl-2, Bcl-xl, Bcl-w or by directly activating 
Bax/Bak. Cytochrome c is released from Apaf-1, which then triggers caspase-9 activation, 
blocks various heat shock protein (HSP) activity and the X-linked inhibitor of apoptosis 
protein (XIAP). The extrinsic and intrinsic pathways converge on the activation of the 
executioner caspases, -3 and -7 that can then cleave key substrates (e.g., ICAD). 
The endoplasmic reticulum (ER) is an organelle that acts as a key trigger in the induction of 
the intrinsic pathway of apoptosis (Xu et al., 2005). Protein misfolding that arises from an 
increased intracellular calcium level can act as a potential ER stressor. Under persistent 
stress, apoptosis is triggered by a mitochondrial-mediated pathway (Smith & Deshmukh, 
2007), and this process requires Bax for the initiation of the pathway and Apaf-1 for cell 
death execution (Smith & Deshmukh, 2007).  
9. Intrinsic and extrinsic pathways of apoptosis 
Apoptosis can be initiated by two different routes known as extrinsic death receptor 
pathway, and intrinsic mitochondrial pathway (see Henshall and Simon, 2005).  
In the extrinsic pathway, a cell death-promoting stimulus activates an initiator caspase via a 
recruitment scaffold. Activation of the cell surface-expressed death receptors, such as the 
TNF superfamily (TNFR1; TNF receptor 1) or Fas, causes the death effector domains (DED) 
within the prodomain to bind to homologous regions on the death receptor (DR) adaptor 
proteins, such as Fas-associated death domain (FADD), which forms an intracellular 
complex known as the DISC (death-inducing signaling complex), leading to caspase-8 
activation (Henshall, 2005, Thornberry and Lazebnik, 1998).  
The caspase cascade is initiated by caspase-8 and culminates with the activation of 
executioner caspases, such as caspase-3, which cleave intracellular structural and survival 
proteins and activate enzymes responsible for DNA fragmentation (Henshall and Simon, 
2005, Thornberry and Lazebnik, 1998).  
The intrinsic pathway is triggered following the disruption of intracellular organelle 
homoeostasis or DNA damage (Verhagen et al., 2000). This pathway is characterized by 
mitochondrial dysfunction that causes the release of apoptogenic factors, such as 
cytochrome c, which activates Apaf-1 (apoptotic protease-activating factor 1) and caspase-9 
and is followed by downstream executioner caspase activation and cell death (Figure 3). 
Smac/DIABLO is released following mitochondrial damage and blocks active caspase 
inhibitors (Verhagen et al., 2000).  
The cross-talk between the two apoptotic pathways can occur through the cleavage of Bid 
by activated caspase-8. Cleavage of Bid leads to truncated Bid (tBid) formation, which 
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translocates into the mitochondria and induces the release of cytochrome c and 
Smac/DIABLO (Figure 3) (Madesh et al., 2002). 
10. Seizures activate apoptosis 
Several studies have indicated that seizures can activate the intrinsic and extrinsic apoptotic 
pathways in the brain (Henshall, 2007). The release of cytochrome c, Apaf-1, activated 
caspase-9 and -3 and subsequent DNA fragmentation in the rat hippocampus after a short 
SE duration indicate activation of the intrinsic pathway (Turski et al., 1983; Leite et al., 1990). 
Further, the intrinsic pathway can be activated by calcium. Pro-apoptotic Bcl-2 proteins 
(Bad, Bid and Bim) can be activated via calcium-dependent mechanisms, and each protein 
was found to be activated by seizures in vivo (Weiss et al., 1986; Mello et al., 1993). 
The importance of the Bcl-2 family in human epilepsy has been studied extensively. 
Elevated Bcl-w, reduced Bim and normal levels of Bcl-xl, Bax, Bad and Bid have been 
reported in the hippocampus obtained from patients with intractable seizures (Murphy et 
al., 2007; Shinoda et al., 2004, Yamamoto et al., 2006a). Serum analysis has also provided 
indirect evidence for the modulation of Bcl-2 in patients with epilepsy (El-Hodhod et al., 
2006). These Bcl-2 expression patterns may reflect the repertoire of genes that regulate cell 
death that may lower the vulnerability of the brain to further neuronal loss (El-Hodhod et 
al., 2006). Indeed, repeated electroshock seizures in rats and mice, a protocol used to evoke a 
damage-refractory state, adjust the balance of pro- and anti-apoptotic Bim and Bcl-w levels 
and demonstrate a similar pattern to those observed in patients (Murphy et al., 2007; 
Shinoda et al., 2004).  
The secondary role of the extrinsic pathway in cell death during seizures was demonstrated 
by the presence of caspase-8 cleavage in the early stages following the seizures (Henshall et 
al., 2001). The cleavage of a select group of caspases (-3, -7, -8 and -9) was detected in the 
hippocampus of rats after repeated electroshock seizures, indicating that the progression 
of apoptosis signaling may occur (Yamamoto et al., 2006b, Schindler et al., 2006, 
Yamamoto et al., 2006c). 
In addition, activated TNFR1 and DISC were detected in a seizure-damaged hippocampus 
from rats (Henshall et al., 2003; Shinoda et al., 2003), and patients with TLE (Yamamoto et 
al., 2006).  
Currently, it is not known whether TNF is beneficial or toxic to neurons. TNF may enhance 
injury induced by ischemia and trauma (Barone et al., 1997; Meistrel et al., 1997) as well as 
provide neuroprotection by inducing the expression of anti-apoptotic and antioxidative 
proteins (Yang et al., 2002). The dual effect of TNF is mediated by different TNF receptors, 
with the p55 TNFR1 mediating the neurotoxic effect and p75 TNF receptor 2 (TNFR2) 
eliciting the neuroprotection (Yang et al., 2002). By blocking protein synthesis, TNFR1 can 
trigger apoptosis and cause stress to the ER in the hippocampus of a patient during seizures 
(Yamamoto et al., 2006; Shinoda et al., 2003). These data suggest that glutamate 
excitotoxicity is not the only mechanism resulting in cell death after seizures. Efforts have 
been made to determine the temporal order of intrinsic and extrinsic pathway activation to 
clarify the relevance of these signaling pathways in neuronal death that is secondary to 
seizures.  
In summary, apoptosis signaling pathways contribute to the neurodegenerative mechanism 
elicited by seizures and may be involved in epileptogenesis. Several apoptotic regulatory 
proteins have homeostatic functions in the cells involved with seizure or epilepsy 
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susceptibility, such as Bcl-2 members, Bax and Bak, which regulate intracellular calcium at 
the ER membrane (White et al., 2005). In this vein, altered levels of Bcl-2 proteins in the TLE 
patient’s brain may influence a spectrum of intracellular responses, including excitability. It 
has been reported that caspases can have other functions in addition to apoptotic signaling. 
The importance of activated caspases in normal cells during development and signaling has 
recently been extended to the CNS where these proteases have been shown to contribute to 
axon guidance, synaptic plasticity and neuroprotection (McLaughlin, 2004; Lamkanfi et al., 
2007). Finally, efforts have been made to elucidate the physiological and pathological role of 
Bcl-2 proteins and caspases in the brain.  
11. Caspase activity in temporal lobe epilepsy 
Several reports have shown that seizures can occur after the activation of caspase-1 
(Eriksson et al., 1999), caspase-3 (Becker et al., 1999; Kondratyev and Gale 2000; Weise et al., 
2005), caspase-8 (Tan et al., 2002) or caspases-2 and -9 (Henshall et al., 2001).  
Henshall et al. (2001) and Li et al. (2006) reported that caspase-8 and -9 are activated in the 
hippocampus 40 min after focal SE was induced by kainic acid. The different location of 
caspase expression after SE suggests different functions in the brain. Weise et al. (2005) 
reported the expression of activated caspase-3 in hippocampal neurons after pilocarpine-
induced SE while other authors (Narkilahti et al., 2003; Ferrer et al., 2000) have detected 
active caspase-3 primarily in astrocytes and, to a lesser degree, in neurons. These data 
suggest that caspase-3 could exert an important role in the astrocytic death following SE and 
may have other unknown functions. 
Using biochemical and immunohistochemistry assays, we have demonstrated that 
inflammatory caspase-1 and the apoptotic executioner caspase-3 are activated in the 
hippocampus of rats at 90 min after the seizure onset and at 7 days after SE (latent period) 
(in preparation). Interestingly, the most intense caspase activity was observed in the latent 
period where the highest amount of neuronal death occurs. The neuronal damage is 
necessary to generate spontaneous seizures in this model (Turski et al., 1983).  
The activation of caspase-1 by SE induced by pilocarpine is involved in inflammatory 
mediator generation. Fantuzzi et al. (1999) demonstrated that caspase-1 is specifically 
required for processing pro-IL-1β and pro-IL-18 to their active forms. IL-1β can modulate 
the hyperexcitability by increasing glutamate release (Kamikawa et al., 1998), inhibiting 
glutamate reuptake by glial cells (Ye and Sontheimer, 1996) and increasing the calcium 
influx mediated by NMDAR through activation of Src family kinases (Viviani et al., 2003). 
There are a growing number of studies showing the role of inflammation in the injury 
process caused by seizures (Ravizza et al., 2006; Vezzani et al., 1999; 2000). Thus, caspase-1 
inhibition may be a promising anticonvulsant and neuroprotective therapy. 
12. Caspase inhibition as neuroprotective strategy in temporal lobe epilepsy 
Because caspases are differentially activated during epileptogenesis as demonstrated by 
Gorter et al. (2007) using microarray assays, caspase selective inhibitors are considered 
potential targets for novel neuroprotective and anticonvulsant agents for epilepsy 
(Kondratyev and Gale, 2000; Henshall et al., 2001; Ravizza et al., 2006). Inhibition of caspase-
1 reduced seizures in rats, whereas the deletion of the caspase-1 gene delayed acute seizure 
onset (Ravizza et al., 2006). Inhibition of caspase-3 and -9 provides neuroprotection after SE 
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was induced by kainate (Henshall et al., 2001), and the inhibition of caspase-8 may attenuate 
neuronal death by decreasing cleaved Bid, caspase-9, and the release of cytochrome c from 
mitochondria (Li et al., 2006).  
The caspase inhibition was also used as a neuroprotective strategy against injury caused by 
SE induced by pilocarpine (Persike et al., 2008).  
Several studies determined that tellurium compounds, as the non-toxic AS-101, ammonium 
trichloro(dioxoethylene-O,O′) tellurate, exert anti-apoptotic, anti-inflammatory, and 
immunomodulatory effects (Okun et al., 2007a; Sredni et al., 2007). These effects are 
primarily caused by the unique tellurium-thiol chemistry, which enables the interaction 
between the tellurium compound with the reactive cysteine residues of the inflammatory 
and apoptotic caspases leading to caspase inhibition (Albeck et al., 1998; Okun et al., 2007b). 
AS-101 not only interacts with catalytic thiols from cysteine proteases but also interacts with 
non-catalytic thiols (Okun et al., 2007b). It has been demonstrated that AS-101 can 
upregulate the anti-apoptotic proteins Bcl-2, p21Ras, PI3 kinase and the glial cell line 
derived neurotrophic factor (GDNF), and AS-101 can inhibit IL-1β and caspase-1 and -3 
(Makarovsky et al., 2003; Okun et al., 2006a,b; Sredni et al., 2007). AS-101 is currently being 
tested in Phase II clinical trials in cancer patients (Sredni et al., 1995, 1996, Frei et al., 2008) 
and was recently suggested as a promising agent for treatment of Parkinson's disease 
(Sredni et al., 2007). 
A compound of tellurium(IV), the organotelluroxetane RF-07 (see Figure 2), is an analogue 
of AS-101 (Persike et al., 2008). The administration of RF-07 prior to pilocarpine significantly 
blocked the behavioral and electrographic symptoms of SE in rats (Figure 3). To evaluate if 
this activity could be related to caspase inhibition, RF-07 was used in an “in vitro” assay to 
test recombinant caspases -3 and -8. RF-07 showed a potent inhibitory effect on both caspase 
-3 and -8 (Persike et al., 2008). The RF-07 was also tested in hippocampal homogenates from 
rats euthanized 90 min after pilocarpine-induced SE. RF-07 was the most potent inhibitor of 
caspase-like activity compared with commercial caspase inhibitors (Persike et al., 2008). 
Based on the results of this study, RF-07 inhibits not only caspases but other proteases that 
were activated during seizures, such as cathepsins, matrix metalloproteinases and 
plasminogen activators (see Figure 4). 
 
 
Fig. 2. The molecular structure of the neuroprotector tellurium(IV) compound, (4-{2-Chloro-
3-[chloromethylidene]-1-oxa-2l4-telluraspiro[3.5]non-2-yl}phenyl Methyl Ether). 
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Taken together, these data show that RF-07 represents a promising anti-epileptic and/or 
agent for epilepsy. Further investigations are ongoing to elucidate the mechanisms by which 
RF-07 inhibits pilocarpine-induced seizures. Studies using proteomic analysis may help to 







Fig. 3. Electroencephalographic recording showing the blockade of the brain high 
amplitude and frequency discharges (HAFD) following RF-07 injected prior to pilocarpine 
in rats. (A) N-methyl-scopolamine did not change the control recordings. N-methyl-
scopolamine was used to prevent the peripheral effects of pilocarpine. The electrographic 
seizure started 10 min after pilocarpine administration and was highly synchronized in 
the hippocampus and cortex. (B) The rats were pre-treated systemically with RF-07 15 min 
prior to pilocarpine. As shown, rats did not develop seizures, which exhibited 
electrographic activity in the hippocampus and cortex similar to the pre-pilocarpine 
pattern (Persike et al., 2008). 
 






Fig. 4. A hypothetical diagram showing the signaling pathways modulated by RF-07. As 
previously described for AS-101, the RF-07 can bind to the cysteine residues of several 
proteins, such as Ras, cathepsins and caspases-1, -3 and -8. By binding to Ras, RF-07 
increased the enzymatic activity, but upon binding to caspases, inhibited its activity. Ras 
activates ERKs, which then induces the expression of Bcl-2 to protect neurons from 
oxidative stress and mitochondrial disruption. The inhibition of caspases -1, -3 and -8 can 
prevent apoptosis and reduce the production of the pro-inflammatory cytokine IL-1β. In 
parallel, RF-07 could inhibit IL-10 production in addition to an increase in the ratio of 
GSH/GSSG. This inhibition would result in GDNF/IL-6 upregulation. By inhibiting 
cathepsin, RF-07 reduced the degradation of extracellular matrix components (Based on 
Sredni et al., 2007; Cunha et al., 2005 and Gorter et al., 2007).  
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Temporal lobe epilepsy is a progressive epileptic syndrome in which most of patients 
exhibit hippocampal sclerosis characterized by pyramidal cell degeneration, astrogliosis and 
aberrant mossy fiber sprouting in the inner molecular layer of the dentate gyrus. We have 
demonstrated that the caspase-mediated inflammatory process has been reported as a 
possible mechanism involved with the pathogenesis of TLE, and caspase inhibitors could be 
a promising therapeutic strategy. The knowledge about the physiological role of caspases in 
the CNS could improve our understanding about the balance between mediators of survival 
and cell death in the epileptogenesis.  
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1. Introduction 
Mitochondria are responsible for the supply of the majority of ATP in human cells  
via respiration and oxidative phosphorylation (OXPHOS). Mitochondria also play a central 
role in numerous cellular processes including energy production, intracellular Ca2+ 
homeostasis, biosynthesis of pyridine nucleotides and amino acids, and β-oxidation of fatty 
acids. On the contrary, mitochondria are also involved in the generation of reactive  
oxygen species (ROS), and initiation and execution of apoptotic cell death. Accumulating 
evidence show that defects in one or more of these functions may contribute to 
mitochondrial encephalomyopathies and other neuromuscular diseases. The term 
“mitochondrial encephalomyopathies” was coined by pediatric neurologists to call the 
attention of clinicians when the brain disease was first reported in children with 
mitochondrial alterations in their muscle biopsies (Shapira et al., 1977). Clinically, 
mitochondrial encephalomyopathies are common disorders that are a result of mutations 
affecting genes encoding proteins of important mitochondrial function (Leonard & Schapira, 
2000a). Most mitochondrial diseases, such as mitochondrial myopathy, lactic acidosis and 
stroke-like episodes (MELAS), are maternally inherited and frequently manifested as 
encephalomyopathies (Taylor et al., 2004). Furthermore, typical clinical features of 
mitochondrial encephalomyopathies include weakness and retardation of the heart, skeletal 
muscle and brain, where mitochondria are relatively abundant. Common symptoms of 
mitochondrial encephalomyopathies include loss of cognitive function, sensorineural 
deafness, optic atrophy, fluctuating encephalopathy, ataxia, seizures, dementia, migraine, 
stroke-like episodes, spasticity, cardiomyopathy, proximal myopathy and exercise 
intolerance (Stollberger & Finsterer, 2006). 
Epilepsy and seizures are common features of mitochondrial dysfunction associated with 
mitochondrial encephalomyopathies and have been considered the most common 
neurological disorders. According to the electroencephalograph (EEG) and seizure 
procedures, epilepsy is often an important sign in the early progression of mitochondrial 
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Epilepsy and seizures are common features of mitochondrial dysfunction associated with 
mitochondrial encephalomyopathies and have been considered the most common 
neurological disorders. According to the electroencephalograph (EEG) and seizure 
procedures, epilepsy is often an important sign in the early progression of mitochondrial 
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encephalomyopathies (Canafoglia et al., 2001). Epilepsy is characterized by spontaneous and 
recurrent unprovoked seizures that may lead to numerous changes with events of cascades 
at the cellular level of neurons. Neuronal excitability can be affected by mitochondrial 
dysfunction including depletion of ATP, generation of ROS, disruption of Ca2+ homeostasis, 
defects in biosynthesis and metabolism of neurotransmitters. However, the mechanism by 
which mitochondrial dysfunction leads to the onset and progression of epilepsy is still 
unclear. In this article, we focus on the potential role of mitochondrial function in the 
pathophysiology of mitochondrial encephalomyopathies. Firstly, we discuss the biochemical 
consequences of mitochondrial dysfunction-elicited oxidative stress in affected cells of 
patients with mitochondrial encephalomyopathies. Secondly, we address the possible 
molecular mechanisms involving in the regulation of communication between defective 
mitochondria and the nucleus, which is termed “mitochondrial retrograde signaling” in the 
pathogenesis of mitochondrial encephalomyopathies. Moreover, we also explore the role of 
mitochondria in the regulation of Ca2+ homoeostasis in neuron excitability that influences 
the normal function of neurons and proceeds towards epileptic seizures. Finally, we discuss 
the role of stress responsive gene, Sirt1, in the signaling pathway of the cross-talk between 
mitochondria and the nucleus to be a defense mechanism against neuronal degeneration in 
the patients with mitochondrial encephalomyopathies. We believe that the above-mentioned 
information will help us gain a deeper insight into the mechanisms underlying the 
pathogenesis of epilepsy in patients with mitochondrial disease and guide us to develop 
novel therapeutic strategies for better treatment of human diseases caused by mitochondrial 
dysfunction. 
2. Oxidative stress and mitochondrial encephalomyopathies 
Typical mitochondrial myopathy and encephalomyopathies are caused by mutations in the 
mtDNA or nuclear DNA that affect the respiratory chain directly (Bertini & D'Amico, 2009). 
Since mitochondria are responsible for the supply of the majority of ATP in human cells via 
respiration and OXPHOS, the defective mitochondria in affected tissue cells cause not only 
inefficient ATP production but also increased production of ROS. The symptoms of 
mitochondrial encephalomyopathies and neuromuscular disorders caused by mitochondrial 
dysfunction-elicited oxidative stress have been proven to be similar to those documented in 
the patients with mitochondrial diseases (Fernández-Checa et al., 2010). Oxidative stress 
elicited by mitochondrial dysfunction can further increase oxidative damage to various 
biomolecules in mitochondria. Hence, it has been proposed that the vicious cycle is 
propagating in mitochondrial diseases and results in the widely observed accumulation of 
oxidative damage and mutation of mtDNA, which ultimately leads to a progressive decline 
in the bioenergetic function of mitochondria that affects tissue cells in patients with 
mitochondrial encephalomyopathies (Fukui & Moraes, 2008). Recently, Katayama and 
coworkers demonstrated that the occurrence of 8-OHdG-positive neurons was significantly 
increased in the peri-lesional cortices as compared with the non-lesional and control cortices 
in the patients with MELAS syndrome (Katayama et al., 2009). Importantly, the spread 
frequency of stroke-like lesions in MELAS patients was significantly reduced after treatment 
with the antioxidant edaravone. In addition, a key finding was that failure of adaptive 
responses to oxidative stress (e.g., DNA repair system) in the brain during epileptogenesis 
could lead to an increase in the susceptibility of mitochondria to oxidative damage (Jarrett et 
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al., 2008). The mitochondrial base excision repair (BER) pathway involves a highly 
coordinated process catalyzed by the sequential actions of the DNA repair enzymes 8-
oxoguanine glycosylase (OGG1) and DNA polymerase gamma (POLG). It was reported that 
the RNA and protein expression levels of OGG1 and POLG were decreased during chronic 
epilepsy in an animal model (Lin et al., 2010). They found that spontaneous seizures 
coincided with an accumulation of mtDNA damage, increased mitochondrial H2O2, and 
impaired mtDNA repair, which suggest a contribution of mitochondrial defects to 
epileptogenesis. On the other hand, the regulation of antioxidant enzymes against oxidative 
stress in the cells with defective mitochondria also plays an important role in the 
pathophysiology of mitochondrial encephalomyopathies (Wu et al., 2010). Several animal 
models with the disruption of the antioxidant enzymes such as manganese superoxide 
dismutase (Mn-SOD) and glutathione peroxidase 1 (GPx-1) genes could lead to 
neuromuscular disorders that are similar to those documented in the patients with 
mitochondrial diseases (Li et al., 1995; Esposito et al., 2000). Taken together, the increase of 
oxidative stress and oxidative damage and the dysregulation of antioxidant enzymes are 
involved in the deterioration of bioenergetic function of the affected tissues, especially in the 
brain and skeletal muscle from patients with mitochondrial encephalomyopathies, which 
depend on mitochondrial function for supply of most of the ATP (Wei & Lee, 2003). Recent 
studies conducted in our own and other laboratories have provided compelling evidence to 
support the notion that oxidative stress elicited by impairment of the respiratory chain in 
the affected tissues of patients plays a role in the pathogenesis and progression of 
mitochondrial diseases and seizure generation (Waldbaum et al., 2010a; Wu et al., 2010). 
3. Biochemical hallmarks in mitochondrial encephalomyopathies 
A wide spectrum of the clinical phenotypes in the patients with mitochondrial 
encephalomyopathies is mostly associated with the defects in the structure or function of 
mitochondria. The histological and histochemical examinations of affected tissues have 
provided useful clues to determine the mitochondrial defects in the diagnosis of these diseases 
(Alhatou et al., 2004). There are well-established dye-staining methods for the assay of enzyme 
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Complex II) in affected muscle fibers and brain (DiMauro et al., 2002). Usually, the succinate 
dehydrogenase (SDH) activity staining clearly shows the subsarcolemmal accumulation of 
mitochondria (SDH-positive) and the activity assay of COX is particularly useful in the 
evaluation of mitochondrial myopathies (COX-negative fibers) because Complex IV contains 
subunits encoded by both the mtDNA and nuclear DNA (Taylor et al., 2004). Recently, 
Folbergrová et al. (2010) reported that the persistent inhibition of Complex I led to the 
overproduction of ROS, which could contribute to the neuronal injury in a rat model of 
seizures and in the patients with epileptogenesis. In a previous study, we observed a 
significant decrease in the copy number of mtDNA in the leukocytes of patients with 
mitochondrial encephalomyopathies including MERRF and MELAS syndromes, respectively 
(Liu et al., 2006). The amplitude of change was related to the proportion of mutant mtDNA, 
which may serve as a biomarker in the pathogenesis and progression of the mitochondrial 
diseases. Similarly, a recent study revealed that large amounts of mtDNA with a deletion were 
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skin fibroblasts from affected tissues, we have been able to intensively study the pathogenesis 
of mitochondrial encephalomyopathies. Firstly, we found that the glucose metabolism was 
shifted to enhanced anaerobic glycolysis in the cells from patients with mitochondrial 
myopathy and encephalopathy. This is consistent with a previous report that glycolysis is up-
regulated to compensate for the inefficient ATP production by mitochondrial OXPHOS 
(Pallotti et al., 2004). Although the increase in glycolysis occurred in affected cells is still 
equivocal, it revealed cellular adaptation for affected cells to cope with the energy crisis (Qian 
& van Houten, 2010). Secondly, neuronal mitochondria are important for intracellular Ca2+ 
sequestration, which suggests that mitochondria can modulate neuronal excitability and 
synaptic transmission which are altered in the patients with epilepsy (Tang & Zucker, 1997). 
Indeed, loss of Ca2+ buffering in hippocampal mitochondria has been demonstrated in kainate-
treated chronic epileptic rats (Kunz et al. 1999). Besides, substantial alterations of 
mitochondrial Ca2+ homeostasis were also the predominant feature in cybrids harboring the 
mtDNA mutation associated with MERRF syndrome (Brini et al., 1999). Finally, since the 
oxidative damage to proteins was accumulated in the defective mitochondria from the affected 
tissue cells, an efficient mitochondrial protein quality control system was also essential for the 
survival of patients with mitochondrial encephalomyopathies (Luce et al., 2010). It has been 
reported that the mitochondrial Lon protease and heat-shock protein 60 (HSP60) were 
dysregulated in cultured skin fibroblasts established from patients with MERRF and MELAS 
syndromes, respectively (Wu et al., 2010). In addition, the decreased expression of 
mitochondrial HSP60 within the abnormal mitochondria was found in the subsarcolemmal 
region of muscle from the patients with mitochondrial encephalomyopathies, but HSP60 was 
over-expressed in the intermyofibrillar mitochondria (Carrier et al., 2000). This finding 
suggests that the processing and integration of imported precursor proteins are impaired in 
the subsarcolemmal mitochondrial aggregates of the ragged-red fibers (RRF), whereas the 
biosynthesis, import and assembly of proteins may still be efficient in the biogenesis of 
intermyofibrillar mitochondria of these muscle fibers. 
4. Mitochondrial dysfunction-induced cell death and mitochondrial 
encephalomyopathies 
Evidence showed that tissue degeneration caused by cell death has been implicated in 
numerous mitochondrial diseases including mitochondrial encephalomyopathies, 
neuromuscular disorders and neurodegenerative diseases (Sayre et al., 2008). It is 
important to unravel the molecular mechanism underlying decreased cell viability in the 
process of epileptogenesis in the mitochondrial encephalomyopathies. There are at least 
two mechanisms implicated in neuronal cell death, including activation of the excitotoxic 
cascades (mitochondrial Ca2+ overload; excessive stimulation of glutamate receptors, 
nitric oxide overproduction; elevated oxidative stress and ROS overproduction), and 
induction of apoptosis. In this section, we focus on the involvement of programmed cell 
death (apoptosis) in the mitochondrial encephalomyopathies and provoked epilepsy. 
Apoptosis is the best understood cell death that can could be manipulated to control the 
destiny of cells. Indeed, apoptotic pathway has been considered a major physiological 
process in triggering cell death, which is critical for morphogenesis, tissue homeostasis as 
well as pathogenesis of diverse diseases (Hetts, 1998). Notably, mitochondria play an 
important role in the initiation, execution and regulation of apoptosis since mitochondria 
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can release specific proteins and factors to trigger the apoptotic pathway. MtDNA 
mutation-elicited mitochondrial dysfunction may result in insufficient supply of ATP, 
excess generation of ROS, elevated oxidative stress, membrane lipids peroxidation, 
disruption of mitochondrial membrane potential, dysregulation of excitotoxicity, and 
imbalanced distribution of intracellular Ca2+ ions (Kann & Kovacs, 2007). All of these 
changes can trigger activation of the cascades of caspases and pro-apoptotic proteins, and 
result in apoptosis.  
Clinically, many researchers tried to clarify the correlation between apoptosis-related cell 
death and pathogenic mechanism involved in the defects in muscle and brain of patients 
with mitochondrial encephalomyopathies. Many well-documented studies have revealed 
that apoptosis is involved in the progression of muscle myopathy (Aure et al., 2006; Umaki 
et al., 2002). Studies showed significant signs of apoptosis in the COX- negative muscle 
fibers in muscle biopsies from patients who harbored high proportions of specific point 
mutations in tRNA genes of mtDNA. Distinct expressions of 8-OHdG, 4-HNE, Mn-SOD, 
cytochrome c and DNase I were detected in the COX-negative muscle fibers accompanied 
by apoptotic markers. These results suggest the importance of apoptosis and the 
relationship of the oxidative stress with the severity of the muscle myopathy in 
mitochondrial diseases. Liu and coworkers also showed progressive cortical volume loss in 
patients with recurrent neocortical epilepsy (Liu et al., 2003). Accumulating evidence 
substantiated that apoptosis plays a role in seizure-induced neuron death as well as brain 
damages and also as a cause and consequence for epileptogenesis (Chuang et al., 2009b; 
Weise et al., 2005). It has been reported that an increase in the expression of caspases 
molecules was observed in temporal cortex of patients with epilepsy (Henshall et al., 2000). 
Increased production of ROS, NO and peroxynitrite was also reported to proceed apoptotic 
cell death in vulnerable brain regions (Chuang et al., 2009a, 2009b). On the other hand, 
inhibition of pro-apoptotic proteins and caspases activation could reduce seizure-induced 
neuronal cell death in experimental animal models. It has been reported that inhibition of 
caspase 3 was efficacious in the protection against neuronal cell loss in several models of 
brain injury (Liou et al., 2003). Either by short interfering RNA molecules targeting Bim in 
human cells or by knockout of Bim in a mouse model could reduce cell death and decrease 
the degeneration of hippocampal CA3 neurons following seizures (Murphy et al., 2010). In 
addition, the mice lacking the pro-apoptotic protein, Puma, were found to have a reduced 
neuronal death by 50% in the hippocampus (Engel et al., 2010). Moreover, a recent study 
also showed that Bcl-w was an endogenous neuroprotectant in mice and patients with 
temporal lobe epilepsy (Murphy et al., 2007).  
The above-mentioned studies showed the potential neuroprotective effect in epilepsy by 
targeting apoptosis with caspase inhibitors and genetic manipulation of pro-apoptotic 
proteins after onset of seizures in animals. Targeting apoptosis signaling pathways to 
prevent mitochondrial dysfunction-induced neuronal cell death may be a potential strategy 
for treatment of the patients with mitochondrial encephalomyopathies. However, some 
researchers showed that reducing cell death by administration of apoptotic inhibitor had no 
improvement of epilepsy symptoms in experimental animals (Narkilahti et al., 2003). These 
results revealed the complex cause and consequence of epileptogenesis and epileptic 
seizures. Therefore, the approach of inhibiting apoptosis to improve epileptic seizures 
should be evaluated with caution although it is still a potential candidate to collaborate with 
other antiepileptic drugs. 
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5. Mechanism of mitochondrial dysfunction caused neuronal excitability 
Abnormality of Ca2+ homeostasis is thought to be associated with the pathophysiology of 
neurodegenerative diseases (Mattson, 2007). The disease progression in patients often 
occurred following epileptic seizures, a cardinal and early symptom of mitochondrial 
diseases, especially in MERRF and MELAS syndromes (Okumura et al., 2008). Investigators 
also demonstrated that defects of mitochondrial respiratory chain could evoke seizures by 
using partial inhibition of ETC enzymes to cause deficiency of cytochrome c oxidase 
(Yamamoto & Tang, 1996). During the episode of epileptic seizures, extreme neuronal cell 
activity is associated with excessive cytosolic Ca2+ influx. It is noteworthy that dysregulation 
of Ca2+ handling in neurons might be a consequence of mtDNA mutation. The energy 
deficiency and ROS overproduction are the major stressors in human cells harboring 
disease-associated mtDNA mutations, which play an important role in the induction of the 
signaling cascades emitted from dysfunctional mitochondria to the nucleus. The 
abnormality of Ca2+ homeostasis induced by insufficiency of cellular ATP and oxidative 
damage is a potential link between mitochondrial dysfunction and epilepsy-induced 
hyperexcitability in neurons of patients with mitochondrial encephalomyopathies.     
5.1 Redox modulation of Ca2+ homeostasis 
Mitochondria play an important role in the regulation of Ca2+ homoeostasis by effective Ca2+ 
buffering (Tang & Zucker, 1997). Mitochondria can transiently accumulate substantial 
amounts of Ca2+ from the cytosol through the rapid uptake and relatively slow release of the 
Ca2+ ions. Therefore, it is possible that mitochondrial defect could have an impact on Ca2+ 
homoeostasis in cells. Abnormal Ca2+ homoeostasis has been reported in various cell types 
with defects in mitochondrial OXPHOS function (Willems et al., 2008). Many studies also 
proved that cells with mtDNA mutations could result in the dysregulation of mitochondrial 
Ca2+ buffering and reduction of the Ca2+ influx. The increase in the concentration of cytosolic 
Ca2+ was observed in the fibroblasts from patients with mitochondrial encephalomyopathies 
including MELAS and MERRF. The affected cells have elevated levels of Ca2+ ions and 
cannot normally induce Ca2+ influx in response to agonist-stimulated Ca2+ uptake by 
mitochondria (Brini et al., 1999; Moudy et al., 1995). It remains unclear as to how a 
pathogenic mtDNA mutation affects Ca2+ homeostasis. It is thought that mitochondrial Ca2+ 
uptake is dependent on the mitochondrial membrane potential, and thus mitochondrial 
deficiency-related decline of membrane potential plays an important role in defects of Ca2+ 
homeostasis. It has been proved that diminishment of mitochondrial membrane potential by 
an uncoupling agent can interfere with the uptake of Ca2+ by mitochondria and thus alter 
the transient cytosolic Ca2+ levels in neurons (Werth & Thayer, 1994). Indeed, defect in the 
mitochondrial Ca2+ handling was observed in the skin fibroblasts of patients with the 
MERRF syndrome. It was reported that cybrids harboring mtDNA mutation derived from a 
patient with MERRF syndrome exhibited a reduced uptake of the Ca2+ ions by mitochondria 
in response to histamine stimuli (Brini et al., 1999). 
Another important factor involving in the dysregulation of cellular Ca2+ homeostasis is 
excessive ROS production induced by mitochondrial dysfunction. More and more studies 
have supported that ROS and cellular redox state can directly modulate Ca2+ signaling 
through regulation of ion transporters (Hool & Corry, 2007). ROS have been shown to 
increase the Ca2+ channel activity through directly oxidizing the redox-sensing thiols on the 
Ryanodine receptor channel, and thereby induce the Ca2+ uptake from plasma membrane 
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(Werth & Thayer, 1994), and on IP3 receptor mediating Ca2+ release from ER which leads to 
elevated cytosolic Ca2+ (Suzuki & Ford, 1992). On the other hand, alteration of cellular redox 
states such as the lower GSH/GSSG and NADH/NAD+ ratios have been reported to 
modulate Ca2+ homeostasis by elevating the activity of Ca2+ channels and inhibiting the Ca2+ 
pump (Kourie, 1998; Zima et al., 2004). In general, Ca2+ can be re-uptake by the SR/ER Ca2+ 
ATPase following Ca2+ release from SR/ER Ca2+ stores or Ca2+ influx from PM to maintain 
the concentration of cytosolic Ca2+. However, the Ca2+ ATPase activity is also sensitive to the 
redox state, but unlike activation of oxidized receptor channels, it is inhibited by oxidative 
modification and ROS (Kaplan et al., 2003). As described above, mtDNA mutations can elicit 
over-production of intracellular ROS, which not only damages cellular biomolecules but 
also change the redox homeostasis of affected cells. Elevated oxidative stress results in a 
decrease of the GSH/GSSG ratio in the skin fibroblasts and cybrids harboring mtDNA 
mutation established from patients with mitochondrial diseases. A decrease in the GSH 
levels and gluthathione reductase activity has been observed in the plasma and brain 
regions of epileptic patients (Mueller et al., 2001). A large amount of studies have shown 
that the GSH concentration and the activity of Na+/K+ ATPase were decreased and affected 
the Ca2+ pump in the striatum and hippocampus during pilocarpine-induced seizures. It 
was also demonstrated that restoration of the level of GSH by lipoic acid could abolish the 
seizure episodes in the rat (de Freitas, 2010). A recent study showed that the tissue levels of 
GSH, and GSH/GSSG ratio were persistently altered throughout the onset of 
epileptogenesis in experimental temporal lobe epilepsy (Waldbaum et al., 2010b). The shift 
of redox state to oxidation would disrupt the Ca2+ homeostasis through the stimulation of 
Ca2+ influx and the interference of the Ca2+ pump, leading to dysregulation of the cytosolic 
Ca2+ concentration and the perturbation of Ca2+ signaling pathways. These findings imply 
that redox-dependent alterations of Ca2+ signaling cascades may contribute to the onset and 
progression of epileptogenesis.  
5.2 Inhibition of Ca2+ exchangers by energy deficiency  
The defects in the respiration and OXPHOS cause a depletion of ATP, and thus compromise 
the removal of Ca2+ ions by Ca2+-ATPase. Cytoplasmic Ca2+ concentration is also maintained 
by the ATP-dependent Ca2+ pump (Leo et al., 2005). Therefore, reduction in ATP synthesis 
could result in the accumulation of cytosolic Ca2+ (Buttgereit & Brand, 1995). A reduction in 
the capacity of Ca2+ clearance might lead to a disruption of Ca2+ homeostasis. Besides, lactic 
acidosis might be associated with an increase of cytosolic Ca2+ ions in patients with 
mitochondrial diseases. An increase in glucose uptake and the rate of glycolysis was 
observed in the epileptic loci during seizure episodes, which may result in elevated lactate 
production that is well documented in patients with mitochondrial diseases (Cornord et al., 
2002). Intracellular acidification has been shown to inhibit the plasma membrane Na+/H+ 
exchanger (Anderson et al., 2003), which causes an increase in cytosolic Na+ concentration 
and thus interfere with Na+/Ca2+ exchange through inhibition of the exchange of cellular 
Ca2+ for extracellular Na+, leading to cellular accumulation of Ca2+ ions. These findings 
suggest that mitochondrial dysfunction-induced insufficient supply of ATP might be 
another important factor contributing to elevated seizure susceptibility in human epileptic 
patients through alteration of ion transporters. The scenario described above can explain 
why an elevation of cytosolic Ca2+ ions is often observed in human cells harboring 
pathogenic mtDNA mutations, especially from MERRF and MELAS patients, respectively.   
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(Werth & Thayer, 1994), and on IP3 receptor mediating Ca2+ release from ER which leads to 
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5.3 Pathological effect of defective Ca2+ dyshomeostasis 
Proper regulation of the Ca2+ influx is critical to neuronal cell function, and to transduce 
electrochemical signals into molecular signals. Perturbed Ca2+ homeostasis would cause 
excessive amounts of Ca2+ within the neurons leading to dysfunction of a variety of cellular 
processes, followed by degeneration and cell death. When defective mitochondria alter the 
cellular Ca2+ dynamics, it might affect the specificity of Ca2+ signals and subsequently result 
in the induction of improper signaling cascades. Intriguingly, it has been reported that 
peripheral mitochondria accumulate more Ca2+ than do those in perinuclear region (Collins 
et al., 2002). We have observed that pathogenic mtDNA mutations can alter the distribution 
and movement of mitochondria, which would affect the regulation of local Ca2+ ions (Ma et 
al., 2005). Thus, the pathogenic deficit of Ca2+ signaling might further affect the brain 
function. Besides, slow elevation of cytosolic Ca2+ ions can lead to a corresponding increase 
in mitochondrial Ca2+ concentration. This physiological increase in mitochondrial Ca2+ ions 
could positively regulate mitochondrial metabolism through activation of TCA cycle 
enzymes, boosting the biosynthesis of reduced respiratory substrates, and stimulation of 
adenine nucleotide transporter (ANT) and Complex V to promote the production of ATP 
(Das & Harris, 1990; Mc Cormack & Denton, 1993). However, it has been proposed that the 
sustained uptake of mitochondrial Ca2+ results in the inhibition of Complex I and Complex 
III activities, which consequently increase the ROS production (Batandier et al., 2004; 
Jekabsone et al., 2003). When Ca2+ ions are overloaded to mitochondria, it temporarily 
provokes a pathological signal leading to the opening of the permeability transition pore 
(PTP) to block the intracellular Ca2+ homeostasis by Ca2+ release, and the subsequent 
induction of apoptosis through cytochrome c release (Crompton, 1999). Therefore, the 
great amplitude of Ca2+ transient in cells harboring a pathogenic mutation of mtDNA may 
increase the risk of inducing cell death processes. Aforementioned investigations have 
provided compelling evidence to support the notion that disturbed Ca2+ homeostasis 
elicited by mitochondrial dysfunction in the affected tissues, especially in the neurons of 
the patients, plays an important role in the epileptogenesis and disease progression of 
encephalomyopathies.  
6. Sirtuin-mediated cellular adaptation in epileptogenesis 
There are increasing evidence to reveal that sirtuins play a critical role in regulation of 
metabolism and the aging process through several pathways (Bordone & Guarente, 2005). 
Sirt1 is the most extensively studied sirtuin that mediates NAD+-dependent deacetylation of 
target proteins and thereby regulates many cellular functions. Overexpression or increase of 
the activity of Sirt1 has been reported to be neuroprotective in several neurodegenerative 
diseases. The most important mechanism contributory to Sirt1-induced protective effect is 
related to the regulation of cell survival (de Oliveira et al., 2010). In addition to alleviating 
the cell death and inducing the repair system, Sirt1 can modulate cellular response to 
oxidative stress and promote mitochondrial function (Gerhart-Hines et al., 2007). In human 
cells with mitochondrial dysfunction, increase of oxidative stress and damage may trigger 
apoptosis, which is closely related to seizure-induced cell loss. To cope with oxidative stress, 
the antioxidant defense system has evolved to dispose of excess intracellular ROS. Indeed, 
an imbalanced expression of antioxidant enzymes has been reported in different brain 
regions of animals in several studies of experimental status epilepticus. Induction of Mn-
SOD and catalase expression was observed in picrotoxin-induced seizures. The catalase 
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levels have been also reported to increase following electrically induced seizures (de Freitas, 
2009). Contrary to Mn-SOD and catalase, the GPx showed a tendency to decrease in the 
animals with status epileptic seizures (Shin et al., 2008). Interestingly, the abnormal 
expression of antioxidant enzymes was commonly found in the affected tissues of patients 
with mitochondrial encephalomyopathies caused by pathogenic mtDNA mutations. In 
previous studies, we observed increased levels of intracellular ROS and imbalanced 
expression of antioxidant enzymes in skin fibroblasts established from patients with the 
MERRF syndrome (Wu et al., 2010). Increase in the expression and activity of Mn-SOD 
rather than other antioxidant enzymes was observed in skin fibroblasts from MERRF and 
CPEO patients, respectively, which suggests that the expression of antioxidant enzymes was 
altered and failed to cope with the increase of oxidative stress in tissue cells with 
mitochondrial defects. Recent studies showed that Sirt1 plays a critical role in the 
detoxification of ROS since it can deacetylate and activate some of the Foxo family proteins, 
which in turn increase the transcription of Mn-SOD and catalase genes expressions(Brunet 
et al., 2004). Several studies have suggested that Sirt1 is a stress responsive gene. In one of 
our previous studies, we showed that oxidative stress could increase Sirt1 protein 
expression in human skin fibroblasts upon treatment with 150-300 μM H2O2 (Wu et al., 
2010). Increased Sirt1 protein expression was also observed in skin fibroblasts from patients 
with some of the mitochondrial diseases as compared to normal subjects. Therefore, it is 
possible that increased expression of Sirt1 in affected tissue cells of patients with 
mitochondrial encephalomyopathies could lead to abnormal expression of antioxidant 
enzymes in response to mitochondrial dysfunction, which might contribute to epileptic 
conditions.  
On the other hand, Sirt1 may exert the calorie restriction-induced anti-aging effect by 
modulation of the mitochondrial function. It can promote mitochondrial respiration through 
deacetylation and activation of the transcription activity of PGC-1α, a master regulator of 
mitochondrial biogenesis (Nemoto et al., 2005). It is well known that mitochondrial 
biogenesis is induced in the affected tissue cells of patients with mitochondrial diseases as a 
compensatory adaptation to compromised bioenergetic function due to defects in OXPHOS, 
despite the fact that increase in the number of mitochondria might have little contribution to 
the bioenergetic outcome. In one of our previous studies, we demonstrated that most of the 
patients with mitochondrial diseases frequently display abnormal mitochondrial 
proliferation along with an increase in the mitochondrial mass and gene expression of 
mtTFA (Wu et al., 2010). In addition, we also showed that increased oxidative stress is 
involved in the aberrant mitochondrial proliferation. Similarly, a change in the number of 
mitochondria has been reported in some of the patients with seizures or epilepsy. These 
findings led us to conjecture that compensatory induction of Sirt1 elicited by oxidative stress 
may be responsible for the unusual cellular status and neurotoxicity in epileptics. This also 
suggests that Sirt1 may be involved in the signaling pathway of the cross-talk between 
defective mitochondria and the nucleus to regulate cellular adaptation to mtDNA mutation-
elicited oxidative stress. 
7. Therapeutic approaches to target mitochondrial bioenergetics and 
oxidative stress in epilepsy  
Therapies for epileptic seizures have largely focused on reducing neuronal excitability and 
hence alleviating the frequency of occurrence of seizures and epilepsy. Recent therapeutic 
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approaches tend to seek for antiepileptogenic drugs that may inhibit the targets involved in 
the pathogenesis of epileptogenesis. Mitochondrial dysfunction triggering neuron cell death 
has been considered as a major contribution to the onset of seizures and is related to the 
resistance to epileptic therapy. Thus, therapies targeting mitochondrial bioenergetics and 
oxidative stress pathways could have neuroprotective effect and would be able to improve 
the seizure activity and attenuate the severity of epilepsy. Administration of creatine is 
frequently used and has been shown to protect brain injury in animal models of ALS, 
Huntington’s disease and MPTP-induced Parkinsonism (Ferrante et al., 2000; Matthews et 
al., 1999). Creatine can move through blood to brain and increase the pool of 
phosphocreatine/creatine by mitochondrial creatine kinase to boost the neuronal energy 
level. Supplementation of creatine was observed to attenuate hypoxia-induced seizures in 
both rats and rabbits. Creatine was also found to be neuroprotective in epilepsy induced by 
pilocarpine (Holtzman et al., 1998). These observations suggest that creatine treatment has 
the potential neuroprotective effect for patients with epilepsy, although it remains to be 
proven by clinical trials. Additionally, diet modification by caloric restriction or ketogenic 
diet has been used to inhibit seizure susceptibility in epileptic EL mice through a reduction 
of glucose metabolism (Todorova et al., 2000). Accumulating evidence support that chronic 
use of ketogenic diet can alter mitochondrial function, which includes promotion of 
mitochondrial biogenesis, decrease of ROS production and induction of GSH biosynthesis 
that ultimately lead to cellular adaption and restoration of mitochondrial redox state (Jrrett 
et al., 2008).  
On the other hand, to interfere with increased ROS during the onset of epilepsy appears to 
be another possible strategy for therapy. Natural antioxidant compounds such as vitamin C 
and E, melatonin and catalase have been shown to decrease oxidative stress and alleviate 
the seizure-induced brain injury (MacGrego et al., 1996; Tan et al., 1998). It has been 
reported that clinical trial of vitamin E as a therapy for epilepsy is controversial because it 
failed to improve seizure activity in pediatric patients. Similarly, although the Mn-SOD 
knockout mice was shown to exhibit age-dependent spontaneous and handling-induced 
seizures (Liang & Patel, 2004), and even more susceptible to kainate-induced seizures and 
neuron cell death, the SOD mimetics only reduced oxidative stress and oxidative damage 
but not the behavioral seizures (Rong et al., 1999). Hence, the therapeutic effect of 
antioxidants on epileptogenesis remains to be further investigated.           
8. Conclusion  
Mitochondrial dysfunction has been identified as a potential cause of epileptic seizures. 
Specific mtDNA mutations leading to the impairment of mitochondrial respiration and 
OXPHOS might be associated with epileptic phenotype. Because mitochondria supply the 
majority of ATP in neurons by OXPHOS and maintain the cellular Ca2+ homeostasis, their 
dysfunction can influence neuronal excitability and synaptic transmission, which may be 
responsible for epileptogenesis. Mitochondria play critical roles in energy metabolism, 
apoptosis and Ca2+ homeostasis, and respond to intrinsic and external stimuli through a 
variety of retrograde signaling pathways. Thus, mitochondrial dysfunction may trigger 
events involved in the cascades of the communication between mitochondria and the 
nucleus to mediate physiological adaptation of human cells through genetic or metabolic 
regulation. This may subsequently lead to alterations of the antioxidant defense system, 
activation of Ca2+ signaling, modulation of mitochondrial biogenesis and OXPHOS function. 
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The energy deficiency and ROS overproduction are the major stressors in human cells 
harboring disease-associated mtDNA mutations, which may play an important role in the 
induction of the retrograde signaling cascades sent from dysfunctional mitochondria to the 
nucleus. These events could interfere with Ca2+ homeostasis through decrease of the 
mitochondrial Ca2+ buffering capacity and affecting the Ca2+ influx and pump, which lead to 
the abnormal change of the cytosolic Ca2+ concentration and perturbation of Ca2+-related 
signaling pathways that ultimately trigger the neuronal cell death. Therefore, it is reasonable 
to consider mitochondria as promising targets of neuroprotective treatment of the patients 
with epilepsy. In conclusion, a better understanding of the mechanisms underlying 
epileptics elicited by mitochondrial dysfunction will provide novel information for the 
design of therapeutic approaches to treat patients with epilepsies or seizures caused by or 
associated with mitochondrial encephalomyopathies. 
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1. Introduction 
Epilepsy is one of the most common neurological problems worldwide affecting 
approximately 1% of the population (Browne & Holmes, 2000; Chang & Lowenstein, 2003). 
It is characterized by recurrent unprovoked behavioural seizures (Beck & Elger, 2008).  
In recent decades, the relationship between epilepsy and the neuroendocrine system has 
gained a great deal of interest and many researchers as neurologists, endocrinologists and 
basic scientists have investigated it. The main issue is whether hormonal changes in relation 
to epilepsy are due to seizures activity per se or to consequential effects of antiepileptic 
drugs. To understand the far-reaching effects of epilepsy and antiepileptic medications on 
hormonal system and vice versa, several studies have been recently performed. Their results 
are interesting but still controversial and the neuroendocrine regulation of epilepsy is far to 
be clearly explained. 
However, considering that a role of hormones in epilepsy is known and in part well 
described, this chapter would firstly review the endocrine regulation mediated by sex 
hormones, prolactin (PRL), growth hormone (GH), thyrotropin-releasing hormone (TRH), 
adrenocortical axis and neuropeptide Y (NPY). More recently, also other new hormones 
have been investigated in this field, bringing to light ghrelin. Ghrelin is a 28 amino acid 
peptide predominantly produced by the stomach (Kojima et al., 1999). It was discovered as 
the first natural ligand of the orphan growth hormone segretagogues receptor 1a (GHS-R1a), 
which exerts, through its activation, a strong GH-releasing activity (Arvat et al., 2001; 
Howard et al., 1996; Kojima et al., 1999; Kojima & Kangawa, 2005; van der Lely et al., 2004). 
It also influences glucose and insulin metabolism and controls food and energy intake 
through many neuroendocrine systems (van der Lely et al., 2004). Furthermore, several 
evidences suggest that ghrelin not only plays a metabolic role but it is also involved in sleep-
wake regulation, affective status, learning and memory processes (Steiger et al., 2011; van 
der Lely et al., 2004). Besides, the recent discovery of ghrelin has also provided an important 
insight to the neuroendocrine knowledge in epilepsy. In fact, a relationship between ghrelin 
and epilepsy has been already shown in animal and human models, although the results are 
sometimes conflicting. Thus, this chapter would secondly describe the intriguing ghrelin 
role in relation to seizures activity and discuss open questions and future perspectives. 
2. The interplay between epilepsy and the endocrine system 
Epilepsy and antiepileptic drugs affect hormones and neuroendocrine system. The 
relationship between epilepsy and the endocrine system is described, in particular for sex 
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hormones, GH and NPY system. More recently, the role of new hormones in epilepsy like 
ghrelin and its modulation on GH and NPY has been investigated (Berilgen et al., 2006; 
Gallagher et al., 1984; Morrell, 2003; Obay et al., 2007; Quigg, 2002; Stroud et al., 2005).  
Overall, endocrine disorders related to epilepsy or antiepileptic drugs are a consequence of 
the influence of epileptogenic lesions, epilepsy or anticonvulsant medications on the 
endocrine control centers in the brain. Antiepileptic drugs also impact on peripheral 
endocrine glands, metabolism of hormones and binding proteins, weight and insulin 
sensitivity (Opaleke & Helmers, 2007). 
2.1 Hypothalamus-pituitary-gonads axis 
Sex steroids and hypothalamus-pituitary-gonads axis is the most investigated system in 
epilepsy. Seizures have consequences, in both sexes, on various aspects of the sexual and 
reproductive functioning and endocrine dysfunctions are reported during childhood, 
adolescence and adulthood (Opaleke & Helmers, 2007). Postictal hormonal alterations are 
not relevant after a single seizure; however, endocrine discharges can follow serial 
uncontrolled seizures, even unrecognized simple partial seizures (Luef, 2010). This is 
particularly common in temporal lobe epilepsy and it is probably related to the direct 
connections between this lobe and the reproductive neuroendocrine axis (Opaleke & 
Helmers, 2007). For example, menstrual disturbances are more frequent in women with 
epilepsy as compared with those without epilepsy (Svalheim et al., 2003), both in adulthood 
and in paediatric age (Herzog et al., 1986). In females with epilepsy the most described 
reproductive endocrine disorder is the polycystic ovary syndrome (Bilo et al., 1988; Herzog 
& Schachter, 2001). Other common forms of reproductive dysfunctions in women with 
epilepsy include: hypothalamic amenorrhea with low gonadotropin and estrogen levels and 
diminished luteinizing hormone (LH) response to the gonadotropin-releasing hormone 
(GnRH) (Herzog et al., 1986), poly- or oligo-menorrhea, hirsutism, functional 
hyperprolactinemia with galactorrhea, sub- or infertility and premature menopause (Bauer 
& Cooper-Mahkorn, 2008). Decreased libido, abnormal semen analysis with reduced sperm 
count, abnormal sperm morphology and impaired motility and reduced fertility have also 
been overrepresented in males with epilepsy (Isojarvi et al., 2004). Antiepileptic drugs, as 
well as seizures, seem to contribute to these sexual and reproductive dysfunctions. These 
alterations are likely related to a liver enzyme induction, which leads to an increase of the 
sex hormone-binding globulin and a reduction of the bioavailability of serum-free sex 
hormone levels in both genders (Opaleke & Helmers, 2007). In contrast, testosterone and 
androgens are elevated in association with valproate treatments (Herzog et al., 2006; Isojarvi 
et al., 2004). Clinical data on gonads dysfunctions led to investigate the role of sex hormones 
on epilepsy mechanisms. 
The ovarian sex steroids act in the central nervous system and alter the frequency and the 
severity of seizures. In human and animal models, estrogen is a potent proconvulsant and 
progesterone has anticonvulsant properties (Reddy & Rogawski, 2009). Studies also 
suggested that these hormones might have complex effects depending on many factors like 
the endocrine state and their relative concentration and metabolism (Scharfman & 
MacLusky, 2006). In particular, estrogen can stimulate an increase of excitatory 
neurotransmitters such as glutamate via the N-methyl-D-aspartate (NMDA) receptor and a 
decrease of inhibitory neurotransmitters such as dopamine, through non-genomic 
mechanisms (S.S. Smith, 1989) and gamma-aminobutyric acid (GABA) (Ledoux et al., 2009). 
Estrogen has also an effect on the synaptic areas of neurons leading to an increase of 
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dendritic spines and cell-to-cell contacts and promoting the hypersynchronization seen in 
epilepsy. This can contribute to a lowering of the seizure threshold in both hippocampus 
and amygdala (S.S. Smith, 1989). In addition, it has been observed that estradiol, in parallel 
with its proconvulsant action, has a mitigating effect to reduce the seizure severity, related 
to facilitated and increased release of NPY (Ledoux et al., 2009). Progesterone exerts an 
inhibitory effect via metabolites such as allopregnanolone, which is a GABA-A receptor-
modulating neurosteroid. In fact, progesterone increases the seizure threshold and also has 
antianxiety and sedating effects (Backstrom et al., 1984; Mayewska et al., 1986; Paul & 
Purdy, 1992).  
Androgen metabolites also have some effect on seizure susceptibility, in animals and 
humans, through testosterone’s conversion, with either anticonvulsant or proconvulsant 
abilities. In particular, aromatization of testosterone to 17beta-estradiol reduces the seizure 
threshold, whereas 3alfa-androstanediol, which derives by the testosterone’s reduction to 
5alfa-dihydrotestosterone, has an anticonvulsant effect through a powerful modulation of 
GABA-A receptor (Reddy, 2004).  
2.2 Prolactin 
Acute variations in PRL, as well as in gonadotropin levels, following generalized and partial 
seizures, support the hypothesis of a relationship between temporolimbic epileptiform 
discharges and reproductive endocrine disorders. In fact, epileptic activity in the temporal 
structures may propagate to the hypothalamus, altering the hypothalamic regulation of PRL 
release via a PRL inhibitory factor or dopamine (Parra et al., 1980). In particular, PRL is 
elevated during phases of simple partial seizures when consciousness is preserved and also 
rises during the subsequent seizure evolution (Meierkord et al., 1994). Thus, PRL has an 
immediate postictal elevation, as well as LH, both thought to have clinical values in the 
diagnosis of epilepsy (Abbott et al., 1980).  
2.3 Noradreline, vasopressin and oxytocin 
It has also been described a fast serum increase of noradreline, vasopressin and oxytocin 
during and after prolonged epileptic temporal seizures. In fact, noradreline, vasopressin and 
oxytocin levels are low during the aura but rapidly increase during the phase in which the 
epileptic activity evolves from a simple partial to complex partial and finally to the 
generalisation. In particular, the peak of oxytocin and noradrenaline characterizes the phase 
of the generalised attack, whereas vasopressin levels peak in the postictal time and remain 
constantly high for several hours. These findings suggest that the length or the intensity of 
seizures is important factors influencing the hormonal concentration of noradrenaline, 
vasopressin and oxytocin, as well as PRL, during limbic seizures (Meierkord et al., 1994). 
2.4 Growth hormone and insulin-like growth factor-1 
Although most of the data on the physiology of epilepsy are related to sex-hormones, other 
neuro-hormones have been investigated. 
A role of GH in epilepsy has been shown. Epileptic seizures are a side effect of the rhGH 
replacement therapy (Clayton & Cowell, 2000). In particular, the Kabi International Growth 
Study (KIGS), a 10-year wide observational study about the GH therapy, recorded seizures as 
the seventh side effect of the treatment with a prevalence of about 0.5% (Wilton, 1999). The fact 
that GH has revealed as an important factor in epileptogenesis also emerged from a study 
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dendritic spines and cell-to-cell contacts and promoting the hypersynchronization seen in 
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and amygdala (S.S. Smith, 1989). In addition, it has been observed that estradiol, in parallel 
with its proconvulsant action, has a mitigating effect to reduce the seizure severity, related 
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inhibitory effect via metabolites such as allopregnanolone, which is a GABA-A receptor-
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GABA-A receptor (Reddy, 2004).  
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release via a PRL inhibitory factor or dopamine (Parra et al., 1980). In particular, PRL is 
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during and after prolonged epileptic temporal seizures. In fact, noradreline, vasopressin and 
oxytocin levels are low during the aura but rapidly increase during the phase in which the 
epileptic activity evolves from a simple partial to complex partial and finally to the 
generalisation. In particular, the peak of oxytocin and noradrenaline characterizes the phase 
of the generalised attack, whereas vasopressin levels peak in the postictal time and remain 
constantly high for several hours. These findings suggest that the length or the intensity of 
seizures is important factors influencing the hormonal concentration of noradrenaline, 
vasopressin and oxytocin, as well as PRL, during limbic seizures (Meierkord et al., 1994). 
2.4 Growth hormone and insulin-like growth factor-1 
Although most of the data on the physiology of epilepsy are related to sex-hormones, other 
neuro-hormones have been investigated. 
A role of GH in epilepsy has been shown. Epileptic seizures are a side effect of the rhGH 
replacement therapy (Clayton & Cowell, 2000). In particular, the Kabi International Growth 
Study (KIGS), a 10-year wide observational study about the GH therapy, recorded seizures as 
the seventh side effect of the treatment with a prevalence of about 0.5% (Wilton, 1999). The fact 
that GH has revealed as an important factor in epileptogenesis also emerged from a study 
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performed by Kato and co-workers, on an amygdala-kindled mice model obtained with 
electrodes stimulation (Kato et al., 2009). Furthermore, a role of GH for neuronal development, 
cognitive functions and neuroprotection during hypoxic-ischemic injury, has been reported 
(Harvey & Hull, 2003; Lyuh et al., 2007; Mahmoud & Grover, 2006; Nyberg, 2000; Ramsey et 
al., 2004; Scheepens et al., 2001). However, KIGS was the first study that evidenced that GH 
enhances epileptic seizures progression. This is a consequence of the increase of endogenous 
GH expression and the signalling of the hormone itself along neuronal circuits, which 
propagate kindling-stimuli in hippocampus and cortex, but not in the pituitary (Kato et al., 
2009). Moreover, the injection of GH into the hippocampus strongly promotes the progression 
of the kindling, whereas the direct administration of an inhibitor, such as octreotide, elicits a 
delay in the behavioural development during epileptogenesis (Kato et al., 2009). In particular, 
GH is involved in a biochemical pathway that seems to affect excitatory postsynaptic 
potentials on hippocampal synaptic transmission via the modulation of a-amino-3-hydroxy-5-
methylisoxazole-4-propionate and NMDA-receptor (Mahmoud & Grover, 2006).  
Pathophysiological events, such as ischemia and status epilepticus, increase cell 
proliferation through insulin-like growth factor-1 (IGF-1). Its expression is up-regulated in 
the reactive microglia near to the subgranular zone of the dentate gyrus at 2-days after a 
status epilepticus. It firstly promotes the release of glutamate; secondly, mitogen-activated 
protein kinase (MAPK) cascade and finally it increases the rate of proliferation of cell’s 
progenitors (Aberg et al., 2000, 2003; Choi et al., 2008; Kurihara et al., 2000). Probably the 
involvement of GH signalling not regards the GH-receptor (GHR); in fact, an increase of 
neuronal proliferation in the subgranular zone of the dentate gyrus has been shown in GHR 
knockout mice (Ransome & Turnley, 2008). The neuronal plasticity related to GH suggests 
the possibility of therapeutic interventions against neurodegenerative disorders in the older 
age; however, recent data also indicate that these newly generated neurons are integrated 
into epileptogenic networks in animal models (Siebzehnrubl & Blumcke, 2008), suggesting 
that neurogenesis contributes to promote susceptibility to seizures. 
2.5 Thyrotropin-releasing hormone  
Over the past years, the neuromodulatory role of TRH has been investigated. TRH 
participates to the regulation of hypothalamic-pituitary-thyroid axis but it is also a 
neuropeptide and it exerts its functions in the brain, particularly in the hippocampus and in 
other neural tissues (Gary et al., 2003; Kubek et al., 1977; Nillni & Sevarino, 1999). There are 
several findings that support an anticonvulsant effect of TRH in the regulation of seizure 
susceptibility (Jaworska-Feil et al., 1999, 2001; Knoblanch & Kubek, 1997a, 1997b; Kubek et 
al., 1989; Kubek & Garg, 2002; Wan et al., 1998). Its mechanism of action is poorly 
understood; however, it seems to be implicated in a protection against neuronal 
overexcitability. In fact, some authors reported that TRH could inhibit the effects of the 
glutamate-induced toxicity, in a dose-dependent manner, in cultured fetal rat hippocampal 
neurons (Pizzi et al., 1999; Veronesi et al., 2007). Furthermore, a paradoxical secretary peak of 
GH to TRH is more frequent during a status epilepticus. A GH release after an intravenous 
TRH administration in patients with a status epilepticus suggests an abnormal regulation of 
GH as a consequence of the long-standing epileptic activity (Lindborn et al., 1999). 
2.6 Hypothalamic-pituitary-adrenocortical system 
A marked hormonal dysregulation of the hypothalamic-pituitary-adrenocortical system, 
independent of administered medications, has been found in patients with epilepsy. In fact, 
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in these patients increased circulating levels of cortisol and adrenocorticotropic hormone 
(ACTH) are measured, relating to a deficient inhibitory feedback system after the 
suppression by dexamethasone (Zobel et al., 2004). These data have been confirmed by 
Galimberti and co-workers who reported decreased levels of dehydroepiandrosterone 
sulphate (DHEAS), in women with frequent seizures; this is not merely due to enzyme-
inducing antiepileptic drugs (Galimberti et al., 2005). These findings recognize the 
involvement of the hippocampus and/or amygdala, which are target regions for the control 
of hypothalamic-pituitary-adrenocortical system and which contribute to the generation and 
propagation of seizures (Aliashkevich et al., 2003; Heimer, 2003). Furthermore, repetitive 
seizures themselves induce a hypothalamic-pituitary-adrenocortical dysfunction, in relation 
to chronic stressful events, which is independent of the localization of the epileptogenic 
focus (Checkley, 1996; De Kloet, 1995; Holsboer, 2001; Kudielka et al., 1999).  
Increased basal cortisol levels, measured in salivary samples, have been recently described 
in patients with psychogenic nonepileptic seizures as independent of the acute occurrence of 
seizures; in addition, a basal hypercortisolism is present in patients with a trauma history, 
underling an involvement of psychological stress factors (Bakvis et al., 2010). However, 
further studies about the time of the onset of a blunted inhibitory control of hypothalamic-
pituitary-adrenocortical system, are important to understand if this discharge is only a 
secondary effect of seizures or whether it also determines a susceptibility to epilepsy (Zobel 
et al., 2004). At this regard, it is known that the hypercortisolism observed in several 
neuropsychiatric disorders is partially due to reduced neuronal outgrowth and plasticity 
with a lower hippocampus volume and cognitive deficits (McEwen et al., 1992; Sapolsky, 
2000; Sapolsky et al., 1986; Sheline et al., 1996).  
In addition, opposite effects on neuron survival have been attributed to cortisol and 
DHEAS. Cortisol exerts a neurotoxic effect, affecting cerebral glucose metabolism and 
enhancing calcium influx in hippocampal neurons (McEwen & Magarinos, 1997; Sapolsky et 
al., 1986). By contrast, DHEAS has a neuroprotective activity, inhibiting GABA-induced 
chloride transmembrane transport and antagonizing NMDA negative effects on neurons in 
relation to an increased calcium influx (Baulieu & Robel, 1996; Beyenburg et al., 2001; 
Kimonides et al., 1998; Mayewska, 1995; Watzka et al., 2000). Thus, these mechanisms are 
involved in neuron excitability and seizures. However, an intracerebroventricular injection 
of DHEAS in animals induces seizures (Czlonkowska et al., 2000), so the actual effects in 
vivo remain further unclear.  
Instead it is widely demonstrated that ACTH has a neurotrophic effect, promoting recovery 
from damages in both the peripheral and central nervous system (Darlington et al., 1996; 
Kokubo et al., 2002), the ACTH mechanism in epilepsy is not fully understood. It has an 
anticonvulsant action by itself, enhancing GABA-receptors via deoxycorticosterone 
synthesis (Rogawski & Reddy, 2002) and downregulating corticothropin releasing hormone 
(CRH) expression, which is a proconvulsant agent in the immature brain (Baram & Hatalski, 
1998). Actually, ACTH is well accepted as an effective therapy for infantile spasms, one of 
the intractable types of epilepsy that occurs in infancy and early childhood (Mackay et al., 
2004). 
2.7 Neuropeptide Y 
NPY, which is widely distributed throughout the central nervous system, including the 
hippocampus, is an endogenous anticonvulsant; it is known to prevent seizures in rats (De 
Quidt & Emson, 1986) by increasing the seizure threshold (Dubè et al., 1999). Although the 
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performed by Kato and co-workers, on an amygdala-kindled mice model obtained with 
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GH to TRH is more frequent during a status epilepticus. A GH release after an intravenous 
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independent of administered medications, has been found in patients with epilepsy. In fact, 
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in these patients increased circulating levels of cortisol and adrenocorticotropic hormone 
(ACTH) are measured, relating to a deficient inhibitory feedback system after the 
suppression by dexamethasone (Zobel et al., 2004). These data have been confirmed by 
Galimberti and co-workers who reported decreased levels of dehydroepiandrosterone 
sulphate (DHEAS), in women with frequent seizures; this is not merely due to enzyme-
inducing antiepileptic drugs (Galimberti et al., 2005). These findings recognize the 
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of hypothalamic-pituitary-adrenocortical system and which contribute to the generation and 
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seizures; in addition, a basal hypercortisolism is present in patients with a trauma history, 
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Instead it is widely demonstrated that ACTH has a neurotrophic effect, promoting recovery 
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(CRH) expression, which is a proconvulsant agent in the immature brain (Baram & Hatalski, 
1998). Actually, ACTH is well accepted as an effective therapy for infantile spasms, one of 
the intractable types of epilepsy that occurs in infancy and early childhood (Mackay et al., 
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NPY, which is widely distributed throughout the central nervous system, including the 
hippocampus, is an endogenous anticonvulsant; it is known to prevent seizures in rats (De 
Quidt & Emson, 1986) by increasing the seizure threshold (Dubè et al., 1999). Although the 
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relationship between NPY and epilepsy has not been completely investigated in humans, 
the extensively studies in animal models suggest a critical role of NPY in regulating the 
excessive synaptic excitation associated with an epileptic seizure (Colmers et al., 1987; Haas 
et al., 1987).  
Plasma concentrations of NPY were lower in human patients with atypical febrile 
convulsions than those with typical ones, suggesting that low NPY levels could increase the 
risk of long-lasting seizures or recurrent febrile convulsions and make patients more 
susceptible to epilepsy, independently by gender, both in adults (Lin et al., 2007) and 
children (Lin et al., 2010).  
Recently, ghrelin has been isolated from the stomach and has been recognized as the first 
endogenous ligand of the GSH-R1a (Korbonits et al., 2004; Weikel et al., 2003). Ghrelin is 
able to stimulate GH secretion but it also has pleiotropic activities, it influences cardiac and 
gastrointestinal functions, carbohydrate metabolism, adipose and reproductive tissues, 
sleep, feeding and energy intake. The control of food and energy intake is mediated by 
effects on NPY (Korbonits et al., 2004; Tolle et al., 2002; van der Lely et al., 2004; Weikel et 
al., 2003). Given the relationship between epilepsy and NPY, some authors focused their 
attention on this new hormone. Actually, the physiologic role of ghrelin in this complex 
network has not been clearly established and the association between epilepsy and ghrelin is 
still controversial. However, the recent discovery of ghrelin has provided an important 
insight to this field and we will focus on these new aspects. 
3. Ghrelin regulation and functions 
Ghrelin is a 28 amino acid peptide predominantly produced by the stomach, particularly 
in the A/X-like cells that account for 20-25% of all the endocrine cells in the oxyntic 
mucosa (Kojima et al., 1999). It was discovered as the first natural ligand of the orphan 
GHS-R1a, which exerts, through its activation, a strong GH-releasing activity (Howard et 
al., 1996; Kojima et al., 1999; Kojima & Kangawa, 2005; van der Lely et al., 2004); for its 
binding to and the activation of the GHS-R1a, the acylation of ghrelin with a medium 
fatty n-octanoic acid on the Ser3 residue seems to be essential. This mechanism is largely 
unknown (Kojima et al., 1999; van der Lely et al., 2004). Despite this background, 
uncylated ghrelin (UAG), which is devoid of the n-octanoil group at Ser3, is the most 
abundant circulating form and the ratio between UAG and acylated ghrelin (AG) is either 
3:1 or 4:1 (Gauna et al., 2004; Kojima et al., 1999; Kojima & Kangawa, 2005; Korbonits et 
al., 2004). The regulation of AG and UAG circulating levels has not yet been clearly 
defined. It is thought that UAG could be produced directly from the ghrelin gene, via a 
different pathway to the acylated form or alternatively it could be derived by the 
deacylation of ghrelin (Liu et al., 2008; Soares & Leite-Moreira, 2008). Very recently 
ghrelin O-acyltransferase (GOAT), an enzyme catalyzing the addition of the octanoyl-
group, has been identified (Gualillo et al., 2008). It is not known at present whether the 
GOAT levels regulate changes in ghrelin acylation or, on the contrary, if GOAT itself 
depends on different metabolic conditions. Originally AG was supposed to be the only 
biologically active hormonal form (Broglio et al., 2008; Kojima & Kangawa, 2005; van der 
Lely et al., 2004); however, there is increasing evidence that demonstrates that UAG is 
also a biologically active molecule, although it is unable to cross the blood brain barrier 
and to exert a direct action on hypothalamus-pituitary (Broglio et al., 2004a; Gauna et al., 
2005; Gil-Campos et al., 2006; Wiedmer et al., 2007). This is consistent with the hypothesis 
 
Ghrelin Regulation in Epilepsy 
 
157 
of the existence of some GHS-R subtypes that are activated independently by the ghrelin’s 
acylation (Kojima et al., 1999; Kojima & Kangawa, 2005; van der Lely et al., 2004).  
Ghrelin is predominantly expressed and secreted by the stomach (Kojima et al., 1999), unless 
during fetal life, when the major site of its production is the endocrine pancreas (Chanoine 
& Wong, 2004). Ghrelin expression has also been demonstrated in several other tissues, such 
as adrenal gland, breast, testis, thyroid, myocardium, muscle and colon (Gnanapavan et al., 
2002; van der Lely et al., 2004). The ghrelin target, GHS-R1a, is remarkably expressed in the 
hypothalamus-pituitary unit and, in parallel with ghrelin, it has also been demonstrated in 
several peripheral endocrine and non-endocrine tissues (van der Lely et al., 2004).  
This widespread distribution could mediate the multiple actions of ghrelin. In addition to 
the GH releasing effect, ghrelin emerged as one of the most powerful orexigenic and 
adipogenic agents known so far (Arvat et al., 2001; Cummings et al., 2001; Korbonits et al., 
2004; Leite-Moreira & Soares, 2007; van der Lely et al., 2004). The NPY and Agouti-related 
protein (AgRP) co-mediate ghrelin’s effects on energy balance in the hypothalamus, in the 
arcuate nucleus (Chen et al., 2004; Gil-Campos et al., 2006; van der Lely et al., 2004). 
Furthermore, ghrelin regulation of energy balance also seems to be influenced by efferent 
and afferent fibers of the vagal nerve and other neuroendocrine factors as orexins, GABA, 
cocaine-amphetamine regulated transcript (CART) and CRH (Asakawa et al., 2001b; Gil-
Campos et al., 2006; Leite-Moreira & Soares, 2007). The adipogenic action of ghrelin consists 
of an increase in fat mass induced by a reduction of cellular fat oxidation and a promotion of 
adipogenesis. This action can reflect both its orexigenic action and central modulator effect 
on energy expenditure (Gil-Campos et al., 2006; Leite-Moreira & Soares, 2007; Thompson et 
al., 2004; van der Lely et al., 2004; Wiedmer et al., 2007). Furthermore, several studies clearly 
indicated the existence of direct effects on the adipose tissue (Thompson et al., 2004; van der 
Lely et al., 2004; W. Zhang et al., 2004); at least in part, this is due to a decrease in fat 
utilization and an increase in fat tissue content (Leite-Moreira & Soares, 2007; Tschop et al., 
2000; van der Lely et al., 2004). Additionally, considering adipose tissue, UAG and AG are 
active in modulating lipolysis, such both UAG and AG seem to affect in the same way 
adipocyte function and to determine a lipogenic pattern (Muccioli et al., 2004). In contrast, 
UAG and AG play opposite effects on food intake, gastric emptying, pancreatic beta-cell 
secretion and glucose metabolism (Prodam et al., 2008). In fact, if AG may contribute to the 
worsening of insulin sensitivity, suggesting a diabetogenic function, UAG could exert its 
metabolic actions counterbalancing those of AG, at least in part at the pancreatic level 
(Ariyasu et al., 2005; Broglio et al., 2004a; Gauna et al., 2005). 
Considering ghrelin regulation, in humans it has a pulsatory secretion, with higher secretion 
at night-time as it undergoes circadian variations with a decrease following food ingestion 
that suggests a metabolic control (Cummings, 2006; Cummings et al., 2001; van der Lely et 
al., 2004). The depth and duration of ghrelin decrease after a meal is related to the total 
amount of calories ingested and to the type of the macronutrients, such as carbohydrates 
and proteins in spite of less effective suppression led by lipids (Prodam et al., 2006; Leite-
Moreira & Soares, 2007; van der Lely et al., 2004). In particular, meals inhibited secretion of 
both AG and UAG. Acylation may be regulated independently of secretion by nutrient 
availability in the gut or by esterases that cleave the acyl-group (Liu et al., 2008). 
Furthermore, ghrelin secretion is also under cholinergic control (Broglio et al., 2004b) and it 
is regulated by other factors that are involved in energy balance and metabolism, such as 
glucan-like peptide 1 (GLP-1), peptide YY (PYY), oxyntomodulin, urocortin, thyroid 
hormones, glucocorticoids, insulin and gonadal steroids (Baldelli et al., 2006; Gil-Campos et 
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relationship between NPY and epilepsy has not been completely investigated in humans, 
the extensively studies in animal models suggest a critical role of NPY in regulating the 
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convulsions than those with typical ones, suggesting that low NPY levels could increase the 
risk of long-lasting seizures or recurrent febrile convulsions and make patients more 
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children (Lin et al., 2010).  
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able to stimulate GH secretion but it also has pleiotropic activities, it influences cardiac and 
gastrointestinal functions, carbohydrate metabolism, adipose and reproductive tissues, 
sleep, feeding and energy intake. The control of food and energy intake is mediated by 
effects on NPY (Korbonits et al., 2004; Tolle et al., 2002; van der Lely et al., 2004; Weikel et 
al., 2003). Given the relationship between epilepsy and NPY, some authors focused their 
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network has not been clearly established and the association between epilepsy and ghrelin is 
still controversial. However, the recent discovery of ghrelin has provided an important 
insight to this field and we will focus on these new aspects. 
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Ghrelin is a 28 amino acid peptide predominantly produced by the stomach, particularly 
in the A/X-like cells that account for 20-25% of all the endocrine cells in the oxyntic 
mucosa (Kojima et al., 1999). It was discovered as the first natural ligand of the orphan 
GHS-R1a, which exerts, through its activation, a strong GH-releasing activity (Howard et 
al., 1996; Kojima et al., 1999; Kojima & Kangawa, 2005; van der Lely et al., 2004); for its 
binding to and the activation of the GHS-R1a, the acylation of ghrelin with a medium 
fatty n-octanoic acid on the Ser3 residue seems to be essential. This mechanism is largely 
unknown (Kojima et al., 1999; van der Lely et al., 2004). Despite this background, 
uncylated ghrelin (UAG), which is devoid of the n-octanoil group at Ser3, is the most 
abundant circulating form and the ratio between UAG and acylated ghrelin (AG) is either 
3:1 or 4:1 (Gauna et al., 2004; Kojima et al., 1999; Kojima & Kangawa, 2005; Korbonits et 
al., 2004). The regulation of AG and UAG circulating levels has not yet been clearly 
defined. It is thought that UAG could be produced directly from the ghrelin gene, via a 
different pathway to the acylated form or alternatively it could be derived by the 
deacylation of ghrelin (Liu et al., 2008; Soares & Leite-Moreira, 2008). Very recently 
ghrelin O-acyltransferase (GOAT), an enzyme catalyzing the addition of the octanoyl-
group, has been identified (Gualillo et al., 2008). It is not known at present whether the 
GOAT levels regulate changes in ghrelin acylation or, on the contrary, if GOAT itself 
depends on different metabolic conditions. Originally AG was supposed to be the only 
biologically active hormonal form (Broglio et al., 2008; Kojima & Kangawa, 2005; van der 
Lely et al., 2004); however, there is increasing evidence that demonstrates that UAG is 
also a biologically active molecule, although it is unable to cross the blood brain barrier 
and to exert a direct action on hypothalamus-pituitary (Broglio et al., 2004a; Gauna et al., 
2005; Gil-Campos et al., 2006; Wiedmer et al., 2007). This is consistent with the hypothesis 
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of the existence of some GHS-R subtypes that are activated independently by the ghrelin’s 
acylation (Kojima et al., 1999; Kojima & Kangawa, 2005; van der Lely et al., 2004).  
Ghrelin is predominantly expressed and secreted by the stomach (Kojima et al., 1999), unless 
during fetal life, when the major site of its production is the endocrine pancreas (Chanoine 
& Wong, 2004). Ghrelin expression has also been demonstrated in several other tissues, such 
as adrenal gland, breast, testis, thyroid, myocardium, muscle and colon (Gnanapavan et al., 
2002; van der Lely et al., 2004). The ghrelin target, GHS-R1a, is remarkably expressed in the 
hypothalamus-pituitary unit and, in parallel with ghrelin, it has also been demonstrated in 
several peripheral endocrine and non-endocrine tissues (van der Lely et al., 2004).  
This widespread distribution could mediate the multiple actions of ghrelin. In addition to 
the GH releasing effect, ghrelin emerged as one of the most powerful orexigenic and 
adipogenic agents known so far (Arvat et al., 2001; Cummings et al., 2001; Korbonits et al., 
2004; Leite-Moreira & Soares, 2007; van der Lely et al., 2004). The NPY and Agouti-related 
protein (AgRP) co-mediate ghrelin’s effects on energy balance in the hypothalamus, in the 
arcuate nucleus (Chen et al., 2004; Gil-Campos et al., 2006; van der Lely et al., 2004). 
Furthermore, ghrelin regulation of energy balance also seems to be influenced by efferent 
and afferent fibers of the vagal nerve and other neuroendocrine factors as orexins, GABA, 
cocaine-amphetamine regulated transcript (CART) and CRH (Asakawa et al., 2001b; Gil-
Campos et al., 2006; Leite-Moreira & Soares, 2007). The adipogenic action of ghrelin consists 
of an increase in fat mass induced by a reduction of cellular fat oxidation and a promotion of 
adipogenesis. This action can reflect both its orexigenic action and central modulator effect 
on energy expenditure (Gil-Campos et al., 2006; Leite-Moreira & Soares, 2007; Thompson et 
al., 2004; van der Lely et al., 2004; Wiedmer et al., 2007). Furthermore, several studies clearly 
indicated the existence of direct effects on the adipose tissue (Thompson et al., 2004; van der 
Lely et al., 2004; W. Zhang et al., 2004); at least in part, this is due to a decrease in fat 
utilization and an increase in fat tissue content (Leite-Moreira & Soares, 2007; Tschop et al., 
2000; van der Lely et al., 2004). Additionally, considering adipose tissue, UAG and AG are 
active in modulating lipolysis, such both UAG and AG seem to affect in the same way 
adipocyte function and to determine a lipogenic pattern (Muccioli et al., 2004). In contrast, 
UAG and AG play opposite effects on food intake, gastric emptying, pancreatic beta-cell 
secretion and glucose metabolism (Prodam et al., 2008). In fact, if AG may contribute to the 
worsening of insulin sensitivity, suggesting a diabetogenic function, UAG could exert its 
metabolic actions counterbalancing those of AG, at least in part at the pancreatic level 
(Ariyasu et al., 2005; Broglio et al., 2004a; Gauna et al., 2005). 
Considering ghrelin regulation, in humans it has a pulsatory secretion, with higher secretion 
at night-time as it undergoes circadian variations with a decrease following food ingestion 
that suggests a metabolic control (Cummings, 2006; Cummings et al., 2001; van der Lely et 
al., 2004). The depth and duration of ghrelin decrease after a meal is related to the total 
amount of calories ingested and to the type of the macronutrients, such as carbohydrates 
and proteins in spite of less effective suppression led by lipids (Prodam et al., 2006; Leite-
Moreira & Soares, 2007; van der Lely et al., 2004). In particular, meals inhibited secretion of 
both AG and UAG. Acylation may be regulated independently of secretion by nutrient 
availability in the gut or by esterases that cleave the acyl-group (Liu et al., 2008). 
Furthermore, ghrelin secretion is also under cholinergic control (Broglio et al., 2004b) and it 
is regulated by other factors that are involved in energy balance and metabolism, such as 
glucan-like peptide 1 (GLP-1), peptide YY (PYY), oxyntomodulin, urocortin, thyroid 
hormones, glucocorticoids, insulin and gonadal steroids (Baldelli et al., 2006; Gil-Campos et 
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al., 2006; Korbonits et al., 2004; Leite-Moreira & Soares, 2007; van der Lely et al., 2004; 
Wiedmer et al., 2007).  
As mentioned below, the circulating levels of ghrelin are firstly modulated by energy 
balance and nutrition status; in particular, ghrelin levels are negatively associated with body 
mass index, with ghrelin secretion increased in anorexia and cachexia and reduced in 
obesity, with normalization achieved through the recovery to an ideal body weight (Tschop 
et al., 2001; Leite-Moreira & Soares, 2007; van der Lely et al., 2004). Furthermore, circadian 
ghrelin secretion is abnormal in obesity, as there is an absent or an altered ghrelin elevation 
during fasting (Perreault et al., 2004) and an abolished or a blunted increase during the night 
or sleep deprivation (Vazquez et al., 2006; Yildiz et al., 2004) and blunted suppression 
following a meal (English et al., 2002). The most likely explanations could be that low 
ghrelin levels in essential obesity are related to increased insulin resistance and consequent 
hyperinsulinemia with weight excess. However, it may also reflect a compensatory 
mechanism by communicating to central regulatory centres that energy stores are 
sufficiently filled (Cummings, 2006; van der Lely et al., 2004). Therefore, conditions 
characterized by insulin resistance, such as polycystic ovarian syndrome (Pagotto et al., 
2002), type 2 diabetes and metabolic syndrome (Erdmann et al., 2005; Langenberg et al., 
2005), have low ghrelin levels too.  
The only clinical exception to this picture is the Prader-Willi syndrome, a complex multi-
systemic genetic disease caused by the lack of expression of paternally inherited genes 
imprinted and located in the chromosome 15q11-q13 region (Goldstone et al., 2008; Nicholls 
et al., 1989). Although genotype-phenotype correlations have been widely described, it can 
be summarized that Prader-Willi syndrome is characterized by typical features including 
neonatal hypotonia, uncontrolled and precocious hyperphagia, severe obesity with typical 
fat distribution, short stature, hypogonadism and other somatic, endocrine and 
psychological problems (Goldstone et al., 2004; Goldstone et al., 2008). These many 
phenotypes may depend on hypothalamus-pituitary and brain signalling derangements 
(Bellone et al., 2011). Interestingly, it has to be underlined that the Prader-Willi syndrome 
neuroendocrine and metabolic patterns are partly different to what occurs in simple obesity; 
in fact, unlike essential obesity, patients with Prader-Willi syndrome show elevated ghrelin 
levels (DelParigi et al., 2002; Goldstone, 2004; Paik et al., 2004, 2006). Since the exact 
pathogenetic mechanism leading to the Prader-Willi syndrome phenotype are at present 
unknown, ghrelin hypersecretion has been obviously hypothesized to participate in the 
development of at least some symptoms such as hyperphagia and weight excess (DelParigi 
et al., 2002; Paik et al., 2004). However, growing data suggested that hyperghrelinemia in 
Prader-Willi syndrome could be more likely a compensatory mechanism to other 
biochemical and hormonal alterations, in particular neonatal hypoglycaemia and relative 
hypoinsulinemia, to restore normal glucose levels or glucose sensing (Bellone et al., 2011).  
Several studies also suggested that ghrelin is one of the mediators of behaviours linked to 
food intake and body weight and of those associated with psychological stress, mood and 
anxiety (Chuang & Zigman, 2010). In fact, ghrelin rises in response to stressful events both 
in mice (Lutter et al., 2008b) and humans (Rouach et al., 2007). It has been proposed that 
higher ghrelin levels help in promoting antidepressant-like behavioural adaptations (Lutter 
et al., 2008b); for example it increases neuronal activity in brain reward centers in humans 
when images of appealing food are shown (Malik et al., 2008). Studies about the relationship 
between ghrelin and mood showed that a GSH-R1a polymorphism is related to major 
depressive disorders (Nakashima et al., 2008). Mechanisms by which ghrelin is able to 
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modulate mood are not completely explained; however, ghrelin’s action on mood seems to 
be due to: 1) direct and indirect feedbacks on the orexin system; 2) interactions with 
neuronal circuits involved in motivation and rewards; 3) effects on reward-associated 
memories and the ability to experience pleasure; 4) modulation of hippocampal 
neurogenesis and brain inflammation (Lutter et al., 2008a, 2008b; Chuang & Zigman, 2010). 
By contrast, other studies suggested that rising ghrelin would contribute to the development 
of stress-induced depression and anxiety (Asakawa et al., 2001a; Carlini et al., 2002, 2004; 
Carvajal et al., 2009).  
Furthermore, increasing evidence indicates that ghrelin not only plays a role in anxiety and 
stress, but it is also involved in promoting learning behaviour and memory processes and in 
sleep-wake regulation (Steiger et al., 2011). In particular, a sleep-promoting potential of 
ghrelin has been supported (Steiger et al., 2011). Szentirmai and co-workers reported that 
ghrelin knock out rodents sleep less than wild type ones (Szentirmai et al., 2007). In 
according to a sleep-promoting effect of ghrelin, knockout mice for ghrelin had impaired 
physiologic sleep regulation and thermoregulatory responses too. Thus, in response to 
fasting at 17 °C, these knockout mice presented hypothermic bousts associated with a 
reduced sleep (Szentirmai et al., 2009).  
Furthermore, also previous studies in humans suggested a sleep-promoting effect of ghrelin, 
with the evidence of its peaks around the sleep onset (Dzaja et al., 2004). This finding was 
not supported by Schussler and co-workers, who described in subjects with higher 
nocturnal ghrelin levels, a lower time spent in the stage 1 of sleep that means shallow sleep 
suggesting a promotion of sleep by ghrelin (Schussler et al., 2005). Schussler and co-workers 
also showed increased ghrelin levels during the recovery night after a sleep deprivation 
period, supporting the idea that an endogenous substance diverse from ghrelin accumulates 
during the sleep deprivation and it is a candidate to be a promoting factor of sleep. Higher 
ghrelin levels in sleep deprivation, in association with other hormonal derangements, could 
be a root cause of the dysregulation of hunger, appetite and metabolism linked to sleep loss 
or sleep alterations (Van Cauter et al., 2008; Van Cauter & Knutson, 2008). In addition, 
ghrelin levels are lower in the insomnia patients across the night (Motivala et al., 2009).  
In conclusion, the action of ghrelin includes much more than the energetic homeostasis and 
affects a more complex pathway not yet known. 
4. Ghrelin and epilepsy: In vitro and in animal studies 
A relationship between ghrelin and epilepsy has been demonstrated in animal and human 
models, although the results are still controversial (Dag et al., 2010).  
Some studies suggested an anticonvulsant effect of ghrelin. In fact, the intraperitoneally 
injection of ghrelin was able to delay or prevent the development of pentylenetetrazole 
(PTZ)-induced seizures in rats, supporting the hypothesis of an inhibitory effect on the 
emergence and the severity of seizures. However, dose-dependent ghrelin administrations 
reduced but not completely abolished the intensity of PTZ-induced seizures in rats (Obay et 
al., 2007). The mechanism related to the antiepileptic and the preventive role of ghrelin has 
been explained, firstly, through the enhancing of NPY and GABA activity in the brain 
(Cowley et al., 2003). In the arcuate nucleus of the hypothalamus, ghrelin fibers form axo-
somatic and axo-dendritic contacts with both proopiomelanocortin (POMC) and 
NPY/AgRP neurons (Cowley et al., 2003). The direct link between the brain-derived ghrelin 
and the central melanocortin system has been supported by electrophysiological 
 
Underlying Mechanisms of Epilepsy 
 
158 
al., 2006; Korbonits et al., 2004; Leite-Moreira & Soares, 2007; van der Lely et al., 2004; 
Wiedmer et al., 2007).  
As mentioned below, the circulating levels of ghrelin are firstly modulated by energy 
balance and nutrition status; in particular, ghrelin levels are negatively associated with body 
mass index, with ghrelin secretion increased in anorexia and cachexia and reduced in 
obesity, with normalization achieved through the recovery to an ideal body weight (Tschop 
et al., 2001; Leite-Moreira & Soares, 2007; van der Lely et al., 2004). Furthermore, circadian 
ghrelin secretion is abnormal in obesity, as there is an absent or an altered ghrelin elevation 
during fasting (Perreault et al., 2004) and an abolished or a blunted increase during the night 
or sleep deprivation (Vazquez et al., 2006; Yildiz et al., 2004) and blunted suppression 
following a meal (English et al., 2002). The most likely explanations could be that low 
ghrelin levels in essential obesity are related to increased insulin resistance and consequent 
hyperinsulinemia with weight excess. However, it may also reflect a compensatory 
mechanism by communicating to central regulatory centres that energy stores are 
sufficiently filled (Cummings, 2006; van der Lely et al., 2004). Therefore, conditions 
characterized by insulin resistance, such as polycystic ovarian syndrome (Pagotto et al., 
2002), type 2 diabetes and metabolic syndrome (Erdmann et al., 2005; Langenberg et al., 
2005), have low ghrelin levels too.  
The only clinical exception to this picture is the Prader-Willi syndrome, a complex multi-
systemic genetic disease caused by the lack of expression of paternally inherited genes 
imprinted and located in the chromosome 15q11-q13 region (Goldstone et al., 2008; Nicholls 
et al., 1989). Although genotype-phenotype correlations have been widely described, it can 
be summarized that Prader-Willi syndrome is characterized by typical features including 
neonatal hypotonia, uncontrolled and precocious hyperphagia, severe obesity with typical 
fat distribution, short stature, hypogonadism and other somatic, endocrine and 
psychological problems (Goldstone et al., 2004; Goldstone et al., 2008). These many 
phenotypes may depend on hypothalamus-pituitary and brain signalling derangements 
(Bellone et al., 2011). Interestingly, it has to be underlined that the Prader-Willi syndrome 
neuroendocrine and metabolic patterns are partly different to what occurs in simple obesity; 
in fact, unlike essential obesity, patients with Prader-Willi syndrome show elevated ghrelin 
levels (DelParigi et al., 2002; Goldstone, 2004; Paik et al., 2004, 2006). Since the exact 
pathogenetic mechanism leading to the Prader-Willi syndrome phenotype are at present 
unknown, ghrelin hypersecretion has been obviously hypothesized to participate in the 
development of at least some symptoms such as hyperphagia and weight excess (DelParigi 
et al., 2002; Paik et al., 2004). However, growing data suggested that hyperghrelinemia in 
Prader-Willi syndrome could be more likely a compensatory mechanism to other 
biochemical and hormonal alterations, in particular neonatal hypoglycaemia and relative 
hypoinsulinemia, to restore normal glucose levels or glucose sensing (Bellone et al., 2011).  
Several studies also suggested that ghrelin is one of the mediators of behaviours linked to 
food intake and body weight and of those associated with psychological stress, mood and 
anxiety (Chuang & Zigman, 2010). In fact, ghrelin rises in response to stressful events both 
in mice (Lutter et al., 2008b) and humans (Rouach et al., 2007). It has been proposed that 
higher ghrelin levels help in promoting antidepressant-like behavioural adaptations (Lutter 
et al., 2008b); for example it increases neuronal activity in brain reward centers in humans 
when images of appealing food are shown (Malik et al., 2008). Studies about the relationship 
between ghrelin and mood showed that a GSH-R1a polymorphism is related to major 
depressive disorders (Nakashima et al., 2008). Mechanisms by which ghrelin is able to 
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modulate mood are not completely explained; however, ghrelin’s action on mood seems to 
be due to: 1) direct and indirect feedbacks on the orexin system; 2) interactions with 
neuronal circuits involved in motivation and rewards; 3) effects on reward-associated 
memories and the ability to experience pleasure; 4) modulation of hippocampal 
neurogenesis and brain inflammation (Lutter et al., 2008a, 2008b; Chuang & Zigman, 2010). 
By contrast, other studies suggested that rising ghrelin would contribute to the development 
of stress-induced depression and anxiety (Asakawa et al., 2001a; Carlini et al., 2002, 2004; 
Carvajal et al., 2009).  
Furthermore, increasing evidence indicates that ghrelin not only plays a role in anxiety and 
stress, but it is also involved in promoting learning behaviour and memory processes and in 
sleep-wake regulation (Steiger et al., 2011). In particular, a sleep-promoting potential of 
ghrelin has been supported (Steiger et al., 2011). Szentirmai and co-workers reported that 
ghrelin knock out rodents sleep less than wild type ones (Szentirmai et al., 2007). In 
according to a sleep-promoting effect of ghrelin, knockout mice for ghrelin had impaired 
physiologic sleep regulation and thermoregulatory responses too. Thus, in response to 
fasting at 17 °C, these knockout mice presented hypothermic bousts associated with a 
reduced sleep (Szentirmai et al., 2009).  
Furthermore, also previous studies in humans suggested a sleep-promoting effect of ghrelin, 
with the evidence of its peaks around the sleep onset (Dzaja et al., 2004). This finding was 
not supported by Schussler and co-workers, who described in subjects with higher 
nocturnal ghrelin levels, a lower time spent in the stage 1 of sleep that means shallow sleep 
suggesting a promotion of sleep by ghrelin (Schussler et al., 2005). Schussler and co-workers 
also showed increased ghrelin levels during the recovery night after a sleep deprivation 
period, supporting the idea that an endogenous substance diverse from ghrelin accumulates 
during the sleep deprivation and it is a candidate to be a promoting factor of sleep. Higher 
ghrelin levels in sleep deprivation, in association with other hormonal derangements, could 
be a root cause of the dysregulation of hunger, appetite and metabolism linked to sleep loss 
or sleep alterations (Van Cauter et al., 2008; Van Cauter & Knutson, 2008). In addition, 
ghrelin levels are lower in the insomnia patients across the night (Motivala et al., 2009).  
In conclusion, the action of ghrelin includes much more than the energetic homeostasis and 
affects a more complex pathway not yet known. 
4. Ghrelin and epilepsy: In vitro and in animal studies 
A relationship between ghrelin and epilepsy has been demonstrated in animal and human 
models, although the results are still controversial (Dag et al., 2010).  
Some studies suggested an anticonvulsant effect of ghrelin. In fact, the intraperitoneally 
injection of ghrelin was able to delay or prevent the development of pentylenetetrazole 
(PTZ)-induced seizures in rats, supporting the hypothesis of an inhibitory effect on the 
emergence and the severity of seizures. However, dose-dependent ghrelin administrations 
reduced but not completely abolished the intensity of PTZ-induced seizures in rats (Obay et 
al., 2007). The mechanism related to the antiepileptic and the preventive role of ghrelin has 
been explained, firstly, through the enhancing of NPY and GABA activity in the brain 
(Cowley et al., 2003). In the arcuate nucleus of the hypothalamus, ghrelin fibers form axo-
somatic and axo-dendritic contacts with both proopiomelanocortin (POMC) and 
NPY/AgRP neurons (Cowley et al., 2003). The direct link between the brain-derived ghrelin 
and the central melanocortin system has been supported by electrophysiological 
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demonstration: ghrelin increases the firing of arcuate NPY/AgRP neurons, which increase 
GABA-ergic inhibitory post-synaptic currents into POMC neurons (Cowley et al., 2001). 
Secondly, ghrelin can be considered as an anticonvulsant agent by stimulating vagal nerve 
(Macdonalds, 1997). In fact vagal nerve stimulations are associated with a reduction of the 
seizure frequency more than 50% in about 30% of patients who are refractory to epilepsy 
treatments (Ben-Menachem et al., 1999; Handforth et al., 1998; Morris & Mueller, 1999).  
The oxidative stress in the central nervous system in relation to discharges in the epileptic 
rat brain has been reported in several rodent models of epilepsy (Bruce & Baudry, 1995; 
Erakovic et al., 2003; Singh & Pathak, 1990; Veerendra Kumar & Gupta, 2003). At this 
regard, there is emerging evidence that oxidative stress and mitochondrial dysfunctions 
result as a consequence and a cause of seizures (Patel, 2002). In fact, free oxygen radicals 
contribute to the genesis of seizure activity by direct inactivation of glutamine synthase and 
glutamate decarboxylase, such promoting an abnormal build-up of excitatory (glutamate) 
and inhibitory GABA neurotransmitters (Atmaca & Fry, 1996; Oliver et al., 1990; Sudha et 
al., 2001). In addition, seizure itself is associated with an important production of reactive 
oxygen species (Mueller et al., 2001). It has also been suggested that oxidative stress could 
occur during anticonvulsant therapies, likely related to detrimental effects on the 
antioxidant defence system, in particular with a significant decrease in plasma glutathione 
levels (Ono et al., 2000; Uma Devi et al., 2006). In the light of this knowledge, Obay and co-
workers supported the hypothesis that ghrelin might be an antioxidant and an anti-
inflammatory agent therefore it exerted protective effects in PTZ-induced epileptic rats 
(ISeri et al., 2005; Obay et al., 2007). In particular, in PTZ-induced epileptic rats there was an 
increase in the oxidative stress, with higher lipid peroxidation in erythrocytes, liver and 
brain tissues, whereas enzymes which have antioxidant activities (superoxide dismutase -
SOD, catalase -CAT) and glutathione levels were significantly reduced; all these alterations 
are prevented by an intraperitoneally ghrelin pretreatment (Obay et al., 2008).  
Recently, neuroprotective effects of ghrelin on pilocarpine-induced seizures in rodent 
models have also been investigated (Xu et al., 2009). Pilocarpine-induced seizures cause a 
neuronal loss in the hippocampus and ghrelin seems to be able to protect hippocampal 
neurons against this cell death. According with previous studies reporting that ghrelin 
activates the phosphoinositide-3-kinase (PI3K)/Akt pathway in hypothamalamic neurons 
(Chung et al., 2007), a mechanism which plays a central role in intracellular processes such 
as survival and proliferation (Cuevas et al., 2001; Franke et al., 1997; Henshall et al., 2002), it 
has been demonstrated that ghrelin strongly up-regulates the seizure-induced decrease in 
phospho-PI3K and phospho-Akt in the hippocampus, rescuing neuronal cells from death 
induced by seizures (Xu et al., 2009). Furthermore, anti-apoptotic actions of ghrelin are also 
confirmed by data of the effects on mithocondrial pathways (Miao et al., 2007; Xu et al., 
2009; Y. Zhang et al., 2007). In particular, pilocarpine-induced seizures result in increased 
Bax and decreased Bcl-2 with consequentially a decreased ratio of Bcl-2 to Bax and an 
activation of caspase-3 in the hippocampus at 24 h after pilocarpine treatments. The ghrelin 
pretreatment prevents the decreased ratio of Bcl-2 to Bax induced by seizures and inhibits 
caspase-3 activation, such protecting by the hippocampal neuronal damage (Xu et al., 2009). 
However, it is unclear whether the neuroprotective effect of ghrelin is due to the activation 
of the GHS-R1a or of an unknown receptor in hippocampus (Xu et al., 2009).  
Ghrelin also prevents the kainic acid-induced activation of microglia and astrocytes and the 
expression of pro-inflammatory mediators as well as tumor necrosis factor alpha, 
interleukin-1bheta and cyclooxygenase-2 with the inhibition of the matrix 
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metalloproiteinase-3 expression which is related to the damaged of hippocampal neurons 
(Lee et al., 2010). 
A recent study showed not only the effect of ghrelin in the penicillin-induced seizures, 
confirming its antiepileptic action but also the role of nitric oxide (NO) on the effect of 
ghrelin (Aslan et al., 2009). In fact, several effects exerted by ghrelin involve NO pathway by 
stimulating NO synthesis (Korbonits et al., 2004) whom role has also been investigated in 
neurological diseases such as epilepsy (Bosnak et al., 2007; Gaskin et al., 2003; Korbonits et 
al., 2004; S. E. Smith et al., 1996). Indeed, the antiepileptiform activity of ghrelin was 
reversed by a non specific nitric oxide synthase inhibitor (L-NAME), but not by a selective 
neuronal nitric oxide synthase inhibitor (7-NI). This evidence indicated that ghrelin could 
need an activation by the endothelial nitric oxide synthase (NOS)/NO route in the brain and 
suggested NO as an intermediate effector in the functional balance between excitatory and 
inhibitory neurotransmitter systems related to ghrelin (Aslan et al., 2009). 
Some studies have been conduced also in animals focusing on regulation of ghrelin 
secretion in epilepsy or after seizures. Blood AG levels decreased after the PTZ-induced 
seizures in rats with a similar but not significant trend for UAG and total blood ghrelin 
levels (Ataie et al., 2011). These decreases could be modulated by hormones which inhibit 
the production, acylation or secretion of ghrelin, such as somatostatin and leptin (Ataie et 
al., 2011). Somatostatin, preferentially released from neurons under conditions of high 
neuronal activation, for example during seizures (Vezzani & Hoyer, 1999), is able to blunt 
ghrelin secretion in animals (Shimada et al., 2003; Silva et al., 2005; van der Lely et al., 2004) 
and humans (Broglio et al., 2002, 2007; van der Lely et al., 2004). In addition, it has been 
reported that somatostatin decreases the GOAT expression (Gahete et al., 2010; Gualillo et 
al., 2008). Then, a rapid rebound of UAG levels respect to those of AG, related to this 
mechanism, may explain the partial reduction of UAG and total ghrelin levels after the PTZ-
induced seizure (Ataie et al., 2011). Moreover, some studies described high serum leptin 
levels in rats after seizures (Bhatt et al., 2005; Hum et al., 2009), which could directly inhibit 
ghrelin secretion as shown in other animal models (Kamegai et al., 2004). Another possible 
explanation about lower AG blood levels, is an increased uptake of AG by brain structures 
influenced by pathophysiological events to modulate epileptic discharges (Ataie et al., 2011; 
Banks et al., 2002). Furthermore, other mechanisms such as proteolysis of AG and 
degradation into non-UAG metabolities could occurr during seizures (De Vriese et al., 2004; 
Ni et al., 2010); both of them may contribute to the reduction of blood ghrelin levels 
immediately after the epileptic seizures in animals (Ataie et al., 2011).  
In conclusion, ghrelin can be considered as a neuroprotective agent, exerting antiepileptic, 
antioxidant or anti-inflammatory properties at least in vitro and in animal models. 
However, the anticonvulsant ghrelin mechanism has not been yet completely understood, in 
particular the regulation of its secretion after seizures.  
5. Ghrelin and epilepsy in humans 
The attention of researchers has been directed to investigate the role of ghrelin in epilepsy 
firstly in animals and secondly in humans.  
In one of the first studies in epileptic subjects, serum total ghrelin levels were higher in 
patients than in controls, in contrast to data in animal models (Ataie et al., 2011; Berilgen et 
al., 2006; Obay et al., 2007). In addition to its effect on weight regulation and glucose and 
lipid metabolism, ghrelin has also been shown to act on the release of GH, ACTH and PRL 
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demonstration: ghrelin increases the firing of arcuate NPY/AgRP neurons, which increase 
GABA-ergic inhibitory post-synaptic currents into POMC neurons (Cowley et al., 2001). 
Secondly, ghrelin can be considered as an anticonvulsant agent by stimulating vagal nerve 
(Macdonalds, 1997). In fact vagal nerve stimulations are associated with a reduction of the 
seizure frequency more than 50% in about 30% of patients who are refractory to epilepsy 
treatments (Ben-Menachem et al., 1999; Handforth et al., 1998; Morris & Mueller, 1999).  
The oxidative stress in the central nervous system in relation to discharges in the epileptic 
rat brain has been reported in several rodent models of epilepsy (Bruce & Baudry, 1995; 
Erakovic et al., 2003; Singh & Pathak, 1990; Veerendra Kumar & Gupta, 2003). At this 
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metalloproiteinase-3 expression which is related to the damaged of hippocampal neurons 
(Lee et al., 2010). 
A recent study showed not only the effect of ghrelin in the penicillin-induced seizures, 
confirming its antiepileptic action but also the role of nitric oxide (NO) on the effect of 
ghrelin (Aslan et al., 2009). In fact, several effects exerted by ghrelin involve NO pathway by 
stimulating NO synthesis (Korbonits et al., 2004) whom role has also been investigated in 
neurological diseases such as epilepsy (Bosnak et al., 2007; Gaskin et al., 2003; Korbonits et 
al., 2004; S. E. Smith et al., 1996). Indeed, the antiepileptiform activity of ghrelin was 
reversed by a non specific nitric oxide synthase inhibitor (L-NAME), but not by a selective 
neuronal nitric oxide synthase inhibitor (7-NI). This evidence indicated that ghrelin could 
need an activation by the endothelial nitric oxide synthase (NOS)/NO route in the brain and 
suggested NO as an intermediate effector in the functional balance between excitatory and 
inhibitory neurotransmitter systems related to ghrelin (Aslan et al., 2009). 
Some studies have been conduced also in animals focusing on regulation of ghrelin 
secretion in epilepsy or after seizures. Blood AG levels decreased after the PTZ-induced 
seizures in rats with a similar but not significant trend for UAG and total blood ghrelin 
levels (Ataie et al., 2011). These decreases could be modulated by hormones which inhibit 
the production, acylation or secretion of ghrelin, such as somatostatin and leptin (Ataie et 
al., 2011). Somatostatin, preferentially released from neurons under conditions of high 
neuronal activation, for example during seizures (Vezzani & Hoyer, 1999), is able to blunt 
ghrelin secretion in animals (Shimada et al., 2003; Silva et al., 2005; van der Lely et al., 2004) 
and humans (Broglio et al., 2002, 2007; van der Lely et al., 2004). In addition, it has been 
reported that somatostatin decreases the GOAT expression (Gahete et al., 2010; Gualillo et 
al., 2008). Then, a rapid rebound of UAG levels respect to those of AG, related to this 
mechanism, may explain the partial reduction of UAG and total ghrelin levels after the PTZ-
induced seizure (Ataie et al., 2011). Moreover, some studies described high serum leptin 
levels in rats after seizures (Bhatt et al., 2005; Hum et al., 2009), which could directly inhibit 
ghrelin secretion as shown in other animal models (Kamegai et al., 2004). Another possible 
explanation about lower AG blood levels, is an increased uptake of AG by brain structures 
influenced by pathophysiological events to modulate epileptic discharges (Ataie et al., 2011; 
Banks et al., 2002). Furthermore, other mechanisms such as proteolysis of AG and 
degradation into non-UAG metabolities could occurr during seizures (De Vriese et al., 2004; 
Ni et al., 2010); both of them may contribute to the reduction of blood ghrelin levels 
immediately after the epileptic seizures in animals (Ataie et al., 2011).  
In conclusion, ghrelin can be considered as a neuroprotective agent, exerting antiepileptic, 
antioxidant or anti-inflammatory properties at least in vitro and in animal models. 
However, the anticonvulsant ghrelin mechanism has not been yet completely understood, in 
particular the regulation of its secretion after seizures.  
5. Ghrelin and epilepsy in humans 
The attention of researchers has been directed to investigate the role of ghrelin in epilepsy 
firstly in animals and secondly in humans.  
In one of the first studies in epileptic subjects, serum total ghrelin levels were higher in 
patients than in controls, in contrast to data in animal models (Ataie et al., 2011; Berilgen et 
al., 2006; Obay et al., 2007). In addition to its effect on weight regulation and glucose and 
lipid metabolism, ghrelin has also been shown to act on the release of GH, ACTH and PRL 
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(Arvat et al., 2001; Korbonits et al., 2004, van der Lely et al., 2004). Besides, it is proposed 
that higher ghrelin levels could facilitate the emergence of seizures by affecting GH and PRL 
secretion and by disrupting hormonal homeostasis (Berilgen et al., 2006). Furthermore, 
ghrelin has been described as a factor in sleep regulation able to promote the slow-wave 
sleep and prolong non rapid eye movements (NREM) sleep during the night (Weikel et al., 
2003; Van Cauter et al., 2008; Van Cauter & Knutson, 2008). Therefore, higher serum levels 
of ghrelin in epileptic patients might be interpreted as a contributing factor to the genesis of 
seizures, considering that NREM is the stage in which seizures tend to occur (Berilgen et al., 
2006). Finally, authors suggested that higher serum ghrelin levels indicate a predisposition 
toward seizure activity (Berilgen et al., 2006).  
Greco and co-workers reported that circulating ghrelin levels in epileptic patients treated 
with valproic acid were decreased and they were significantly lower than those of patients 
who did not gain weight; however, this study did not rule out whether lower ghrelin levels 
were due to weight accrual or puberty (Greco et al., 2005). Taking into account antiepileptic 
treatments and weight, another study demonstrated that circulating ghrelin levels were 
decreased in young epileptic prepubertal normal weight children treated with 
carbamazepine and valproic acid during the first years of therapy, prior to and independent 
of a consistent drug-induced weight gain (Ness-Abramof & Apovian, 2005; Prodam et al., 
2009). The choice to enrol only young prepubertal children was related to avoid the well-
known modulation of ghrelin secretion by pubertal stage and age (van der Lely et al., 2004). 
In fact, the study of Berilgen and co-workers showed controversial results considering all 
epileptic subjects from childhood to adulthood and their data may be explained by a 
multitude of factors including the recruitment of an older population with a longer history 
of antiepileptic therapy and the different auxological stages (Berilgen et al., 2006; Prodam et 
al., 2009). Moreover, although ghrelin levels were reduced in the entire sample, patients 
under treatment with valproic acid showed higher ghrelin levels than those under 
carbamazepine, suggesting an involvement of valproic acid in a positive feedback 
regulation of ghrelin levels (Berilgen et al., 2006; Prodam et al., 2009).  
This study also demonstrated a positive correlation between lower ghrelin levels and the 
negative variation of the height standard deviation score with respect to the baseline of 
therapy with carbamazepine in patients who were drug-naïve, hypothesizing that lower 
ghrelin levels could worsen the variation height standard deviation score (Prodam et al., 2009). 
The fact that physical growth seems to be affected in paediatrics patients with epilepsy also 
emerges in a study recently performed by El-Khayat and co-workers (El-Khayat et al., 2010). 
Height was lower in patients with epilepsy and they presented significantly lower levels of 
GH and IGF-1 after provocation with L-dopa compared to the control group (El-Khayat et al., 
2010). Actually, the question arises whether the decreased GH release might be related to the 
direct negative effect on the hypothalamus-pituitary axis due to seizure activity per se or to 
antiepileptic drugs. Likely, these findings can be explained as a consequence of a hormonal 
imbalance related to both events (El-Khayat et al., 2010). A possible mechanism is the 
reduction of GABA concentration and of GABA receptor binding that are both demonstrated 
in cortical epileptic specimens (Bakay & Harris, 1981). In fact, GABA agonists are able to 
stimulate GH release (Tamminga et al., 1978). Instead, the possible role of enzyme inducing 
antiepileptic drugs on promoting GH metabolism wasn’t evident in this study (El-Khayat et 
al., 2010). The reduction of height associated with lower GH and IGF-1 levels in children with 
epilepsy might be a consequence of lower ghrelin levels or of a blunted ghrelin action on 
pituitary (van der Lely et al., 2004; Zizzari et al., 2005).  
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The most recent study was designed to indicate candidate biomarkers for the diagnosis of 
epilepsy and for the monitoring of the response to anticonvulsant drugs, dosing ghrelin and 
other hormones with simpler and non-invasive tests (Aydin et al., 2009). Besides, Aydin and 
co-workers recorded lower ghrelin levels in serum and saliva, in association with higher 
serum and saliva levels of nesfatin-1 (Aydin et al., 2009). Nesfatin-1 is a satiety hormone 
recently discovered, expressed in hypothalamic nuclei (Kohno et al., 2008; Oh-I et al., 2006; 
Pan et al., 2007; T. O. Price et al., 2007) in epileptic patients. These results were more evident 
before the starting of antiepileptic treatments and they weren’t explained yet. However, it 
has been hypothesized that an excessive release of nesfatin-1 might cause an excitotoxicity, 
stimulating hyperpolarization and depolarization in paraventricular and arcuate nuclei (T. 
O. Price et al., 2007; C. J. Price et al., 2008). However, the question whether higher nesfatin-1 
and lower ghrelin levels are a root cause of epilepsy or epilepsy modulates them has not 
been answered yet (Aydin et al., 2009).  
Similar results were reported by Dag and co-workers who showed that serum 
chromogranin A and obestatin were up-regulated whereas serum total ghrelin were down-
regulated in epileptic patients previously or currently treated with drugs, with salivary 
hormone concentrations resembling those in serum (Dag et al., 2010). Chromogranin A is an 
acidic glycoprotein located in the secretary vesicles of neurons and endocrine cells (Hendy 
et al., 1995), actually known as a stress indicator (Zheng & Moritani, 2008). Instead, 
obestatin, a bioactive peptide hormone, derives from the pre-proghrelin sequence and it is 
also involved in a wide range of physiological functions. It was considered as a ghrelin 
antagonist but more recent findings not confirm this role (Tang et al., 2008; J. V. Zhang et al., 
2005). The exact mechanism of the relationship between ghrelin and obestatin has not been 
completely explained, in particular in epileptic patients. An important unresolved question 
is why ghrelin and obestatin levels do not show parallel decrements or increments since 
they are products of the same gene (Dag et al., 2010). However, also these data supported 
that ghrelin levels are reduced in epilepsy and that saliva might be a good alternative for 
measuring these hormones in the diagnosis and follow-up of epilepsy (Dag et al., 2010). 
In addition, some authors found reduced high density lipoprotein (HDL)-cholesterol serum 
levels in epileptic patients (Aydin et al., 2009; Dag et al., 2010); so a parallel decrease both in 
ghrelin and HDL-cholesterol concentrations may be expected, because ghrelin is a HDL-
cholesterol-associated hormone (Beaumont et al., 2003).  
Therefore, more studies are needed to clarify the complex pathway system involved in 
epilepsy and, in particular, the exact role of ghrelin and obestatin. 
6. Conclusions 
Epilepsy and antiepileptic drugs affect the neuroendocrine system and seizure threshold 
may be alterated in relation to these hormonal modifications. Actually, the knowledge about 
neuroendocrine regulation in epilepsy is far to be complete and it is yet elusive. However, 
current findings suggest a complex network in which hormones play a crucial role as both 
as a cause and as a consequence of the epileptic activity. Thus, further studies are needed, in 
particular to fully define the role of new identified hormones, as ghrelin. Since the current 
knowledge, the effects of ghrelin include much more than those on pituitary and energy 
homeostasis. Increasing evidence indicates that ghrelin plays a role in anxiety and stress, in 
promoting learning behaviour, memory processes and sleep-wake regulation. Considering 
ghrelin pleiotropic functions, it has a relationship with epilepsy and seizures. Actually, the 
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imbalance related to both events (El-Khayat et al., 2010). A possible mechanism is the 
reduction of GABA concentration and of GABA receptor binding that are both demonstrated 
in cortical epileptic specimens (Bakay & Harris, 1981). In fact, GABA agonists are able to 
stimulate GH release (Tamminga et al., 1978). Instead, the possible role of enzyme inducing 
antiepileptic drugs on promoting GH metabolism wasn’t evident in this study (El-Khayat et 
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stimulating hyperpolarization and depolarization in paraventricular and arcuate nuclei (T. 
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acidic glycoprotein located in the secretary vesicles of neurons and endocrine cells (Hendy 
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ghrelin and HDL-cholesterol concentrations may be expected, because ghrelin is a HDL-
cholesterol-associated hormone (Beaumont et al., 2003).  
Therefore, more studies are needed to clarify the complex pathway system involved in 
epilepsy and, in particular, the exact role of ghrelin and obestatin. 
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may be alterated in relation to these hormonal modifications. Actually, the knowledge about 
neuroendocrine regulation in epilepsy is far to be complete and it is yet elusive. However, 
current findings suggest a complex network in which hormones play a crucial role as both 
as a cause and as a consequence of the epileptic activity. Thus, further studies are needed, in 
particular to fully define the role of new identified hormones, as ghrelin. Since the current 
knowledge, the effects of ghrelin include much more than those on pituitary and energy 
homeostasis. Increasing evidence indicates that ghrelin plays a role in anxiety and stress, in 
promoting learning behaviour, memory processes and sleep-wake regulation. Considering 
ghrelin pleiotropic functions, it has a relationship with epilepsy and seizures. Actually, the 
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results of the studies in vitro and in vivo are still controversial. However, it could be assured 
that ghrelin has anticonvulsant properties. In fact, focusing on regulation of ghrelin 
secretion in epilepsy or after seizure activity, blood ghrelin levels are shown decreased both 
in experimental epileptic rodents and in humans. Therefore ghrelin results as a 
neuroprotective agent, exerting antiepileptic, antioxidant and anti-inflammatory effects on 
neuronal brain cells. A better understanding of ghrelin’s activities may help to develop new 
therapeutic approaches to epilepsy, the most common neurological problem worldwide 
and, in particular, to refractory seizure forms. 
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results of the studies in vitro and in vivo are still controversial. However, it could be assured 
that ghrelin has anticonvulsant properties. In fact, focusing on regulation of ghrelin 
secretion in epilepsy or after seizure activity, blood ghrelin levels are shown decreased both 
in experimental epileptic rodents and in humans. Therefore ghrelin results as a 
neuroprotective agent, exerting antiepileptic, antioxidant and anti-inflammatory effects on 
neuronal brain cells. A better understanding of ghrelin’s activities may help to develop new 
therapeutic approaches to epilepsy, the most common neurological problem worldwide 
and, in particular, to refractory seizure forms. 
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1. Introduction 
Glutamate receptors are classified into two groups: metabotropic glutamate receptors 
(mGluRs) and ionotropic glutamate receptors (iGluRs). The ionotropic glutamate receptors 
are superfamily of ligand-gated cation channels that encompass three receptor families 
identified by the agonists that selectively activate them: N-methyl-D-aspartate (NMDA), α-
amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA), and kainic acid (KA) receptors 
(Dingledine et al. 1999, Mayer & Armstrong 2004, Kew & Kemp 2005). KA is a potent 
exogenous agonist of KA receptors and AMPA receptors, and systemic administration of 
KA produces epilepsy in rats and mice accompanied by neuronal damage mainly in limbic 
structures. In particular, hippocampal pyramidal neurons are highly vulnerable to the 
excitotoxicity of KA (Sperk et al. 1983). KA-induced seizures in rodents have been widely 
used as a model of human temporal lobe epilepsy on the basis of both behavioral and 
pathological similarities (Ben-Ari 1985). 
KA receptors are comprised of five different subunits: KA1, KA2, GluR5, GluR6 and GluR7 
(Lilliu et al. 2002, Porter et al. 1997). It is reported that GluR6 subunit-deficient and Jnk3 gene 
knock-out mice resistance to KA-induced seizures and neuronal toxicity (Yang et al. 1997, 
Mulle et al. 1998). And the Glur6 midiated JNK3 (c-Jun N-terminal kinase 3) signaling 
pathway has been pay more attention in the study of neuron damage during epilepsia. C 
terminus of GluR6 can bind to the PDZ1 domain of the postsynaptic density protein 
PSD95/SAP90 through specific interaction (Garcia et al. 1998, Mehta et al. 2001). Previous 
studies have also shown that MLK3 (mixed lineage kinase-3), an upstream kinase of JNK 
(Tibbles et al. 1996), can interact with the SH3 (Src homology) domain of PSD95 (Savinainen 
et al. 2001). The triple complex GluR6-PSD95-MLK3 may exist and facilitate JNK activation.  
In our previous studies on brain ischemia, it has demonstrated that KA enhanced the 
assembly of GluR6-PSD95-MLK3 module, increased the autophosphorylation of MLK3 and 
the phosphorylation of MKK7 (mitogen-activated protein kinase kinase 7), JNK3, c-Jun and 
Bcl-2 (B-cell lymphoma 2), raised the expression of Fas-Ligand (FasL) and caused the release 
of Bax (Bcl-2 associated x protein) from Bcl-2/Bax dimmers and the release of cytochrome c 
from mitochondria (Pei et al. 2006). Consequently, the activation of Caspase 3 led to delayed 
neuronal death in the hippocampal CA1/CA3 subfield (Tian et al. 2005, Pei et al. 2005, Pan et 
al. 2005). The activation of mitochondrion-linked apoptotic signaling pathways after 
seizures, including activation of caspase-9, -3, and -8, has also been reported (Henshall et al. 
2000). And we further found that KA-induced neuronal death is mediated by the GluR6-
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et al. 2001). The triple complex GluR6-PSD95-MLK3 may exist and facilitate JNK activation.  
In our previous studies on brain ischemia, it has demonstrated that KA enhanced the 
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the phosphorylation of MKK7 (mitogen-activated protein kinase kinase 7), JNK3, c-Jun and 
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al. 2005). The activation of mitochondrion-linked apoptotic signaling pathways after 
seizures, including activation of caspase-9, -3, and -8, has also been reported (Henshall et al. 
2000). And we further found that KA-induced neuronal death is mediated by the GluR6-
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PSD95-MLK3 signaling module via FasL/Fas and cytochrome c pathways in KA-induced 
seizures and interference of the interaction between GluR6 and PSD95 with a peptide can 
protect neurons from KA-induced death (Liu et al. 2006). 
Regulation of GluR6 mediated apoptotic pathway has emerged as a possible approach to 
protect neuron damage against seizure. One idea is down-regulating excitatory GluR6-
containing KA receptors by activation of inhibitory GABA receptors. GABA plays a key role in 
modulating neuronal activity via distinct receptor systems, the ionotropic GABAA and 
metabotropic GABAB receptors. It has been proposed that coactivation of GABAA and GABAB 
receptors induced by muscimol and baclofen respectively can result in neuroprotection during 
in vitro ischemia (Costa et al. 2004), and coapplication of the two agonists is more effective than 
when solely used (Zhang et al. 2007). Data acquired from our lab demonstrated that 
coapplication of muscimol with baclofen has neuroprotective effects in rat hippocampal CA1 
and CA3 regions and inhibits the assembly of the GluR6-PSD95-MLK3 signaling module and 
subsequently activates JNK downstream signaling pathways (Li et al.). 
2. Neuroprotective effects of peptide Tat-GluR6-9c and GABA receptors 
activation against neuronal death induced by KA in rat hippocampus 
Based on our previous study, activation of GluR6-PSD95-MLK3 signaling is an important 
reason for neuron death in rat KA-induced epilepsy model. Interference of this signaling might 
have protective effects against neuron death, so we designed two different strategies to carry 
out the goal. First, we constructed a peptide comprising the conserved nine COOH-terminal 
residues of GluR6 (Arg-Leu-Pro-Gly-Lys-Glu-Thr-Met-Ala, named GluR6-9c), which was 
fused to Tat protein (cell-membrane transduction domain of the human immunodeficiency 
virus-type 1, Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg). The Tat-GluR6-9c peptide can 
be delivered into hippocampal neurons and destroy the interaction between GluR6 and 
PSD95, and further suppress the GluR6-PSD95-MLK3 signaling. Second, elevating the 
inhibition of GABA receptors can significantly decrease KAR-mediated excitation in KA-
induced epilepsy. The major finding is that Muscimol and/or Baclofen can suppress the 
assembly of the GluR6-PSD95-MLK3 signaling. One possible explanation is that the activation 
of GABAA receptor by muscimol can induce the hyperpolarization of postsynaptic nrurons via 
activating ligand-gated Cl- channels, which decrease the depolarization of the neurons 
(Attwell et al. 1993), and activation of G protein-coupled GABAB receptor by baclofen can 
attenuate glutamate release from presynaptic neurons (Moldavan et al. 2006). The mechanism 
and roles of these two strategies are described below. 
2.1 Assembly of the GluR6-PSD95-MLK3 signaling module during seizure induced by 
KA in hippocampal CA1 and CA3/DG regions 
Immunoprecipitation and immunoblotting were performed to examine the interactions of 
GluR6 and MLK3 with PSD95 at various times of KA injection. The interactions of GluR6 
and MLK3 with PSD95 increased rapidly after KA injection, reached peak levels at 6 h, and 
then gradually decreased to control levels at 3 days in both CA1 and CA3/DG regions. 
2.2 Tat-GluR6-9c peptide suppresses the increased assembly of the GluR6-PSD95-
MLK3 signaling module induced by KA in hippocampal CA1 and CA3/DG regions 
Tat-GluR6-9c, a GluR6 C terminus-containing peptide conjugated to the cell membrane 
transduction sequence of the human immunodeficiency virus Tat protein, can be delivered 
 




into hippocampal neurons in vitro and in vivo. Reciprocal immunoprecipitation experiments 
demonstrated that the peptide perturbed the GluR6-PSD95-MLK3 signaling module. 
Administration of Tat-GluR6-9c 40 min prior to KA injection diminished the increased 
interactions of GluR6 and MLK3 with PSD95 at 6 h after kainate treatment in CA1 and 
CA3/DG subregions, whereas the protein levels of GluR6, PSD95, and MLK3 were not 
altered. 
2.3 Tat-GluR6-9c inhibits the activation of MLK3, MKK7, and JNK induced by KA in 
hippocampal CA1 and CA3/DG regions 
KA treatment resulted in a remarkable increase in the phosphorylation of MLK3 in CA1and 
CA3/DG regions. Pretreatment with Tat-GluR6-9c significantly diminished the increase in 
the phosphorylation of MLK3. And, the activation of MKK7 and JNK at 6 h after KA 
injection was significantly suppressed by application of the Tat-GluR6-9c peptide in CA1 
and CA3/DG regions. 
2.4 Tat-GluR6-9c inhibits the phosphorylation of c-Jun and the expression of FasL 
induced by KA in hippocampal CA1 and CA3/DG regions 
The phosphorylation and expression of transcription factor c-Jun was significantly increased 
at 6 and 12 h in both CA1 and CA3/DG regions after KA injection. Prior administration of 
Tat-GluR6-9c significantly diminished the increase in phospho-c-Jun at 6 h after KA 
treatment. The protein levels of c-Jun were not affected. The increased phosphorylation of c-
Jun leads to increased expression of FasL. The expression of FasL increased rapidly at 6 h 
and returned to the basal level at 3 days in CA1 and CA3/DG regions. Prior application of 
Tat-GluR6-9c diminished the increased expression of FasL. 
2.5 Tat-GluR6-9c decreases Bax expression and increases Bcl-2 expression induced 
by KA in hippocampal CA1 and CA3/DG regions 
It is known that Bcl-2 is an anti-apoptotic protein, whereas Bax is an pro-apoptotic protein. 
The expression of Bax increased dramatically at 6 h after KA injection and lasted 3 days, 
whereas the level of Bcl-2 decreased sharply at 6 h after KA injection and reached the lowest 
at 3 days in the CA1 region. Prior application of Tat-GluR6-9c resulted in the decreased 
expression of Bax at 6 h after KA treatment in both CA1 and CA3/DG regions, whereas the 
level of Bcl-2 was obviously increased at 6 h after KA injection. 
2.6 Tat-GluR6-9c attenuates Bax translocation and the release of cytochrome c 
induced by KA in Hippocampal CA1 and CA3/DG regions 
A previous study reported mitochondrial Bax accumulation after seizure (Henshall et al. 
2002). Tat-GluR6-9c can inhibit Bax translocation in the mitochondrial fraction in both CA1 
and CA3/DG regions. Moreover, Tat-GluR6-9c inhibited the release of cytochrome c from 
mitochondria to the cytosol in CA1 and CA3/DG fields. 
2.7 Tat-GluR6-9c inhibits the activation of caspase-3 and neuronal apoptosis induced 
by KA in hippocampal CA1 and CA3/DG regions 
Tat-GluR6-9c pretreatment diminished the activation of caspase-3 at 6 h after KA injection. 
TUNEL (Terminal Transferase dUTP Nick End Labeling) staining was used to examine the 
apoptosis of CA1 and CA3 neuronal cells in the hippocampus. Administration of Tat-GluR6-
 
Underlying Mechanisms of Epilepsy 
 
182 
PSD95-MLK3 signaling module via FasL/Fas and cytochrome c pathways in KA-induced 
seizures and interference of the interaction between GluR6 and PSD95 with a peptide can 
protect neurons from KA-induced death (Liu et al. 2006). 
Regulation of GluR6 mediated apoptotic pathway has emerged as a possible approach to 
protect neuron damage against seizure. One idea is down-regulating excitatory GluR6-
containing KA receptors by activation of inhibitory GABA receptors. GABA plays a key role in 
modulating neuronal activity via distinct receptor systems, the ionotropic GABAA and 
metabotropic GABAB receptors. It has been proposed that coactivation of GABAA and GABAB 
receptors induced by muscimol and baclofen respectively can result in neuroprotection during 
in vitro ischemia (Costa et al. 2004), and coapplication of the two agonists is more effective than 
when solely used (Zhang et al. 2007). Data acquired from our lab demonstrated that 
coapplication of muscimol with baclofen has neuroprotective effects in rat hippocampal CA1 
and CA3 regions and inhibits the assembly of the GluR6-PSD95-MLK3 signaling module and 
subsequently activates JNK downstream signaling pathways (Li et al.). 
2. Neuroprotective effects of peptide Tat-GluR6-9c and GABA receptors 
activation against neuronal death induced by KA in rat hippocampus 
Based on our previous study, activation of GluR6-PSD95-MLK3 signaling is an important 
reason for neuron death in rat KA-induced epilepsy model. Interference of this signaling might 
have protective effects against neuron death, so we designed two different strategies to carry 
out the goal. First, we constructed a peptide comprising the conserved nine COOH-terminal 
residues of GluR6 (Arg-Leu-Pro-Gly-Lys-Glu-Thr-Met-Ala, named GluR6-9c), which was 
fused to Tat protein (cell-membrane transduction domain of the human immunodeficiency 
virus-type 1, Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg). The Tat-GluR6-9c peptide can 
be delivered into hippocampal neurons and destroy the interaction between GluR6 and 
PSD95, and further suppress the GluR6-PSD95-MLK3 signaling. Second, elevating the 
inhibition of GABA receptors can significantly decrease KAR-mediated excitation in KA-
induced epilepsy. The major finding is that Muscimol and/or Baclofen can suppress the 
assembly of the GluR6-PSD95-MLK3 signaling. One possible explanation is that the activation 
of GABAA receptor by muscimol can induce the hyperpolarization of postsynaptic nrurons via 
activating ligand-gated Cl- channels, which decrease the depolarization of the neurons 
(Attwell et al. 1993), and activation of G protein-coupled GABAB receptor by baclofen can 
attenuate glutamate release from presynaptic neurons (Moldavan et al. 2006). The mechanism 
and roles of these two strategies are described below. 
2.1 Assembly of the GluR6-PSD95-MLK3 signaling module during seizure induced by 
KA in hippocampal CA1 and CA3/DG regions 
Immunoprecipitation and immunoblotting were performed to examine the interactions of 
GluR6 and MLK3 with PSD95 at various times of KA injection. The interactions of GluR6 
and MLK3 with PSD95 increased rapidly after KA injection, reached peak levels at 6 h, and 
then gradually decreased to control levels at 3 days in both CA1 and CA3/DG regions. 
2.2 Tat-GluR6-9c peptide suppresses the increased assembly of the GluR6-PSD95-
MLK3 signaling module induced by KA in hippocampal CA1 and CA3/DG regions 
Tat-GluR6-9c, a GluR6 C terminus-containing peptide conjugated to the cell membrane 
transduction sequence of the human immunodeficiency virus Tat protein, can be delivered 
 




into hippocampal neurons in vitro and in vivo. Reciprocal immunoprecipitation experiments 
demonstrated that the peptide perturbed the GluR6-PSD95-MLK3 signaling module. 
Administration of Tat-GluR6-9c 40 min prior to KA injection diminished the increased 
interactions of GluR6 and MLK3 with PSD95 at 6 h after kainate treatment in CA1 and 
CA3/DG subregions, whereas the protein levels of GluR6, PSD95, and MLK3 were not 
altered. 
2.3 Tat-GluR6-9c inhibits the activation of MLK3, MKK7, and JNK induced by KA in 
hippocampal CA1 and CA3/DG regions 
KA treatment resulted in a remarkable increase in the phosphorylation of MLK3 in CA1and 
CA3/DG regions. Pretreatment with Tat-GluR6-9c significantly diminished the increase in 
the phosphorylation of MLK3. And, the activation of MKK7 and JNK at 6 h after KA 
injection was significantly suppressed by application of the Tat-GluR6-9c peptide in CA1 
and CA3/DG regions. 
2.4 Tat-GluR6-9c inhibits the phosphorylation of c-Jun and the expression of FasL 
induced by KA in hippocampal CA1 and CA3/DG regions 
The phosphorylation and expression of transcription factor c-Jun was significantly increased 
at 6 and 12 h in both CA1 and CA3/DG regions after KA injection. Prior administration of 
Tat-GluR6-9c significantly diminished the increase in phospho-c-Jun at 6 h after KA 
treatment. The protein levels of c-Jun were not affected. The increased phosphorylation of c-
Jun leads to increased expression of FasL. The expression of FasL increased rapidly at 6 h 
and returned to the basal level at 3 days in CA1 and CA3/DG regions. Prior application of 
Tat-GluR6-9c diminished the increased expression of FasL. 
2.5 Tat-GluR6-9c decreases Bax expression and increases Bcl-2 expression induced 
by KA in hippocampal CA1 and CA3/DG regions 
It is known that Bcl-2 is an anti-apoptotic protein, whereas Bax is an pro-apoptotic protein. 
The expression of Bax increased dramatically at 6 h after KA injection and lasted 3 days, 
whereas the level of Bcl-2 decreased sharply at 6 h after KA injection and reached the lowest 
at 3 days in the CA1 region. Prior application of Tat-GluR6-9c resulted in the decreased 
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level of Bcl-2 was obviously increased at 6 h after KA injection. 
2.6 Tat-GluR6-9c attenuates Bax translocation and the release of cytochrome c 
induced by KA in Hippocampal CA1 and CA3/DG regions 
A previous study reported mitochondrial Bax accumulation after seizure (Henshall et al. 
2002). Tat-GluR6-9c can inhibit Bax translocation in the mitochondrial fraction in both CA1 
and CA3/DG regions. Moreover, Tat-GluR6-9c inhibited the release of cytochrome c from 
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Tat-GluR6-9c pretreatment diminished the activation of caspase-3 at 6 h after KA injection. 
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9c 40 min before KA injection significantly decreased TUNEL-positive cells. Tat-GluR6-9c 
significantly decreased neuronal degeneration (Fig. 1). 
 
 
Fig. 1. Neuroprotection of peptide Tat-GluR6-9c in hippocampal CA1 and CA3 subfields. 
2.8 Muscimol and baclofen suppress the increased assembly of the GluR6-PSD95-
MLK3 signaling module induced by KA in hippocampal CA1 and CA3/DG regions 
The GABA receptors can be activated by two GABA agonists: muscimol, a GABAA agonist, 
and baclofen, a GABAB agonist. Reciprocal immunoprecipitation experiments suggested 
that the administration of two agonists resulted in the disassembly of GluR6-PSD95-MLK3 
signaling module. Co-administration of muscimol and baclofen 40 min prior to KA injection 
diminished the increased interactions of GluR6 and MLK3 with PSD95 at 6 h after KA 
treatment in CA1 and CA3/DG subregions, whereas the protein levels of GluR6, PSD95 and 
MLK3 were not altered. 
2.9 Muscimol and baclofen inhibit the activation of MLK3, MKK7 and JNK3 induced  
by KA in hippocampal CA1 and CA3/DG regions 
Pretreatment with muscimol and baclofen significantly diminished the increase of the MLK3 
phosphorylation. Meanwhile, the activation of MKK7 at 6 h after KA injection was 
 




significantly suppressed by co-application of muscimol and baclofen in CA1 and CA3/DG 
regions. Furthermore, similar results were obtained with JNK3. 
2.10 Muscimol and baclofen inhibit the phosphorylation of c-Jun and the expression 
of FasL induced by KA in hippocampal CA1 and CA3/DG regions 
Prior administration of muscimol and baclofen significantly diminished the increase of 
phospho-c-Jun at 6 h after KA treatment. Prior application of musimol and baclofen 
attenuated the increased expression of FasL at 6 h induced by KA in hippocampal CA1 and 
CA3/DG regions. 
2.11 Muscimol and baclofen decrease Bax expression and increase Bcl-2 expression 
induced by KA in hippocampal CA1 and CA3/DG regions 
Prior application of muscimol and baclofen resulted in the decreased expression of Bax at 6 
h after KA treatment in both CA1 and CA3/DG regions, whereas the level of Bcl-2 was 
obviously increased at 6 h after KA injection. 
2.12 Muscimol and baclofen attenuate Bax translocation and the release of 
cytochrome c induced by KA in hippocampal CA1 and CA3/DG regions 
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KA administration compared with the saline control in both CA1 and CA3/DG regions. In 
the cytosolic fraction, cytochrome c immunoreactivity was evident as a single band at 6 h of 
KA injection. However, it was weakly detected in the saline group. A significant amount of 
mitochondrial cytochrome c was detected in the saline group, and it decreased at 6 h after 
KA injection corresponding to a marked increase in the cytosolic fraction. Moreover, 
muscimol and baclofen inhibited the release of cytochrome c from mitochondria to the 
cytosol in CA1 and CA3/DG fields. 
2.13 Muscimol and baclofen inhibit the activation of caspase-3 and neuronal 
apoptosis induced by KA in hippocampal CA1 and CA3/DG regions 
Muscimol and baclofen pretreatment diminished the activation of caspase-3 at 6 h after KA 
injection. Furthermore, significant numbers of TUNEL-positive cells were observed in the 
KA-treated group after 7 days, but administration of muscimol and baclofen 40 min before 
KA injection significantly decreased TUNEL-positive cells. 
3. Conclusion 
KA induced the assembly of the GluR6-PSD95-MLK3 signaling module and subsequently 
activated JNK downstream signaling pathways, ultimately resulting in neuronal cell death. 
Application of Tat-GluR6-9c, a GluR6 C terminus-containing peptide, suppressed the 
clustering of GluR6 in the postsynaptic regions by competitively binding to the PDZ1 
domain of PSD95 and subsequently inhibited the assembly of the GluR6-PSD95-MLK3 
signaling module. As a result, the peptide attenuated the activation of MLK3 and JNK. 
Furthermore, Tat-GluR6-9c inhibited the activation of the nuclear and non-nuclear pathways 
of JNK induced by KA. Notably, the peptide had neuroprotective effects against rat epileptic 
brain damage. In conclusion, the kainate receptor subunit GluR6 plays an important role in 
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brain damage induced by KA, and Tat-GluR6-9c provides a new approach for epileptic 
seizure therapy. 
Co-application of muscimol (GABAA receptor agonist) and baclofen (GABAB receptor 
agonist) inhibited the assembly of the GluR6-PSD95-MLK3 signaling module. The two 
agonists attenuated the activation of MLK3 and JNK. Furthermore, muscimol and baclofen 
inhibited the activation of the nuclear and non-nuclear pathways of JNK induced by KA. 
Notably, the coapplication the two agonists had neuroprotective effects against rat epileptic 
brain damage. This highlighted that the balance between neuronal excitation and inhibition 
is critical for maintaining normal function. 
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1. Introduction  
Since the demonstration that the hippocampus slice exposed to low calcium external 
solution is able to sustain nonsynaptic epileptiform activity, it has been accepted that 
nonsynaptic interactions may be sufficient, in some conditions, for generating seizure like 
activity in cortical network. Recently, evidences have suggested that the reductions in 
calcium are not essential for nonsynaptic mechanisms to contribute to epileptic activity. 
Therefore, evidences allow demonstrating that the conjoint actuation of nonsynaptic 
mechanisms and nonsynaptic connections are able to induce and sustain seizures. The 
nonsynaptic mechanisms considered in this context are all mechanisms which are not 
directly involved with synaptic transmission, but comprehending important action on the 
homeostasis equilibrium and, consequently, on the neuronal excitability.  
The non-synaptic connections are all types of neuronal coupling that are not mediated by 
synaptic transmission. The concomitant actuation of nonsynaptic mechanisms and 
connections seems to be a relevant process for the seizure intensity modulation. Therefore, it 
may be conjectured that the nonsynaptic mechanisms and connections could be considered 
a natural target for investigations aiming to control refractory seizures. Within this 
perspective, the scope of the present chapter will cover the following topics: 
• nonsynaptic events: experimental induction and electrophysiological characteristics; 
• nonsynaptic mechanisms; 
• nonsynaptic connections; 
• biophysical aspects of the nonsynaptic epileptiform activities; 
• possible targets for controlling refractory seizures. 
2. Nonsynaptic epileptiform events 
In in vivo experiments, chemically induced focal cortical seizures were observed to be 
sometimes preceded by small reductions in [Ca2+]o and to become intense during the 
paroxysms (Heinemann et al., 1977; Krnjevic et al., 1980). Those findings lead to suspect that 
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synaptic transmission. The concomitant actuation of nonsynaptic mechanisms and 
connections seems to be a relevant process for the seizure intensity modulation. Therefore, it 
may be conjectured that the nonsynaptic mechanisms and connections could be considered 
a natural target for investigations aiming to control refractory seizures. Within this 
perspective, the scope of the present chapter will cover the following topics: 
• nonsynaptic events: experimental induction and electrophysiological characteristics; 
• nonsynaptic mechanisms; 
• nonsynaptic connections; 
• biophysical aspects of the nonsynaptic epileptiform activities; 
• possible targets for controlling refractory seizures. 
2. Nonsynaptic epileptiform events 
In in vivo experiments, chemically induced focal cortical seizures were observed to be 
sometimes preceded by small reductions in [Ca2+]o and to become intense during the 
paroxysms (Heinemann et al., 1977; Krnjevic et al., 1980). Those findings lead to suspect that 
 
Underlying Mechanisms of Epilepsy 
 
190 
the calcium reduction may influence the course to the paroxysms. As the description by 
Jefferys & Haas (1982) and Taylor & Dudek (1982) show, it is well known that the 
hippocampus slice exposed to low calcium external solution is able to sustain nonsynaptic 
epileptiform activity. Based on the fact that low Ca2+ seizures occur in conditions of 
suppressed excitatory synaptic transmission, experimental findings demonstrate that 
nonsynaptic interactions may be sufficient, in some situations, for generating seizurelike 
activity in cortical network (Konnerth et al., 1986). More recently, evidences have suggested 
that the reductions in calcium are not essential for nonsynaptic mechanisms to contribute to 
epileptic activity (Bikson et al., 2002). Therefore, the nonsynaptic connections may have 
wider relevance than it could be initially suspected.  
The nonsynaptic epileptiform activity was first observed in CA1 region of hippocampus 
slice involving the use of solutions with low [Ca2+]. Later, observations of the occurrence of 
prolonged field bursts in the dentate gyrus (DG) have been reported (Schweitzer et al., 
1992). These authors pointed out the effect of deletion of Ca2+ from the bath solution on 
burst firing in CA3, CA1, and DG. When a calcium-free 5 mM [K+]o solution was used, 
spontaneous bursts could still be observed in CA3 and CA1, but not in DG. However, at 9 
mM [K+]o, although absent in CA3 and CA1, in DG spontaneous bursts characterized by an 
abrupt prolonged negative shift in the extracellular field potential could be observed 
followed by the appearance of large paroxysmal population spikes. The DG spontaneous 
bursts exhibited similarity to the “maximal dentate activation” (MDA), observed in vivo in 
the same region (Somjen et al., 1985; Stringer et al., 1989, 1991; Stringer & Lothman, 1991). 
Therefore, the ability of each region to generate or sustain nonsynaptic epileptiform activity 
depends on the circumstances, more specifically on the level of calcium reduction and 
potassium increase. 
In the hippocampus, especially in the DG, the tight packing of the cell bodies of neurons and 
glial cells constitutes an adequate substrate for the nonsynaptic connections. In high-
potassium and zero-Ca2+ conditions the granule cells have some endogenous bursting 
capabilities able to sustain synchronization and, consequently, spontaneous epileptiform 
activity (Pan & Stringer, 1996). As these observations have been made in the absence of 
synaptic transmission, because Ca2+ has been deleted from the bath solution, 
synchronization mechanisms must have nonsynaptic origin (Schweitzer et al., 1992; Pan & 
Stringer, 1996) and could be mediated by gap-junctions, ionic fluctuations, or field effect.  
It is known that the electrical signaling in neurons and glial cells is based on the activities of 
the ion pumps and carriers that establish transmembrane ionic gradients, and on the 
operation of ionic channels that generate current and voltage response based on 
electrodiffusion. Therefore, the cellular mechanisms described in the present study and 
investigated in the context of the epilepsy, by means of a computational simulation, are: 
membrane ionic currents, Na+/K+-ATPase, cotransporters, and exchangers. The cell activity 
of the network was nonsynaptically connected using extracellular electrodiffusion 
calculation, as well as the electric field effect and the gap-junctional coupling. 
2.1 Experimental induction and electrophysiological characteristics 
2.1.1 Inducing non-synaptic epileptiform activity and experimental apparatus  
Hippocampal slices from Wistar rats were prepared (4-6 weeks old, male). After eutanized 
in a CO2 chamber, the brains were removed. Transverse slices (400 µm) through the 
hippocampus were cut with a tissue chopper. After cutting, slices were stored in an 
oxygenated holding chamber for ≥ 1 h before recording. All recordings were acquired in an 
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interface-chamber and continuously perfused with artificial cerebrospinal fluid (ACSF) at 
32°C under a stream of humidified 95% O2/5% CO2. Composition of the ACSF was (in mM): 
NaCl 127, KCl 2, MgSO4 1.5, KH2PO4 1.1, NaHCO3 26, CaCl2 2 and glucose 10. All solutions 
were bubbled constantly with 95% O2/5% CO2. Slices were allowed to equilibrate for 1 h in 
normal ACSF. Recording electrodes were made of microfilament capillary thin-walled glass 
(0.9 mm ID, 1.2 mm OD) pulled on a micropipette puller (DMZ Universal Puller – Zeitz-
Instruments). Electrodes were filled with 2 M NaCl and had impedances between 5 and 10 
MΩ. Recording electrodes were placed in the cell body layer of the region of interest. 
Nonsynaptic epileptiform activity was induced in the hippocampus by changing to ACSF 
containing 0-added calcium and high potassium. The potassium was raised to 6 mM to 
induce epileptiform activity in the CA1 region and was raised to 8 mM to induce 
epileptiform activity in the dentate gyrus. The non-synaptic epileptiform activity can take 
more than an hour to appear, but once it appears, the interval between field bursts and the 
burst duration remain stable for many hours (Bikson et al., 1999; Pan & Stringer, 1996).  
In our laboratory, the interface-chamber is a variant of those used in several studies aimed at 
studying with in vitro slices (Pan & Stringer, 1996; Schwartzkroin, 1975). The chamber 
consists of two coupled modules: the perfusion module and the heating module. The slice 
perfusion module (top view of the chamber, Fig. 1) consists of two cylinders and an acrylic 
base, which attaches superiorly to the heating module (see side view of the chamber, Fig. 1). 
The central cylinder is where a Millipore membrane (0.4 µm Millicell culture plate inserts; 
Milleppori, Bedford, MA, USA) is inserted. The slices are deposited on the membrane. The 
region in between the membrane and the acrylic base has approximately 0.34 ml, allowing 
the solution in contact with the slices, through the membrane, to be constantly renewed. The 
acrylic base has small holes through which carbogen, after crossing the water bath of the 
heating module, can humidify and oxygenate the slices. A disc-shaped lid covers the 
perfusion module ensuring homogeneity of the environment surrounding the slice. The lid 
has a central hole that allows insertion of the recording electrode and the carbogen release. 
 
  
Fig. 1. Interface chamber. Schematic diagram of the interface chamber. (left) superior view – 
(right) lateral view. (1) perfusion solution entry; (2) Millipore membrane; (3) brain slices; (4) 
thermometer; (5) ground wire; (6) solution output; (7) holes for conduct the warm and 
moisturized carbogen into the chamber; (8) carbogen bubbler; (9) heating the perfusion 
solution; (10) heater; (11) chamber external cylinder; (12) carbogen release; (13) carbogen 
input. 
 
Underlying Mechanisms of Epilepsy 
 
190 
the calcium reduction may influence the course to the paroxysms. As the description by 
Jefferys & Haas (1982) and Taylor & Dudek (1982) show, it is well known that the 
hippocampus slice exposed to low calcium external solution is able to sustain nonsynaptic 
epileptiform activity. Based on the fact that low Ca2+ seizures occur in conditions of 
suppressed excitatory synaptic transmission, experimental findings demonstrate that 
nonsynaptic interactions may be sufficient, in some situations, for generating seizurelike 
activity in cortical network (Konnerth et al., 1986). More recently, evidences have suggested 
that the reductions in calcium are not essential for nonsynaptic mechanisms to contribute to 
epileptic activity (Bikson et al., 2002). Therefore, the nonsynaptic connections may have 
wider relevance than it could be initially suspected.  
The nonsynaptic epileptiform activity was first observed in CA1 region of hippocampus 
slice involving the use of solutions with low [Ca2+]. Later, observations of the occurrence of 
prolonged field bursts in the dentate gyrus (DG) have been reported (Schweitzer et al., 
1992). These authors pointed out the effect of deletion of Ca2+ from the bath solution on 
burst firing in CA3, CA1, and DG. When a calcium-free 5 mM [K+]o solution was used, 
spontaneous bursts could still be observed in CA3 and CA1, but not in DG. However, at 9 
mM [K+]o, although absent in CA3 and CA1, in DG spontaneous bursts characterized by an 
abrupt prolonged negative shift in the extracellular field potential could be observed 
followed by the appearance of large paroxysmal population spikes. The DG spontaneous 
bursts exhibited similarity to the “maximal dentate activation” (MDA), observed in vivo in 
the same region (Somjen et al., 1985; Stringer et al., 1989, 1991; Stringer & Lothman, 1991). 
Therefore, the ability of each region to generate or sustain nonsynaptic epileptiform activity 
depends on the circumstances, more specifically on the level of calcium reduction and 
potassium increase. 
In the hippocampus, especially in the DG, the tight packing of the cell bodies of neurons and 
glial cells constitutes an adequate substrate for the nonsynaptic connections. In high-
potassium and zero-Ca2+ conditions the granule cells have some endogenous bursting 
capabilities able to sustain synchronization and, consequently, spontaneous epileptiform 
activity (Pan & Stringer, 1996). As these observations have been made in the absence of 
synaptic transmission, because Ca2+ has been deleted from the bath solution, 
synchronization mechanisms must have nonsynaptic origin (Schweitzer et al., 1992; Pan & 
Stringer, 1996) and could be mediated by gap-junctions, ionic fluctuations, or field effect.  
It is known that the electrical signaling in neurons and glial cells is based on the activities of 
the ion pumps and carriers that establish transmembrane ionic gradients, and on the 
operation of ionic channels that generate current and voltage response based on 
electrodiffusion. Therefore, the cellular mechanisms described in the present study and 
investigated in the context of the epilepsy, by means of a computational simulation, are: 
membrane ionic currents, Na+/K+-ATPase, cotransporters, and exchangers. The cell activity 
of the network was nonsynaptically connected using extracellular electrodiffusion 
calculation, as well as the electric field effect and the gap-junctional coupling. 
2.1 Experimental induction and electrophysiological characteristics 
2.1.1 Inducing non-synaptic epileptiform activity and experimental apparatus  
Hippocampal slices from Wistar rats were prepared (4-6 weeks old, male). After eutanized 
in a CO2 chamber, the brains were removed. Transverse slices (400 µm) through the 
hippocampus were cut with a tissue chopper. After cutting, slices were stored in an 
oxygenated holding chamber for ≥ 1 h before recording. All recordings were acquired in an 
 
Biophysical Aspects of the Nonsynaptic Epileptiform Activity 
 
191 
interface-chamber and continuously perfused with artificial cerebrospinal fluid (ACSF) at 
32°C under a stream of humidified 95% O2/5% CO2. Composition of the ACSF was (in mM): 
NaCl 127, KCl 2, MgSO4 1.5, KH2PO4 1.1, NaHCO3 26, CaCl2 2 and glucose 10. All solutions 
were bubbled constantly with 95% O2/5% CO2. Slices were allowed to equilibrate for 1 h in 
normal ACSF. Recording electrodes were made of microfilament capillary thin-walled glass 
(0.9 mm ID, 1.2 mm OD) pulled on a micropipette puller (DMZ Universal Puller – Zeitz-
Instruments). Electrodes were filled with 2 M NaCl and had impedances between 5 and 10 
MΩ. Recording electrodes were placed in the cell body layer of the region of interest. 
Nonsynaptic epileptiform activity was induced in the hippocampus by changing to ACSF 
containing 0-added calcium and high potassium. The potassium was raised to 6 mM to 
induce epileptiform activity in the CA1 region and was raised to 8 mM to induce 
epileptiform activity in the dentate gyrus. The non-synaptic epileptiform activity can take 
more than an hour to appear, but once it appears, the interval between field bursts and the 
burst duration remain stable for many hours (Bikson et al., 1999; Pan & Stringer, 1996).  
In our laboratory, the interface-chamber is a variant of those used in several studies aimed at 
studying with in vitro slices (Pan & Stringer, 1996; Schwartzkroin, 1975). The chamber 
consists of two coupled modules: the perfusion module and the heating module. The slice 
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the solution in contact with the slices, through the membrane, to be constantly renewed. The 
acrylic base has small holes through which carbogen, after crossing the water bath of the 
heating module, can humidify and oxygenate the slices. A disc-shaped lid covers the 
perfusion module ensuring homogeneity of the environment surrounding the slice. The lid 
has a central hole that allows insertion of the recording electrode and the carbogen release. 
 
  
Fig. 1. Interface chamber. Schematic diagram of the interface chamber. (left) superior view – 
(right) lateral view. (1) perfusion solution entry; (2) Millipore membrane; (3) brain slices; (4) 
thermometer; (5) ground wire; (6) solution output; (7) holes for conduct the warm and 
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solution; (10) heater; (11) chamber external cylinder; (12) carbogen release; (13) carbogen 
input. 
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The heating module is composed of four heating points and two bubblers that disperse 
carbogen in the water. The equipment, computer controlled, is capable of maintaining the 
temperature around 34 º C. The water in the bath warms the perfusion solution when it 
flows through the tube, around the central cylinder. 
To monitor regions of the slices where the activities spontaneously emerge and to guide the 
electrode positioning and also to evaluate the extension of the recruitment, the slices were 
transilluminated from below using a halogen lamp from the illuminating system of the 
upright binocular microscope (model SMZ 1500 – Nikon, Japan). The slices were viewed 
from above through a 3× or 4× objective, depending on the size of the region studied. The 
video images were captured using a CCD camera (Cool SNAP-Pro cf 1.4 megapixel cooled, 
USA). The images were processed on-line for composing the STF images. For this purpose 
the frames were digitalized by means of a frame-grabber board (DC10 Plus, Pinnacle, USA), 
controlled by an acquisition software developed in MatLab platform. All the images were 
captured at a rate of 30 frames per second. Optionally, the images can be processed offline. 
In this case, all captured frames were stored on a DVD disc. The electrographic signal was 
used to control the range of frames to be captured.  
To obtain images of the light transmittance changes (LTC), the calculation was carried out 
similarly to the method described by Andrew et al. (1996). Briefly, the averages of the 
corresponding pixels of the first 50 frames, before the wave propagation, formed the control 
image (Tcont), which was subtracted, pixel by pixel, from each subsequent experimental 
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Using a gray intensity scale, the series of LTC images revealed areas of the slice where the 
light transmittance changes with time. To condense on a single image the spatiotemporal 
features (STF) of paroxysmal activity, the contour of the layer involved in the activity is 
resembled by a polygonal, drawn manually, by setting pixel positions that are then linked 
forming the polygonal (Figure 2.A). 
The STF images were built column by column. For each LTC image, the average intensity of 
the pixels of a square region (21×21 pixels) centered in each pixel of the polygonal was 
calculated. These values are the intensities of each pixel of the column obtained rectifying 
the polygonal over a vertical line. The STF image is composed disposing these columns, 
from left to right, following the temporal sequence (Figure 2.B and 2.C). 
2.1.2 Electrophysiological and spatial characteristics 
Electrographically, the non-synaptic epileptiform activity, recorded in the extracellular 
space of the granular layer of the dentate gyrus, is characterized by ictogenic period with 
intense population spikes bursts with amplitudes around 10 mV, duration between 30 – 60s 
and interevent interval around 50s (Fig. 3). These bursts are always accompanied by a 
negative DC-shift (5-10 mV). Concurrently to the electrographic manifestations, the optical 
images show that the spatial recruitment engages a portion of the granular layer, preferably 
the infra-piramidal portion. Although it is possible to estimate with two electrodes the 
velocity of propagation of the events in the order of mm/s, it is not unusual to observe the 
 
 




Fig. 2. Schematic representation of the procedure for composing the STF images. (A) The 
brain slice and the polygonal representing the contour of the layer of interest. (B) Temporal 
sequence of frames showing the rectified polygonal extracted from each of them. (C) 
Disposing each polygonal rectified and side by side, the STF images are composed and the 
pixels are calculated according to the equation 1. The scale indicates the percentage of the 
light transmittance change according to equation (1). 
simultaneous build up of the whole neuronal region recruited, identified by no delays 
between the signals, suggesting a synergistic excitation of the neuronal tissue involved 
(Fig 2) The paroxysmal activity sustains stable for up to 3-4h after Ca2+ washout has begun. 
In our experiments, spreading depression usually appears spontaneously after this period. 
This occurrence of a few episodes of spreading depression normally precedes the 
irreversible deterioration of the preparation (Fig. 3).  
In a substantial portion of the slices investigated in our laboratory, the increase of the DC 
shift can be associated with a decrease of the population spikes amplitude. This observation, 
when correlated with the optical signal, shows that it is not always valid to inspect 
synchrony by means of evaluating the population spikes amplitudes. In fact, as exemplified 
in Fig. 4, the eugenol effect, a blocker of sodium voltage-sensitive channel, is the reduction 
of the neuronal population recruited, accompanied by increase of the population spike 
amplitudes and decrease of the DC shift amplitude. Correlating this observation with the 
biophysical mechanisms of the bursts generation, analyzed in session 5.2, it can be proposed 
that the population spike amplitude can also be modulated by the transmembrane ionic 
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gradients. These gradients, when involving a large neuronal population, may change 
significantly resulting the decrease of the action potentials amplitude and, therefore, of the 
population spikes. In these circumstances, the association with synchronism decrease 
doesn’t make sense.  
 
 
Fig. 3. STF image of a sequential nonsynaptic bursts and the transition to spreading 
depression. Simultaneous extracellular potential is shown in the bottom. The scale indicates 
the percentage of the light transmittance change according to equation (1). 
 
              (A)                                (B)                                       (C)                                      (D) 
 
Fig. 4. Optical image and extracellular potential measured simulataneously. (A) 
Hippocampus slice magnified to show details of the dentate gyrus ( A: apex; SP: 
suprapiramidal; IP: infrapiramidal ). Along of the granular layer, the poligonal line used to 
extract the STF images shown in (B – before eugenol), (C – during eugenol) and (D - after 
eugenol).  
3. Nonsynaptic mechanisms 
The processes of neuronal depolarization and hyperpolarization can not be described 
simply by Na+ channels and voltage-sensitive K+ or by the movement of Na+, K +, Cl-
associated with the activation of neurotransmitter receptors. In fact, for processes that 
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involve the activation of populations of neurons and glial cells synchronously, such as 
epileptiform activity, in particular those of origin not only synaptic, ionic balance is also 
determined by the activity of a large number of pumps, exchangers and cotransporters. The 
net effect of the performance of these mechanisms is therefore critical to cellular excitability. 
It is important to observe that ion flux associated with transporter molecules is electrically 
neutral and is mediated by ionic gradients established primarily by Na/K pump. Therefore, 
as pointed out by Schwartzkroin at al. (1998), the identification of the nonsynaptic 
mechanisms participating on this dynamic process and their location (e.g. neuron versus 
glia) is critical to our understanding of excitability controls. In this item, we will describe the 
nonsynaptic mechanisms whose actions on the epileptiform activity will be considered in 
our investigation.  
3.1 Na/K pump 
The pumping process mediated by the Na/K pump is an ionic transport mechanism 
responsible for maintaining the Na+ and K+ transmembrane concentration gradients, 
essentials for several cellular functions. The Na/K pump promotes the coupled Na+ efflux 
and K+ influx, in a 3:2 rate and using the energy liberated by the ATP hydrolyses (Glitsch, 
2001). Nowadays, the functioning of the Na/K pump in terms of the Albers-Post alternating 
gate model (Scheiner-Bobis, 2002; Horisberger, 2004) is very well accepted. The Na/K pump 
is conceived as ionic channel with two gates, one external and other internal. The opening 
and closing of these gates are coupled and controlled by phosphorylation and 
dephosphorylation of the Na/K-ATPase, occurring alternately and promoting the transport 
of Na+ to the extra- and K+ to the intracellular space.  
3.2 Cation-chloride co-transporter and exchanger mechanisms  
Investigations from hippocampal slices in vitro show that cation chloride cotransporter 
antagonists block epileptiform activity in a variety of seizure models, regardless of the 
synaptic mechanisms involved. For example, furosemide blocked epileptiform activity in 
the zero-calcium model in which all chemical synaptic activities are absent, and in which 
epileptiform discharges must be fully mediated by mechanisms other than chemical 
synapses. Other in vitro studies showed that furosemide decreases the cellular swelling 
during conditions of increased [K+]o and blocks ECS decreases in hippocampal slices during 
stimulation-evoked discharges and epileptiform activity. These results show that the cation-
chloride antagonists affect some mechanisms common to all seizure models tested, 
including those that are not dependent on chemical synaptic interactions, and therefore, are 
required for maintenance of epileptiform activity. 
At the start of investigations into the cotransporter it was difficult to differentiate one type 
of cation-chloride cotransporter (CCC) from the other. However, it is currently known that 
the CCC family in mammals consists of nine members encoded by the genes Slc12a1-9. Two 
members are Na-K-2Cl cotransporters (NKCCs; isoforms NKCC1 and KCC2), one is an Na-
Cl cotransporter (NCC), and four are K-Cl cotransporters (KCCs; isoforms KCC1-4). The 
physiological roles of the remaining two CCCs (CIP1 or Slc12a8, and CCC9 or Slc12a9) are 
yet unknown. With the exception of NKCC2 and NCC, which are predominantly found in 
kidney, all CCCs are expressed in neurons or glial cells—or both—at least at some stage of 
CNS development. For all CCCs members, the Na-K ATPase generates plasmalemmal K+ 
and Na+ gradients that provide the main source of energy for their function. The transport 
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stoichiometry of CCCs renders them electrically silent, thus they do not directly influence 
the neuronal membrane potential (Blaesse et al., 2009).  
The NKCC has the following characteristics (Russell, 2000): 1) displacement of ions through 
the NKCC requires that all three ionic species (Na+, K+ and Cl-) are simultaneously present 
in a same face of the membrane, 2) furosemide and congeners bind to proteins co-carrier 
and inhibit the transport of the three ions; 3) under normal ionic conditions, it functions 
with the influx of ions and the process has a stoichiometry of 1 (Na+): 1 (K+): 2 (Cl-) for the 
majority of cells. However, during epileptiform events, which occur in large influxes of Na+ 
and Cl-, the direction of flow can reverse NKCC, therefore carrying the ions to the 
extracellular environment. The magnitude and direction of ion flux mediated by the NKCC, 
described by Geck and Pfieffer (1985), are functionally proportional to the difference 
between the products of concentrations. 
Similar to NKCC, the KCC is characterized by a cotransporter protein that mediates the 
movement of ions, obligatorily coupled in the same direction (in this case, K+ and Cl-). The 
direction of flow depends on the concentration gradients of the two ions across the 
membrane. Thus, under normal conditions, the KCC promotes the efflux of ions K+ and Cl-. 
The KCC is also blocked by the diuretic furosemide and its congeners, but with less 
efficiency. In most cells where the KCC has been found, their main function seems to be the 
regulation of cell volume by removal of K+ ions and the Cl- intracellularly. As with the 
NKCC, the KCC flow is functionally proportional to the difference between the products of 
ions concentrations (Hochman et al., 1999). 
Another type of ion transporter similar to the cotransporter mechanisms is the exchangers. 
These transporters activity constitutes an electroneutral transport based on the simultaneous 
exchange of a pair of anions or cations. These mechanisms are present in the 
hippocampus and their functions are associated with transmembrane ionic gradient 
recovery, cell volume regulation, and pH (Chesler, 2003). The exchangers under 
investigation in our group are Na+/H+ and HCO3−/Cl−. The last exchanger is considered 
to have, in each side, sites whose affinities are exclusive to the ions involved. However, 
for the Na+/H+ exchanger, there are evidences of different behaviour; the enzyme is 
known to have also affinity to K+ (Sychrova, 2004).  
3.3 Osmotic regulation and cell volume changes 
Investigating the effect of osmolarity on synchronized neuronal activities supported by non-
synaptic mechanisms, Dudek et al. (1990) found that decreasing the extracellular osmolarity, 
which reduces extracellular volume, the epileptiform bursts become more intense. 
Additionally, the increase in osmolality with solutes which do not permeate the cell 
membranes, causing an increase in extracellular volume, ends up blocking or lowering 
epileptiform discharges. Therefore, reductions in extracellular volume can enhance the 
synchronization between hippocampal CA1 neurons mediated by non-synaptic 
communications. Indeed, while changes in the volume of the extracellular space (ECS) are 
small during normal physiological activity, during synchronized excitatory activity, such as 
bursts of epileptiform discharges, such variations can be considerable. Specifically in the 
case of non-synaptic epileptiform activity, the consequence of these changes in ECS can be: 
(i) effect of extracellular ion accumulation would be magnified due to the reduced level of 
dilution (ii) ephaptic interactions, mediated by current flow through ECS, would increase 
due to the high resistance of the ECS. 
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3.4 Membrane ionic currents 
The main ionic species involved in the nonsynaptic paroxysms are sodium, potassium and 
chloride. These ions flow through the neuronal and glial membranes. During the excitation 
process of the nonsynaptic bursts their actuations, therefore, are not related with the 
neurotransmission through the synaptic cleft. The permeability changes of each ionic specie 
through the corresponding channels are responsible for the changes in the intracellular 
potential. The ionic channel types considered in the present investigation were: sodium and 
potassium voltage dependent channels, persistent sodium channels, A-type potassium 
channel, chloride channel (with constant permeability), chloride channel voltage channel, 
sodium, potassium and chloride fluxes through gap junctions, sodium, potassium and 
chloride channels with constant permeability (Fig. 5) 
4. Nonsynaptic connections 
The types of nonsynaptic interactions that may be involved in the synchronization include: 
electrotonic interactions mediated by gap-junctions (Naus et al., 1991; Perez-Velazques et al., 
1994), changes in extracellular space (Roper et al., 1992), field effects (Jefferys & Haas, 1982; 
Taylor & Dudek, 1982; Dudek et al., 1986), and extracellular ionic fluctuations (Taylor & 
Dudek, 1984). In the hippocampus, especially in the DG, the tight packing of the cell bodies 
of neurons and glial cells constitutes an adequate substrate for the nonsynaptic connections. 
In high-potassium and zero-Ca2+ conditions the granule cells have some endogenous 
bursting capabilities able to sustain synchronization and, consequently, spontaneous 
epileptiform activity (Pan & Stringer, 1996). As these observations have been made in the 
absence of synaptic transmission, because Ca2+ has been deleted from the bath solution, 
synchronization mechanisms must have nonsynaptic origin (Schweitzer et al., 1992; Pan & 
Stringer, 1996) and could be mediated, as already mentioned, by gap-junctions, ionic 
fluctuations, or field effect (Fig. 6) 
 
      
                          (A)                                                (B)                                               (C) 
Fig. 5. Diagramatic conception of the tissue and its cell membranes component 
representation. (A) DG granullar layer – neurons (blue/green) in the dendate gyrus 
surrounded by astrocytic processes (red) (extracted from J. Breunig, Rakic Lab.) allows to 
extract the basic constituents. From the squared region in (A) and magnified in (B), it can be 
defined the functional unit of the tissue. From this functional unit an additional 
magnification (C) allow to define the main components of the neuronal and glial 
membranes. Na+ (orange), K+ (orange) and Cl- (red) channels, Na/K pumps (brown), 
cotransporters (green) and exchangers (blue).  
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5. Biophysical aspects of the nonsynaptic epileptiform activities 
The complexity of the mechanisms involved in the nonsynaptic epileptiform activities 
comprehend a puzzle where the collection of experimental data is not enough to unravel the 
biophysical aspects of the initiation, the build up, and the termination of these activities. In 
other words, the main mechanisms responsible for the transition from the interictal to the ictal 
state must be explored by means of a methodology able to translate all experimental 
observations in a single systemic representation of the neuronal tissue that is the source of the 
activity. In this section, we show the mathematical description of subcellular mechanisms 
suspected to have significant involvement in the non-synaptic epileptiform activity. Next, 
neurons and glial cells are represented by the composition of these mechanisms. Finally, with 
population of neurons and glial cells, nonsynaptically connected, the neuronal tissue is 
represented and the epileptiform activities can be computationally simulated. With the 
simulations, the mechanisms are manipulated allowing investigating their contributions.  
 
   
                  (A)                                                   (B)                                                    (C) 
Fig. 6. Nonsynaptic connections can be seen magnifing the squared region of the functional 
unit represented in (A). In (B), the ionic flow through ionic channels (green, red and blue), 
pumps (brown), cotransporters and exchangers (not shown) results extracellular ionic 
concentration changes which consists a nonsynaptic connection. The gap-junctions are the 
second type of nonsynaptc connections which also is responsible for the mutual coumpling 
between neurons. In (C), the third type of nonsynaptic connectons, the eletric field effect. 
The electric field generated by the ionic currents trough a given cell membrane is able to 
interfere with the intracellular potential of the immediate vicinity cells.  
5.1 Modelling the dentate gyrus 
5.1.1 Geometric representation of the cell body layer 
The cell body layer of the DG, characterized by a packing of neurons and glial processes, 
was represented by a network of functional units. Each functional unit was composed by the 
cell body of a neuron and a segment of a glial process, as depicted in Fig. 7 (left). The 
specific geometry of each cell population was not characterized, only the threedimensional 
(3D) distribution of the functional units, representing the cell body layer, was incorporated. 
To simulate the experimental maneuver for inducing the nonsynaptic epileptiform activity 
in the hippocampal slice maintained in an interface chamber, the bathing fluid was 
represented by two shells of compartments covering the inferior and lateral sides of the cell 
body layer. The internal shell was composed by compartments with inactive membranes 
allowing the electrodiffusion of ions through the extracellular space. The most external shell 
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was composed by compartments with constant ionic concentrations, representing the 
relative infinite volume of the bathing fluid in respect to the extracellular volume of each 
functional unit. The superior face of the cell body layer was not covered and depicted the 
slice in the liquid/gas interface. As there is no fluidic perfusion at this face, the ionic 
gradient was null in the orthogonal direction. In Fig. 7 (right), a schematic representation of 
the interfaces neuron/extracellular/glial cells, with the corresponding mechanisms 





Fig. 7. Left: (A) DG granullar layer—the picture of the neurons (blue/green) in the dentate 
gyrus surrounded by astrocytic processes (red) (extracted from J. Breunig, Rakic Lab) 
allows to extract the basic constituents (B) of the functional unit (C), which will form the 
nodes of the tridimensional computational network used to simulate the DG (D). Right: 
Schematic representation of the interfaces neuron/extracellular/glial cells with the 
corresponding mechanisms embedded in the simulated membranes. Each neuron is 
connected to the neurons of the functional units of the immediate vicinity. The glial cells 
connection with the vicinity is mediated exclusively by the extracellular space. Modified 
from Almeida et al (2008). 
5.1.2 Mathematical description 
The fluxes through the ionic channels, gap-junctions, or Na/K pumps were described by 
GHK current equation (Hille, 1992): 
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where c, typeφ  is the flux of the ion C associated to the type (channel, pump, gap junction) of 
mechanism described, Pc,type is the permeability, Vk is the transmembrane potential in the 
case of the ionic channels and the electrogenic current pump. When referring to gap-
junctions, Vk is the potential difference between the neighboring cells connected by the 
connexins, [ ]iC and [ ]oC are the intracellular and extracellular concentration, respectively. 
When calculating the gap-junction current, [ ]oC is replaced by the intracellular ionic 
concentration of the cell connected, zc is the valence of the ion C, F (96.487  C/mmol) the 
Faraday constant, R (8.314 mV.C/K.mmol) the gas constant and T (210.16 K) the 
temperature.  
The permeabilities of the sodium and potassium voltage dependent channels were simulated 
using the Hodgkin-Huxley formalism (Supplemental Material – Almeida et al., 2008). The 
ionic permeability parameters ,
neuron
Na fastP  (7.78×10-4 cm/s), 
neuron






K AP (3.60 × 10
−4 cm/s), ,
neuron




Cl volt dependP − (1.08 × 10
−5 cm/s) and neuronAP (2.04 × 10
−3 cm/s) are the quantitative representation 
of the population of each mechanism (in this case, channels or pumps) involved. Since these 
parameters were adjusted to reproduce the activity inductions, they were considered as 
investigation parameters. This means that these parameters were adjusted heuristically aiming at 
reproducing the activities, as well as investigating the preponderance of each mechanism for 
generating the events and their characteristics, always respecting the experimental 
observations. These experimental observations were collected from experiments carried out in 
our laboratory or from published data, like Xiong and Stringer (2000) and Pan and Stringer 
(1996). Based on this inspection, the associations observed between each parameters and their 
influences on the activities are, basically: i) ,
neuron
Na fastP   - depolarizing phase of the action potential; 
ii) neuronKP  - polarizing phase of the action potential, neuronal excitability and extracellular 
potassium accumulation; iii) ,
neuron
Na persistentP  – initial cell depolarization (preceding the action 
potential firing), neuronal excitability and action potential frequency; iv) ,
neuron
K AP  – action 
potential frequency; v) ,
neuron
Cl constP  and ,
neuron
Cl volt dependP −  – neuronal resting potential and extracellular 
chloride concentration; vi) neuronAP  – Na/K pump activity. 
The parameters Pgj,Na (6.73 × 10-8 cm/s), Pgj,K (9.92 × 10-8 cm/s) and Pgj,Cl (1.84 × 10-8 cm/s) 
represent the intercellular permeability through the gap-junctions. The adjustment of these 
parameter was guided by the experiments from MacVicar and Dudek (1982). The 
permeability parameters for the glial cells, PNaglia (1.00 × 10-8 cm/s), PKglia (1.08 × 10-7 cm/s) 
and PClglia (2.50 × 10-8 cm/s), were adjusted aiming at reproducing the resting potential 
typical for these cells (Pan & Stringer, 1996). The Na/K pump parameter, PAglia (2.04 × 
10−2 cm/s), was tuned to control the [Na+]i of the glial cells and also to contribute to 
controlling the [K+]o during the epileptiform events. The activation and inactivation factors 
values (mfast = 0.03, hfast = 0.78, n = 0.1, wpers = 0.0003, aA = 0.1, bA = 0.8) of the voltage 
dependent channels correspond to the resting state defined before the activities induction. 
The sodium potassium ATPase function was modeled considering the main reactions 
involved, always following the Albers–Post model (Heyse et al., 1994; Rodrigues et al., 
2008). From the reactions describing the Albers–Post cycles, two reactions were derived, one 
for the forward cycle, 3NaiEi + 2KoEo + ATPEi ↔ Ai, and other for the reverse cycle, 
3NaoEo + 2KiEi + ADPEi + PEi ↔ Ao.  
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The reactions predict the formation of a fictitious ion A+, product of each exchange of 3 Na+ 
by 2 K+, in the intra- or extracellular space, depending on the cycle direction. The reactions 
from the Albers–Post model were used to predict the substates formation and to deduce 
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The investigations carried on by Nakao and Gadsby (1989) about the Na/K pump activity 
dependence on the extracellular concentrations of Na+ and K+ allowed to guide the pump 
parameters adjustment. During the experiments, [ADP] was kept constant and equal to 0 
mM and a Na+-free solution was used as extracellular medium. Therefore, normalizing the 
current in terms of the current for [K+]o = 5.4 mM, from equation 2, the following equation 
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where ΦAp,pumpnorm is the normalized pump current. Using this equation to fit a curve to the 
experimental data, KKo was estimated (KKo = 0.094 mM). Once this constant was determined, 
considering the experimental conditions described by the authors, [Na+]o = 150 mM and  
Vm = 0 mV, and with the previous value determined for KKo, KNao could be calculated finding 
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The intracellular sodium dissociation constant, KNai, was adjusted using the data from 
Barmashenko et al. (1999). These authors measured the Na/K pump current in relation  
to the intracellular Na+. The cells used in the investigation were kept in K+-free solution 
and the transmembrane potential was clamped in 0 mV. The normalized current 
(normalization with respect to [Na+]i = 50 mM) could then be described using the  
next equation. By a curve fitting to the experimental data, KNai was estimated equal to 
0.856 mM. 
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Na persistentP  – initial cell depolarization (preceding the action 
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neuron
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The reactions predict the formation of a fictitious ion A+, product of each exchange of 3 Na+ 
by 2 K+, in the intra- or extracellular space, depending on the cycle direction. The reactions 
from the Albers–Post model were used to predict the substates formation and to deduce 
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The investigations carried on by Nakao and Gadsby (1989) about the Na/K pump activity 
dependence on the extracellular concentrations of Na+ and K+ allowed to guide the pump 
parameters adjustment. During the experiments, [ADP] was kept constant and equal to 0 
mM and a Na+-free solution was used as extracellular medium. Therefore, normalizing the 
current in terms of the current for [K+]o = 5.4 mM, from equation 2, the following equation 
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where ΦAp,pumpnorm is the normalized pump current. Using this equation to fit a curve to the 
experimental data, KKo was estimated (KKo = 0.094 mM). Once this constant was determined, 
considering the experimental conditions described by the authors, [Na+]o = 150 mM and  
Vm = 0 mV, and with the previous value determined for KKo, KNao could be calculated finding 
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The intracellular sodium dissociation constant, KNai, was adjusted using the data from 
Barmashenko et al. (1999). These authors measured the Na/K pump current in relation  
to the intracellular Na+. The cells used in the investigation were kept in K+-free solution 
and the transmembrane potential was clamped in 0 mV. The normalized current 
(normalization with respect to [Na+]i = 50 mM) could then be described using the  
next equation. By a curve fitting to the experimental data, KNai was estimated equal to 
0.856 mM. 
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 (7) 
Hansen et al. (2002) measured the Na/K pump activation with respect to intracellular Na+ in 
the presence of intracellular K+ (80 mM). The experiments were conducted with intra and 
extracellular ADP-free and Na+-free solutions. These conditions gave the following equation 
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 (8) 
Using this equation for the curve fitting to the experimental data, KKi was estimated equal to 
4.831 mM. 
Friedrich et al. (1996) studied the Na/K pump dependence on intracellular ATP. The 
experiments were conducted with ADP-free intracellular medium and the transmembrane 
potential was clamped in 0 mV. The Equation (6), describing the normalized current with 
respect to current for [ATP] = 0.204 mM, could then be deduced. Using this equation for 
calculating the best curve fitting to experimental data, the ATP dissociation constant, KATP, 
was estimated equal to 0.155 mM. 
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 (9) 
The lacking of information about the Na/K pump activity with respect to the intracellular 
ADP and P, the intracellular dissociation constant of ADP and P, KADP,Pi, was estimated 
assuming that the formation and consuming rate of ATP are equal. Additionally, this 
constant must be high enough to reduce the pump rate in the reverse direction, when Na+ is 
transported to the intracellular medium and K+ to the extra. To provide these conditions 
KADP,P was assumed equal to 5 mM. 
The ratio between the equilibrium constants KAi and KAo, of the Na/K pump reactions, could 
be calculated by means of the reverse potential of the Na/K pump. Therefore, the condition 
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Glistsch (2001) estimated the Na/K pump reverse potential equal to –232 mV. Substituting 
in Equation (10), and taking into account the normal intra and extracellular [Na+] and [K+], 
and the corresponding dissociation constants, the ratio [A+]o/[A+]i can be described in terms 
of KAo /KAi. The convenient substitutions allowed estimating KAo /KAi equal to 0.012. Since 
each parameter of this ratio could not be estimated, it was necessary to concentrate 
parameters: 
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where PAcell is a parameter related to the density of the Na/K pumps and was considered an 
investigative parameter and its value was attributed directly simulating the epileptiform 
activity. 
The equations (12) and (13) were derived from reactions describing the KCC enzyme 
interaction with its ligands. The neuronal and glial KCC co-transporters proportionality 
constants convey the expression intensity of these enzymes in the cellular membranes. In 
this case, the constant QKCCneur (4.21 × 10-3 μmol/s.cm2) was assumed as an investigative 
parameter. Therefore, its value was adjusted along the investigation about the Cl- and K+ 
levels control, during the nonsynaptic epileptiform activities induction. On the other hand, 
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Payne (1997) measured the Rb+ influx by the KCC cotransporters in dependence on the 
[Rb+]o and [Cl-]o. For each variation of Rb+ or Cl-, the initial rate of the Rb+ influx was 
measured. Since for the cation-chloride cotransporters the Rb+ and K+ affinities were 
undistinguishable, the K+ effects on the cotrasnporters could be inferred using Rb+ in the 
investigations. The experiments carried out by Payne (1997), were used to adjust the 
dissociation constants for K+ ( ,,
o neur




Cl KCCK  = 92.02 mM). Considering 
the corresponding conditions, the following equations were deduced and used to simulate 
the experimental data from Payne (1997). The first one was obtained considering the [Rb+]o 
changing and keeping the [Cl-]o constant. The second equation for [Cl-]o changing, keeping 
[Rb-]o constant.  
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For the neurons, the intracellular dissociation constants for K+ and Cl-, in the membrane 
internal face, respectively KK,KCCi,neur and KCl,KCCi,neur were assumed equal to that at the 
external face. This simplification assumes that the KCC cotransporters are mainly influenced 
by the K+ and Cl- transmembrane gradients and less by the enzyme affinities.  
In the case of K+ and Cl- dissociation constants for the glial KCC cotransporters, , ,
i glia
K KCCK  
(2.3 mM), , ,
i glia








Cl KCCK  (500 mM), the parameters were 
adjusted to maintain the steady state of the intracellular concentrations of the glial cells.  
The neuronal and glial proportionality constants of the NKCC cotransporters, neurNKCCQ  
(4.72 × 10-3 μmol/s.cm2) and gliaNKCCQ  (2.80 × 10-2 μmol/s.cm2), were used to represent the 
expression intensity of the cotransporter enzymes in the cells membrane. Supposing that 
this expression intensity guides the contribution of the mechanisms to the activities studied, 
these parameters were considered as investigative parameters. In this sense, they were 
adjusted aiming at contributing for the intra and extracellular ionic concentrations of Na+, 
K+ and Cl-.  
Concerning the NKCC dissociation constants, the values were estimated simulating 
experimental data. Tas et al. (1987) measured, in rat brain astrocytes, the Rb+ influx, 
promoted by these cotransporters in dependence on the extracellular concentrations of Na+, 
K+ and Cl-. The measurements were carried out for cells incubated in Na+-free solution (A), 
in [K+] = 1 mM (B) and in Cl--free solution (C). To adjust the parameters, like as with the 
KCC cotransporters, the Na+, K+ and Cl- intracellular concentrations were admitted null, 
respectively, in (A), (B) and (C) conditions. The following corresponding equations (16, 17 
and 18) were used to simulate the Rb+influx, ΦNKCCnorm, in dependence on the Na+, K+ and 
Cl- concentrations.  
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 Φ =     ++   
 (18) 
Analogously to KCC, the extracellular dissociation constants for Na+, K+ and Cl−, in the 
membrane internal face, ,
neur
Na NKCCK  (70.0 mM), ,
neur
K NKCCK (2.33 mM), ,
neur
Cl NKCCK (25.0 mM), 
,
glia
Na NKCCK  (70.0 mM), ,
glia
K NKCCK  (2.33 mM) and ,
glia
Cl NKCCK  (25.0 mM), were assumed equal to 
their values at the internal face. Therefore, the direction of net movement of Na+, K+ and Cl- 
through the cotransporter will be very sensitive Na+, K+ and Cl- transmembrane gradients. 
The chloride exchangers were implemented in the model aiming at obtaining the internal 




HCO ClQ − (9.81 × 10-5 μmol/s.cm2), 3 ,
glia
HCO Cl
Q − (3.38 × 10-4 μmol/s.cm2), 
,
neur
Cl exchK  (6.00 mM) and ,
glia
Cl exchK  (0.10 mM) were considered as equilibrium parameters and 
were adjusted for the steady state. 
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 (19) 
Similarly to the chloride exchangers, the sodium exchangers were also included to obtain 
the internal ionic equilibrium of the cells during the steady state (Equation 20). For the same 
reasons, the equilibrium parameters ,
neur
Na exchQ (1.09 × 10-4 μmol/s.cm2), 
,
glia
Na exchQ (7.94 × 10
−4 μmol/s.cm2), ,
neur
Na exchK  (10.0 mM) and ,
glia
Na exchK  (13.0 mM) were adjusted 
for the steady state. According to Sychrová (2004), K+ may also be transported by the 
sodium exchangers. In the model this function helped to control the level of K+ 
accumulation (Equation 21). Therefore, the parameters ,
neur
K exchK  (800 mM) and ,
glia
K exchK  (300 
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 (21) 
The electric field effect on the extracellular space at the immediate vicinity of the sources 










=  , (22) 
where dn means the distance between the current source ’n’ and the neuron, and τ a constant 
that translates the resistivity of the medium at the vicinity of the neuron.  



















This equation was deduced to translate a sigmoidal dependence of τ on the Volextra, where 
Volextra, representing the extracellular volume, was calculated by means of the equation 42. 
The parameter τ  (6.25 × 10-3 mV.s/mM) controls the population spikes amplitude and was 
adjusted to reproduce the typical amplitudes observed experimentally in our laboratory in 
the same conditions of the simulation. Therefore, this parameter was assumed as 
experimental parameter. 
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This equation was deduced to translate a sigmoidal dependence of τ on the Volextra, where 
Volextra, representing the extracellular volume, was calculated by means of the equation 42. 
The parameter τ  (6.25 × 10-3 mV.s/mM) controls the population spikes amplitude and was 
adjusted to reproduce the typical amplitudes observed experimentally in our laboratory in 
the same conditions of the simulation. Therefore, this parameter was assumed as 
experimental parameter. 
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The electric field effect on the membranes on the immediate vicinity of the sources was 
estimated by: 
 elect effect extra,fastI εV− = , (24) 
where ε (7.30 × 10-6 mA/ mV.m2) was used to tune the field effect in the simulations. This 
experimental parameter was adjusted to reproduce the findings from Snow and Dudek (1986). 
It was tuned to obtain an electrical field effect to induce an intracellular depolarization 
around 50% of the population spikes.  
Hence, 
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The equilibrium fluxes ,
neuron
Na leakΦ  (-1.73 × 10-8 mmol/s.cm2), ,
neuron
K leakΦ  (-3.95 × 10-8 mmol/s.cm2), 
,
neuron
Cl leakΦ  (-3.00 × 10-8 mmol/s.cm2), ,
glia
Na leakΦ  (-1.39 × 10-7 mmol/s.cm2), 
,
glia
K leakΦ  (−2.43 × 10
−7 mmol/s.cm2) and ,
glia
Cl leakΦ  (-2.23 × 10-7 mmol/s.cm2) are related to the 
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steady state in normal conditions, therefore, before perfusion with high K+ solution. In this 
sense, they were assumed as steady state parameters and adjusted to keep the resting 
conditions stable. 
The equation used to calculate the extracellular electrodiffusion effect on the ionic 
concentration changes was: 
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The extracellular electrical field, V∇
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, was estimated by the following equation: 
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and 2V∇  was estimated in terms of the V∇

. The first term of (35) was deduced assuming 
the continuity of the ionic currents along the extracellular space. The value of the parameters 
DNa (1.33 × 10-5 cm2/s), DK (1.96 × 10-5 cm2/s), and DCl (2.03 × 10-5 cm2/s), as constants, were 
obtained from the literature (Hille, 1992). The tortuosity (λ = 1.6) is an experimental parameter 
and along the granular layer was extracted from (Nicholson, 2001). In the case of the lateral 
shell of the network simulating this layer, the tortuosity was increased (λ = 4.0) aiming at 
representing the layers in between the solution and the granular layer. With this 
simplification, the computation could be reduced.  
The functional unity dimensions, Δx, Δy e Δz, were admitted equal to 20 μm, assuming that the 
diameters of the neuronal and glial cells can be considered around 10 μm. The iteration 
interval, Δt, adopted was 0.1 ms. This value was defined considering the compromise between 
the computational time of the simulations and the maximal numerical error acceptable.  
The transmembrane potential was estimated by the following equation: 
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The electric field effect on the membranes on the immediate vicinity of the sources was 
estimated by: 
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steady state in normal conditions, therefore, before perfusion with high K+ solution. In this 
sense, they were assumed as steady state parameters and adjusted to keep the resting 
conditions stable. 
The equation used to calculate the extracellular electrodiffusion effect on the ionic 
concentration changes was: 
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obtained from the literature (Hille, 1992). The tortuosity (λ = 1.6) is an experimental parameter 
and along the granular layer was extracted from (Nicholson, 2001). In the case of the lateral 
shell of the network simulating this layer, the tortuosity was increased (λ = 4.0) aiming at 
representing the layers in between the solution and the granular layer. With this 
simplification, the computation could be reduced.  
The functional unity dimensions, Δx, Δy e Δz, were admitted equal to 20 μm, assuming that the 
diameters of the neuronal and glial cells can be considered around 10 μm. The iteration 
interval, Δt, adopted was 0.1 ms. This value was defined considering the compromise between 
the computational time of the simulations and the maximal numerical error acceptable.  
The transmembrane potential was estimated by the following equation: 
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where Ielect-effect is the current referred to the electric field effect, and γ and ζ representing the 
ionic leakage through the membrane. The parameters γneur (8 mMcm/s), ξneur (72 mMcm/s), 
γglia (1 mMcm/s) and ξglia (70 mMcm/s) were adjusted aiming at establishing 
transmembrane potentials, for neurons and glial cells, in the same range observed 
experimentally (Pan & Stringer, 1996) and, therefore, were assumed as steady state 
parameters. The superficial area of the neuronal membrane, Am, was estimated assuming a 
spherical cellular body for the granular cells and with diameter equal to 20 μm. This allowed 
to estimate Am = 1.26 × 10-5 cm2. The parameter Agj, which represents the area of each gap-
junction pore, is equal to 1.77 x 10-14 cm2 (Jeffery, 1995).  
The extracellular field potential sensed by a microelectrode was calculated in terms of the 
extracellular electric field, as the following equation describes: 





where λ represented a trajectory linking the electrode tip position to a remote point in the 
bath solution.  
The following equation describes the volume change of the cells and the extracellular space: 
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= + − +  , (41) 
where 
   , tan intextra total cons t neurVol Vol Vol −= − , (42) 
int ,[ ] /i i ra neursS n Vol= , 
int ,[ ] /o o ra neursS n Vol= , 
i
sn  (9.01 × 10-10 mmol) and 
o
sn (3.15 × 10-11 
mmol) represent the quantity of the impermeant solutes S, int ra neurVol −  (4.19 × 10-12 dm3) the 
neuronal intracellular volume, extraVol  (3.15 × 10-13 dm3) the extracellular volume of the 
functional unit and , tantotal cons tVol (4.19 × 10-12 dm3) the total volume of the functional unit. 
The parameters ν (4.50 × 10-17 cm2/s) and osn (3.15 × 10-11 mmol), assumed as investigative 
parameters, act on the cell volume variation along of the neuronal discharges. The parameter 
i
sn (9.01 × 10-10 mmol) is a steady state parameter and was adjusted to keep the volume 
constant when the system is in steady state conditions. 
The neuronal and glial initial volumes were determined considering spherical cellular 
bodies with diameter equal to 20 μm. The extracellular volume was calculated according to 
the extracellular volume fraction, assumed equal to 0.07, considering that the bursts 
inductions were obtained placing the slices in an interface chamber. 
Some parameters were involved in almost all equations described above. This is the case of 
the initial ionic concentrations of the extracellular medium ([Na]o = 131 mM, [K]o = 4 mM, 
[Cl]o = 130 mM). These values were admitted equal to the values commonly used in the 
experimental investigations. The intracellular concentrations ([Na]i,neur = 10 mM, [K]i,neur = 
130 mM, [Cl]i,neur = 9 mM, [Na]i,glia = 10 mM, [K]i,glia = 130 mM, [Cl]i,glia = 9 mM) were 
adjusted in the ranges normally assumed experimentally (Kager et al., 2002; Xiong & 
Stringer, 2000; Almeida et al, 2004). The neuronal transmembrane potential at the steady 
state was considered equal to –69 mV. This value was assumed reasonable because 
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experimentally the Ca2+-free solution induces a desinhibition that leads to a depolarization 
around the same level (Pan & Stringer, 1996). For glial cells, the initial transmembrane 
potential was set around –79 mV and this value is in the range of the experimental 
observations (Orkand, 1991). Normally, it is assumed that the glial intracellular potential is 
more negative because of the elevated K+ permeability of the membrane of these cells.  
The equations of the model were solved numerically by means of the finite difference 
method and the maximum error tolerance was 10-4. The computational language used was 
FORTRAN 90. To run the simulations, a computer cluster was necessary. The main 
configuration used for the simulations presented: (1) One front end Athlon 64 3000+ Dual 
Core, 2 GB RAM, 300 GB HD; (2) 10 Slaves Athlon 64 3000+ Dual Core, 2 GB RAM, 80 GB 
HD; (3) One switch with 16 ports; (4) Operational System Rocks Cluster 4.1 (Linux), and 
(5) FORTRAN 90 and MPI (message passing interface). 
5.2 Investigating the biophysics of the nonsynaptic epileptiform activity 
Comparing the measured and simulated extracellular potential, as shown in Fig. 8, it can be 
observed that all main features of the extracellular potential were captured by the 
simulations. The simulation corresponds to the experimental maneuver for inducing the 
nonsynaptic epileptiform activities. The [K+]o of the compartments representing the bath 
solution was increased from 4 to 8 mM. The cells of the network were coupled exclusively 
with nonsynaptic connections, as described in item 5.1, aiming at representing the deletion 
of Ca2+ in the bath solution. The great advantage offered by the computational simulation is 
that once the experimental data are reproduced, then it is possible to analyze all 
mechanisms and variables involved and infer about the biophysics.  
The model allows predicting the concomitant concentration changes along the period 
preceding the paroxysm induction and also along the paroxysm, when the interictal and 
ictal states transitions occur, as it is seen in Fig. 8. The DC-shift components of the nonsynaptic 
events simulated were in agreement with the experimental data and were calculated (see 
equations 35 and 36) based on the hypothesis of being generated by a Goldman-Hodgkin-Katz 
potential established along the extracellular space, therefore, the same mechanism proposed 
for the DC-shift during spreading depression (Almeida et al., 2004).  
As described in our previous work (Almeida et al. 2008), the simulations show that Cl- 
concentration changes, in response to the [K+]o increase, are able to promote the Cl- Nernst 
potential overcoming the transmembrane potential (Fig. 8). These changes are the main 
responsible cause of the excitation sustained along of the paroxysm. Therefore, it should be 
treated as a target for the paroxysms reduction. This means that the mechanisms involved 
must be investigated. The first step is to analyze the ion flux of each mechanism, shown in 
Fig. 8. It can be observed that the cotransporters, in particular the NKCC, exhibited valuable 
contributions for the changes, differently from the exchangers, which were almost 
insensitive to the [K+]o increase. Before induction, the Cl- efflux by KCC was greater than its 
influx by NKCC and this situation changed in the course of the induction. This can also be 
associated with situations in which the excitability of a brain region increases and the 
recruited neuronal depolarization is enough to increase the [K+]o. From the simulation we 
can propose that brain regions under these circumstances are able to induce nonsynaptic 
epileptiform activity. The biophysical process captured by the simulation can then be 
described. In normal conditions, the KCC cotransporter is responsible for the Cl- extrusion, 
counteracted by the NKCC cotransporter, which is in charge of the Cl- influx. The [K+]o 
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where Ielect-effect is the current referred to the electric field effect, and γ and ζ representing the 
ionic leakage through the membrane. The parameters γneur (8 mMcm/s), ξneur (72 mMcm/s), 
γglia (1 mMcm/s) and ξglia (70 mMcm/s) were adjusted aiming at establishing 
transmembrane potentials, for neurons and glial cells, in the same range observed 
experimentally (Pan & Stringer, 1996) and, therefore, were assumed as steady state 
parameters. The superficial area of the neuronal membrane, Am, was estimated assuming a 
spherical cellular body for the granular cells and with diameter equal to 20 μm. This allowed 
to estimate Am = 1.26 × 10-5 cm2. The parameter Agj, which represents the area of each gap-
junction pore, is equal to 1.77 x 10-14 cm2 (Jeffery, 1995).  
The extracellular field potential sensed by a microelectrode was calculated in terms of the 
extracellular electric field, as the following equation describes: 
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The neuronal and glial initial volumes were determined considering spherical cellular 
bodies with diameter equal to 20 μm. The extracellular volume was calculated according to 
the extracellular volume fraction, assumed equal to 0.07, considering that the bursts 
inductions were obtained placing the slices in an interface chamber. 
Some parameters were involved in almost all equations described above. This is the case of 
the initial ionic concentrations of the extracellular medium ([Na]o = 131 mM, [K]o = 4 mM, 
[Cl]o = 130 mM). These values were admitted equal to the values commonly used in the 
experimental investigations. The intracellular concentrations ([Na]i,neur = 10 mM, [K]i,neur = 
130 mM, [Cl]i,neur = 9 mM, [Na]i,glia = 10 mM, [K]i,glia = 130 mM, [Cl]i,glia = 9 mM) were 
adjusted in the ranges normally assumed experimentally (Kager et al., 2002; Xiong & 
Stringer, 2000; Almeida et al, 2004). The neuronal transmembrane potential at the steady 
state was considered equal to –69 mV. This value was assumed reasonable because 
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experimentally the Ca2+-free solution induces a desinhibition that leads to a depolarization 
around the same level (Pan & Stringer, 1996). For glial cells, the initial transmembrane 
potential was set around –79 mV and this value is in the range of the experimental 
observations (Orkand, 1991). Normally, it is assumed that the glial intracellular potential is 
more negative because of the elevated K+ permeability of the membrane of these cells.  
The equations of the model were solved numerically by means of the finite difference 
method and the maximum error tolerance was 10-4. The computational language used was 
FORTRAN 90. To run the simulations, a computer cluster was necessary. The main 
configuration used for the simulations presented: (1) One front end Athlon 64 3000+ Dual 
Core, 2 GB RAM, 300 GB HD; (2) 10 Slaves Athlon 64 3000+ Dual Core, 2 GB RAM, 80 GB 
HD; (3) One switch with 16 ports; (4) Operational System Rocks Cluster 4.1 (Linux), and 
(5) FORTRAN 90 and MPI (message passing interface). 
5.2 Investigating the biophysics of the nonsynaptic epileptiform activity 
Comparing the measured and simulated extracellular potential, as shown in Fig. 8, it can be 
observed that all main features of the extracellular potential were captured by the 
simulations. The simulation corresponds to the experimental maneuver for inducing the 
nonsynaptic epileptiform activities. The [K+]o of the compartments representing the bath 
solution was increased from 4 to 8 mM. The cells of the network were coupled exclusively 
with nonsynaptic connections, as described in item 5.1, aiming at representing the deletion 
of Ca2+ in the bath solution. The great advantage offered by the computational simulation is 
that once the experimental data are reproduced, then it is possible to analyze all 
mechanisms and variables involved and infer about the biophysics.  
The model allows predicting the concomitant concentration changes along the period 
preceding the paroxysm induction and also along the paroxysm, when the interictal and 
ictal states transitions occur, as it is seen in Fig. 8. The DC-shift components of the nonsynaptic 
events simulated were in agreement with the experimental data and were calculated (see 
equations 35 and 36) based on the hypothesis of being generated by a Goldman-Hodgkin-Katz 
potential established along the extracellular space, therefore, the same mechanism proposed 
for the DC-shift during spreading depression (Almeida et al., 2004).  
As described in our previous work (Almeida et al. 2008), the simulations show that Cl- 
concentration changes, in response to the [K+]o increase, are able to promote the Cl- Nernst 
potential overcoming the transmembrane potential (Fig. 8). These changes are the main 
responsible cause of the excitation sustained along of the paroxysm. Therefore, it should be 
treated as a target for the paroxysms reduction. This means that the mechanisms involved 
must be investigated. The first step is to analyze the ion flux of each mechanism, shown in 
Fig. 8. It can be observed that the cotransporters, in particular the NKCC, exhibited valuable 
contributions for the changes, differently from the exchangers, which were almost 
insensitive to the [K+]o increase. Before induction, the Cl- efflux by KCC was greater than its 
influx by NKCC and this situation changed in the course of the induction. This can also be 
associated with situations in which the excitability of a brain region increases and the 
recruited neuronal depolarization is enough to increase the [K+]o. From the simulation we 
can propose that brain regions under these circumstances are able to induce nonsynaptic 
epileptiform activity. The biophysical process captured by the simulation can then be 
described. In normal conditions, the KCC cotransporter is responsible for the Cl- extrusion, 
counteracted by the NKCC cotransporter, which is in charge of the Cl- influx. The [K+]o 
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elevation increases the driving force for NKCC influx. This influx increase provides more Cl- 
to the intracellular space, increasing, by its turn, the driving force for KCC extrusion. 
However, the dynamic equilibrium occurs for Cl- accumulated in the intracellular space. 
This accumulation is sufficient to make the Cl- Nernst potential overcoming the 
transmembrane potential. In these circumstances, the inward Cl- current through the 
channels become outward, inducing the neuronal depolarization.  
The simulations showing the concomitant ionic concentration changes and fluxes allow 
analyzing the mechanisms acting along the transitions between itcal and interictal states. AS 
shown in Fig. 8, in the extracellular space, the [Na+] and [Cl−] decreased quickly at the 
transition of the states, reached a trough, followed by a slow increase until the end of the 
ictal state (transition to the interictal state), from which the concentrations returned quickly 
to the baseline. Almost the same behavior was exhibited by the [K+]o, however in an 
inverted manner. In the neuronal intracellular space, the simulations showed, during the 
ictal state, the [Na+] and [Cl−] increasing slowly and monotonically and [K+] decreasing also 
monotonically. The recovery of the concentrations along the interictal state did not have the 
same time course. Different from the extracellular, where the concentrations return quickly 
to the baseline, in the intracellular the [K+] increase covers almost the entire interictal state, 
as well as the [Na+] and [Cl−] reduction. Of course, these changes have a definitive influence 
on the Nernst potential of each ionic specie and, therefore, on the excitability.  
During the ictal period, the direction of the transmembrane passive ionic fluxes simulated, 
as illustrated in Fig. 8, in almost all the cases, were guided by the transmembrane 
concentration gradient. The Na+ flux through the ionic channels was directed to the 
intracellular space and the K+ to the extracellular. The Cl- flux direction was in some 
situations against its transmembrane concentration gradient, sustained by the 
transmembrane electric field originated from the Nernst potential of this ion overcoming the 
transmembrane potential. According to the simulations, these were observed during the 
interictal state and during the interval between subsequent action potentials along the ictal 
period (Almeida et.al, 2008). 
Through the Na/K pump, the Na+ and K+ fluxes were, as expected, against their gradients. 
Sensitive to intracellular Na+, the pump increased its activity during the ictal period, when 
Na+ accumulated in the intracellular space. Only about the end of the period, the pump 
started to decrease the Na+ efflux. This decrease happened simultaneously with the Na+ 
influx decrease through the voltage dependent channels. The Na+ influx by the 
cotransporter NKCC as well as its efflux by the Na+/H+ exchanger had minor changes on 
their intensities along the neuronal activity transition from the interictal to the ictal state. 
However, their baselines showed significant magnitude, sustaining the ionic equilibrium 
during the interictal state (Fig. 8). The K+ influx through the pump, in comparison with its 
efflux through the channels, behaves similarly to Na+, however, with inverted flow 
direction. The K+ fluxes through the NKCC cotransporter and the Na+/H+ exchanger also 
had the same behavior as described for Na+ and its H+ exchanger. On the other hand, the 
neuronal KCC cotransporter not only had a significant baseline, but the changes on the 
transitions from the interictal to ictal states were also prominent. The Cl− fluxes simulated 
suggest that the cotransporter mechanisms were the ones mainly responsible for the intra- 
and extracellular concentration changes of this ion. The Cl− accumulation in the intracellular 
space during the ictal state was mediated by the NKCC cotransporter, which happened with 
almost the same flux along of the ictal state. The Cl− efflux was dominated by the KCC 
cotransporter and during the ictal state it was always smaller than the Cl− NKCC influx. 
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Only at the transition between the ictal/interictal states, the KCC efflux overcame the NKCC 
influx and was responsible for the intracellular Cl− concentration decrease. 
  
 
Fig. 8. Nonsynaptic epileptiforme activity simulated. (A) Extracellular potential; 
Concomitantly, (B) intra- and extra-cellular ionic concentrations and (C) Nernst potential for 
Na+, K+ and Cl-, and the transmembrane potential. Detailed in (D) the fluxes associated with 
each nonsynaptic mechanism considered in the model.  
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elevation increases the driving force for NKCC influx. This influx increase provides more Cl- 
to the intracellular space, increasing, by its turn, the driving force for KCC extrusion. 
However, the dynamic equilibrium occurs for Cl- accumulated in the intracellular space. 
This accumulation is sufficient to make the Cl- Nernst potential overcoming the 
transmembrane potential. In these circumstances, the inward Cl- current through the 
channels become outward, inducing the neuronal depolarization.  
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shown in Fig. 8, in the extracellular space, the [Na+] and [Cl−] decreased quickly at the 
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to the baseline. Almost the same behavior was exhibited by the [K+]o, however in an 
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monotonically. The recovery of the concentrations along the interictal state did not have the 
same time course. Different from the extracellular, where the concentrations return quickly 
to the baseline, in the intracellular the [K+] increase covers almost the entire interictal state, 
as well as the [Na+] and [Cl−] reduction. Of course, these changes have a definitive influence 
on the Nernst potential of each ionic specie and, therefore, on the excitability.  
During the ictal period, the direction of the transmembrane passive ionic fluxes simulated, 
as illustrated in Fig. 8, in almost all the cases, were guided by the transmembrane 
concentration gradient. The Na+ flux through the ionic channels was directed to the 
intracellular space and the K+ to the extracellular. The Cl- flux direction was in some 
situations against its transmembrane concentration gradient, sustained by the 
transmembrane electric field originated from the Nernst potential of this ion overcoming the 
transmembrane potential. According to the simulations, these were observed during the 
interictal state and during the interval between subsequent action potentials along the ictal 
period (Almeida et.al, 2008). 
Through the Na/K pump, the Na+ and K+ fluxes were, as expected, against their gradients. 
Sensitive to intracellular Na+, the pump increased its activity during the ictal period, when 
Na+ accumulated in the intracellular space. Only about the end of the period, the pump 
started to decrease the Na+ efflux. This decrease happened simultaneously with the Na+ 
influx decrease through the voltage dependent channels. The Na+ influx by the 
cotransporter NKCC as well as its efflux by the Na+/H+ exchanger had minor changes on 
their intensities along the neuronal activity transition from the interictal to the ictal state. 
However, their baselines showed significant magnitude, sustaining the ionic equilibrium 
during the interictal state (Fig. 8). The K+ influx through the pump, in comparison with its 
efflux through the channels, behaves similarly to Na+, however, with inverted flow 
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Only at the transition between the ictal/interictal states, the KCC efflux overcame the NKCC 
influx and was responsible for the intracellular Cl− concentration decrease. 
  
 
Fig. 8. Nonsynaptic epileptiforme activity simulated. (A) Extracellular potential; 
Concomitantly, (B) intra- and extra-cellular ionic concentrations and (C) Nernst potential for 
Na+, K+ and Cl-, and the transmembrane potential. Detailed in (D) the fluxes associated with 
each nonsynaptic mechanism considered in the model.  
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Observations on the effect of the antiepileptic furosemide (Geck& Pfeiffer, 1985; Alvarez-
Leefman, 1990) are in accordance with the hypothetical Cl- current sustaining the 
nonsynaptic epileptiform activities. It has been observed that furosemide, a blocker of the 
NKCC and KCC cotransporters, blocks spontaneous epileptiform activities induced in a 
variety of experimental maneuvers and models. The blockage can be explained considering 
the blockage of the net effect of both cotransporters, therefore the Cl- influx. This suggests 
that the preferential blockage or depression of the NKCC activities would be more efficient 
and that it would be a possible target for an antiepileptic drug. The simulation of this 
hypothesis, shown in Fig. 9, confirms the assumption and experimental observations also 
corroborate this finding (Haglund & Hochman, 2005).  
 
 
Fig. 9. Simulated experimental maneuver. (A) simultaneous blockage of NKCC and KCC, 
inducing a Cl- Nernst potential negative in respect to the transmembrane potential. (B) 
NKCC blockage, when the polarization is even more effective than in (B). (C) KCC blockage, 
promoting excitability increase. (D) Inhibition by means of the negativity of the Br- Nernst 
potential in respect to the membrane potential. 
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Focusing the same target, another possible strategy for the seizure control would be to 
counteract the Cl- Nernst potential depolarization. An anion capable of permeating the Cl- 
channels and, at the same time, having low affinity to KCC and NKCC enzymes – thus able 
to sustain a more negative Nernst potential - would be a good candidate. In fact, this seems 
to be the bromide effect, whose mechanisms are being investigated in our group. A 
simulation of the resultant effect of such kind of anion is shown in Fig. 9.  
Analyzing the excitatory and inhibitory contributions of each mechanism involved 
(Almeida et al. 2008) it was possible to demonstrate that the Na+ current was the most 
intense during the ictal state and that it was counteracted along the whole ictal state by the 
Na/K pump electrogenic current. The simulations shown in Fig. 10 suggest that it was 
exactly when the electrogenic current pump overcame the Na+ current through the channels 
that the ictal states finalized, therefore, the ictal/interictal transition took place. In contrast, 
along the interictal state, the Cl− current was the most prominent. This current decreased  
 
 
Fig. 10. Nonsynaptic burst simulation. (MP) membrane potential; (EP) extracellular 
potential. Na+ fluxes shown on the bottom traces: (blue) voltage dependent channels. (black) 
Na/K pump. When the efflux trough the Na/K pump overcame the influx trough the 
voltage dependent channels, the event terminates.  
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during the state and, at the same time, Na+ current increased in almost the same rate. The 
crossing point of the currents occurred about the end of the state and was immediately 
followed by the transition point between the interictal/ictal states. The most important 
contributors for this transition were again Na+ current and the pump electrogenic current. 
The abrupt increase of the Na+ current allowed the excitatory current overcoming the 
inhibitory pump current due to the electrogenic effect. These observations emphasize the 
importance to target the Cl- mechanisms responsible for its intracellular accumulation and 
also to counteract is Nernst potential. Additionally, the Na+ influx is also revealed as 
another possible target, placing in perspective strategies to antagonize ionic currents 
through Na+ persistent channels.  
6. Possible targets for controlling refractory seizures 
From the biophysical mechanisms suggested by the simulations, the therapeutic use of 
bumetanide and bromide may be proposed combined for the treatment of patients with 
refractory epilepsy (Almeida et al., 2011). Bumetanide would reduce intracellular chloride 
concentration and bromide would reinforce EGABA negativity, as seen in Fig. 9, where the 
systemic effects of bumetanide and bromide are depicted. Although acting through different 
mechanisms, both drugs reduce neuronal excitability. Once the effects are complementary, 
the doses of bumetanide and bromide could be reduced and, consequently, their side effects  
 
 
Fig. 11. Block diagram indicating the systemic action of the conjoint effect of bumetanide, 
bromide, and GABAA agonist. Bromide acts by blocking NKCC activity. This co-transporter 
is responsible for Cl– influx, which induces the accumulation of this ion in the intracellular 
space, inducing an increase in excitability. An NKCC antagonist is, therefore, able to 
counteract the chloride accumulation, decreasing excitability. Bromide acts directly on 
EGABA, improving its negativity and also decreasing excitability. The conjoint effects of an 
NKCC antagonist and bromide are therefore complementary. The clinical observation of 
seizure reduction could be indicative of induced EGABA negativity with respect to Vm 
(intracellular potential), when the use of GABAergic drugs can be useful. NKCC=Na+, K+, 
2Cl– co-transporter; EGABA=GABA reverse potential. Extracted from Almeida et al. 2011. 
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would be minimized as well. In fact, in a recent case reported on the use of bumetanide for 
treatment of autism, the authors did not observe, at the dosage investigated, any side effect 
(Franciolini & Nonner, 1987). To overcome the severe side effects of bromide described 
(Meierkord et al., 2000), it is paramount that bromide be administered with care, that follow-
up testing be carried out, and that serum bromide levels be monitored periodically. We also 
propose that effort should be directed to find anions or anionic compounds that can replace 
bromide with the aim of avoiding its side effects. These proposals reflect a new perspective 
on the use of bromide: valuing its clinical efficacy associated with a reduction of its side 
effects. Furthermore, we also hypothesize that clinical observation of seizure reduction 
would be indicative of EGABA negativity (Fig. 11). Under such clinical conditions, after the 
effect of bumetanide and bromide has already been established, shifting GABA from 
excitation to inhibition, the administration of GABA agonists should be considered in the 
treatment of uncontrollable seizures. With the action of these agonists, it is assumed that the 
doses of bumetanide and bromide could be further reduced. 
7. Conclusion  
The investigation of the biophysical aspects of the nonsynaptic epileptiform activities may 
guide the design of experimental investigations aiming at unraveling the intricate 
interdependence of the several process that are not only responsible for the neuronal 
activities but also for the ionic homeostasis of the whole network. The development of 
antiepileptic medications targeted to the conditions that sustain seizures would be 
facilitated if the basic mechanisms, in terms of their complex interdependence during 
normal or epileptiform activities, were taken into consideration. Such kind of approach 
would offer the necessary information for designing pharmacological agents able to 
antagonize the interplay of the mechanisms responsible for maintaining the homeostasis 
that favour the conditions for the abnormal functions. 
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1. Introduction  
Epilepsy is a disorder primarily characterized by the spontaneous recurrence of unprovoked 
seizures. Seizures can be triggered by multiple factors including genetic mutations, head 
injury, toxins, a fever, high or low blood sugar, a tumor, electrolyte imbalance, drug 
withdrawal; and are also a core component of developmental and degenerative disorders 
(Loscher and Brandt 2010). However, not all patients that have seizures go on to develop 
epilepsy, and the mechanisms of epileptogenesis are still poorly understood. Only a small 
number of genetic mutations identified in ion channels or proteins associated with these 
channels have been directly linked to causing epilepsy (Greenberg and Pal 2007). In fact, 
complex epidemiological studies indicate that the interplay of environmental factors with 
relatively minor genetic alterations may contribute to the difference between the 
susceptibility to suffer seizures, and the development of epilepsy (Ottman et al. 1996). 
Evidence is emerging that epileptogenesis involves changes in the expression patterns of 
several classes of functionally or genomically-grouped genes that coordinate neural 
development, homeostasis and stress responses, and neural network formation (Lukasiuk et 
al. 2006 and references therein). This has led to speculation that minor and modifiable 
changes outside the open reading frames of affected genes could alter the course of epilepsy. 
How entire groups of genes may be co-regulated with precision during different stages of 
neural development and function could be the result of epigenetic changes in histone and 
chromatin structure and DNA methylation that accompany shifts in neural “state.”   
Chromatin structure and function can be altered to silence gene expression by DNA 
methylation leading to the recruitment of methyl-DNA binding proteins and histone 
deacetylation. Histones can also be modified at their N-terminus by phosphorylation, 
acetylation, methylation, ubiquitination, ADP ribosylation, carbonylation, SUMOylation, 
glycosylation and biotinylation. Here we will focus on DNA methylation and histone 
acetylation, and discuss how these epigenetic modifications could regulate developmental 
alterations that may contribute to the process of epileptogenesis. We will summarize how 
epigenetic changes may both regulate and be regulated by activity-dependent synaptic 
plasticity, and how involvement of common mechanisms underlying glial-neuronal 
interactions could lead to epileptogenesis. Finally, we will discuss how intervening in epilepsy 
by treating with widely-used drugs that themselves can alter chromatin state (like Valproic 
Acid) may further affect ongoing epileptogenesis, and discuss which specific epigenetic 
modifications may be novel therapeutic targets for the treatment of epilepsy. 
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2. Epigenetics and development 
With limited exceptions, all cells in the human body have an identical genotype, and yet 
development produces a wide range of differentiated cell types with distinct functions that 
form highly specialized tissues and organs. This is especially true in the immensely complex 
and highly structured central nervous system (CNS). Cells differentiate from a stem cell to 
become increasingly specialized through a process of state-dependent (stage- and lineage-
specific) gene activation and gene silencing, as many genomic regions become folded into 
heterochromatin, and are excluded from transcription (silenced) (MacDonald and Roskams 
2009). Thus, progressive cell differentiation results, in part, from the epigenetic regulation of 
gene expression, which has been operationally defined as the study of heritable changes in 
gene function that are independent of changes in the underlying DNA sequence (Berger et 
al. 2009).  
2.1 Chromatin and histone modifications 
Both DNA and its associated histone proteins are subject to epigenetic modifications that 
change the overall structure of chromatin and the physical appearance of DNA within the 
nucleus (Goldberg, Allis and Bernstein 2007) (Figure 1). The fundamental unit of eukaryotic 
chromatin is the nucleosome, and it is composed of 147 base pairs of DNA wrapped around 
an octamer of four core histone proteins (H3, H4, H2A and H2B). The core histones are 
predominantly globular with flexible tails located at the N-terminus (Luger et al. 1997, 
Strahl and Allis 2000, Wade 2001). These tails vary in length and are composed of amino 
acids that allow for at least nine distinct types of modifications: phosphorylation, 
acetylation, methylation, ubiquitination, ADP ribosylation, carbonylation, SUMOylation, 
glycosylation and biotinylation (reviewed in Kouzarides 2007). Histone modifications 
correlate with gene activation or repression (Jenuwein and Allis 2001), and recently, histone 
domains containing both activating and repressive modifications have been identified 
(Azuara et al. 2006, Bernstein et al. 2005, Bernstein et al. 2006). These modifications can be 
context-dependent allowing gene transcription or silencing depending on the localization in 
the coding region versus the regulatory regions flanking the promoter (Kouzarides 2007, 
Vakoc et al. 2005). In addition to distinct histone modifications, DNA methylation can also 
silence gene transcription; and there is evidence of significant cross-talk between these 
processes to dynamically modify chromatin structure in response to external stimuli 
(Bernstein, Meissner and Lander 2007, Fuks 2005, Goldberg et al. 2007, Kouzarides 2007). 
Both DNA and histone proteins are subject to epigenetic modifications like DNA 
methylation and histone acetylation that change the overall structure of chromatin, and alter 
the extent to which DNA is wrapped around histones and therefore the availability of genes 
to be activated.  
2.1.1 DNA methylation 
DNA methylation takes place post-synthesis, and is a chief determinant of the stability of 
gene expression states (Jaenisch and Bird 2003). In vertebrates, and in humans specifically, 
DNA methylation happens almost exclusively within cytosine–phosphate–guanine (CpG) 
dinucleotides, and 70-80% of all CpG dinucleotides are methylated (Ehrlich et al. 1982); 
(reviewed in Bird 2002, Goll and Bestor 2005). DNA methylation is catalyzed by DNA 
methyltransferases, or DNMTs, which covalently bind a methyl group to position C5 of 
cytosine residues (Bird 1992). DNA methylation represses transcription directly by  
 
 




Fig. 1. Epigenetic regulation in the nucleosome (modified from the NIH 
http://nihroadmap.nih.gov/EPIGENOMICS/images/epigeneticmechanisms.jpg) Both DNA 
and histone proteins are subject to epigenetic modifications like DNA methylation and histone 
acetylation that change the overall structure of chromatin, and alter the extent to which DNA 
is wrapped around histones and therefore the availability of genes to be activated. 
inhibiting the binding of specific transcription factors, and indirectly, by recruiting methyl-
CpG-binding (MBD) proteins and their associated repressive chromatin remodeling 
activities (Robertson 2005). DNMT1 is the predominant enzyme in mammals, and is 
responsible for maintenance methylation (post-replicative restoration of hemi-methylated 
sites to full methylation), whereas DNMT3A and DNMT3B are thought to be involved 
primarily in de novo methylation (Laird 2003). Methylation is necessary for mammalian 
development, and mice with DNMT knocked out die during development (Li, Bestor and 
Jaenisch 1992, Okano et al. 1999). This absolute requirement for DNA methylation in 
development likely reflects the diverse range of cellular functions and pathologies to which 
it contributes, including silencing of repetitive and centromeric sequences, tissue-specific 
gene expression, genomic imprinting, maintenance of X chromosome inactivation, 
carcinogenesis and aging (Bird 2002, Jaenisch and Bird 2003, Jones and Baylin 2002, Paulsen 
and Ferguson-Smith 2001).  
2.1.2 Histone deacetylation 
Histone deacetylases (HDACs) regulate gene expression by removing the acetyl groups of 
specific lysine residues from histone protein tails, thereby increasing their positive charge, 
and enhancing their interaction with the negatively charged phosphate groups in the DNA 
backbone. The functional consequence of deacetylation is to stabilize compacted forms of 
chromatin, which can restrict binding of transcription factors to promoter regions of genes. 
This is a reversible reaction, and histone acetyl transferases (HATs) can add acetyl groups to 
lysine residues, removing the positive charge and loosening the chromatin from the histone 
core. In general, increased histone acetylation (hyperacetylation) is associated with 
increased transcriptional activity, whereas decreased acetylation (deacetylation or 
hypoacetylation) is associated with repression of gene expression (Strahl and Allis 2000, 
Wade 2001). There are four main classes of HDACs which are grouped into class I, class II, 
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lysine residues, removing the positive charge and loosening the chromatin from the histone 
core. In general, increased histone acetylation (hyperacetylation) is associated with 
increased transcriptional activity, whereas decreased acetylation (deacetylation or 
hypoacetylation) is associated with repression of gene expression (Strahl and Allis 2000, 
Wade 2001). There are four main classes of HDACs which are grouped into class I, class II, 
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class III and class IV based on their sequence homology to their yeast orthologues Rpd3, 
HdaI and Sir2, respectively (de Ruijter et al. 2003, Gregoretti, Lee and Goodson 2004). The 
classical HDACs are comprised of Class I (HDACs 1, 2, 3, and 8), Class II (HDACs 4, 5, 6, 7, 
9, and 10), and Class IV (HDAC 11), and are zinc-dependent enzymes with divergent 
patterns of expression in the brain (Bjerling et al. 2002, Fischle et al. 2002, Yang and Seto 
2008). Class I HDACs have a highly conserved sequence homology and are relatively small 
proteins (377–488 amino acids) that primarily localize in the nucleus. Class II HDACs are 
larger proteins (669–1215 amino acids) that are capable of shuttling in and out of the nucleus 
in response to cellular signals like activity-dependent calcium release (de Ruijter et al. 2003, 
Yang and Seto 2008). The lone class IV member, HDAC11, shows sequence similarity to both 
class I and class II HDACs, but phylogenetic analysis reveals that it is divergent enough to 
warrant a separate class (Gao et al. 2002, Gregoretti et al. 2004). Class III HDACs or sirtuins 
are nicotinamide adenine dinucleotide (NAD+) dependent and may be important for 
linking metabolic state in cells to gene expression (Guarente and Picard 2005).  
3. Epigenetically regulated developmental changes in the brain can lead to 
epilepsy 
As many cell types throughout the brain differentiate, there is a concurrent shift in 
expression of DNMTs, HATs and HDACs that subsequently alter the compaction of 
chromatin. Developmental changes in epigenetic state thus underlie distinct shifts in gene 
expression that ultimately allow for structural and functional organization of the brain 
through control of neuro- and gliogenesis, and activity-dependent synaptic plasticity. Each 
stage of neural development carries a signature gene expression pattern, with a progressive 
restriction in the expression of developmentally regulated genes as maturation proceeds 
(Schuurmans and Guillemot 2002, Tietjen et al. 2003, Abramova et al. 2005, Lim et al. 2006). 
How repression or silencing as a result of epigenetic changes in chromatin contributes to 
these shifts in gene expression is slowly becoming better understood. Perhaps more 
importantly, improper regulation of each of these steps can lead to a variety of pathologies - 
apoptosis, alterations in neuro- and gliogenesis, aberrant neuronal migration, ectopic 
integration of neurons and glia causing structural malformations, and the formation of 
hyperexcitable circuits, all of which may contribute to seizure activity. Moreover, seizure 
activity itself can exacerbate many of these pathologies, and further perturb epigenetic 
factors, resulting in epileptogenesis and cognitive impairment.   
3.1 Methylation state modulates neuro- and gliogenesis 
In general, the known developmental effects of DNA methylation on gene expression 
involve long-term silencing of gene expression such as the establishment of parental-specific 
imprints during meiosis and X-chromosome inactivation (Jaenisch and Bird 2003), but 
recently much attention has been paid to its role in regulating gene expression during 
neuro- and gliogenesis. DNMTs are directly involved in neuronal maturation and survival 
(Fan et al. 2001, MacDonald, Gin and Roskams 2005, Feng et al. 2005). In a study by Fan and 
colleagues, conditional knock out of DNMT1 in nestin-positive cells is prenatal lethal, but 
mosaic mice with 30% of their neural cells missing DNMT1 survive into adulthood (Fan et 
al. 2001). In these animals, DNMT1-deficient neural precursor cells give rise to hypo-
methylated progeny cells, including postmitotic neurons. However, within three weeks 
postnatal, all DNMT1-negative cells are eliminated, suggesting that these neurons were not 
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stable enough to functionally mature (Fan et al. 2001). The de novo DNMTs (DNMT3a and 
DNMT3b) are sequentially expressed during neurogenesis, and are critical for regulating 
genes directly implicated in neurogenesis and neural function (Jin et al. 2008, Feng et al. 2005). 
Dnmt3b may be important for the early phase of neurogenesis, while Dnmt3a regulates 
prenatal progenitors as well as the maturation of post-mitotic neurons (Feng et al. 2005).  
DNMT1 is also a critical cell-intrinsic determinant of astrocyte differentiation. For example, the 
promoter of glial fibrillary acid protein (GFAP) is methylated in progenitor cells during the 
neurogenic stages of embryonic development, but at later stages during gliogenesis, the 
promoter becomes demethylated (Teter et al. 1996). Methylation of the STAT binding element 
within the GFAP promoter inhibits association of activated STATs with the glial promoter 
(Takizawa et al. 2001), thereby repressing transcription of GFAP and preventing cells from 
proceeding down an astroglial lineage during the neurogenic stages of brain development 
(reviewed in MacDonald and Roskams 2009). However, if DNMT1 is knocked out, precocious 
astroglial differentiation occurs, presumably through hypomethylation of the GFAP promoter 
and other genes encoding the core components of the gliogenic JAK-STAT pathway (Fan et al. 
2005). Since neurons rely on radial glial cells in order to migrate to the appropriate position 
during development, one consequence of precocious astrocyte formation could be the loss of 
radial glial “guide wires” and subsequent structural malformations caused by aberrant 
neuronal migration. These structural malformations are increasingly being discovered in 
epileptic patients as brain imaging technology advances (Scaravilli 1998).  
MBD proteins are also regulators of neurogenesis, particularly in adult neurogenic niches like 
the subventricular zone. While MBD1 knockout mice are viable and appear relatively normal, 
they do have decreased neuronal differentiation of adult stem cells and diminished 
hippocampal neurogenesis (Zhao et al. 2003). MeCP2 is perhaps the best characterized MBD 
protein, because mutations within its coding region cause Rett syndrome (Amir et al. 1999, 
Bienvenu and Chelly 2006). Analysis of MeCP2 knockout mice revealed aberrant regulation of 
factors responsible for neurotransmitter biosynthesis and for promoting the differentiation and 
maturation of various neural cell types (Urdinguio et al. 2008), suggesting that MeCP2 
regulates genes that are known to be involved in epileptogenesis. Furthermore, because 
seizures occur in many Rett patients (Glaze, Schultz and Frost 1998), there is strong evidence 
for a direct relationship between dysregulated MBD proteins and epilepsy.         
3.2 Acetylation state modulates neuro- and gliogenesis 
HDAC1 and HDAC2 are expressed at distinct stages of neuronal commitment and 
differentiation during CNS development (MacDonald and Roskams 2008), allowing them to 
modulate gene expression across neurodevelopmental stages. HDAC1 is enriched in 
progenitors clustered in neurogenic zones throughout the CNS (MacDonald and Roskams 
2008). Neural progenitors that maintain the expression of HDAC1 largely differentiate into 
glial cells, while those that lose HDAC1 expression and begin to upregulate HDAC2 
differentiate into neurons (MacDonald and Roskams 2008). In fact, HDAC1 is also highly 
expressed in the corpus callosum during oligodendrocyte differentiation, and when HDACs 
are inhibited, oligodendrocytes fail to differentiate and cause hypomyelination in the corpus 
callosum of postnatal rats (Shen, Li and Casaccia-Bonnefil 2005). Further to this, an elegant 
body of work has placed Class 1 HDACs, and HDAC1 in particular, as a critical regulator of 
the production and differentiation of oligodendrocyte precursor cells (Shen and Casaccia-
Bonnefil 2008). HDAC1 can also directly regulate stem cell proliferation, as HDAC1 null 
animals display a significant reduction in cell proliferation (Lagger et al. 2002). HDAC2, on 
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class III and class IV based on their sequence homology to their yeast orthologues Rpd3, 
HdaI and Sir2, respectively (de Ruijter et al. 2003, Gregoretti, Lee and Goodson 2004). The 
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9, and 10), and Class IV (HDAC 11), and are zinc-dependent enzymes with divergent 
patterns of expression in the brain (Bjerling et al. 2002, Fischle et al. 2002, Yang and Seto 
2008). Class I HDACs have a highly conserved sequence homology and are relatively small 
proteins (377–488 amino acids) that primarily localize in the nucleus. Class II HDACs are 
larger proteins (669–1215 amino acids) that are capable of shuttling in and out of the nucleus 
in response to cellular signals like activity-dependent calcium release (de Ruijter et al. 2003, 
Yang and Seto 2008). The lone class IV member, HDAC11, shows sequence similarity to both 
class I and class II HDACs, but phylogenetic analysis reveals that it is divergent enough to 
warrant a separate class (Gao et al. 2002, Gregoretti et al. 2004). Class III HDACs or sirtuins 
are nicotinamide adenine dinucleotide (NAD+) dependent and may be important for 
linking metabolic state in cells to gene expression (Guarente and Picard 2005).  
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As many cell types throughout the brain differentiate, there is a concurrent shift in 
expression of DNMTs, HATs and HDACs that subsequently alter the compaction of 
chromatin. Developmental changes in epigenetic state thus underlie distinct shifts in gene 
expression that ultimately allow for structural and functional organization of the brain 
through control of neuro- and gliogenesis, and activity-dependent synaptic plasticity. Each 
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integration of neurons and glia causing structural malformations, and the formation of 
hyperexcitable circuits, all of which may contribute to seizure activity. Moreover, seizure 
activity itself can exacerbate many of these pathologies, and further perturb epigenetic 
factors, resulting in epileptogenesis and cognitive impairment.   
3.1 Methylation state modulates neuro- and gliogenesis 
In general, the known developmental effects of DNA methylation on gene expression 
involve long-term silencing of gene expression such as the establishment of parental-specific 
imprints during meiosis and X-chromosome inactivation (Jaenisch and Bird 2003), but 
recently much attention has been paid to its role in regulating gene expression during 
neuro- and gliogenesis. DNMTs are directly involved in neuronal maturation and survival 
(Fan et al. 2001, MacDonald, Gin and Roskams 2005, Feng et al. 2005). In a study by Fan and 
colleagues, conditional knock out of DNMT1 in nestin-positive cells is prenatal lethal, but 
mosaic mice with 30% of their neural cells missing DNMT1 survive into adulthood (Fan et 
al. 2001). In these animals, DNMT1-deficient neural precursor cells give rise to hypo-
methylated progeny cells, including postmitotic neurons. However, within three weeks 
postnatal, all DNMT1-negative cells are eliminated, suggesting that these neurons were not 
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stable enough to functionally mature (Fan et al. 2001). The de novo DNMTs (DNMT3a and 
DNMT3b) are sequentially expressed during neurogenesis, and are critical for regulating 
genes directly implicated in neurogenesis and neural function (Jin et al. 2008, Feng et al. 2005). 
Dnmt3b may be important for the early phase of neurogenesis, while Dnmt3a regulates 
prenatal progenitors as well as the maturation of post-mitotic neurons (Feng et al. 2005).  
DNMT1 is also a critical cell-intrinsic determinant of astrocyte differentiation. For example, the 
promoter of glial fibrillary acid protein (GFAP) is methylated in progenitor cells during the 
neurogenic stages of embryonic development, but at later stages during gliogenesis, the 
promoter becomes demethylated (Teter et al. 1996). Methylation of the STAT binding element 
within the GFAP promoter inhibits association of activated STATs with the glial promoter 
(Takizawa et al. 2001), thereby repressing transcription of GFAP and preventing cells from 
proceeding down an astroglial lineage during the neurogenic stages of brain development 
(reviewed in MacDonald and Roskams 2009). However, if DNMT1 is knocked out, precocious 
astroglial differentiation occurs, presumably through hypomethylation of the GFAP promoter 
and other genes encoding the core components of the gliogenic JAK-STAT pathway (Fan et al. 
2005). Since neurons rely on radial glial cells in order to migrate to the appropriate position 
during development, one consequence of precocious astrocyte formation could be the loss of 
radial glial “guide wires” and subsequent structural malformations caused by aberrant 
neuronal migration. These structural malformations are increasingly being discovered in 
epileptic patients as brain imaging technology advances (Scaravilli 1998).  
MBD proteins are also regulators of neurogenesis, particularly in adult neurogenic niches like 
the subventricular zone. While MBD1 knockout mice are viable and appear relatively normal, 
they do have decreased neuronal differentiation of adult stem cells and diminished 
hippocampal neurogenesis (Zhao et al. 2003). MeCP2 is perhaps the best characterized MBD 
protein, because mutations within its coding region cause Rett syndrome (Amir et al. 1999, 
Bienvenu and Chelly 2006). Analysis of MeCP2 knockout mice revealed aberrant regulation of 
factors responsible for neurotransmitter biosynthesis and for promoting the differentiation and 
maturation of various neural cell types (Urdinguio et al. 2008), suggesting that MeCP2 
regulates genes that are known to be involved in epileptogenesis. Furthermore, because 
seizures occur in many Rett patients (Glaze, Schultz and Frost 1998), there is strong evidence 
for a direct relationship between dysregulated MBD proteins and epilepsy.         
3.2 Acetylation state modulates neuro- and gliogenesis 
HDAC1 and HDAC2 are expressed at distinct stages of neuronal commitment and 
differentiation during CNS development (MacDonald and Roskams 2008), allowing them to 
modulate gene expression across neurodevelopmental stages. HDAC1 is enriched in 
progenitors clustered in neurogenic zones throughout the CNS (MacDonald and Roskams 
2008). Neural progenitors that maintain the expression of HDAC1 largely differentiate into 
glial cells, while those that lose HDAC1 expression and begin to upregulate HDAC2 
differentiate into neurons (MacDonald and Roskams 2008). In fact, HDAC1 is also highly 
expressed in the corpus callosum during oligodendrocyte differentiation, and when HDACs 
are inhibited, oligodendrocytes fail to differentiate and cause hypomyelination in the corpus 
callosum of postnatal rats (Shen, Li and Casaccia-Bonnefil 2005). Further to this, an elegant 
body of work has placed Class 1 HDACs, and HDAC1 in particular, as a critical regulator of 
the production and differentiation of oligodendrocyte precursor cells (Shen and Casaccia-
Bonnefil 2008). HDAC1 can also directly regulate stem cell proliferation, as HDAC1 null 
animals display a significant reduction in cell proliferation (Lagger et al. 2002). HDAC2, on 
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the other hand, is necessary to inhibit astrocyte differentiation, while HDAC1 is not 
(Humphrey et al. 2008). Taken together, HDAC2 may be involved in silencing glial gene 
expression, while HDAC1 likely silences neuronal genes. 
HDAC1 and HDAC2 have been proposed to work in concert through large multi-protein 
complexes like REST nuclear protein (RE-1 silencing transcription factor, also called NRSF) 
and Co-REST. Through these complexes, HDAC-mediated acetylation can enable the 
transcriptional repression of genes containing a repressor element-1 (RE1/NRSE) in their 
promoter (Huang, Myers and Dingledine 1999). Because many neuron-specific genes that 
encode ion channels, synaptic vesicle proteins and neurotransmitter receptors contain an 
RE-1 motif, it has been proposed that REST silences these genes in all other cell types and 
acts as a master regulator of neurogenesis and neuronal differentiation (Ooi and Wood 2007, 
Ballas and Mandel 2005, Hsieh and Gage 2005). Intriguingly, REST is responsible for 
regulating the expression of several genes implicated in epileptogenesis, including growth 
factors, ion channels, neurotransmitter receptors, gap junctions, and neurosecretory vesicles, 
as well as those involved in seminal neural developmental processes and adult neurogenesis 
(reviewed in Qureshi and Mehler 2009, Qureshi and Mehler 2010) 
In summary, abnormal activity of epigenetic mediators including DNMTs, MBDs, HDACs 
and repressor complexes could result in altered neuro- and gliogenesis, aberrant migration 
of newly born cells, and improper integration of these cells into circuits, thereby causing 
hyper-excitable circuits and seizures (Figure 2).  
 
 
Fig. 2. Epigenetic gene regulation can dynamically impact numerous physiological 
processes in the nervous system.  
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Epigenetic state can be altered by extrinsic factors such as environmental stimulation and 
pharmacological manipulation, and internal factors that regulate neuronal activity. Since 
epigenetic factors such as DNMTs, MBDs, HDACs and repressor complexes modulate 
processes that include neuro- and gliogenesis, neural cell migration, and activity-dependent 
synaptic plasticity; dysregulation of these epigenetic factors can lead to apoptosis, neuronal 
hyperexcitability, impaired glial function, and ultimately can contribute to seizure activity, 
epileptogenesis, and epilepsy. Conversely, the hyperexcitability associated with epilepsy 
can also impact the expression of genes that regulate epigenetic state.   
4. Epilepsy modulates epigenetic state and affects brain morphology 
Clearly a dysregulation of epigenetic factors during development causes changes in neuro- 
and gliogenesis that may increase the likelihood of developing seizures, but the reversed 
scenario can also occur. It is now clear that seizures themselves can regulate epigenetic 
factors that then affect neurogenesis, neuronal migration, synapse formation, and neural 
activity.  
It is well established that seizures cause alterations in neurogenesis in animal models and 
humans, but there is an age-dependent paradoxical effect in how seizures alter cell genesis 
in the CNS. For example, there is a postictal decrease in dentate granule cell birth in one 
week old rats subjected multiple brief seizures (Houser 1990, McCabe et al. 2001, Liu et al. 
2003). This postictal decrease is age-related because a similar seizure paradigm performed in 
adult rats causes an increase in dentate granule cell birth (Houser 1990, McCabe et al. 2001, 
Liu et al. 2003). Furthermore, these effects depend on the frequency and severity of the 
seizures. Acute seizure activity causes a proliferative surge in neural stem cells of the 
subgranular zone of the hippocampus leading to increased production of new neurons 
during the first few weeks after the seizure episode, while chronic epilepsy is associated 
with declined hippocampal neurogenesis (Houser 1990, Parent et al. 1997, Scharfman, 
Goodman and Sollas 2000, McCabe et al. 2001, Porter 2008, Kuruba, Hattiangady and Shetty 
2009). Surgically resected hippocampi from children with extra-hippocampal seizures also 
reveal a significant decrease in hippocampal neurons (Mathern et al. 1994), suggesting that 
the rate of cell death is exceeding the rate of neurogenesis and potential cell replacement.   
Other pathologies associated with epilepsy-induced dysregulation of epigenetic factors 
include altered neuronal migration and increased mossy fiber (MF) sprouting. Examination 
of surgically resected hippocampal tissue from patients with temporal lobe epilepsy (TLE) 
confirms aberrant supragranular inner molecular layer MF sprouting, and a pathology 
known as granule cell dispersion (GCD), which has been linked to decreased expression of 
the glycoprotein Reelin (Haas et al. 2002, Haas and Frotscher 2010, Mathern et al. 1994). 
Reelin is critical for mediating neuronal migration throughout the CNS, and hippocampal 
patterning during brain development (Stanfield and Cowan 1979, Forster, Zhao and 
Frotscher 2006), and its expression is regulated directly by promoter methylation (Levenson, 
Qiu and Weeber 2008, Kobow et al. 2009). Recently, hippocampal tissue samples from TLE 
patients revealed increased promoter methylation in TLE specimens compared to controls, 
and this was significantly correlated with GCD (Kobow et al. 2009), implying that chronic 
epilepsy can cause epigenetic changes that may exacerbate disease pathology. In fact, 
seizure activity can perturb the migration of newly born neurons postnatally, resulting in 
their ectopic location in the hilus (and even as far as CA3), aberrant synapse formation, and 
consequently enhanced excitability (Scharfman et al. 2000).  
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Seizures can induce histone modifications for a number of genes involved in neuronal 
plasticity and synapse formation, including the neurotrophin brain-derived neurotrophic 
factor (BDNF) and the glutamate receptor GluR2 (Tsankova, Kumar and Nestler 2004, 
Huang, Doherty and Dingledine 2002). Seizure activity induces acetylation of the BDNF 
promoter, thereby up-regulating BDNF (Tsankova et al. 2004). BDNF upregulation 
following seizure activity is thought to contribute to epileptogenesis, and BDNF infusion in 
epileptic animals can trigger seizure-like events (Scharfman, Goodman and Sollas 1999). In 
addition, transgenic mice that overexpress BDNF display heightened seizure susceptibility, 
spontaneous seizures and hyperexcitability of the hippocampus (Croll et al. 1999). 
Furthermore, BDNF has been shown to attenuate γ-aminobutyric acid (GABA)ergic inhibitory 
neurotransmission (Tanaka, Saito and Matsuki 1997), which can lead to an imbalance in 
neuronal excitatory transmission. At the same time, seizure activity leads to deacetylation of 
histones at the GluR2 promoter, and reduced expression of the receptor, resulting in enhanced 
AMPA receptor-mediated epileptogenesis (Sanchez et al. 2001). Thus, seizure activity can 
induce epigenetic changes that contribute to epileptogenesis, but why does this occur? It is 
highly likely that seizure activity harnesses much of the same molecular machinery involved 
in activity-dependent synapse formation and learning and memory.  
5. Epigenetic factors can both regulate, and be regulated by, synaptic 
plasticity 
Repeated patterns of synaptic transmission lead to diverse forms of synaptic plasticity at 
excitatory and inhibitory synapses, including long-term potentiation (LTP) and long-term 
depression (LTD), whereby the strength of synaptic transmission is increased or decreased 
respectively (reviewed in Malenka and Bear 2004). Certain forms of LTP and LTD are long 
lived and are dependent on lasting changes in gene expression (Borrelli et al. 2008). Based 
on the critical role that epigenetics plays in mediating lasting alterations in gene expression, 
DNA and histone modifiers are poised to provide a mechanism that both encodes and 
stabilizes these changes in synaptic strength. This is already the case in mice who over-
express HDAC2 in neurons, and exhibit decreased dendritic spine density, synapse number, 
synaptic plasticity and memory formation (Guan et al. 2009). These results suggest that 
deacetylation may cause transcriptional repression of the neuronal genes involved in 
forming and maintaining functional synapses. Since seizures result in synchronized 
neuronal firing, it is possible that they trigger the same types of epigenetic responses as LTP, 
and that aberrant stabilization of hyper-excitable circuits could lead to progressive 
epileptogenesis. Theoretically, specific treatment of the area of seizure-genesis with targeted 
HDAC2 inhibition could thus interrupt this cycle, and may be a promising therapeutic 
strategy.  
DNA methylation can also be dynamically regulated by synaptic activity. For example, 
neuronal activity and learning can produce DNA methylation of distinct genomic sites in 
the human brain (Siegmund et al. 2007), and this methylation signature varies by brain 
region (Ladd-Acosta et al. 2007). These observations are consistent with the recent findings 
that DNA methylation can occur rapidly and reversibly in the nervous system (Levenson et 
al. 2006) in contrast to the previous dogma that methylation state is permanent. BDNF 
exemplifies this principle, and is demethylated upon neuronal activity. It is proposed that 
neural activity via increases in cellular Ca2+ levels and activation of Ca2+/calmodulin 
kinases leads to the phosphorylation of MeCP2, and its release from the CoREST complexes 
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on the BDNF promoter (Ballas et al. 2005), resulting in increased BDNF expression 
(reviewed in Borrelli et al. 2008). Increased BDNF expression is associated with alterations in 
GABA receptor subunit composition which can lead to reduced neuronal inhibition 
(Lagrange, Botzolakis and Macdonald 2007), and increased excitatory neurotransmission by 
enhancing presynaptic glutamate release and phosphorylating NMDA receptors (Takei et al. 
1997, Lin et al. 1998). Thus, DNA methylation is regulated by neuronal activity, and in turn 
can also influence neural plasticity through the regulation of activity-dependent neuronal 
genes. Collectively, this neuronal excitability can play a modulatory role in learning and 
memory, but in the context of disease, it can feed-forward into the cycle of epileptogenesis.  
6. Environmental and nutritional factors that influence epigenetic state and 
vulnerability to epilepsy 
In mammalian development, the prenatal and postnatal periods are characterized by dynamic 
structural and functional re-organization of the brain, as its pathways become shaped by 
stimulation and experience. During this highly plastic period, environmental experiences 
influence neural structure, synaptic strength, and consequently our behavior. There is 
increasing evidence that epigenetic factors are at the interface of environment and gene 
regulation, and that changes in epigenetic state are stable enough to be heritable, but not static, 
thereby allowing future experience to modify them. A particularly good example of this is 
maternal diet, which can cause heritable changes in epigenetic state that then alter gene 
expression and behavior in offspring. Mechanistically, protein-restricted diets can inhibit 
DNMTs and cause hypomethylation of specific gene promoters in the offspring (Lillycrop et 
al. 2007). In addition, folate and vitamin B12 are essential cofactors for the methylation cycle, 
thus deficiencies in these vitamins also inhibit DNMTs and DNA methylation, which can 
cause oxidative stress and neuronal cell death (Kruman et al. 2002, Duan et al. 2002, Seshadri et 
al. 2002, Shea, Lyons-Weiler and Rogers 2002). Another B-vitamin, biotin, modulates 
chromatin regulation through histone biotinylation (Hassan and Zempleni 2006). Moreover, 
biotin deficiency can cause epilepsy as well as other clinical features including hypotonia, 
ataxia, mental retardation, and fetal malformations (Zempleni et al. 2008). These studies 
suggest that eating a diet with plenty of protein and foods rich in B vitamins may help lower 
seizure vulnerability through epigenetic regulation of gene expression. In fact, a ketogenic diet 
(high fat, adequate protein, low carbohydrate) has been used for decades to control refractory 
seizures in children (Lefevre and Aronson 2000, Stafstrom 2004), and a recent study by 
Garriga-Canut et al. provides a potential epigenetic mechanism for the antiepileptic properties 
of the ketogenic diet and of a potentially new treatment for epilepsy, 2-deoxy-D-glucose (2DG) 
(Garriga-Canut et al. 2006). Metabolic intermediates including NADH can modulate co-
activators and co-repressors, thereby linking energy availability to chromatin structure and 
transcriptional output (Guarente and Picard 2005). Since 2DG is a glycolytic inhibitor, it may 
act as a small molecule regulator of the NAD+ HDAC III sirtuins, thereby repressing 
transcription of genes that contribute to epileptogenesis. In fact, Garriga-Canut and colleagues 
(2006) show that 2DG can reduce the progression of epileptogenesis in kindled rats by raising 
the after-discharge threshold, reinforcing that diet can induce changes in epigenetic state that 
impact the development of epilepsy.  
Prenatal and postnatal stress can also influence epigenetic state and neurodevelopment, 
subsequently changing our behavior patterns. Early-life stress can cause epigenetic changes 
in the methylation status of certain promoters including the glucocorticoid receptor (GR). 
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on the BDNF promoter (Ballas et al. 2005), resulting in increased BDNF expression 
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(2006) show that 2DG can reduce the progression of epileptogenesis in kindled rats by raising 
the after-discharge threshold, reinforcing that diet can induce changes in epigenetic state that 
impact the development of epilepsy.  
Prenatal and postnatal stress can also influence epigenetic state and neurodevelopment, 
subsequently changing our behavior patterns. Early-life stress can cause epigenetic changes 
in the methylation status of certain promoters including the glucocorticoid receptor (GR). 
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Stress can increase levels of DNA methylation in the NGFI-A binding site of the GR 17 
promoter and decrease histone H3-K9 acetylation (a marker of transcriptional activation), 
the functional consequence of which is a heightened stress response (Weaver et al. 2004, 
Weaver et al. 2007). Severe early-life stress can increase excitotoxic cell death of 
hippocampal neurons (Brunson et al. 2003), whereas prenatal stress contributes to the 
susceptibility for febrile convulsions, afebrile seizures, and cerebral palsy (Greenwood et al. 
1998, Weinstock 2001). Perhaps the most striking finding is that maternal stress in the latter 
half of pregnancy lowers the seizure threshold, potentially increasing seizure susceptibility 
in the unborn offspring (Edwards et al. 2002). Thus the nervous system is particularly 
sensitive to alterations in epigenetic regulation, probably because of the fine balance needed 
to maintain heritable cellular memory while still being capable of adapting to changing 
environmental conditions.  
7. DNA methylation inhibitors and HDAC inhibitors are potential epigenetic 
targets for epilepsy treatment 
Since epigenetic factors play such an important role in regulating gene expression during 
neuro- and gliogenesis and key phases of synaptic plasticity and learning, pharmacological 
manipulation of these factors in targeted time windows in the etiology of disease holds 
enormous therapeutic potential. This is particularly important for a complex disease like 
epilepsy which involves multiple genes and downstream effectors. Recent evidence has 
emerged that modifying chromatin structure can indeed alter the disease course of epilepsy, 
and serves as a fertile ground for exploring targeted remodeling of chromatin as a potential 
therapeutic strategy in epilepsy (summarized in Table 1).  
7.1 DNA methylation inhibitors and treatment of epilepsy 
In humans, a variety of mental retardation syndromes with an epileptic phenotype 
including Rett syndrome, Fragile-X, Rubinstein–Taybi, Prader-Willi and Angelman 
syndromes, have all been linked to mutations or disruptions in methylation factors (Egger et 
al. 2004), suggesting that methylation inhibitors may be a novel therapeutic target for 
epilepsy. Current generation DNMT inhibitors are methylcytosine analogues that reduce 
DNA methylation through covalent sequestering of DNMTs as opposed to the direct 
removal of methyl groups from DNA (Juttermann, Li and Jaenisch 1994). These inhibitors 
are widely used clinically for their anti-cancer efficacy (reviewed in Das and Singal 2004), 
but have not been systematically evaluated to treat epilepsy. The DNMT inhibitors 5-
azacytidine (5azaC) and zebularine can effectively inhibit DNA methylation in neurons and 
block LTP and memory formation (Levenson et al. 2006, Miller, Campbell and Sweatt 2008, 
Miller and Sweatt 2007), suggesting that they are good candidate drugs to evaluate in 
epilepsy paradigms. When both agents were applied in a Rett syndrome mouse model, 
treatment facilitated a significant decrease in frequency of miniature excitatory post-
synaptic currents (mEPSCs) and rate of spontaneous synaptic vesicle fusion (Nelson et al. 
2008). Since decreasing mEPSCs can reduce neuronal excitability, methylation inhibitors 
may possess anti-seizure properties, and should thus be tested in more classic epilepsy 
models. In addition to methylcytosine analogs, DNA methylation can be reversed 
pharmacologically by increasing histone acetylation through the use of HDAC inhibitors 
(Cervoni and Szyf 2001, Milutinovic et al. 2007), underscoring that multiple epigenetic 
factors work in a concerted manner to regulate gene expression and careful consideration of  
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undesired secondary effects of such compounds must be taken when designing a 
therapeutic approach.  
7.2 HDAC inhibitors and treatment of epilepsy 
HDAC inhibitors (HDACi) are classified into six groups based on their chemical structures: 
(1) hydroxamic acids, including TSA and SAHA; (2) small-molecular-weight carboxylates, 
including sodium butyrate, valproic acid, and sodium phenylbutyrate; (3) benzamides, 
including MS-275 and CI-994; (4) epoxyketones, including AOE and trapoxin B; (5) cyclic 
peptides, including depsipeptide and apicidin; and (6) hybrid molecules, such as CHAP31 
and CHAP50 (Drummond et al. 2005 and references there in). Most HDACi are broad-
spectrum within the classical HDAC family, and isoform-specific inhibitors have been difficult 
to design due to the high sequence homology within the catalytically-active sites of HDACs 
(Bieliauskas and Pflum 2008). Therefore, the majority of published studies have employed 
HDAC inhibitors that have multiple secondary targets within and beyond the CNS, but 
collectively, a compelling argument can be made to explore their efficacy in most epilepsy 
paradigms. Hydroxamic acids encompass the broadest set of HDACi, and primarily inhibit 
class I/II HDACs when used in the nanomolar range (Bieliauskas and Pflum 2008), however 
side effects in patients have been reported, particularly with TSA (Villar-Garea and Esteller 
2004). In contrast, the carboxylates are very well tolerated in animals and humans, and have 
been used in dose escalating studies in the clinic (Atmaca et al. 2007). HDAC inhibitors have 
been extensively studied in models of neurodegenerative disease (Hahnen et al. 2008), and 
some agents–such as valproic acid (VPA), sodium butyrate and LBH589–are now being tested 
in clinical trials in patients with spinal muscular atrophy (SMA), Huntington’s disease (HD), 
Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS). 
The most widely used HDAC inhibitor, Valproate (VPA), has been used as an anti-epileptic 
therapeutic agent for over 40 years, and its effects in the nervous system have recently been 
reviewed in detail elsewhere (MacDonald and Roskams 2009, Loscher 1999). However, VPA 
has primarily been used for its multitude of effects on CNS excitation pathways that have 
not taken into account its HDAC inhibition activity. Briefly, VPA can (1) increase the level of 
the inhibitory neurotransmitter γ-aminobutyric acid (GABA), (2) reduce sodium 
conductance through voltage-gated sodium channels, (3) suppress N-methyl-D-aspartate 
(NMDA) receptor-mediated excitation, (4) have teratogenic activity in both humans and 
mouse models. 
While VPA is well tolerated and can attenuate seizure activity, evidence suggests that it is 
not truly antiepileptic. In other words, VPA can acutely and chronically reduce the risk of 
recurrent seizures, but treatment does not alter the development of epilepsy (Shinnar and 
Berg 1996, Haut and Shinnar 2008). One possible explanation for this dichotomy is that even 
though VPA augments presynaptic GABA release (reviewed in Loscher 1999), thereby 
conferring antiseizure properties, VPA also increases BDNF expression (Fukumoto et al. 
2001) and can reduce GABAA receptor γ2 subunit, GAD65, GAD67, and KCC2 expression 
(Fukuchi et al., 2009), thus impairing GABAergic function over time and potentially shifting 
the balance of neurotransmission to a more hyperexcitable state. Furthermore, GABAergic 
signaling regulates neurogenesis and neuronal differentiation of immature neurons (Ben-Ari 
2002), so VPA-mediated alterations in GABAergic neurotransmission could impair 
neurogenesis and subsequently cause cognitive impairment, particularly in children and 
adolescents where brain development is still very actively occurring. In fact, mice lacking 
MeCP2 from GABA-releasing neurons consequently have impaired GABA function, and 
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display many of the characteristic symptoms of Rett syndrome and autism (Chao et al.). 
Thus, if inhibitory neurogenesis is indeed perturbed as a secondary action of this 
compound, treating patients with VPA to control seizures could inadvertently hasten the 
progression of epilepsy. However, in a recent study, treatment with VPA following kainic 
acid-induced seizures did inhibit hippocampal neurogenesis, but surprisingly improved 
cognitive impairment compared with controls who received kainic acid alone (Jessberger et 
al. 2007). This contradiction supports the hypothesis that seizure-induced neurogenesis can 
be detrimental, but the consequences of chronically inhibiting neurogenesis are likely to be 
harmful.  
A final potential use for HDAC inhibitors in treating epilepsy is in enhancing the survival of 
neurons in existing circuits that might otherwise succumb to excitotoxic cell death due to 
hyper-excitation and the resulting ionic imbalances. A growing body of evidence places 
HDAC inhibition capable of mediating survival signaling, cytoskeletal stabilization in 
neurons, and CREB-mediated signaling following ischemia and oxidative stress (reviewed 
in Sleiman et al. 2009). With the development and testing of new generations of specific 
HDAC inhibitors that are not only CNS-permeable, but usable in short-term pulses in 
animal models of appropriate neurological diseases, it is possible that HDACi-mediated 
neuroprotection and stabilization of existing brain circuitry is a potential mechanism for 
preventing the spread or progression of epilepsy, and limiting the accompanying cognitive 
deficits that result from poorly controlled seizures in epileptic patients. 
8. Conclusions 
After sequencing the human genome – and the genomes of numerous other species, it is 
apparent that organisms with a higher order of complexity within their CNS have acquired 
a more complex non-coding genome. The majority of this sequence is comprised of 
regulatory elements that contextually modulate protein expression and function. Although a 
large part of development is due to the complex transcriptional regulation required of 
multiple members of the same gene family, it is likely that analysis of the structural 
organization, the regulation of the non-coding genome, and the role of epigenetics in 
modulating these phenomena will reveal a more in-depth understanding of our own human 
phenotype. Within these unique DNA modifications are clues to the origin, susceptibility, 
and progression of neurological disease, including epilepsy.  
Epigenetic processes are certainly involved in the development and progression of epilepsy, 
and epilepsy, in turn, can change the epigenetic landscape of the CNS (summarized in  
Fig 2). Regardless of whether seizures begin early or later in life; the processes outlined 
above (synaptic plasticity, neuro-gliogenesis, and neuroprotection) are ongoing 
developmental processes that are all mediated by epigenetic changes in chromatin structure. 
Those same changes in chromatin--based on environment, stimulation, and developmental 
programs--drive the individual biology within distinct CNS cells. Thus epigenetics provides 
a mechanism whereby CNS cells can react to internal and external stimuli, and record the 
experience in both a modifiable and heritable manner. The emergence of genomic 
diagnostics, coupled with high resolution imaging to pinpoint functionally “normal” versus 
“aberrant” cellular responses to these stimuli, will allow us to identify the aberrant circuitry 
that leads to the progression of epilepsy and its underlying pathology.  
Concurrent with this, advances in combinatorial chemistry and high throughput screening 
approaches will allow for the ongoing and rapid development of subtype-specific HDAC 
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display many of the characteristic symptoms of Rett syndrome and autism (Chao et al.). 
Thus, if inhibitory neurogenesis is indeed perturbed as a secondary action of this 
compound, treating patients with VPA to control seizures could inadvertently hasten the 
progression of epilepsy. However, in a recent study, treatment with VPA following kainic 
acid-induced seizures did inhibit hippocampal neurogenesis, but surprisingly improved 
cognitive impairment compared with controls who received kainic acid alone (Jessberger et 
al. 2007). This contradiction supports the hypothesis that seizure-induced neurogenesis can 
be detrimental, but the consequences of chronically inhibiting neurogenesis are likely to be 
harmful.  
A final potential use for HDAC inhibitors in treating epilepsy is in enhancing the survival of 
neurons in existing circuits that might otherwise succumb to excitotoxic cell death due to 
hyper-excitation and the resulting ionic imbalances. A growing body of evidence places 
HDAC inhibition capable of mediating survival signaling, cytoskeletal stabilization in 
neurons, and CREB-mediated signaling following ischemia and oxidative stress (reviewed 
in Sleiman et al. 2009). With the development and testing of new generations of specific 
HDAC inhibitors that are not only CNS-permeable, but usable in short-term pulses in 
animal models of appropriate neurological diseases, it is possible that HDACi-mediated 
neuroprotection and stabilization of existing brain circuitry is a potential mechanism for 
preventing the spread or progression of epilepsy, and limiting the accompanying cognitive 
deficits that result from poorly controlled seizures in epileptic patients. 
8. Conclusions 
After sequencing the human genome – and the genomes of numerous other species, it is 
apparent that organisms with a higher order of complexity within their CNS have acquired 
a more complex non-coding genome. The majority of this sequence is comprised of 
regulatory elements that contextually modulate protein expression and function. Although a 
large part of development is due to the complex transcriptional regulation required of 
multiple members of the same gene family, it is likely that analysis of the structural 
organization, the regulation of the non-coding genome, and the role of epigenetics in 
modulating these phenomena will reveal a more in-depth understanding of our own human 
phenotype. Within these unique DNA modifications are clues to the origin, susceptibility, 
and progression of neurological disease, including epilepsy.  
Epigenetic processes are certainly involved in the development and progression of epilepsy, 
and epilepsy, in turn, can change the epigenetic landscape of the CNS (summarized in  
Fig 2). Regardless of whether seizures begin early or later in life; the processes outlined 
above (synaptic plasticity, neuro-gliogenesis, and neuroprotection) are ongoing 
developmental processes that are all mediated by epigenetic changes in chromatin structure. 
Those same changes in chromatin--based on environment, stimulation, and developmental 
programs--drive the individual biology within distinct CNS cells. Thus epigenetics provides 
a mechanism whereby CNS cells can react to internal and external stimuli, and record the 
experience in both a modifiable and heritable manner. The emergence of genomic 
diagnostics, coupled with high resolution imaging to pinpoint functionally “normal” versus 
“aberrant” cellular responses to these stimuli, will allow us to identify the aberrant circuitry 
that leads to the progression of epilepsy and its underlying pathology.  
Concurrent with this, advances in combinatorial chemistry and high throughput screening 
approaches will allow for the ongoing and rapid development of subtype-specific HDAC 
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inhibitors (and drugs to modify other histone marks such as methylation and 
phosphorylation). Because the pharmacological manipulation of epigenetic factors is a 
growing target for many diseases (notably cancer), the future holds great promise in being 
able to evaluate the therapeutic efficacy of these agents in neurological diseases, and in 
particular, for the beneficial effects they may afford to patients with epilepsy. 
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1. Introduction  
Medial temporal lobe epilepsy (MTLE) is a common syndrome. Many of the cases of medial 
temporal lobe epilepsy often remain resistant to drug therapy. Surgical resection of the 
affected temporal lobe is often final option to control/reduce the seizure frequency. Mesial 
temporal sclerosis which can be unilateral or bilateral is the most common cause of medial 
temporal lobe epilepsy. Accurate preoperative lateralization of the mesial temporal lobe 
sclerosis is essential, because the surgical strategy and outcome is distinctive in this group of 
patients. Currently many non-invasive methods like MRI, EEG and neuropsychological 
assessment are used to achieve this goal. 
Number of studies have shown role of various MRI techniques in lateralizing the seizure 
focus in cases of mesial temporal sclerosis (1-8). Newer quantitative MRI along with 
qualitative MR techniques has improved the overall sensitivity of MRI for the detection of 
MTS (9-12). We planned to examine the relative sensitivity of specific MRI sequences in 
patients with pathologically confirmed MTS. 
2. Materials and methods  
We reviewed results of MRI scans of 44 patients who were subjected to anterior temporal 
lobectomy and had pathological confirmation of MTS. The definition of intractable epilepsy 
is taken when patient is having at least two episodes of seizures per month even after being 
on at least two antiepileptic drugs for at least two years. We compared each combination of 
test results to resected tissue pathology to determine the association with MTS. Patients 
were excluded if imaging revealed other pathologies such as tumors or vascular lesions. 
Epileptogenic temporal lobe was identified by detailed physiological studies (EEG, VEEG) 
and neuropsychological studies in all patients. 
MRI studies- MRI studies were performed using a standard protocol in a Siemens 
Magnetom Vision 1.5 T magnet in all patients. 
Following images were obtained in the temporal lobe protocol- T1(TR-650 ms;TE-14 ms; 
slice thickness-3 mm), PD-T2(TR-2300ms;TE-17 & 102 ms; slice thickness-3mm) and 
FLAIR(TR-9000 ms;TE-105 ms;TI-1800ms;slice thickness-3 mm) images in a plane parallel 
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and perpendicular to the long axis of hippocampus (fig 1) and 3D volume acquisition of the 




    
 
 
    
Fig. 1. T2 W images perpendicular to long axis of hippocampus showing Right mesial 
temporal sclerosis  
 
Demographic variable Measure 
No of patients 
      Male  




Mean age of the patients 28 yrs(11- 45 yrs) 
Mean age of seizure onset 12 yrs(3 mth-32 yrs) 
Mean duration of seizure 17 yrs(3-37 yrs) 
Lt temporal resection 22 
Rt temporal resection 22 
Table 1. Demography of patient population- 
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Quantitative analysis: This included T2 relaxometry and volumetry.  
T2 relaxometry was calculated in a multiple coronal slices from dual echo sequences 
obtained at TEs of 17 and 102 ms with a slice thickness of 3 mm. Hippocampal T2 
relaxometry maps were generated manually from the measured image intensities in the 
hippocampal structures. T2 values were obtained from a predetermined region of interests. 
Measurements were taken from each ROI inside the hippocampus excluding the temporal 
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Fig. 2. A- T2 W image perpendicular to the long axis of hippocampus. B- T2 relaxometry 
map of the same image. C- Outline of hippocampus in cross  section on a T2 relaxometry 
map. 
For volumetric analysis images were transferred to Siemens Magnetom vision workstation. 
Volumetric measurements were performed by outlining the region of interest (ROIs) 
manually on a magnified image (fig 3). Anatomical guidelines for outlining the 
hippocampal formation followed previous protocols (9, 13). 
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Fig. 3. A-T1W MPRAGE 1mm thick image perpendicular to the long axis of hippocampus. 
B- Outline of hippocampus in cross section. 
Qualitative MR analysis: included three parameters signal changes, loss of internal 
architecture and volume loss. 
Visual analysis was performed on T1, T2 and FLAIR images to assess following  
Surgical technique and histological tissue analysis- All surgical procedure was performed 
by neurosurgeon. The resection included a standard neocorticotomy of anterior temporal 
lobe, sparing the superior temporal gyrus. Amygdala and anterior half to two-third of 
hippocampus were resected and sent for pathological analysis. 
The diagnosis of mesial temporal sclerosis was based on the presence of hippocampal 
neuronal loss and gliosis. 
Statistical analysis-Sensitivity of each tests were calculated individually and in multiple 
combinations. The results of each technique are then compared with the outcome results of 
the surgery. 
3. Results 
Visual analysis  
Atrophy: Unilateral hippocampal atrophy was detected in 36 of 44 patients (81%). Bilateral 
atrophy was noted in 2 patients and 6 were normal.  
Signal changes: 39 of 44 patients (88.6%) had signal changes which correspond to the site of 
surgery. 2 patients had bilateral signal changes and lateralization was not possible by signal 
changes. 
Quantitative analysis 
Of the 44 patients only 20 patients could be analysed by the quantitative MR analysis 
because of the non-availability of the raw data. 
T2 relaxometry: Higher abnormal T2 values were noted in 16 of 20 patients (85 %) on the side 
of surgery performed. Normal mean value was taken as 100.2 ± 4.18 msec (right-100.5 msec; 
left-98.9 msec). The cutoff was set 2 SD above the average and was 109 msec (14). Of these 16 
patients 13 had unilateral abnormality and 3 had bilateral abnormality. In patients with 
bilateral abnormality T2 values were higher on the affected side than the contralateral side. 
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Volumetric analysis: 18 of 20 patients (90%) showed decreased volume corresponding to the 
resected side(normal mean value taken as 3571 ± 311 cmm for left and 3696 ± 310 cmm for 
right)(7). Of these 15 were unilateral and correctly lateralized. The remaining 3 had 
significant bilateral atrophy with the smaller size corresponding to the affected side in all 
the patients. Using the right/left volumetric ratio of hippocampal formation, 19 of 20 
patients (95%) showed marked differences, with the ratio correctly lateralizing the affected 
side. The volumetric analysis was normal in one patient. 
 
MRI sequences Sensitivity 
Qualitative 80 % 
T2 relaxometry 85 % 
Volumetry 90 % 
Modality correlation  
Visual analysis which took into account both the FLAIR signal changes and visual 
qualitative atrophy led to correct lateralization in 39 of 44 patients(88.6%). Remaining 5 
patients did not have either volume loss or signal changes. 
Of the 20 patients in which we had quantitative data only 16 (80%) could be correctly 
lateralized by the visual qualitative analysis. Of the remaining four patients 2 patients  
had higher T2 relaxation values with correct lateralization and 3 had smaller volume 
lateralizing to the affected side. With combined visual analysis and T2 relaxometry analysis 
18 patients (90%) were lateralized correctly. When we combined the results of visual 
analysis and volumetric analysis 19 patients (95 %) were lateralized correctly. On combining 
all the three modalities all the 20 patients (100%) patients were lateralized correctly;  
one patient who had normal volume bilaterally was showing high T2 values on the surgery 
side. 
 
MRI sequences Sensitivity 
Qualitative 80 % 
Qualitative + T2 90 % 
Qualitative + volumetry 95 % 
Qualitative+ T2 + 
volumetry 100% 
4. Discussion  
We compared the sensitivity and relative utility of different MR sequences in patients with 
MTS. This study was specifically designed to assess the sensitivity of the MRI sequences in 
population of highly selected patients with histologically confirmed MTS. Similar to 
 
Underlying Mechanisms of Epilepsy 
 
244 
        
                                                 A                                                             B 
Fig. 3. A-T1W MPRAGE 1mm thick image perpendicular to the long axis of hippocampus. 
B- Outline of hippocampus in cross section. 
Qualitative MR analysis: included three parameters signal changes, loss of internal 
architecture and volume loss. 
Visual analysis was performed on T1, T2 and FLAIR images to assess following  
Surgical technique and histological tissue analysis- All surgical procedure was performed 
by neurosurgeon. The resection included a standard neocorticotomy of anterior temporal 
lobe, sparing the superior temporal gyrus. Amygdala and anterior half to two-third of 
hippocampus were resected and sent for pathological analysis. 
The diagnosis of mesial temporal sclerosis was based on the presence of hippocampal 
neuronal loss and gliosis. 
Statistical analysis-Sensitivity of each tests were calculated individually and in multiple 
combinations. The results of each technique are then compared with the outcome results of 
the surgery. 
3. Results 
Visual analysis  
Atrophy: Unilateral hippocampal atrophy was detected in 36 of 44 patients (81%). Bilateral 
atrophy was noted in 2 patients and 6 were normal.  
Signal changes: 39 of 44 patients (88.6%) had signal changes which correspond to the site of 
surgery. 2 patients had bilateral signal changes and lateralization was not possible by signal 
changes. 
Quantitative analysis 
Of the 44 patients only 20 patients could be analysed by the quantitative MR analysis 
because of the non-availability of the raw data. 
T2 relaxometry: Higher abnormal T2 values were noted in 16 of 20 patients (85 %) on the side 
of surgery performed. Normal mean value was taken as 100.2 ± 4.18 msec (right-100.5 msec; 
left-98.9 msec). The cutoff was set 2 SD above the average and was 109 msec (14). Of these 16 
patients 13 had unilateral abnormality and 3 had bilateral abnormality. In patients with 
bilateral abnormality T2 values were higher on the affected side than the contralateral side. 
Multimodal MRI Evaluation in Intractable Epilepsy 
with Pathologically Confirmed Mesial Temporal Sclerosis 
 
245 
Volumetric analysis: 18 of 20 patients (90%) showed decreased volume corresponding to the 
resected side(normal mean value taken as 3571 ± 311 cmm for left and 3696 ± 310 cmm for 
right)(7). Of these 15 were unilateral and correctly lateralized. The remaining 3 had 
significant bilateral atrophy with the smaller size corresponding to the affected side in all 
the patients. Using the right/left volumetric ratio of hippocampal formation, 19 of 20 
patients (95%) showed marked differences, with the ratio correctly lateralizing the affected 
side. The volumetric analysis was normal in one patient. 
 
MRI sequences Sensitivity 
Qualitative 80 % 
T2 relaxometry 85 % 
Volumetry 90 % 
Modality correlation  
Visual analysis which took into account both the FLAIR signal changes and visual 
qualitative atrophy led to correct lateralization in 39 of 44 patients(88.6%). Remaining 5 
patients did not have either volume loss or signal changes. 
Of the 20 patients in which we had quantitative data only 16 (80%) could be correctly 
lateralized by the visual qualitative analysis. Of the remaining four patients 2 patients  
had higher T2 relaxation values with correct lateralization and 3 had smaller volume 
lateralizing to the affected side. With combined visual analysis and T2 relaxometry analysis 
18 patients (90%) were lateralized correctly. When we combined the results of visual 
analysis and volumetric analysis 19 patients (95 %) were lateralized correctly. On combining 
all the three modalities all the 20 patients (100%) patients were lateralized correctly;  
one patient who had normal volume bilaterally was showing high T2 values on the surgery 
side. 
 
MRI sequences Sensitivity 
Qualitative 80 % 
Qualitative + T2 90 % 
Qualitative + volumetry 95 % 
Qualitative+ T2 + 
volumetry 100% 
4. Discussion  
We compared the sensitivity and relative utility of different MR sequences in patients with 
MTS. This study was specifically designed to assess the sensitivity of the MRI sequences in 
population of highly selected patients with histologically confirmed MTS. Similar to 
 
Underlying Mechanisms of Epilepsy 
 
246 
previous studies we found that qualitative and quantitative analysis are both highly reliable 
in experienced hands with individual sensitivity ranging from 85-95%.  
This study shows that the use of multiple MR techniques in the investigation of patients 
with intractable mesial temporal lobe sclerosis offers advantages over individual modalities. 
The combined sensitivity of all the MR techniques together was 100% for correct 
lateralization of the epileptogenic temporal lobe. 
Visual analysis of FLAIR sequences and T1 W sequences for atrophy demonstrated 
abnormalities in 88.6%. Other published studies show similar results (11). Jack et al reported 
identification of atrophy by visual analysis in 83 % and by signal changes on T2 W images in 
79% of patients of MTS (15). A more recent study using FLAIR found abnormalities in 97% 
of the patients with MTS (16). This suggests that with current MRI techniques the sensitivity 
of visual identification across different centers is relatively reliable. 
However the identification of bilateral hippocampal atrophy by visual analysis may be 
difficult. Only 2 of the 4 patients with bilateral hippocampal atrophy by absolute 
hippocampal volumes demonstrated visually detected bilateral atrophy. The FLAIR 
sequence detected bilateral signal changes in only 2 of these patients. Therefore visual 
analysis is accurate in detecting unilateral MTS but may not be adequate to identify bilateral 
hippocampal atrophy in some patients. 
However visual analysis correctly lateralized the most abnormal hippocampus in most of 
those with volumetric based bilateral hippocampal atrophy. In 3 of the 4 patients with bilateral 
hippocampal atrophy, the more affected side was localized by visual analysis. Though our 
results were influenced by the selection of the patients (only operated patients) previous study 
by Jack et al demonstrated that even in those patients with bilateral symmetric hippocampal 
changes, lateralization and successful surgery is possible (17). 
Some studies have reported that T2 relaxometry is a reliable method to detect MTS. Jackson 
et al originally reported that T2 relaxometry maps were abnormal in all patients with MTS 
(18). However other groups have reported relatively lesser sensitivity (19), in our study the 
sensitivity of T2 relaxometry to identify the affected side is only 85 % similar to other study.  
Majority of the patients who had loss of volume also had longer T2 relaxation. This result 
indicates a strong relationship between the volumetry and T2 relaxometry. However 
literature shows discrepancy between the two techniques (7). 
The different results of T2 relaxometry across studies may be considered to be due to 
different technical reasons. Previously published studies had used multi-echo sequences 
using 8-16 different TEs (7, 18) whereas we have used only dual echo sequences. Other point 
of difference is that earlier studies have used shorter TR (1500 ms) while we have used TR of 
2300 ms (11). 
Convergence of all MRI findings in MTS increases the likelihood of a correct diagnosis. 
Correct lateralization was possible in majority of the patients by qualitative visual analysis; 
quantitative techniques may provide useful information in the rest. Volumetric 
measurements using differential right –left volumes provided localization in 90 % of 
patients, compared to T2 relaxometry which was abnormal in only 85%. Visual analysis 
failed to recognize the signal changes in only one patient who had abnormal T2 relaxation. 
The results of this study suggest that visual qualitative analysis is sensitive in the detection 
of MTS in most patients. Although quantitative techniques increase the sensitivity of 
lateralization these are technically demanding and time consuming with the exception of T2 
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relaxometry. So for routine clinical purpose simple strategy will be to use visual analysis 
and T2 relaxometry to lateralize the MTLE first. If this is not successful then volumetry can 
be used as an additional technique. 
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previous studies we found that qualitative and quantitative analysis are both highly reliable 
in experienced hands with individual sensitivity ranging from 85-95%.  
This study shows that the use of multiple MR techniques in the investigation of patients 
with intractable mesial temporal lobe sclerosis offers advantages over individual modalities. 
The combined sensitivity of all the MR techniques together was 100% for correct 
lateralization of the epileptogenic temporal lobe. 
Visual analysis of FLAIR sequences and T1 W sequences for atrophy demonstrated 
abnormalities in 88.6%. Other published studies show similar results (11). Jack et al reported 
identification of atrophy by visual analysis in 83 % and by signal changes on T2 W images in 
79% of patients of MTS (15). A more recent study using FLAIR found abnormalities in 97% 
of the patients with MTS (16). This suggests that with current MRI techniques the sensitivity 
of visual identification across different centers is relatively reliable. 
However the identification of bilateral hippocampal atrophy by visual analysis may be 
difficult. Only 2 of the 4 patients with bilateral hippocampal atrophy by absolute 
hippocampal volumes demonstrated visually detected bilateral atrophy. The FLAIR 
sequence detected bilateral signal changes in only 2 of these patients. Therefore visual 
analysis is accurate in detecting unilateral MTS but may not be adequate to identify bilateral 
hippocampal atrophy in some patients. 
However visual analysis correctly lateralized the most abnormal hippocampus in most of 
those with volumetric based bilateral hippocampal atrophy. In 3 of the 4 patients with bilateral 
hippocampal atrophy, the more affected side was localized by visual analysis. Though our 
results were influenced by the selection of the patients (only operated patients) previous study 
by Jack et al demonstrated that even in those patients with bilateral symmetric hippocampal 
changes, lateralization and successful surgery is possible (17). 
Some studies have reported that T2 relaxometry is a reliable method to detect MTS. Jackson 
et al originally reported that T2 relaxometry maps were abnormal in all patients with MTS 
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sensitivity of T2 relaxometry to identify the affected side is only 85 % similar to other study.  
Majority of the patients who had loss of volume also had longer T2 relaxation. This result 
indicates a strong relationship between the volumetry and T2 relaxometry. However 
literature shows discrepancy between the two techniques (7). 
The different results of T2 relaxometry across studies may be considered to be due to 
different technical reasons. Previously published studies had used multi-echo sequences 
using 8-16 different TEs (7, 18) whereas we have used only dual echo sequences. Other point 
of difference is that earlier studies have used shorter TR (1500 ms) while we have used TR of 
2300 ms (11). 
Convergence of all MRI findings in MTS increases the likelihood of a correct diagnosis. 
Correct lateralization was possible in majority of the patients by qualitative visual analysis; 
quantitative techniques may provide useful information in the rest. Volumetric 
measurements using differential right –left volumes provided localization in 90 % of 
patients, compared to T2 relaxometry which was abnormal in only 85%. Visual analysis 
failed to recognize the signal changes in only one patient who had abnormal T2 relaxation. 
The results of this study suggest that visual qualitative analysis is sensitive in the detection 
of MTS in most patients. Although quantitative techniques increase the sensitivity of 
lateralization these are technically demanding and time consuming with the exception of T2 
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relaxometry. So for routine clinical purpose simple strategy will be to use visual analysis 
and T2 relaxometry to lateralize the MTLE first. If this is not successful then volumetry can 
be used as an additional technique. 
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1. Introduction  
1.1 Definition 
Gingival fibromatosis (GF) is a slowly progressive, benign, non-bleeding, painless, localized 
or generalized overgrowth of the maxillary and mandibular keratinized gingiva (Baptista, 
2002). It is also recognized as congenital hypertrophy of the gums, gingivae elephantiasis, 
gingival gigantism, symmetrical fibroma of the palate, gingival hyperplasia, gingival 
overgrowth (GO), and congenital macrogengiva (Emerson, 1965). The condition occurs both 
in isolated and syndromic forms, and results from either genetic or acquired mechanisms. 
The most common causes accounting for the isolated forms include the effect of a systemic 
drug treatment and single gene mutations (hereditary GF or HGF). In addition GF can 
manifest within a systemic disease (Häkkinen and Csiszar, 2007). 
1.2 Clinical presentation 
Gingival overgrowth’s dimensions are classified in three grades: grade I: growth confined to 
the interdental papilla, grade II: growth involving both papilla and marginal gingiva, grade 
III: growth which covers three quarters or more of the dental crown (Bökenkamp et al., 
1994). In referral to the period of onset, the overgrowth can be classified as: pre-eruptive (<6 
months of age), during the deciduous dentition (from 6 months to 6 years), during the 
mixed dentition period (6 to 12 years) and during the permanent dentition periods, before 
(12 to 20 years) and after adolescence (age 20 or later). The overgrowth results in dental 
defects, including diastemata, malocclusion, delayed eruption of permanent dentition or 
prolonged retention of primary dentition, causing aesthetic and functional problems. 
Treatment with functional gingivectomy is often followed by recurrence of the overgrowth. 
Given the rarity of HGF, available information about its clinical presentation is based on 
individual observations. The phenotypic spectrum is considerably wide and varies both for 
the number of teeth involved and the degree of clinical expression. The localized forms of 
HGF usually involve the maxillary tuberosities and labial gingiva around the mandibular 
molars. However, the symmetric, generalized form of HGF, involving the labial, lingual and 
palatal gingiva is the most common. Males and females are equally affected. Hyperplastic 
gums may be normal or erythematous and consist of dense, fibrous tissue that feels fixed 
and nodular on palpation. Although the alveolar bone is not usually involved, gingival 
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hyperplasia causes periodontal problems because of difficult oral hygiene. The overgrowth 
can also result in functional and aesthetic problems, create diastemata, prevent or slow the 
growth of teeth and determine facial changes as a result of lip protrusion. The overgrowth 
can also lead to serious speech and chewing problems and may prevent the normal closure 
of the lips (Baptista, 2002). 
The onset of GO usually coincides with the eruption of the permanent incisors, or, 
sometimes, with the eruption of primary dentition. In very rare cases, it can also be 
congenital (Anderson et al., 1969). Since HGF has never been observed in edentulous 
patients, it seems that the presence of dentition is necessary for the development of GO. 
1.3 Histology 
Histological characterization and differentiation has not been possible, to date, for all forms 
of HGF, especially for the syndromic ones. The various forms of HGF have similar 
histological features, suggesting that the pathogenic mutations affect different levels of the 
same cellular or molecular pathway. Hereditary gingival fibromatosis is characterized by 
moderate hyperplasia of the hyperkeratotic epithelium, comprised a network of elongated 
ridges. The epithelial hyperplasia may also be secondary to acanthosis, which has, however, 
only been found in areas of chronic inflammation. Fibrosis occurs with accumulation of 
collagen and elastic and oxytalan fibers in the connective tissue, comprised a few fibroblasts 
and blood vessels. Fibroblasts seem to alternate with thin or thick collagen fibrils. Unlike the 
characteristic "woven basket" arrangement of collagen fibers in the normal gingiva, the ones 
of fibrotic gingiva appear parallel. Rarely, osseous calcifications may be present as well as 
many neurovascular bundles (Kelekis-Cholakis et al., 2002, Doufexi et al., 2005). 
The diagnosis of HGF is based on the collection of clinical history and on clinical 
examination, since no specific immunohistochemical markers have been identified, to date. 
2. Isolated gingival fibromatosis 
2.1 Drug-induced gingival fibromatosis 
The most common cause of isolated GO involves anticonvulsant drug therapy, the use of 
calcium channel blockers for treating angina and hypertension or cyclosporine A for 
preventing the rejection of organs transplanted in subjects affected by autoimmune diseases. 
 
Anticonvulsants Calcium channel blockers Antibiotics 
Phenytoin Nifedipine Cyclosporin A 
Carbamazepine Amlodipine  
Etosuximide Bepridil  
Sodium valproate Felodipine  
Primidone Nitrendipine  
Fenoprofen Nicardine  
Felbamate Verapamil  
Mephenytoin Nimodipine  
Mesuximide   
Phenobarbital   
Phensuximide   
Table 1. Drugs that may induce gingival fibromatosis (Doufexi et al., 2005) 
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Among the first two drugs’ categories, phenytoin and nifedipine are responsible for the 
most frequent forms of GF. The prevalence of GF secondary to drug treatment ranges in 
different studies, from 0 to 100% following long term phenytoin therapy, 0.5 to 83% after 
nifedipine and 8 to 81% following treatment with cyclosporin A (Kataoka et al ., 2005). The 
variability of these figures, which reflects heterogeneity of investigated cases, does not allow 
at present to suggest any empiric risk of developing an adverse reaction to these 
medications. In addition, to date, a correlation between the administered dose and the 
prevalence and severity of GF cannot be established. Nevertheless, it has been found that 
the combined regimen of nifedipine and cyclosporine in children undergoing organ 
transplants increases both the prevalence and severity of GF (Somacarrera et al., 1994). The 
development of GF after drug exposure has been related to an underlying individual genetic 
susceptibility. Possible candidate risk factors have been considered the polymorphic 
mutations in genes affecting the activity of cytochrome P450, which is responsible for the 
hepatic metabolism of drugs implicated in GF (Seymour et al., 2000). 
2.2 Hereditary gingival fibromatosis 
Hereditary gingival fibromatosis is a rare disorder (about one in 750,000 individuals), 
transmitted either as an autosomal dominant or, rarely, an autosomal recessive trait 
(Jorgenson and Cocker, 1974, Takagi et al., 1991). Different inheritance patterns, ages at 
onset and severity of the clinical manifestations in these patients, along with the presence of 
both isolated and syndromic forms reflect the underlying genetic heterogeneity. To date, 
four loci for isolated HGF have been identified, on chromosomes 2p21 (GINGF1, MIM # 
135300), 5q13-q22 (GINGF2, MIM 605544), 2p23.3-p22.3 (GINGF3, MIM 609955) and 11p15 
(GINGF4, MIM 611010). An additional locus has been assigned to chromosome 2p16-p13. 
Sequencing of the 16 known genes, which mapped...GINGF1, in the critical region of 
GINGF1 disclosed a heterozygous frameshift mutation in Son-of-Sevenless-1 (SOS-1) gene, 
which co-segregated with the disease in a Brazilian family (Hart et al., 2002). 
Emerson described in 1965, the segregation of isolated GF in a family, for 4 generations. The 
disease was transmitted to the children from an affected parent, with the exception of a 
woman who, though not affected, transmitted the disease to subsequent generations 
through affected children, down to her great-grandchildren. The only affected male did not 
have children (Emerson, 1965). The transmission of the disease through an unaffected 
woman may be related to a lack of penetrance of the mutation or to mutations of an 
imprinted gene that is expressed only if maternally transmitted.  
Linkage analysis of the entire genome in a Brazilian family with isolated, autosomal 
dominant GF, led to the identification of a locus on chromosome 2p21-p22, named GINGF1. 
Among the 32 family members identified, 12 had GF of varying severity; the youngest 
patient was 4 years old (Hart et al., 1998). Shashi et al have extended linkage analysis to 
more members of the family previously described and characterized the duplication 2p13-
p21, already observed in a child by Fryns et al. (1989). This study restricted the disease-locus 
to a region of 8 Mb on chromosome 2p21, while the chromosomal region found duplicated 
in the child, was proximal to the first, on 2p13-p16 (Fryns et al., 1989, Shashi et al., 1999). 
Genotyping of four Chinese families with the same method, localized the disease-locus in a 
region of 8.7 cM on chromosome 2p21, which overlaps with that found in the Brazilian 
family, by 3.8 cM (Xiao et al., 2000). The sequencing of the 16 known genes present in the 
candidate region, has led to the identification of a heterozygous frameshift mutation, the 
insertion of a cytosine (g.126.142-126.143insC) in the Son-Of-Sevenless gene, 1 (SOS-1). The 
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mutation causes premature termination of the protein and the formation of a chimeric 
product, that consists of 1,105 amino acids, 1,083 amino of which are preserved, towards the 
NH2-terminal, followed by 22 new ones. The premature termination eliminates four 
functional domains near the COOH- terminal, rich in proline, that are necessary for binding 
with wild type Grb2 (Hart et al., 2002). 
Wild type SOS protein consists of three functional segments: the catalytic segment, 
consisting of the Cdc25 domain and the domain of exchange with Ras (REM), a regulatory 
NH2-terminal segment that contains the histone domain, the DH domain and the PH 
domain (homologous to plecstrin) that interacts with PIP2 phosphatidic acid, and the 
COOH-terminal segment that contains binding sites for various proteins including Grb2. 
SOS1 protein acts as a guanine exchange factor (GEF), which links receptor tyrosine kinases 
to the Ras pathway and controls, therefore, cell proliferation, differentiation, vescicle 
trafficking and regulation of the cytoskeleton’s actin. Under the supervision of two classes of 
regulatory proteins, the GEF and those activating the GTPase, the Ras protein functions as a 
molecular switch in the cycle of GDP/GTP. Three Ras-GEFs have been characterized, SOS, 
the guanine nucleotide-releasing factor and the guanylate nucleotide-releasing protein. All 
three control the activity of Ras by catalyzing the release of GDP and the association with 
GTP. Two regulatory regions determine the GEF activity of SOS1: a catalytic site that 
interacts with the nucleotide-free form of Ras and an allosteric site that enhances the 
exchange activity when linked to the nucleotide-bound form of Ras. Growth factors induce a 
rapid dimerization and self-phosphorylation of their receptors. Phosphotyrosine residues in 
the catalytic region of the receptors act as binding sites for the SH2 domains of various 
proteins that function as intracellular messengers. By stimulating the growth factor, SOS is 
recruited from the cytoplasm to the cell membrane as a result of its interaction with Grb2, 
which is linked to the tyrosine residues of the phosphorylated receptor through its SH2 
domain. In this way the interaction between Grb2 and SOS causes the translocation of the 
complex to the cell membrane, where GDP is exchanged with GTP and Ras is activated. 
Although the complex Grb2-SOS1 functions exclusively as a Ras activator, SOS1 may also 
function as a GEF that is specific to the Rac1 GTPase. 
Further studies of the mechanism of Ras activation evidenced the following: after growth 
factor stimulation, SOS translocates to the cell membrane through at least two independent 
sites, the Grb2 binding site located near the COOH-terminal and the lipid-binding domain, 
PH. In addition to facilitate the anchor to the membrane, the interaction with the Grb2 
protein overcomes the negative self-regulation of SOS mediated by its COOH terminal. The 
contact of the PH domain with the membrane phospholipids induces conformational 
changes that allow the binding of Ras.GDP to the allosteric site of SOS, lowering SOS 
activity. The Ras.GTP generated during the low activity period of SOS binds to the same 
allosteric site, carrying this way SOS to its maximum activity. This model explains the 
mechanism of translocation to the cell membrane in association with the regulation of the 
catalytic activity of SOS. Moreover, the interaction of SOS with Ras.GDP or Ras.GTP further 
its position on the membrane (Gureasko et al., 2008). It has also been demontsrated that after 
stimulation with growth factor, Ras is activated both at the Golgi apparatus level and at the 
cell membrane. Activation of Ras at the cell membrane is transitory, while its action at the 
Golgi is delayed and prolonged (Buday et al., 2008). 
Jang et al showed that the total level of SOS1 transcript is lower in gingival fibroblasts of 
patients with HGF in respect to those of normal subjects, suggesting that the mutated SOS1 
transcript is significantly lower than the wild type transcript. However, the silencing of the 
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transcript using RNA interference caused a significant reduction of cell proliferation than 
the one caused by the silencing of the wild type transcript. This suggests that the increased 
proliferation of HGF fibroblasts is mainly due to the function of mutated SOS1. The authors 
also noted that the mutation in the SOS1 protein did not alter its distribution on the cell 
membrane or at the level of organelles and that the mutated SOS1 protein was capable of 
maintaining the activation of the Ras/MAPK pathway, in the absence of stimulation by 
growth factors. Therefore, this study evidenced that the HGF mutation determined the gain 
of function of SOS1, which, in this way, was implicated in the proliferation of fibroblasts 
regardless of binding with Grb2. The authors also proposed the application of RNA 
interference as a method of allele-specific depletion of the HGF mutated SOS1 as a control 
measure of gym hyperplasia (Jang et al., 2007). 
The locus 2p23.3-p22.3 (GINGF3) was identified in a Chinese family of 5 generations with 
autosomal dominant isolated GF, with onset between 2 and 6 years, around the period of 
tooth eruption. The 12 patients examined had GO that varied from mild to severe. Over 70 
genes mapped in the region identified. The direct sequencing of the GPR113 and SEL1 
genes, selected as candidates based on their functions in signal transduction and tumor 
suppression respectively, evidenced no mutations (Ye et al., 2005). 
In 2001, the analysis of a Chinese family with autosomal dominant isolated GF 
segregating through 4 generations, led to the identification of the 5q13-q22 locus 
(GINGF2). Ten of the 20 family members examined showed GF of very early onset, on 
average between 1 and 6 months of age. Forty-five genes were mapped located in the 
region identified, some with known functions in the control of cell growth or cell cycle 
(LY64, RAD17, THBS4, CETN3, GPR11, NAIP, OCLN, RASA1, EFNA5, FER). Among these 
the gene encoding the protein kinase IV, calcium/calmodulin-dependent was proposed as 
a candidate, given the presence of the phenocopy induced by calcium channel blockers 
(CAMK4, MIM 114080) (Xiao et al., 2001). 
Zhu et al observed two large Chinese families with isolated HGF. The disease occured 
only in the offspring of affected or carrier females, suggesting a defect of imprinting. The 
disease segregated, respectively, for 5 and 4 generations and manifested within the first 
year of life. Linkage analysis of the entire genome was positive for the 11p15 locus. The 
11p15 chromosomal region contains at least 14 genes that are subject to imprinting, 
divided into two groups, and is a region rich in tumor suppressor genes. The authors 
researched possible mutations or epimutations in the 14 known genes, localized within 
the region, with negative results. This study did not exclude, however, the presence of 
small interstitial deletions in the regulatory regions of the analyzed genes, not detectable 
with the techniques used or in other genes with maternal expression, localized in the 
region but unknown so far (Zhu et al., 2007). 
2.3 Leukemic gingival fibromatosis 
Gingival overgrowth is frequently associated with FAB M4 and M5 subtypes of acute 
myelogenous leukemia and, rarely, myelodysplastic syndrome (chronic myelomonocytic 
leukemia). The gingival biopsy shows diffuse tumor infiltration, subepithelial. The 
neoplastic cells appear large with pleomorphic nuclei, large nucleoli and eosinophilic 
cytoplasm. Although a risk factor for the development of lesions in cases of extramedullary 
acute myelogenous leukemia, is the presence of cytogenetic abnormalities (t(8; 21), inv16), 
there is, to date, no correlation between specific cytogenetic abnormalities and gingival 
involvement (Vural et al., 2004). 
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2.4 Differential diagnosis 
The drug-induced forms are clinical and histological phenocopies of the hereditary forms, 
which can be distinguished only based on positive family history. In addition, acquired 
forms can be recognized based on the presence of dental plaques and regression following 
elimination of the pathogenic noxa (Doufexi et al., 2005). Generalized GO may also result 
from local inflammation, pregnancy or leukemia. Although the leukemic forms resemble 
HGF, they can be differentiated based on negative family history and histological evidence 
of neoplastic infiltration. 
3. Syndromic gingival fibromatosis 
We classified GF syndromes in two large groups of known and unknown aetiology. In the 
first group, GF has been described as an occasional or constant sign of some syndromes of 
known aetiology, characterized by the fact that the causative molecular lesions affect the 
same cellular pathway.  
The second group consists of the rare reports of GF associated with a variable constellation 
of signs and symptoms that, taken together, represent the group of syndromic GF of 
unknown aetiology. The significant phenotypic overlap of these conditions is underlined by 
the presence of intermediate phenotypes that, to date, cannot be classified with certainty in 
distinct clinical entities. This clinical heterogeneity is reflected into a genetic heterogeneity, 
evidenced by the presence of observations of autosomal dominant or recessive transmission. 
The different conditions or observations are described below, based on a range of variable 
expression, which extends between the association of GF with hypertrichosis up to the 
multi-systemic syndromes of Zimmermann-Laband and Ramon. 
3.1 Definition of hypertrichosis  
Hypertrichosis is defined as the excessive growth of hair, which is distributed normally 
according to a variable spectrum, compared to the one of individuals of the same age, sex 
and ethnicity. Hypertrichosis may present with localized or generalized distribution and 
consist of immature or terminal hair. In the case of generalized hypertrichosis (GH), facial 
hair is accentuated on the frontal, temporal and preauricular regions. The eyebrows may be 
thick or confluent. On the back, hair converges along the midline, where it often forms 
whirls over the spine. The distribution can also be localized, associated with nevi or a spina 
bifida occulta, a previous trauma or irritation from chemicals and some inherited conditions 
autosomal dominant or recessive. Hypertrichosis should be distinguished from hirsutism 
that is excessive hair growth with distribution of male type (upper lip, chin, chest, linea alba, 
thighs and armpits), and that can be idiopathic or associated with overproduction of 
androgens. In contrast to hypertrichosis, the presence of hirsutism in childhood should 
orient towards the exclusion of endocrine causes of virilization. Generalized hypertrichosis 
may be one of the signs of a syndrome or of a metabolic disease (Baumeister, 1995). 
3.2 Syndromic gingival fibromatosis of known aetiology 
The syndromic forms of GF of known aetiology, include some phacomatoses, such as 
neurofibromatosis type 1, tuberous sclerosis and certain metabolic diseases such as alpha-
mannosidosis (MIM #248500), Salla disease (MIM #604369), and I cell disease (MIM 
#252500). In the case of the phacomatoses, the overgrowth is characterized by fibrotic 
changes typical of gum neurofibromas/angiofibromas. In the case of metabolic diseases, 
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histology shows the accumulation of gum-specific molecules, identical to those identified in 
other tissues (Ishigami et al., 1995, Gorlin et al., 2001). Almost all patients with Robinow 
syndrome (MIM # 268310) have gingival hyperplasia with dental crowding (Wilkie, 2008). 
The gingival hyperplasia is observed in 65% of patients with Costello syndrome 
(Hennekam, 2003) and in patients with leprechaunism or Donohue syndrome (MIM 
#246200) (Gorlin et al., 2001). Gingival hyperplasia is a constant feature of the multiple 
osteolysis syndrome of Murray-Puretic-Drescher, while it occurs occasionally in Winchester 
syndrome (MIM #277950) (Gorlin et al., 2001, Mosig et al., 2008). A single epileptic patient 
with Bardet-Biedl syndrome manifested GF, probably secondary to carbamazepine therapy 
(Drugowick et al., 2007). With the exception of the phacomatoses and Costello syndrome, 
that are due to autosomal dominant mutations, all other known disorders with GF are 
inherited as autosomal recessive traits. Sun et al. (2009) demonstrated that generalized 
hypertrichosis terminalis with or without gingival hyperplasia is a contiguous gene disorder 
caused by deletion of chromosome 17q24.2-q24.3. One of the affected individuals displayed 
a phenotype resembling Julia Pastrana (1834-1860), the first known case of GF, 
hypertrichosis, macrocephaly and coarse facies (Bondeson e Miles, 1993).  
3.2.1 Ras-MAPK pathway and gingival overgrowth 
Gingival overgrowth may be an occasional or recurrent feature in some genetic disorders 
caused by alterations in the proteins of the RAS-MAPK pathway. This pathway is regulated 
by the action of the SOS-1 protein, which is mutated in a subset of patients with isolated GF. 
Hart et al., (2007) demonstrated that the overall level of SOS-1 transcript is lower in HGF1 
fibroblasts. The relative level of wild-type SOS-1 transcript appeared to be higher than the 
mutant transcript in HGF1 fibroblasts. The targeting of mutant transcripts by methods of 
RNA interference produced more profound effects on reduction of cell proliferation than the 
targeting of the wild-type, suggesting that the increased proliferation of HGF1 fibroblasts 
was chiefly dependent upon the function of mutant SOS-1. 
Ras proteins are enzymes associated to the cell membrane that fluctuate from the active state 
of binding the active guanosine triphosphate (GTP) to the inactive state of binding with 
guanosine bisphosphate (GDP). The Ras GTPases are key mediators in pathways that 
transmit extracellular stimuli, through receptors on the cell surface, to the cell nucleus. They 
act as molecular switches in the processes of proliferation, differentiation, survival and cell 
death and are activated by different types of cellular receptors or calcium channels, 
upstream of the pathway. The exchange reaction between GDP and GTP is triggered by 
guanine nucleotide exchange factors, including the SOS-1 protein. The activated form of 
association with the GTP interacts with a broad spectrum of effector proteins including Raf, 
MEK1/2 and ERK1/2, and triggers downstream pathways (Aoki et al., 2008). 
The SOS-1 protein is expressed in various tissues and cells, including human gingiva, where 
it can be localized inside the epithelial and stromal cells. The SOS-1-Ras-ERK1/2 pathway 
seems to be the central switch of expression of key molecules of the fibrosis process and of 
HGF. In fact, the activation of this pathway increases the expression of type IV collagen, the 
connective tissue growth factor CTGF, growth factor TGF-b, of the collagenase inhibitors 
TIMP and decreases the expression of metalloprotease MMP that degrades extracellular 
matrix components. The loss of function of metalloprotease type 2, that causes Winchester 
syndrome, results, therefore, in an altered homeostasis of connective tissue with 
accumulation of its physiological substrates, including collagen, fibronectin and laminin. 
Thus, the increased activation of the Ras/MAPK pathway by mutations of the SOS-1 gene 
 
Underlying Mechanisms of Epilepsy 
 
256 
2.4 Differential diagnosis 
The drug-induced forms are clinical and histological phenocopies of the hereditary forms, 
which can be distinguished only based on positive family history. In addition, acquired 
forms can be recognized based on the presence of dental plaques and regression following 
elimination of the pathogenic noxa (Doufexi et al., 2005). Generalized GO may also result 
from local inflammation, pregnancy or leukemia. Although the leukemic forms resemble 
HGF, they can be differentiated based on negative family history and histological evidence 
of neoplastic infiltration. 
3. Syndromic gingival fibromatosis 
We classified GF syndromes in two large groups of known and unknown aetiology. In the 
first group, GF has been described as an occasional or constant sign of some syndromes of 
known aetiology, characterized by the fact that the causative molecular lesions affect the 
same cellular pathway.  
The second group consists of the rare reports of GF associated with a variable constellation 
of signs and symptoms that, taken together, represent the group of syndromic GF of 
unknown aetiology. The significant phenotypic overlap of these conditions is underlined by 
the presence of intermediate phenotypes that, to date, cannot be classified with certainty in 
distinct clinical entities. This clinical heterogeneity is reflected into a genetic heterogeneity, 
evidenced by the presence of observations of autosomal dominant or recessive transmission. 
The different conditions or observations are described below, based on a range of variable 
expression, which extends between the association of GF with hypertrichosis up to the 
multi-systemic syndromes of Zimmermann-Laband and Ramon. 
3.1 Definition of hypertrichosis  
Hypertrichosis is defined as the excessive growth of hair, which is distributed normally 
according to a variable spectrum, compared to the one of individuals of the same age, sex 
and ethnicity. Hypertrichosis may present with localized or generalized distribution and 
consist of immature or terminal hair. In the case of generalized hypertrichosis (GH), facial 
hair is accentuated on the frontal, temporal and preauricular regions. The eyebrows may be 
thick or confluent. On the back, hair converges along the midline, where it often forms 
whirls over the spine. The distribution can also be localized, associated with nevi or a spina 
bifida occulta, a previous trauma or irritation from chemicals and some inherited conditions 
autosomal dominant or recessive. Hypertrichosis should be distinguished from hirsutism 
that is excessive hair growth with distribution of male type (upper lip, chin, chest, linea alba, 
thighs and armpits), and that can be idiopathic or associated with overproduction of 
androgens. In contrast to hypertrichosis, the presence of hirsutism in childhood should 
orient towards the exclusion of endocrine causes of virilization. Generalized hypertrichosis 
may be one of the signs of a syndrome or of a metabolic disease (Baumeister, 1995). 
3.2 Syndromic gingival fibromatosis of known aetiology 
The syndromic forms of GF of known aetiology, include some phacomatoses, such as 
neurofibromatosis type 1, tuberous sclerosis and certain metabolic diseases such as alpha-
mannosidosis (MIM #248500), Salla disease (MIM #604369), and I cell disease (MIM 
#252500). In the case of the phacomatoses, the overgrowth is characterized by fibrotic 
changes typical of gum neurofibromas/angiofibromas. In the case of metabolic diseases, 
 
The Gingival Fibromatoses 
 
257 
histology shows the accumulation of gum-specific molecules, identical to those identified in 
other tissues (Ishigami et al., 1995, Gorlin et al., 2001). Almost all patients with Robinow 
syndrome (MIM # 268310) have gingival hyperplasia with dental crowding (Wilkie, 2008). 
The gingival hyperplasia is observed in 65% of patients with Costello syndrome 
(Hennekam, 2003) and in patients with leprechaunism or Donohue syndrome (MIM 
#246200) (Gorlin et al., 2001). Gingival hyperplasia is a constant feature of the multiple 
osteolysis syndrome of Murray-Puretic-Drescher, while it occurs occasionally in Winchester 
syndrome (MIM #277950) (Gorlin et al., 2001, Mosig et al., 2008). A single epileptic patient 
with Bardet-Biedl syndrome manifested GF, probably secondary to carbamazepine therapy 
(Drugowick et al., 2007). With the exception of the phacomatoses and Costello syndrome, 
that are due to autosomal dominant mutations, all other known disorders with GF are 
inherited as autosomal recessive traits. Sun et al. (2009) demonstrated that generalized 
hypertrichosis terminalis with or without gingival hyperplasia is a contiguous gene disorder 
caused by deletion of chromosome 17q24.2-q24.3. One of the affected individuals displayed 
a phenotype resembling Julia Pastrana (1834-1860), the first known case of GF, 
hypertrichosis, macrocephaly and coarse facies (Bondeson e Miles, 1993).  
3.2.1 Ras-MAPK pathway and gingival overgrowth 
Gingival overgrowth may be an occasional or recurrent feature in some genetic disorders 
caused by alterations in the proteins of the RAS-MAPK pathway. This pathway is regulated 
by the action of the SOS-1 protein, which is mutated in a subset of patients with isolated GF. 
Hart et al., (2007) demonstrated that the overall level of SOS-1 transcript is lower in HGF1 
fibroblasts. The relative level of wild-type SOS-1 transcript appeared to be higher than the 
mutant transcript in HGF1 fibroblasts. The targeting of mutant transcripts by methods of 
RNA interference produced more profound effects on reduction of cell proliferation than the 
targeting of the wild-type, suggesting that the increased proliferation of HGF1 fibroblasts 
was chiefly dependent upon the function of mutant SOS-1. 
Ras proteins are enzymes associated to the cell membrane that fluctuate from the active state 
of binding the active guanosine triphosphate (GTP) to the inactive state of binding with 
guanosine bisphosphate (GDP). The Ras GTPases are key mediators in pathways that 
transmit extracellular stimuli, through receptors on the cell surface, to the cell nucleus. They 
act as molecular switches in the processes of proliferation, differentiation, survival and cell 
death and are activated by different types of cellular receptors or calcium channels, 
upstream of the pathway. The exchange reaction between GDP and GTP is triggered by 
guanine nucleotide exchange factors, including the SOS-1 protein. The activated form of 
association with the GTP interacts with a broad spectrum of effector proteins including Raf, 
MEK1/2 and ERK1/2, and triggers downstream pathways (Aoki et al., 2008). 
The SOS-1 protein is expressed in various tissues and cells, including human gingiva, where 
it can be localized inside the epithelial and stromal cells. The SOS-1-Ras-ERK1/2 pathway 
seems to be the central switch of expression of key molecules of the fibrosis process and of 
HGF. In fact, the activation of this pathway increases the expression of type IV collagen, the 
connective tissue growth factor CTGF, growth factor TGF-b, of the collagenase inhibitors 
TIMP and decreases the expression of metalloprotease MMP that degrades extracellular 
matrix components. The loss of function of metalloprotease type 2, that causes Winchester 
syndrome, results, therefore, in an altered homeostasis of connective tissue with 
accumulation of its physiological substrates, including collagen, fibronectin and laminin. 
Thus, the increased activation of the Ras/MAPK pathway by mutations of the SOS-1 gene 
 
Underlying Mechanisms of Epilepsy 
 
258 
that determine a permanently active form of the coded protein, result in the increase of the 
expression of all pro-fibrotic molecules mentioned above. 
Drugs that induce GF disturb the metabolic pathways involved in the translation of signals 
on behalf of the intracellular calcium ions (Ca2+). This suggests that this pathway is involved 
in the development of fibrosis. Several ion channels located on the cell membrane regulate 
the flow of Ca2+ ions, which, in turn, affects the signal transduction pathways, including the 
Ras/MAPK pathway, directly or indirectly, through proteins that bind Ca2+. Among these, 
the best characterized to date are the calmodulins (CaM) that reduce the expression of TGF- 
β and the activation of ERK1/2. 
Ras proteins also participate in the communication between the insulin-receptor complex on 
the cell surface and the activation of cytosolic proteins downstream. In particular, the 
insulin receptor interacts with the proteins Gab-1, p60dok, Cbl, APS and isoforms of Shc10. 
The phosphorylated tyrosine residues of the activated insulin receptor act as docking sites 
for proteins containing SH2 domains (Src-homology-2). Many of these molecules are 
"adaptors", including proteins PI(3)K and Grb2, which, in turn, bind to the guanine 
nucleotide exchange factors, including the SOS protein-1 and activate the Ras/MAPK 
pathway (Saltiel and Kahn, 2001). However, it is not known whether insulin receptors are 
expressed in gingival tissue. 
In conclusion, the SOS-1-Ras-ERK1/2 pathway regulates genes whose expression is altered 
in HGF and are involved in the process of fibrosis. It might be suggested that a defect at any 
level of this signaling cascade, which increases the expression of pro-fibrotic genes, 
promotes the development of GF. 
It is interesting to observe a gingival phenotype both in NF1, which is caused by loss of 
function of neurofibromin, a negative regulator of Ras activation, and in Costello syndrome, 
caused by gain of function mutations of the H-Ras gene. Although the biochemical functions 
of tuberin and hamartin are not known to date, coded respectively by the TSC1 and TSC2 
genes, we know that tuberin contains a region of homology with proteins that activate small 
GTPases such as Ras protein. The loss of function of tuberin could lead to a continuous 
stimulation of the pathways triggered by Ras. The CMG2 protein, mutated in the Murray-
Puretic-Drescher syndrome, which is consistently associated with gingival hyperplasia, is an 
integrin-like molecule of the cell membrane that regulates cell adhesion to laminin and to 
collagen type IV. The metabolic pathways regulated by CMG2 are not known in detail, to 
date, but it is known that the cell adhesion pathway transmits signals to SOS-1-Ras-ERK1/2 
and therefore there is a possible link between CMG2 and this signaling cascade. The 
differential involvement of multiple tissues or of the gingiva exclusively seems to depend on 
the functional importance of each of the mutated genes in the different cells and tissues 
(Häkkinen and Csiszar, 2007). 
Several heterozygous, gain of function mutations of the SOS-1 gene have been associated 
with a distinct form of Noonan syndrome with high prevalence of ptosis and pulmonary 
valve stenosis, ectodermal symptoms and, generally, the absence of mental and 
developmental retardation. None of the affected with confirmed SOS-1 mutations described 
to date, presented with GF or was predisposed to the development of tumors. Furthermore, 
the mutations described are not associated with any type of tumor (Tartaglia et al., 2007, 
Roberts et al., 2007, Zenker et al., 2007). There were no further observations of HGF due to 
SOS-1 mutations. The C.3248-3249insC mutation in exon 21 of the gene, linked to HGF, has 
not been observed to date in people with Noonan syndrome. All SOS-1 mutations result in a 
gain of function but the one related to HGF is the only frameshift one, resulting in a 
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chimeric, truncated protein. All other SOS-1 mutations described to date do not result in 
truncated proteins. The HGF mutation affects the SOS-1 domain of binding to Grb2 
correlated to its self-negative regulation, but functional studies have shown that this 
mutation does not alter the intracellular localization of SOS-1 or its function of activating the 
Ras/MAPK pathway via ERK1/2 (Jang et al., 2007). 
Mutations in key components of the MAPK pathway that cause prolonged activation of ERK 
are related to the formation of tumors (Aoki et al., 2005). The formation of skin tumors has 
been highlighted in transgenic mice for SOS-1, artificially constructed, with deletion of the 
COOH terminal (Sibilia et al., 2000). It is believed that the activity of the strong promoters 
used in these experiments produces high levels of expression of the mutant protein that 
causes significant increase of ERK activity and leads to transformation. This means, there is 
probably a threshold of protein expression beyond which transformation happens. It is 
assumed that the benign form of the overgrowth in HGF can be interpreted as follows: the 
low levels of mutant SOS-1 that is partially free from self-inhibition could lead to a 
continuous activation of ERK that could be sufficient to cause increased proliferation but not 
cell transformation (Jang et al., 2007). In the presence of a cellular environment with EGFR 
receptor of reduced activity, transgenic mice do not form skin cancers, despite the gain of 
function, and thus the continued activation of the MAPK on behalf of the artificial SOS-1 
protein (Sibilia et al., 2000). 
In conclusion, it is not yet known why the various SOS-1 mutations produce distinct 
phenotypes or why the overgrowth in HGF is confined in the gingival tissue. A specific 
mutation-disease correlation could be hypothesized, secondary to the specific functions of 
the SOS-1 protein in gingival tissue or a tolerance/compensation of the gain of function 
caused by the frameshift mutation, in the other tissues (Jang et al., 2007). 
3.3 Syndromic gingival fibromatosis of unknown aetiology 
A number of subjects with GF associated with variable signs and symptoms can be regarded 
as examples of GF syndromes of unknown etiology, which, in descending order of number 
of observations, include GF, hypertrichosis, epilepsy and/or mental retardation (MR) 
syndrome; Zimmermann-Laband syndrome (MIM %135500); Jones syndrome (Jones et al., 
1997); Ramon syndrome (MIM 2662700); Rutherfurd syndrome (MIM %180900), GF 
syndrome and characteristic facies (MIM 228560). GO is an occasional feature of Sturge-
Weber syndrome (MIM 185300). This anomaly is secondary to angiomatous proliferation, 
worsened by GF caused by treatment of the epileptic symptoms (Bhansali et al., 2008). In 
general, these cases are rare and mostly sporadic, with the exception of Ramon syndrome, 
an autosomal recessive disorder, and single reports of affected sibs pairs, born to unaffected 
parents, presenting with GF, hypertrichosis, epilepsy and/or MR or manifesting the 
Zimmermann-Laband syndrome or intermediate phenotypes (Gorlin et al., 2001). 
Taking into account the GF syndromic forms of unknown aetiology mentioned above, the 
existence in the literature of not clearly distinct phenotypes becomes evident, given the 
rarity of the observations and the significant overlap of signs/symptoms. There are 
“wide” clinical spectrums such as Ramon and ZL syndromes, which include a set of 
signs/symptoms that have also been observed individually associated with GF. The 
constant segregation of the association of GF with acro-osteolysis or cherubism, all three 
very rare signs, suggests that the ZL and Ramon syndromes are distinct clinical genetic 
entities. The two syndromes share, with different frequencies, the observations of GF, 
hypertrichosis, epilepsy and MR, an association described as an isolated clinical entity, 
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that determine a permanently active form of the coded protein, result in the increase of the 
expression of all pro-fibrotic molecules mentioned above. 
Drugs that induce GF disturb the metabolic pathways involved in the translation of signals 
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not been observed to date in people with Noonan syndrome. All SOS-1 mutations result in a 
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and retinal alterations of the pigmentosum type (Koch et al., 1992, Parkin and Law, 2001). 
It has been suggested that the association of isolated GF with hypertrichosis is the 
minimum clinical expression of the phenotypic spectrum of the ZLS (Lacombe et al., 1994) 
but that should probably be differentiated, given the absence of any further 
signs/symptoms (Robertson et al., 1998). An important hallmark is the finger hypoplasia, 
especially of the feet, and/or of the nails with or without an underlying hypoplasia of the 
terminal phalanges, especially in a patient without cognitive impairment and/or 
organomegaly, both non-mandatory symptoms of the ZLS. Based on the observation of 
the association of this last sign to GF and a hyperextensibility of the small joints Bakaeen 
and Scully (1991) reported the recurrence of the syndrome of ZL, in the children of a 
couple of cousins. 
The unclear distinction between the phenotype of ZL and GF, hypertrichosis, epilepsy, 
MR, has been highlighted by several observations of intermediate phenotypes. Vontobel 
et al (1973) described a sporadic patient, who presented GF, congenital generalized 
hypertrichosis, mild hypoplasia of the fingernails and, especially, the feet, and 
acromegaloid features acromegaloidi that were not due to an underlying endocrinological 
disorder. The patient had psychomotor retardation (she walked alone at the age of 2 
years, spoke the first phrases at 3-4 years), but her IQ was normal. Göhlich-Ratman et al 
(2000) observed the recurrence, in two sisters, daughters of first cousins, of coarse facies, 
profound MR with severe language impairment, early onset gingival hyperplasia, 
hypertrichosis and generalized tonic-clonic seizures with onset at 2 years of age. Both also 
had brachydactyly type E with bilateral shortness of metacarpals III-V and 
brachitelephalangy of the first finger, hypoplastic toenails, and bilateral sandal gap. The 
authors rule out ZLS for the lack of open bite and hepatomegaly, signs, however, that are 
not present in all patients with ZL reported in the literature. They speculate, however, 
that this is a broader phenotype than that observed by Anavi et al (1989) or a distinct 
syndrome of autosomal recessive GF. 
However, the assumption that all these clinical features are part of the same phenotypic 
spectrum seems validated by the observation of segregation of distinct phenotypes from a 
father to his two sons. The father, at the age of 45, presented with GF, hypertrichosis, 
hearing loss and hypotelephalangism with brachydactyly and nail hypoplasia of the 
thumbs. His 13-year-old son had the same clinical picture, along with hypertrichosis, in the 
absence of MR. A second son, of 10 months, had inherited the paternal GF and defects of the 
fingers. The mother and the only daughter were not affected (Haytac and Ozcelik, 2007). 
Gingival overgrowth variably associated with GH, MR or epilepsy has been described as a 
distinct, isolated disorder, with an autosomal dominant inheritance pattern (Anderson et al., 
1969, Horning et al., 1985, Cuestas-Carnero and Bornancini, 1988), or as a manifestation of 
more complex disorders similar to ZLS (Gorlin et al., 2001). It was suggested that the 
association of GO, GH, MR or epilepsy could represent the mildest expression of ZLS. 
Distinguishing features in the former include absence of additional features, in particular 
nail hypoplasia with or without hypotelephalangism, mostly affecting the hands (Lacombe 
et al., 1994, Robertson et al., 1998). Clinical variability between patients with GO, GH, MR or 
epilepsy likely reflects genetic heterogeneity is also supported by different inheritance 
patterns (Nevin et al., 1971, Bakaeen and Scully, 1991, Haytac and Ozcelik, 2007). All these 
disorders can be lumped in a continuum of increasing severity, from the mildest phenotypes 
displaying GO, GH, MR and epilepsy to the most complex disorders reported by Göhlich-
Ratman et al (2000) and Ramon et al (1967). 
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4. Generalized hypetrichosis, tonic-clonic seizures with onset in the first 
months of life, severe mental retardation and gingival overgrowth unrelated 
to the antiepileptic treatment 
We had the opportunity to evaluate an 8-year old girl that was referred for genetic 
counselling because of MR and convulsions. She was the first daughter of healthy non-
consanguineous Italian parents. A younger sister was clinically normal. At birth, the mother 
was 24-years-old and the father 29. Family history was unremarkable. Pregnancy was 
complicated by threatened miscarriage during the first trimester, for which the mother 
was advised with bed rest and treated with isoxuprine. No exposure to teratogenic agents 
was reported. Serologic tests for cytomegalovirus, toxoplasmosis and rubella, and triple 
serum marker screening were negative. A standard ultrasound scan at 22½ weeks of 
gestation was normal. The patient was born at 36 weeks of gestation with the use of 
forceps. Birth weight was 3,130 g (50th percentile), length 47 cm (10th percentile) and OFC 
34 cm (25th percentile). She presented with delayed after birth cry and there was, 
transitory, self-resolving cyanosis, obvious generalised hypertrichosis and jaundice, 
which was treated with phototherapy. Apgar scores were not recorded. Cord blood gas 
values were normal, no resuscitation was required and paediatric monitoring did not 
reveal any end-organ dysfunction. The patient developed tremors from the first days of 
life, that, by age of 2 years turned into recalcitrant, generalized, tonic-clonic seizures. The 
episodes were initially unsuccessfully treated with phenobarbital that was substituted 
with sodium valproate. Treatment with sodium valproate easily controlled the seizures 
but this was changed to topiramate after 14 months because the patient was frequently 
observed lethargic. Developmental milestones were delayed: she sat at 9 months and 
walked at 2 years. At the time of the evaluation she was undergoing psychomotricity 
since the last 6 years. 
On physical examination she had presented excessive growth of apparently terminal hair, 
distributed over the upper lip, cheeks, back, arms and forearms and legs. The hair on the 
back converged over the midline, forming whorls over the lower spine. The face and hands 
were otherwise unremarkable. Oral inspection disclosed a grade III GO, covering at least 
threequarters of the tooth crowns (Bökenkamp et al., 1993). Enlarged gingiva was normal in 
colour and felt firm on palpation. The patient was mentally retarded and had not acquired 
yet any language skills. She was 120 cm tall and weighed 21 kg (both on the 3rd percentile). 
On clinical evaluation, the parents were normal. 
Electroencephalography disclosed bilateral parossistic activity over the frontal and temporal 
regions, with a right-side prevalence. Brain computed tomography and magnetic resonance 
imaging, spine radiographs, heart and abdominal ultrasound were unremarkable. Auditory 
brainstem response test and ophthalmologic evaluation were normal. The effect of 
anticonvulsant therapy was monitored with computerized bone mineralometry, which 
showed unremarkable results. Blood levels of total and free testosterone and DHEA-S were 
normal. Metabolic workout including serum lactate, ammonia, amino acids, organic acids, 
cholesterol, very long chain fatty acids, lysosomal enzymes, transferrin isoelectric focusing 
and urinary mucopolisaccarides was normal. Fibroblast chromosome analysis at the 550 
bands level and aCGH analysis at 125 kb of resolution yielded normal results. Parents did 
not give their permission to perform gum biopsy. 
This latter patient presented with a unique association of GH, tonic-clonic seizures with 
onset in the first months of life, severe MR and GO unrelated to antiepileptic treatment, in 
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and retinal alterations of the pigmentosum type (Koch et al., 1992, Parkin and Law, 2001). 
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organomegaly, both non-mandatory symptoms of the ZLS. Based on the observation of 
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had brachydactyly type E with bilateral shortness of metacarpals III-V and 
brachitelephalangy of the first finger, hypoplastic toenails, and bilateral sandal gap. The 
authors rule out ZLS for the lack of open bite and hepatomegaly, signs, however, that are 
not present in all patients with ZL reported in the literature. They speculate, however, 
that this is a broader phenotype than that observed by Anavi et al (1989) or a distinct 
syndrome of autosomal recessive GF. 
However, the assumption that all these clinical features are part of the same phenotypic 
spectrum seems validated by the observation of segregation of distinct phenotypes from a 
father to his two sons. The father, at the age of 45, presented with GF, hypertrichosis, 
hearing loss and hypotelephalangism with brachydactyly and nail hypoplasia of the 
thumbs. His 13-year-old son had the same clinical picture, along with hypertrichosis, in the 
absence of MR. A second son, of 10 months, had inherited the paternal GF and defects of the 
fingers. The mother and the only daughter were not affected (Haytac and Ozcelik, 2007). 
Gingival overgrowth variably associated with GH, MR or epilepsy has been described as a 
distinct, isolated disorder, with an autosomal dominant inheritance pattern (Anderson et al., 
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more complex disorders similar to ZLS (Gorlin et al., 2001). It was suggested that the 
association of GO, GH, MR or epilepsy could represent the mildest expression of ZLS. 
Distinguishing features in the former include absence of additional features, in particular 
nail hypoplasia with or without hypotelephalangism, mostly affecting the hands (Lacombe 
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the absence of other signs and/or symptoms (Douzgou et al., 2009). The clinical features of 
this patient overlapped in part those found in cases of GO associated with GH, MR, epilepsy 
and ZLS or related phenotypes (Araiche and Brode, 1959, Nevin et al., 1971, Vontobel et al., 
1973, Bakaeen and Scully, 1991, Haytac and Ozcelik, 2007). Tonic-clonic seizures have been 
reported so far only in a single patient with ZLS, who did not manifest GH (Chodirker et al., 
1986). Two patients with the GH of Cantu syndrome (CS) presented with GO but manifested 
additional features and had no seizure (Rosser et al., 1989). Following the original 
observation of Anavi et al (1989), concerning a brother-sister pair born to consanguineous 
parents, two additional patients have been reported with similar clinical characteristics, 
including central nervous system (CNS) anomalies and neurological features (Snyder, 1965, 
Kiss, 1990). CNS anomalies were not found in our patient, arguing for a different origin of 
her neurological manifestations. Our patient also resembled Snyder’s case 2, but absence of 
ataxia appeared as the major distinguishing criteria.  
ZLS and Ramon syndrome are considered separate disorders, characterized by the 
association of GO with hypotelephalangism or cherubism. GH, MR, epilepsy and retinal 
changes can be overlapping features (Gorlin et al., 2001, Koch et al, 2002). It seems that these 
two diseases represent the extreme spectrum of the phenotypes exhibiting GO, GH, MR and 
epilepsy. All these disorders can be lumped in a continuum of increasing severity, from the 
mildest phenotypes displaying GO, GH, MR and epilepsy to the most complex disorders 
reported by Göhlich-Ratman et al (2000) and Ramon et al (1967). The unique phenotype of 
our patient, displaying GO, GH, MR and epilepsy without other signs and/or symptoms 
overlaps, in part, with the features observed in the three autosomal recessive disorders 
sharing GO, GH, MR and epilepsy and seems to represent a further example of clinical 
variability within the occurring in GO plus conditions (Table 2). 
4.1 Genetic counselling of gingival fibromatosis 
The genetic counselling of a person with GF begins with the collection of anamnestic data 
such as exposure to GF-inducing drugs, the presence of systemic conditions (pregnancy, 
leukemia), other family members affected, presence of psychomotor retardation and/or 
seizures. Physical examination can evaluate a number of signs/symptoms that may orient 
towards the definition of the recurrence risk (RR). In the absence of other signs/symptoms 
associated, the SOS-1 gene can be sequenced. In case the molecular analysis is negative, a 
linkage analysis of the GINGF2-4 known loci, to date, can be undertaken. The presence of 
hearing loss (Jones syndrome) or corneal opacities (Rutherfurd syndrome) or the association 
with hypertrichosis suggest an autosomal dominant segregation. The presence of cherubism 
confirms the diagnosis of Ramon syndrome, which is autosomal recessive. The finding of 
macrocephaly orients towards the clinical entities described by Canun et al. (2003) and 
Goldblatt and Singer (1992), with different modes of transmission, depending on the 
associated dysmorphisms. The recognition of a pattern of multisystemic anomalies (heart 
disease and/or short stature and/or genitourinary anomalies) associated to GF and 
hypertrichosis may point to specific, rare syndromes of defined RR. The nail hypoplasia 
with or without hypotelephalangism allows the diagnosis of ZL, but does not define the RR. 
Regarding possible patients with the combination of variable GF, hypertrichosis, epilepsy 
and MR, cerebral magnetic resonance imaging and X-rays of hands and/or a 
metacarpophalangeal profile may confirm a 25% RR in the cases, respectively, of CNS 
anomalies or brachydactyly/metacarpy (Figure 1). 
 




1, Horning et al. (1985); 2, Anderson et al. (1969); 3, Cuestas-Carnero and Bornancini (1988); 4, Araiche 
and Brode (1959); 5, Nevin et al. (1971); 6, Vontobel et al. (1973); 7, Bakaeen and Scully (1991); 8, Haytac 
and Oczelik (2007); 9, Gorlin et al. (2001); 10, Rosser (1998); 11, Snyder (1965); 12, Anavi et al. (1989); 13, 
Kiss (1990); 14, Göhlich-Ratman et al. (2000); +, present; - absent; +/-, variable; GO, gingival 
overgrowth; GH generalized hypertrichosis; MR, mental retardation; y, years; RS, Ramon syndrome; 
ZLS, Zimmermann-Laband syndrome; CS, Cantu syndrome; P2, patient 2; BDE, brachydactyly type E; 
CNS, central nervous system; At, ataxia; BA, brain atrophy; SP, spastic paraparesis; Hp, hypotonia; AR, 
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Fig. 1. HGF genetic counselling algorithm; blue arrows, presence; red arrows, absence.  
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The prognosis of patients with syndromic GF is related to the presence of MR, postnatal 
growth failure, epilepsy, heart disease and predisposition to cancer. In the specific patient 
that we described, given a possible diagnosis of ZLS, the monitoring of cardiorespiratory 
function before the age of 18 years or before embarking on exercise programs is suggested. 
5. Conclusion  
The patient that we observed is an example of an extremely rare developmental defect 
present at birth, which is not obvious to the methods currently used for prenatal diagnosis. 
Her condition is part of the 2-3% of congenital dysmorphisms that require genetic 
counselling. The absence of a known genetic lesion narrows the diagnostic approach to the 
clinical-observational aspect. The comparison and classification of this very rare clinical 
observation was essential in defining the risk of recurrence of the family and the patient's 
prognosis. The clinical classification of rare genetic conditions is an essential step, along 
with the descriptions of additional observations and the advances in research, for the 
discovery of their molecular causes, and thus for the care of the patients and their families. 
Of all the branches of medical genetics, genetic counselling of rare congenital dysmorphisms 
represents the field with the greatest impact of the clinical geneticist. This is justified by such 
an association of factors as the high incidence of birth defects and hence the increased 
demand of services of genetic counselling and the rarity of the individual observations, 
which does not, therefore, permit the diagnosis in first level health services and/or by staff 
with a general training in medical genetics. The organization of the clinical genetics service 
in a second or third level facility allows the grouping of these observations in registers or 
databases that permits the comparison of clinical pictures among different patients as well 
as the exchange of opinions with other experts. All these processes depict the clinical 
geneticist as the central, decision-making figure of the genetic counselling of patients with 
rare dysmorphisms. 
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Epilepsy is a neurological disease arising from abnormal and uncontrollable electrical firings 
of a group of neurons appearing in the central nervous system. Experimental epilepsy 
models have been developed to assess the pathophysiology of epileptic seizures and to 
search for new effective anti-epileptic drugs.  
This chapter is designed to describe characteristics of experimental epilepsy models and 
morphological and anatomical changes of brain, particularly hippocampus (Figure 1), in 
these models. Because of the hippocampal neuronal hyperexcitability during epileptic 
seizures, hippocampus has been one of the best choices in terms of target area that reveals 
most efficiently the effects of seizures in experimental epilepsy models. 
The purpose of the study determines which model should be chosen for epilepsies. This 
type of studies may have three purposes: 1. Developing new drugs, 2. Exploring the 
mechanisms, 3. Determining the relationships between basic events and the development of 
events for epilepsy.  
An ideal model of epilepsy should have the following characteristics: 1. Seizures should be 
as the spontaneous recurrent seizures, 2. Seizures should be similar to seizures in humans, 3. 
The EEG pattern should be similar to related type of epilepsy, and 4. The frequency of 
seizures should be sufficient to test acute and chronic effects of drugs. However, there is no 
single model that meets all these criteria.  
Some researchers classify seizures according to generation of the epilepsy model, not 
according to seizures in humans. Experimental models are divided into three groups 
according to this classification: 1. experimental seizures induced by chemical convulsants or 
by electrical stimulation, 2. reflex epilepsies, and 3. idiopathic epilepsies. 
Epileptic seizures are classified in three groups:  
1. Partial seizures, which can be further subdivided into simple partial seizures and complex 
partial seizures. 2. Generalized seizures which can be further subdivided into tonic, clonic, 
tonic-clonic (grand mal), absence (petit-mal) seizures, and status epilepticus. 3. Unclassified 
seizures.  
In experimental epilepsy studies, animal models have been developed according to this 
classification (Table-1). 
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1- Simple partial, acute 
2- Simple partial, chronic 
3- Complex partial 
4- Generalized tonic-clonic 
5- Generalized absence 
6- Status epilepticus. 
 
Animal (the experimental) models of the epilepsies: 
1- Simple partial, acute 4- Generalized tonic-clonic 5- Generalized absence 
 Genetic Thalamic stimulation 
   Penicillin    Photosensitive boboons    Bilateral cortical foci 
   Bicuculline    Audiogenic seizures in mice Systemic penicillin 
   Picrotoxin    Mongolian gerbil  Intraventricular opiates 
   Strychnine    Epilepsy mice   
       Genetically epilepsy-prone 
   rats  
 
2- Simple partial, chronic         
Cortically implanted metals    Maximal electroshock        
   Aluminum hydroxide Chemical convulsants  
   Cobalt    Pentylenetetrazol  
   Zinc    Systemic penicillin (as a    tonic-clonic model) 
 
   Manganese    Picrotoxin 6- Status epilepticus  
   Iron    Bicuculline Lithium-pilocarpine  
Cryogenic injury    Methionine sulfoximide Cobalt-homocystine  
    Bemegride Recurrent stimulation 
       Others  
3- Complex partial    Metabolic derangements  
Kainic acid       Hypoxia  
Tetanus toxin       Hypoglycemia  
Kindling      Hyperbaric oxygen  
    Hypercarbia  
    Drug withdrawal  
    High temperature  
Table 1. Animal (the experimental) models of the epilepsies. 
2. Simple partial, acute 
Penicillin  
The most popular method to study simple partial (focal) seizures has been by application of 
a topical chemical convulsant. Chemical convulsants are widely used for inducing seizures 
easily and rapidly. The common antibiotic, penicillin (a chemical convulsant), was 
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discovered during neurosurgical procedures, in which it was applied to brain to prevent 
infection. When a cottoned pledget soaked in penicillin is placed on exposed rat or cat 
cortex, regionally placed electrodes record recurring interictal spikes within a few minutes. 
These discharges resemble human interictal spikes recorded from cortex. During the 
interictal spike neurons in the region of the focus tend to fire synchronously. If penicillin is 
injected into the neocortex, the injected cortical area becomes a source of epileptic seizures. 
The penicillin epilepsy (PE) model has been one of the most important model for answering 
questions about the neuronal basis of epilepsy. This model is also suitable for analysis of 
spread of seizure activity.  
PE model is one of the most useful acute models in the field of experimental epilepsy 
studies. This model is also essential for analysis in synchronous and spread of epileptogenic 
seizure activity. It allows obtaining EEG records as in acute partial epilepsy by application 
penicillin to cortical surface. Penicillin-induced epileptic activity begins focally, but then 
spread and cause generalized epilepsy. In this regard, it resembles the grand-mal epilepsy.  
PE model leads to neuronal loss in CA1-CA2-CA3 subfields of hippocampus and 
hippocampal volume decrease in rats, in proportion to the given dose. 
However, there are no neuronal loss and volume decrease in dentate gyrus of penicillin 
epileptic rats. 
Bicuculline, Picrotoxin, Strychnine 
Bicuculline is an alkaloid that is used only in experimental studies. There are structural 
similarities between bicuculline and penicillin. Picrotoxin is a poisonous crystalline plant 
compound, found primarily in the fruit of the climbing plant Anamirta cocculus. Strychnine 
is a poisonous alkaloid that is obtained from seeds of the nux vomica tree (S. nux-vomica) 
and related plants of the genus Strychnos. Strychnine acts as a non-competitive blocker of 
inhibitory glycine. It was shown that topical application of 5% bicuculline to temporal cortex 
generates paroxysmal depolarization in cats, after a few seconds. 
Bicuculline, picrotoxin and strychnine are antagonists to the action of the inhibitory 
neurotransmitter GABA, and generate epileptiform activity, in particular by blocking 
GABAA receptors. The GABAA antagonists, bicuculline or picrotoxin, greatly increase burst 
firing in dopaminergic neurons whereas GABAB antagonists cause a modest shift away from 
burst firing towards pacemaker-like firing. The three principal GABAergic inputs to nigral 
dopaminergic neurons arise from striatum, globus pallidus and from the axon collaterals of 
nigral pars reticulata projection neurons, each of which appear to act in vivo primarily on 
GABAA receptors.  
Bicuculline induced status epilepticus with duration of 1 or 2 h leads to morphological 
changes in fronto-parietal cortex and hippocampus of rats. Astrocytic edema and wide-
spread neuronal changes of two different kinds occur in the fronto-parietal cortex of the 
animals. Type 1 injured neurons are characterized by condensation of karyoplasms and 
cytoplasm (type 1a), which in some neurons become so intense that the nucleus can no 
longer be clearly discerned (type 1b). The type 2 injured neurons have slit-formed 
cytoplasmic vacuoles chiefly caused by dilatation of the rough endoplasmic reticulum. In 
the hippocampus the most conspicuous alteration is astrocytic edema which is most marked 
around the perikarya of pyramidal neurons in CA1-CA4 and subiculum. In the dentate 
gyrus the edema is less pronounced and, when present, affects particularly the hilar zone of 
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the stratum granulosum. The nerve cell changes are less pronounced than in the cerebral 
cortex. The vast majority of the hippocampal pyramidal neurons in CA1-CA4 show minor 
configurationally and tinctorial abnormalities (incipient type 1a change). Severe nerve cell 
alterations (type 1b) are present but very rarely affect the pyramidal neurons of CA1-CA4 
and subiculum, whereas in the dentate gyrus pyramidal basket neurons of stratum 
granulosum and pyramidal nerve cells in stratum polymorphic show the severe type 1b 
changes.  
3. Simple partial, chronic 
Cortically implanted metals 
Alumina hydroxide 
The best validated and most realistic models for the epilepsies are those employing 
implantation of metals in brain to generate a state of ‘spontaneously’ recurrent simple 
partial seizures. The prototype of this group of models is the alumina hydroxide gel model. 
In a typical preparation 4% alumina hydroxide will be injected into surgically exposed 
monkey neocortex at a few adjacent sites. A similar model can be produced in the cat. 
Spontaneous and recurrent seizures generally begin one to two months after the injection, 
and persist for as long as several years. The seizures themselves are similar to simple partial 
seizures in humans, with rhythmic jerking of an extremity or face contra lateral to the 
aluminum lesion, and occasional progression to secondarily generalized tonic-clonic 
seizures. Interictal and ictal EEGs appear similar to clinical studies. Neuropathological 
specimens obtained from biopsies in the region of an established alumina focus in monkeys 
show gliosis and distortion of dendritic neuronal trees, similar to the picture seen in human 
neocortical foci.   
Cobalt 
Cortical implantation of cobalt can produce chronic or subacute models of recurrent seizures 
in animals. GABA receptors have been found to be decreased in the region of cobalt foci of 
rat motor cortex, 2-3 weeks after establishment of the focus. Furthermore in the unilateral 
cobalt model, the lack of anatomic differences in the white or gray matter outside the areas 
of MR signal loss caused by cobalt suggests no widespread cerebral injury. 
Zinc, Copper, Manganese, Iron 
Intraventricular application of the metals, such as zinc, copper, manganese, iron leads 
seizures. These effects of these metals are thought to be occur by blocking Na,K-ATPase 
membrane pump.  
A chronic model for experimental epilepsy can be generated by injecting 10 µl zinc sulfate 
into rabbit hippocampus. In this model, epileptic seizure continues for weeks and clinical or 
electrophysiological aspects are similar to complex partial and secondary generalized 
seizures in addition to simple partial seizures. Neuronal loss in both hippocampus and 
cerebellum has been found after intracortical zinc injection. Also, zinc model generates 
spontaneous epileptic seizures and generalized convulsions in rabbits but not in rats. It 
should be remembered that aluminum model generates spontaneous seizures in rats.  
In oxygen and glucose deprivation model of trans-synaptic Zn2+ movement, Ca-A/K 
channels have been expected to play a late role in neuronal injury. It is suggested with 
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strong presynaptic activation, basal numbers of Ca-A/K channels permit sufficient 
Zn2+entry to mediate rapid neuronal damage in a study of oxygen and glucose deprivation 
model. These observations may provide new rationale for neuroprotective strategies 
targeting Ca-K channels and Zn2+ passage through them in conditions of ischemia or 
epilepsy, which are associated with rapid synaptic Zn2+release. 
Cryogenic injury 
One model that doesn’t require injection of exogenous drugs into brain is cryogenic or 
freeze exogenous drugs into brain is cryogenic or freeze lesion model for partial simple 
seizures. Ethylchloride lesions or cold trauma from a liquid nitrogen probe produces a 
highly epileptogenic lesion, giving rise to seizures within a few hours of the lesion and 
persisting for a few days. Substantial cerebral edema generally accompanies the lesion. 
4. Complex partial 
Complex partial seizures are usually arise from the limbic lobe, including amygdala, 
hippocampus, and less often, temporal neocortex or extratemporal structures.  
Kainic acid 
Kainic acid (KA) is a rigid analog of the putative excitatory neurotransmitter, glutamate and 
potent agonist of the AMPA/kainate class of glutamate receptors. KA has been used to 
induce limbic seizures. Systemic and intracerebral administration of KA initially induces a 
characterized pattern of seizure activity that lasts for hours, followed by a latent seizure-free 
period of weeks, preceding the development of spontaneous recurrent focal seizures that 
begin between 3 and 4 weeks. Injection of KA is followed by cytotoxic brain edema, 
characterized by massive swelling of perineuronal and perivascular astroglia, resulting in 
parenchymal necrosis of the affected region. 
Primary interest in KA has derived from its ability to produce relatively selective lesions 
of cell bodies in brain, while sparing axons of passage. For reasons that are still 
incompletely understood, KA has an especially prominent toxic effect on hippocampus, 
even when injected systemically, or at brain sites remote from hippocampus. In doses less 
than those required to produce cell injury, KA can induce seizures in hippocampus. 
Animals given KA 4 mg/kg i.v., or 0.8-2.0 μg intra-hippocampally, will show periodic 
arrest of activity, masticatory movements, complex motor activity, and some times 
extension to generalized tonic-clonic activity. Stereo-encephalography shows major spike 
activity originating in the limbic system. KA is a prototype of an excitotoxic compound. 
KA produces an acute or substance model of seizures, lasting hours to days. The 
accompanying hippocampal lesions may be considered to confound the model, or 
alternatively, to portray the pattern of limbic cell damage which can occur with clinical 
status epilepticus. 
KA treated rats have been found to have significantly smaller hippocampus and a 
significant increase in ventricular size. The histological findings were neuronal loss and 
neuronal degeneration in CA1 and CA3 of the hippocampus, which was accompanied by 
strong microglia activation. The MRI of KA treated rats showed enlarged ventricles. 
Volumetric analysis of MRI images demonstrated a significant reduction in hippocampal 
volume of experimental rats 10 days following KA injection, whereas the cingulate cortex, 
retrosplenial cortex, and total brain volumes of these animals were not changed. Even 10 
days after the KA injection neuronal loss was still ongoing.  
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strong presynaptic activation, basal numbers of Ca-A/K channels permit sufficient 
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The dentate gyrus of epileptic KA treated rats are strikingly similar to those of reported for 
human temporal lobe epilepsy, so the findings of neuron loss and axon reorganization in the 
hippocampus of KA treated rats may be important in epileptogenesis.  
The similarities in patterns of neuron loss and granule cell axon reorganization between the 
epileptic human dentate gyrus and that of KA treated rats and other experimental models of 
epilepsy suggest the existence of population of highly vulnerable neurons that can be killed 
by naturally occurring traumatic events (e.g., status epilepticus, head injury, cerebral 
infections) and experimental treatments (e.g., kainate or pilocarpine toxicity and repetitive 
stimulation of the perforant pathway). 
There are also functional similarities in the dentate gyrus of KA treated rats and in human 
temporal lobe epilepsy. So, homologous regions of the dentate gyrus suffer the most severe 
cell loss and axon reorganization in epileptic KA treated rats and in human temporal lobe 
epilepsy. 
In addition, administration of KA activates ionotropic glutamate receptors, and selectively 
induces excitotoxic cell death in the CA3 and CA1 hippocampal subfields and within the 
dentate gyrus, while sparing neurons in the CA2 subfield and the dentate granule cell layer. 
Furthermore, there is a direct relationship between the generation epileptiform activity and 
the extent of damage in hippocampal subfields. Many features of this rodent model, such as 
hippocampal sclerosis and mossy fiber sprouting, resemble human temporal lobe epilepsy. 
As a result the KA model replicates several phenomenological features of human temporal 
lobe epilepsy and can be used as an animal preparation to understand the basic mechanisms 
of epileptogenesis. 
Following a single 9mg/kg KA injection to rats, the most important histopathological 
changes are occur time dependent and include neuronal degeneration, microgliosis, 
astrogliosis. Focus of the neuronal damage in CA1 prior to CA3 damage resembling 
human lesions as opposed to CA3 dominance observed in some rodent models; hilar 
neuronal loss; activated microgliosis; astrogliosis; and aberrant mossy fiber sprouting in 
the inner molecular layer of dentate gyrus. Intracerebroventricular administration of KA 
induces selective neuronal loss in the CA3 subfield and activates glial cells in the rat 
hippocampus.  
Similar to rats, administration of kainic acid (KA) to mice elicits epileptic behavior in a 
dose-dependent manner and causes distinct neuronal degeneration in limbic structures 
such as the hippocampus. KA treated mice show acute neuronal loss in the CA1 and CA3 
regions of hippocampus, which is followed by the activation of glial cells and delayed 
neural cell death. KA treated mice also observe volume decrease in dorsal and ventral 
hippocampus.  
Also, systemic administration of KA to rodents is a widely used experimental model of 
epilepsy and neurodegeneration. This treatment results in the appearance of chronic, 
spontaneous, recurrent seizures and neurodegenerative changes in the dentate gyrus.  
Tetanus toxin 
A model of recurrent, chronic partial seizures can be produced by injection of tetanus toxin 
into rat or cat hippocampus. Categorization of the model with complex partial seizure 
models results from the location of the usual injection site in limbic structures, rather than 
the properties of the toxin itself. The tetanus toxin model resembles those produced by 
injection of other convulsant substances into hippocampus, but it has some intriguing 
idiosyncrasies. 
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Tetanus is a disease produced from the gram-positive bacteria, Clostridium tetani. In the 
disease state toxin is transported from the periphery to the spinal cord, where it is believed 
to interfere with presynaptic release of inhibitory neurotransmitter. In contrast, injection 
into hippocampus of a dose of toxin 3-6 times the mouse probably produces effects only 
locally. Seizures may occur within a day after injection and then on a chronically recurrent 
basis over weeks. A seizure in a rat typically begins with arrest of activity. Followed by 
myoclonic jerks of the front limbs, and in some animals generalized tonic-clonic seizures. 
Whether or not the seizure generalizes depends upon several factors, including spread to 
the cingulate area.  
A single dose of tetanus toxin, injected unilaterally into the hippocampus, produced a time-
dependent neuronal loss in the CA1 pyramidal cell layer accompanied by a reduction in the 
binding of gamma-[3H]aminobutyric acid ([3H]GABA) to GABAA but not GABAB sites in 
the pyramidal cell layer. 
Kindling 
Kindling is a phenomenon by which repeated shocks to various parts of brain result in 
enhanced electrical excitability of brain. Kindling has become one of the most popular ways 
to model long-term plastic changes in brain excitability. Such plastic changes are believed to 
participate not only in epileptogenesis, but also in memory and learning. The kindling 
model is conceptually related to models for long term potentiation, although kindling 
paradigms tend to be more chronic than those for long-term potentiation (LTP), and focus 
more on epileptic changes than on enhanced evoked electrical responses. 
Kindling is usually initiated by electrical stimulation of the amygdala, but most regions of 
forebrain can be kindled. To produce the model, bipolar stimulating wires are implanted in 
amygdala or elsewhere in brain. The animal recovers from the surgery, than daily electrical 
stimulus trains are applied via the electrodes. A fairly wide range of stimulation parameters 
may be effective in induction of kindling. After a few days of stimulation a train of shocks 
begins to induce electrical after discharges, which become progressively more complex and 
prolonged with each kindling stimulus. At this time, the animal is said to be ‘kindled’. If 
continued for a few weeks, rodents exhibit “spontaneous” epileptic seizures. 
Rapid kindling paradigms able to model status epilepticus in rodents, within a few hours or 
days of kindling have been described. Repeated stimulation by excitatory chemicals can also 
produce kindling.  
The amygdala possesses the lowest threshold for the induction of kindling, an established 
experimental model of temporal lobe epilepsy in which daily electrical stimulation results in 
a gradual progression and intensification of limbic motor seizures. 
Kindling through daily administration of brief electrical stimulations to the left basolateral 
nucleus of the amygdala resulted in a significant impairment of LTP in both the lateral 
amygdala and the CA1 of rat hippocampus. In contrast to KA model, DNA fragmentation 
and reactive microglia in the CA1, CA3, and hilus of the dentate gyrus region do not 
detected in the kindling model. Neuronal death occurs as a result of DNA fragmentation in 
hippocampal pyramidal cells in KA model.  
Dentate gyrus of kindled rats is enlarged. The increase in area associated with kindling is 
the result of an enlargement of the molecular layer and the hilus of the dentate gyrus. 
Absolute neuronal counts show no change following kindling in the hilus of the dentate 
gyrus. 
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After kindling, i.e., specific electrical stimulation of the rat ventral hippocampus, cells 
numbers are significantly decrease in hippocampus, the hilus, and dentate gyrus. 
5. Generalized tonic-clonic seizures 
Genetic 
There are no good animal models for primary generalized, spontaneously recurrent tonic-
clonic (grand mal) seizures. Because idiopathic grand mal epilepsy shows a genetic 
component, investigators have attempted to develop models from genetically aberrant 
strains of animals; including baboons, beagles, Mongolian gerbils, mice, and rats. Each of 
these models has distinctions from clinical grand mal, either in the requirement for certain 
types of precipitating stimuli, or other associated non-epileptic deficits. 
Epilepsy mice 
The ‘epilepsy’ (abbreviated ‘El’) mice exhibit seizures that are best induced by vestibular 
stimuli, such as tossing or spinning the mice. Manifestations of seizures in this strain may 
include limb and face automatisms such as chewing and salivating. Electrical discharges 
originate in deep limbic structures. These features are analogous to clinical complex partial 
epilepsy. Like human complex partial epilepsy, seizures may generalize to tonic-clonic 
activity. Heritability of vestibulogenic seizure tendency in El is dominant, but the gene locus 
or loci and neurochemical defects are unknown. EEG studies have revealed that interictal 
discharge originate from parietal cortex and especially from hippocampus. In other words, 
these rats have temporal lobe epilepsy. Degeneration of neurons in stratum pyramidale (in 
CA1-CA2 subfields) and increase of GABA and VIP containing neurons in stratum radiatum 
have been reported in the hippocampus of El mice.    
Genetically epilepsy-prone rats  
Genetically epilepsy-prone rat model is one of the best known genetic epilepsy model. 
Previously it has been known that only audiogenic stimuli can induce seizures in this strain 
but afterwards it has been understood that also many other physical and chemical stimuli 
such as hyperthermia, electroshock, pentylenetetrazol and bicuculline can easily induce 
seizures.  
Maximal electroshock 
Maximal electroshock (MES) is arguably the best studied and most useful animal model of 
seizures. In particular, this model is often used to study of antiepileptic drug development. 
A distinction is made between minimal and maximal seizures. Minimal seizures are 
characterized by a ‘stun reaction’ and clonic movements of the face and forelimbs. Maximal 
seizures show tonic hind-limb extension and flexion, followed by clonus. A MES seizure 
meets criteria if there is tonic hind-limb extension. Studies may choose to evaluate either 
minimal or maximal electroshock seizures. 
Chemical convulsants 
Numerous chemical compounds can induce generalized seizures when administered 
systematically. Pentylenetetrazol, penicillin, bemegride, picrotoxin, bicuculline, strychnine, 
allyglycine, flurothyl, homocysteine are a few of those of greatest interest for epilepsy 
research. 
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Pentylenetetrazol (PTZ) is one of the mostly used chemicals to study of antiepileptic drug 
development. PTZ is tetrazol derivative with consistent convulsive actions in mice, rats, cats 
and primates, when given by the parenteral route. PTZ initially produces myoclonic jerks, 
which than become sustained, and may lead to waves or polyspikes. 
PTZ-treatment leads to hippocampal atrophy in rats. PTZ-treated rats show selective 
neuronal loss and astrocytosis in the hippocampus. MRI studies on PTZ-treated rats show 
decrease in cerebellum volume. 
On the other hand, PTZ treatment needs repeated injections to result in cell loss in 
hippocampus, which might be a result of enhanced activity of glutamergic systems. 
Systemic penicillin as a tonic-clonic model 
Penicillin was discussed above as an agent able to produce acute seizures, when placed on 
cortex. Clinical experience has indicated that high systemic doses of penicillin in humans 
can produce myoclonus, generalized tonic-clonic seizures and encephalopathy. In the 
hospital setting encephalopathy occurs most commonly with i.v. dosages above 20 million 
units per day, especially if concurrent renal failure maintains high levels and alters the 
blood-brain barrier. It was shown that parenteral penicillin could produce generalized 
seizures in cats. 
Other inhibitory antagonists 
Other popular systemic convulsants include picrotoxin, bicuculline, methionine 
sulfoximine, bemegride, allyglycine, strychnine, and certain general anesthetics. 
Bemegride (Megimide) is a glutarimide derivative similar in action to PTZ. It has been used to 
produce  clonic or tonic-clonic seizures, or to activate focal epilepsy. Several of drugs used to 
produce partial seizures when focally applied, for example picrotoxin and bicuculline, will 
produce generalized clonic and tonic-clonic seizures, when given systemically. 
Brain metabolism early in bicuculline-induced generalized tonic-clonic seizures is greatest in 
neocortex and synaptically linked regions, as opposed to brainstem. A potent generalized 
seizure model can be produced by i.v. injection of strychnine. Strychnine interacts with 
GABA-benzodiazepine receptors, but a more important action of strychnine is probably 
against glycine. Glycine is an important inhibitory neurotransmitter in brainstem and spinal 
cord with structural homology to the much larger strychnine molecule. Strychnine serves as 
a non-competitiveinhibitor of glycine receptor. Resulting seizures differ in character from 
those produced by primary GABA antagonists in that they are mainly extensor tonic, with 
little cortical EEG seizure activity.  
Some convulsants apparently act by mimicry of excitatory neurotransmission. It is often 
difficult to induce seizures by systemic administration of glutamate, although monosodium 
glutamate can penetrate to brain and produce convulsions in 10-day-old rats. 
Metabolic derangements 
In clinical practice many metabolic derangements can lead to seizures including, hypoxia, 
hypoglycemia, uremia, drug withdrawal and high temperature. These conditions have not 
in general been useful for studying mechanisms of the epilepsies because they usually 
produce other central nervous system disturbances peculiar to the model employed. Three 
metabolic disturbances have, however, been employed in a few studies of generalized 
seizures; hyperbaric oxygen, and hypercarbia. 
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Hyperthermic seizures-but not hyperthermia alone-results in numerous argyrophilic 
neurons in discrete regions of the limbic system; within 24 hours of seizures, a significant 
proportion of neurons in the central nucleus of the amygdala and in the hippocampal CA3 
and CA1 pyramidal cell layer are affected.  
6. Generalized-absence seizures 
Thalamic stimulation 
The concept of a thalamic reticular formation is able to influence wide areas of cortex. 
Stimulation of midline and intralaminar thalamus can produce absence and EEG spike-
waves. The role of thalamus versus cortex in the generation of absence epilepsy remains a 
subject of great interest and controversy. The thalamic stimulation model for petit mal is, 
however, infrequently used because of the need for chronic electrode implantation, and for 
ongoing stimulation during testing.  
Bilateal cortical foci 
Models of petit mal produced by bilateral cortical foci derive from the hypothesis that 
absence epilepsy is a result of diffuse cortical dysfunction. Application of dilute convulsants 
such as estrogen, PTZ, and penicillin to widespread regions of cat cortex produces bursts. A 
similar model can be produced in rhesus monkeys.  
Systemic penicillin 
Intramuscular injection of 300,000 units/kg of penicillin G into a cat results in recurrent 
episodes of arrested activity, staring, myoclonus, facial-oral twitching and occasional 
progression to generalized tonic-clonic seizures. Seizure activity begins about 1 h after 
injection of drug and continues intermittently for 6-8 h. The EEG shows a variety of spike-
wave morphologies, emerging from a relatively normal background. These features are 
similar to those seen with clinical absence, except of course that clinical absence recurs 
apparently spontaneously for years. 
Clinical absence (petit mal) epilepsy has been hypothesized to originate subcortically, with 
participation of brainstem and thalamic reticular formation. Absence seizures in the feline 
penicillin model have been difficult to reconcile with this hypothesis. Application of 
penicillin to wide regions of cortex, but no to thalamus, can produce SW EEG discharges. 
Discharges in this model probably originate cortically, but are maintained and elaborated by 
recurrent thalamo-cortical circuitry. 
Intraventricular opiates 
Low dose morphine sulfate is believed to be anticonvulsant, but high dose parenteral 
morphine can induce clonic convulsions in rodents. The behavioral-EEG pattern after 
intraventricular opiates can be classified either with the complex partial or the absence 
models of the epilepsies. Relation to petit mal epilepsy has been supported by ontogenetic 
studies of opiate-induced seizures and by thr relatively specific responsiveness of these 
seizures to anti-petit mal agents. 
7. Status epilepticus 
Status epilepticus is a condition characterized by an epileptic seizure that is sufficiently 
prolonged or repeated at sufficiently brief intervals. Certain research questions require 
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models of recurrent seizures or status epilepticus. Many of the chemical convulsants able to 
produce seizures-for example, KA, flurothyl, bicuculline, and PTZ can also produce status 
epilepticus when administered in large quantities to rodents. 
Lithium-pilocarpine 
One recently popularized model of status epilepticus is the lithium-pilocarpine model. In this 
model rats are pretreated with lithium chloride. At least 20 h later the cholinergic agent 
pilocarpine is given. Generalize clonic or tonic-clonic seizure activity begins about 30 min after 
administration of pilocarpine, and continues for several hours. The EEG pattern displays a 
progression very similar to the stages seen in human status epilepticus. Chronic pretreatment 
for one month with daily lithium reduces the convulsant threshold of pilocarpine 26-fold.  
In lithium-pilocarpine treated adult rats, neuronal damage and neuronal death develops 
mainly in the hippocampus, the hilus of the dentate gyrus, the piriform and entorhinal 
cortices, the amygdala, the neocortex and the thalamus. Also, lithium-pilocarpine treatment 
leads to hippocampal damage that is typically observed in the CA1 and CA3 pyramidal cell 
layers and the hilus of the dentate gyrus in mice with status epilepticus. 
Cobalt-homocystine 
Another drug combination able to induce status epilepticus in animals is focal cobalt in 
conjunction with systemic homocysteine. Homocysteine is an agent able on its own to 
produce powerful tonic-clonic seizures. This model also has the advantage of a “focus” for 
frequently recurring seizures. 
 
 
Fig. 1. A representative image for rat hippocampus CA1, CA2 and CA3 subfields. CA1: 
hippocampus CA field, CA2: hippocampus CA2 field, CA3: hippocampus CA3 field, DG: 
dentate gyrus, Hematoxylene and eosin stain, 4X magnification, scale bar = 200 µm. 
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Several electrical paradigms have been suggested as a recipe for producing status 
epilepticus in rats.  
8. Conclusion 
Epilepsy is a group of neurological disorders characterized by clinical aspects, not an only 
specific disease. Seizures are outward signs of epilepsy and occur from time to time. A wide 
variety of models have been developed in order to explore the principal mechanisms of 
epilepsies, develop more effective anti-epileptic drugs epilepsy and determine the 
pathological events underlying different types of epileptic seizures. Summary of the results 
so far obtained from these models: 
1. There is not only one model for answering all questions about epilepsy. 
2. Studies performed by using experimental models, can only explore the basic 
mechanisms of the model which is used. 
3. Some chemical convulsants can induce more than one epilepsy model. Crystallized 
penicillin can induce simple partial, generalized myoclonic, generalized tonic-clonic 
and generalized absence epilepsy when given in different ways. Therefore, EEG and 
behavior should be analyzed to determine the induced model.  
4. Kindling has become one of the most popular models to investigate neurochemical and 
structural long-term changes in brain.  
5. It is not sufficient to use one or a few model in studies of epilepsy. Constantly new and 
better models should be developed to find the best model that answers the question. 
6. Various models should be used constantly to investigate the issues such as the 
molecular mechanisms, genetic background, ion channels and related molecules in the 
cell membrane, second messenger systems.  
Thus, the basic mechanisms of epilepsy will be better understood, more effective drugs and 
treatments will be developed for the type of epileptic seizures. 
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1. Introduction 
In many studies a fundamental difference between two types of generalized epileptic 
activity, convulsive epilepsy and absence non-convulsive epilepsy was described. All forms 
of convulsive epilepsy, both in human and animal models, are characterized by increased 
activity of excitatory amino acid transmitter systems (Hara et al., 2006; Leke et al., 2006; 
Schilling et al., 2006) and/or decreased activity of the inhibitory GABAergic system (Bazyan 
et al., 2001b; Quilichini et al., 2006; Laschet et al., 2007) of the brain. The main difference 
between absence non convulsive epilepsy and convulsive epilepsy is in a fact that 
pharmacological stimulation or inhibition of excitatory glutamate synaptic transmission 
causes relative enhancement or reduction of the severity of absence epilepsy (Ngomba et al., 
2005; Citraro et al., 2006), and increased GABAergic inhibition also leads to enhanced 
absence epilepsy (Coenen et al., 1995; Bouwman et al., 2003; 2004). 
The next fundamental difference between absence epilepsy and other generalized epilepsy 
forms consists in the profile of epileptic discharge. Usually, convulsive epileptic discharges 
appear on the wave of excitation. The gradual growth of excitation reaches the threshold 
level after which epileptic discharges appear. During absence epilepsy, the discharge is 
fundamentally different. A spike–wave discharge consists of an inhibitory phase and an 
action potential. The inhibitory phase is represented by a slow wave on an EEG. The spike is 
an indicator of cell excitation (action potential). A rebound spike appears at the end of the 
inhibitory period, and the cycle repeats again and again (Midzianovskaya et al., 2001). 
In this paper we compared mechanisms underlying two kinds of epileptic activity, 
pentylenetetrazole kindling and absence epilepsy, and their interaction with processes of 
learning, memory, emotional and motivational states. 
2. Pharmacological reminders restore benzodiazepine site density of GABAA 
receptors and conditioned memory: Allosteric plasticity and intraneuronal 
integration by the help of transduction signal 
Interaction of BDZ with its own site activates slow endocellular metabolic reactions through 
activation of protein kinase C (Niles et al., 1997; Nomura et al., 1997; Johnston et al., 1998), 
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1. Introduction 
In many studies a fundamental difference between two types of generalized epileptic 
activity, convulsive epilepsy and absence non-convulsive epilepsy was described. All forms 
of convulsive epilepsy, both in human and animal models, are characterized by increased 
activity of excitatory amino acid transmitter systems (Hara et al., 2006; Leke et al., 2006; 
Schilling et al., 2006) and/or decreased activity of the inhibitory GABAergic system (Bazyan 
et al., 2001b; Quilichini et al., 2006; Laschet et al., 2007) of the brain. The main difference 
between absence non convulsive epilepsy and convulsive epilepsy is in a fact that 
pharmacological stimulation or inhibition of excitatory glutamate synaptic transmission 
causes relative enhancement or reduction of the severity of absence epilepsy (Ngomba et al., 
2005; Citraro et al., 2006), and increased GABAergic inhibition also leads to enhanced 
absence epilepsy (Coenen et al., 1995; Bouwman et al., 2003; 2004). 
The next fundamental difference between absence epilepsy and other generalized epilepsy 
forms consists in the profile of epileptic discharge. Usually, convulsive epileptic discharges 
appear on the wave of excitation. The gradual growth of excitation reaches the threshold 
level after which epileptic discharges appear. During absence epilepsy, the discharge is 
fundamentally different. A spike–wave discharge consists of an inhibitory phase and an 
action potential. The inhibitory phase is represented by a slow wave on an EEG. The spike is 
an indicator of cell excitation (action potential). A rebound spike appears at the end of the 
inhibitory period, and the cycle repeats again and again (Midzianovskaya et al., 2001). 
In this paper we compared mechanisms underlying two kinds of epileptic activity, 
pentylenetetrazole kindling and absence epilepsy, and their interaction with processes of 
learning, memory, emotional and motivational states. 
2. Pharmacological reminders restore benzodiazepine site density of GABAA 
receptors and conditioned memory: Allosteric plasticity and intraneuronal 
integration by the help of transduction signal 
Interaction of BDZ with its own site activates slow endocellular metabolic reactions through 
activation of protein kinase C (Niles et al., 1997; Nomura et al., 1997; Johnston et al., 1998), 
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induces transductional signal and modifies genes expression. In this connection GABAA 
receptor subunit protein expression is reduced (Johnston et al., 1998), while the c-fos gene 
expression is induced (Niles et al., 1997). Neuroactive steroids are analogs of steroid 
hormones, but unlike them they interact with somatodendritic and postsynaptic GABAA 
receptors (Rupprecht, Holsdoer 1999). Interaction of neuroactive steroids with GABAA 
receptor triggers a process of oxygenation, which transforms some endocellular metabolites 
into ligands of endocellular steroid receptors. After linkage of ligands with receptors an 
expression of genes occurs. 
Thus, BDZ site of the GABAA receptor induces intracellular slow metabolic reactions via a 
protein kinase C-dependent mechanism (Niles et al., 1997; Nomura et al., 1997; Johnston et al., 
1998; Ghori et al., 2010; Bignante et al., 2010). In the first part of our study (Bazyan et al., 2001b) 
we investigated long-term components, apparently metabolic components of GABAA 
supramolecular complex in convulsive states, specifically, long-term characteristics of [3H]–
diazepam binding in the cerebellar cortex after an acute injection of PTZ in convulsive doses. 
Acute PTZ treatment 
Male Wistar rats were used. The first series comprised the rats endogenously sensitive and 
resistant to the PTZ. In PTZ-sensitive animals, seizures provoked a significant decrease in 
the Bmax of [3H]–diazepam binding by 16% versus control and by 14% versus resistant rats at 
30 minutes after the termination of seizures, with no change in the Kd. No differences in 
[3H]–diazepam binding between the control and resistant rats at 1 hour after the PTZ 
treatment and the control, sensitive and resistant rats on day 7 after the PTZ treatment were 
found. These results show that initially the characteristics of [3H]–diazepam binding to BDZ 
site in the sensitive and resistant rats were similar, but the PTZ treatment induced a 
greater response of BDZ receptors in sensitive rats versus resistant rats. It means that 
sensitive animals show more intensive allosteric regulation of BDZ site of GABAA 
receptor by PTZ than resistant rats. On day 7 the characteristics of [3H]-diazepam binding 
came back to the initial level. This type of reaction reflected the efficiency of BDZ site 
allosteric regulation by PTZ as opposed to “initial activity”, when the characteristics of 
diazepam binding are different initially. 
The second series comprised the rats, in which a convulsive dose of PTZ (50 mg/kg) 
resulted in seizure scores of 4 to 5 points. They were sacrificed 1 hour or 48 hours later and 
on day 7 after the PTZ treatment. The density (Bmax) of [3H]–diazepam binding sites was 
significantly reduced by 19% at 1 hour after the PTZ treatment and by 16% at 48 hours with 
no change in the Kd. No significant changes were found on day 7. 
PTZ-induced kindling. Acquired sensitivity 
The third series comprised the rats, in which a subconvulsive dose of PTZ (20 mg/kg, once 
daily for 24 days) elicited kindled seizures scoring 4 to 5 points. They were sacrificed 1 hour 
or 48 hours later and on day 7 after the last injection. The rats with kindled seizures scoring 
4 to 5 points were selected from the total population of animals. Daily injections of PTZ (20 
mg/kg) resulted in a gradual increase in sensitivity to PTZ (Bazyan et al., 2001b) and a 
significant decrease in the Bmax of [3H]–diazepam binding by 19% at 1 hour after the PTZ 
treatment and by 16% at 48 hours after the last injection. The binding Kd was unchanged. On 
day 7, no significant changes were observed (Fig. 1A). These findings in the kindled rats are 
similar to the results found after an acute administration of the convulsive dose. Thus, 
kindling led to the establishment of a new level of the BDZ site allosteric regulation by PTZ, 
because PTZ interacts with PCT site and modifies binding of [3H]–diazepam with BDZ site. 
Two Types of Epilepsy Models and Processes of Cognition:  
Pentylenetetrazole Kindling and Absence Epilepsy of WAG/Rij Rats Strain 
 
285 
The high efficiency of the BDZ receptor allosteric regulation, which is produced by 
administering PTZ daily at subconvulsive doses, is termed “allosteric plasticity”. This 
procedure induces a long-term, high sensitivity to low PTZ doses, which is determined by 
the decreasing of BDZ site density in the cerebellar cortex that occurs 48 hours after the 
termination of PTZ treatment with no change in the Kd, and subsequent normalization on 
day 7 (Fig. 1A), therefore, the allosteric plasticity formed the basis for the development of 
high sensitivity to PTZ. 
It is known that kindling can lead to a long-term decrease of the GABAA receptor complex 
density, due to changes in the synthesis of the respective proteins. A series of 40 kindling-
induced seizures (by rapid hippocampal stimulation) led to biphasic alterations of GABAA 
receptor subunit mRNA levels in dentate gyrus with only minor changes in CA1-CA3 
(Kokaia et al., 1994). Up to 4 hours after the last seizure the expression of mRNA for α1 
subunit was slightly decreased in dentate gyrus, whereas marked reductions were observed 
for β3 and γ2 subunits. Between 12 and 48 hours there were major increases of α1 (by 59%) 
and γ2 (by 35%) subunits mRNA levels but no significant changes of β3 subunit mRNA 
expression. The subunits mRNA levels returned to control values in 5 days. These results 
are similar to ours (Fig. 1A). The biphasic changes of GABAA receptor subunits may be 
related to their recombination. 
 
 
Fig. 1. Effects of chronic PTZ treatment and subsequent PTZ challenge on [3H]–diazepam 
binding to membranes from the cerebellar cortex of 3- to 4-months and 10-months rats. A, 
BDZ site density (Bmax) in 3- to 4-months-old rats kindled with PTZ at a dose of 20 mg/kg. 
*pt < 0.05 versus control (n = 6 in each group). B, BDZ site density (Bmax) in 10-months-old 
kindled rats challenged with PTZ (+ PTZ) at a dose of 30 mg/kg. **pt < 0.01, kindled versus 
control; *pt < 0.05, kindled + PTZ versus control; Xpt < 0.05, kindled + PTZ versus kindled 
control (n = 6 in each group). C, BDZ site density (Bmax) and affinity (Kd) in 10-months-old 
rats after acute seizures induced by PTZ at a dose of 30 mg/kg. *pt < 0.05 versus control  
(n = 6 in each group). 
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hormones, but unlike them they interact with somatodendritic and postsynaptic GABAA 
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receptor triggers a process of oxygenation, which transforms some endocellular metabolites 
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diazepam binding in the cerebellar cortex after an acute injection of PTZ in convulsive doses. 
Acute PTZ treatment 
Male Wistar rats were used. The first series comprised the rats endogenously sensitive and 
resistant to the PTZ. In PTZ-sensitive animals, seizures provoked a significant decrease in 
the Bmax of [3H]–diazepam binding by 16% versus control and by 14% versus resistant rats at 
30 minutes after the termination of seizures, with no change in the Kd. No differences in 
[3H]–diazepam binding between the control and resistant rats at 1 hour after the PTZ 
treatment and the control, sensitive and resistant rats on day 7 after the PTZ treatment were 
found. These results show that initially the characteristics of [3H]–diazepam binding to BDZ 
site in the sensitive and resistant rats were similar, but the PTZ treatment induced a 
greater response of BDZ receptors in sensitive rats versus resistant rats. It means that 
sensitive animals show more intensive allosteric regulation of BDZ site of GABAA 
receptor by PTZ than resistant rats. On day 7 the characteristics of [3H]-diazepam binding 
came back to the initial level. This type of reaction reflected the efficiency of BDZ site 
allosteric regulation by PTZ as opposed to “initial activity”, when the characteristics of 
diazepam binding are different initially. 
The second series comprised the rats, in which a convulsive dose of PTZ (50 mg/kg) 
resulted in seizure scores of 4 to 5 points. They were sacrificed 1 hour or 48 hours later and 
on day 7 after the PTZ treatment. The density (Bmax) of [3H]–diazepam binding sites was 
significantly reduced by 19% at 1 hour after the PTZ treatment and by 16% at 48 hours with 
no change in the Kd. No significant changes were found on day 7. 
PTZ-induced kindling. Acquired sensitivity 
The third series comprised the rats, in which a subconvulsive dose of PTZ (20 mg/kg, once 
daily for 24 days) elicited kindled seizures scoring 4 to 5 points. They were sacrificed 1 hour 
or 48 hours later and on day 7 after the last injection. The rats with kindled seizures scoring 
4 to 5 points were selected from the total population of animals. Daily injections of PTZ (20 
mg/kg) resulted in a gradual increase in sensitivity to PTZ (Bazyan et al., 2001b) and a 
significant decrease in the Bmax of [3H]–diazepam binding by 19% at 1 hour after the PTZ 
treatment and by 16% at 48 hours after the last injection. The binding Kd was unchanged. On 
day 7, no significant changes were observed (Fig. 1A). These findings in the kindled rats are 
similar to the results found after an acute administration of the convulsive dose. Thus, 
kindling led to the establishment of a new level of the BDZ site allosteric regulation by PTZ, 
because PTZ interacts with PCT site and modifies binding of [3H]–diazepam with BDZ site. 
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day 7 (Fig. 1A), therefore, the allosteric plasticity formed the basis for the development of 
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It is known that kindling can lead to a long-term decrease of the GABAA receptor complex 
density, due to changes in the synthesis of the respective proteins. A series of 40 kindling-
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After 6 months (about 10-months-old rats) 
For the period of 6 months both the control and kindled rats were kept in the breeding 
facility. At the second stage, the persistence of kindling was studied. Two control groups 
and two groups of kindled rats were treated with 20 and 30 mg/kg PTZ (Bazyan et al., 
2001b). The kindling response of high sensitivity to low PTZ doses was preserved through 
the 6-months rest period after the kindling treatment, but not completely and with some 
attenuation. A subconvulsive dose of PTZ (20 mg/kg) induced no seizures in the control 
rats but elicited seizures in 60% of the kindled rats (1 to 2 points). At the next dose of PTZ 
(30 mg/kg) seizures were observed in 56% of the control rats (maximal scores of 2 to 3 
points) and in 100% of the kindled rats (maximal scores of 3 to 4 points).  
For the study of [3H]-diazepam binding four groups of animals were used (Bazyan et al., 
2001b): 1) control rats, no PTZ challenge; 2) acute seizures control rats, 30 min after the 
termination of acute seizures (2 to 3 points) induced by a PTZ (30 mg/kg) challenge; 3) 
kindled control rats, no PTZ challenge, but with a history of seizures (4 to 5 points) 6 months 
ago; 4) kindling + PTZ challenge, 1 hour (30 min after the termination of seizures, 3 to 4 
points) induced by a PTZ (30 mg/kg) challenge. 
In the kindled control rats with a history of seizures (4 to 5 points) 6 months before, the Bmax 
of [3H]–diazepam binding was reduced to 54% with no change in Kd without a PTZ 
challenge (Fig. 1B). It was shown above that the development of kindling represented the 
development of allosteric plasticity. But 6 months later the BDZ site activity was found to be 
modified. We may suggest, therefore, that allosteric plasticity is an intracellular process and 
the decrease in BDZ site density 6 months after the kindling reflected an ongoing 
intracellular process. 
After a PTZ challenge, the Bmax of [3H]-diazepam binding in the kindled rats was found to 
be enhanced to 78%, still being significantly lower than in the control rats, with no change in 
the Kd. This paradoxical finding can be logically explained as follows. At the time of 
termination of kindling (Fig. 1A), the BDZ site density is reduced to 80.97% versus the 
control 4-months-old rats. After a rest period of 6 months, there was a decrease in BDZ sity 
density to 53.57% in the kindled rats without a PTZ challenge. Acute PTZ administration to 
the kindled rats induced seizures and partially restored the BDZ site density, just to the level 
of BDZ density found in the control 10-months-old rats (77.77%, Fig. 1B), which was 
established 6 months before. At the same time, the Kd of BDZ site binding was unchanged in 
the kindled rats, whereas in the control 10-months-old rats that had seizures after a single 
PTZ challenge BDZ receptors density Bmax and Kd was significantly altered. The PTZ (30 
mg/kg) challenge in the ten-months-old intact rats resulted in seizures (acute seizures, 
scores 2 to 3 points) which were accompanied by a decrease in both indices of [3H]–
diazepam binding: the Bmax to 66%, and the Kd to 73% (Fig. 1C). We suggest that the PTZ 
challenge acted as a reminder to the kindled animals, reproducing the modification of BDZ 
site acquired 6 months ago, irrespective of their current status and animal’s age. 
The increased density of BDZ site of GABAA receptors (versus the kindled control) can be 
interpreted as an enhancement of GABAergic inhibition, while it is thought that seizures are 
based on the process of neuronal hyperactivation accompanied by a reduction in the BDZ 
site density both in kindling-induced (Fig. 1A) and single-dose PTZ-induced seizures. 
Therefore, it is likely that at 6 months, when seizures are retrieved by a PTZ challenge and 
the level of GABAergic inhibition is restored, the level of glutamate receptors may also be 
restored, assuming that they were modified and consolidated in the process of kindling 6 
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months ago. The level of glutamate receptors may only be restored of neuronal GABA and 
glutamate receptors interact within a single integrated system interconnected through 
intracellular transduction signal. 
The interaction and integration of neuronal GABA and glutamate receptors has been 
shown in several studies. Thus, in PTZ-induced kindling the reduction in GABAergic 
functions is blocked by MK-801, an antagonist of NMDA receptors (Corda et al., 1992). 
NMDA receptors are involved in the process of kindling induced by FG 7142, an inverse 
agonist of the BDZ receptor (Stephens & Turski, 1993). Also, the NMDA-induced long-
term potentiation is found to be controlled by the intercellular metabolic systems of the 
GABAA receptor complex, being inhibited by BDZ site agonists (Evans & Viola-McCabe, 
1996; Higashima et al., 1998) and facilitated by its antagonists (Stackman et al., 1996; 
Seabrook et al., 1997). Positive allosteric activation of GABAA receptors bi-directionally 
modulates hippocampal glutamate plasticity and behaviour (Shen et al., 2009). BDZ 
withdrawal anxiety is associated with potentiation of AMPA receptor currents in 
hippocampal CA1 pyramidal neurons attributable to increased synaptic incorporation of 
GluA1-containing AMPA receptors (Shen et al., 2010). 
The differences in BDZ reaction between the PTZ-sensitive and PTZ-resistant rats (Bazyan 
2001b) can be accounted for by differences in the intensity of allosteric regulation of the 
GABAA receptors, based on differences in their subunit composition. We propose, 
accordingly, that the acquisition of high level allosteric regulation by the kindled rats is 
best explained by the intracellular metabolic feedback mechanism which is schematically 
shown in Fig. 2. In this scheme, PTZ interacts with the PCT site of GABAA receptor and 
modifies the BDZ site and GABAA receptor, which in turn alter the concentration of 
second messengers. The second messengers can modify phosphorylation reactions by 
changing protein kinase activities. The cycle is closed by modifications of GABA and BDZ 
sites, leading to changes in density as well as some redistribution of their subunits. In the 
process of kindling the cycle is repeated again and again, resulting in further decreases of 
the GABAA receptor complex. Protein kinases can modify gene expression, acting via a 
secondary nuclear signal and altering the synthesis of the subunits forming the GABAA 
receptor complex, whereby the reduced density, redistribution of the receptor subunits 
and, ultimately, the acquired efficiency of allosteric regulation or allosteric plasticity are 
consolidated. 
As indicated above, changes in cellular phosphorylation levels by protein kinases can 
modify glutamatergic receptors augmenting their responses to endogenous excitatory 
amino acids. The metabolic regulation of a glutamatergic synapse (Fig. 2) is similar to that 
described for hippocampal neurons (Mayford et al., 1995). We added a feedback loop for 
metabolic regulation controlled by NMDA receptors in the hippocampus or by mGlu1 
receptors in the cerebellum, since we assume that the feedback metabolic regulation, or 
autoregulation of glutamatergic and GABAergic receptors, is a necessary condition for 
maintaining the processes of long-term potentiation and long-term depression. The 
regulation of AMPA receptors and autoregulation of NMDA receptors in the hippocampus 
have been studied experimentally (Bayazitov & Kleshchevnikov, 2000).  
Thus, one can assume that plasticity is a result of cooperative activity of GABA and 
glutamatergic receptors integrated into interrelated system. Integration includes also 
automodification of receptors activity. Further, a new level of activity, produced by 
secondary intranuclear signals modifies genes expression and consolidates a newly 
developed activity of receptors. 
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Fig. 2. A tentative model of intraneuronal metabolic integration. GLU-R, glutamatergic 
receptors; GABA(A), GABAA receptor; DA-R, dopamine receptor; E, second messenger 
synthesizing enzyme; SF, phosphorylation substrate; G, G-protein, PK, different type of 
protein kinases; CaMK, calcium/calmodulin-dependent protein kinase. Metabolic reactions 
mediated by glutamatergic receptors are shown as solid lines. Metabolic reactions mediated 
by GABAA receptor are shown as dashed lines. Metabolic reactions mediated by dopamine 
receptors are shown as dotted lines. Intracellular metabolic feedback loops (autoregulation) 
are shown as the respective thick lines. For other details, see in text. 
Interaction of PTZ-induced seizures with learning, memory and emotional state 
It is well known that a convulsive state is an amnesic state. It is also known that convulsive 
disorders are accompanied by mental disorders, such as anxiety and fear, or depressive 
states (Clement et al., 1997; Depaulis et al., 1997; Maxudova & Flesher, 1998). At the same 
time, anxiogenic effects of PTZ are also known [Biggio et al., 1990; Venault et al., 1992; 
Simon et al., 1993]. It was shown [Bazyan et al., 2000b] that haloperidol–induced catalepsy, 
which produces a long-term modification of DA receptors, is modified by defensive 
conditioning. So, the next investigation [Bazyan et al., 2001a] was designed to study the 
modification of seizures by learning; the facilitation of amnesic memory trace retrieval by a 
pharmacological reminder of the emotional state which accompanied the learning processes. 
Passive avoidance conditioning was performed (Bazyan et al., 2001a). The rats were divided 
into three groups according to their levels of learning: group I - high level of learning; group II - 
middle level of learning; group III - low level of learning. PTZ was injected 75 mg/kg and 50 
mg/kg i.p. immediately after the learning session of group I and group II accordingly. 
Amnesia provoked by PTZ seizures was found on days 2. Unconditioned reminder acted as an 
unamnesic agent for group I and evoked memory retrieval on day 2. The effects of 
pharmacological reminder were studied in groups II and III on day 2 (Bazyan et al., 2001a). 
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After conditioning retrieval testing some rats in group II were treated with PTZ (30 mg/kg 
i.p.). The rats in which PTZ elicited seizures were excluded from further experiments. 
Haloperidol, a nonselective dopamine (DA) D2 antagonist, was administered (0.25 mg/kg i.p.) 
to some rats in groups II and III. The amnestic effect of the convulsive PTZ dose of 50 mg/kg 
was canceled by a lower, subconvulsive doze of 30 mg/kg, as well as by haloperidol at a low 
doze of 0.25 mg/kg. The low doze of haloperidol 0.25 mg/kg facilitated memory retrieval in 
the animals of group III. At the same time, this doze of haloperidol had no effect on the latency 
of moving into the dark compartment in untrained animals. The effects of a low dose of 
haloperidol were studied in a separate series of experiments. Rats were treated with 
haloperidol (0.25 mg/kg, i.p.). Haloperidol at 0.25 mg/kg provoked “freezing”. Catalepsy was 
not shown. Herewith, the rats showed the typical pose of fear (hunched), the number of 
dejections was also increased (Bazyan et al., 2001a). Thus, the amnesic memory trace is 
expected to be reproduced by chemicaly different anxiogens, such as haloperidol. Hence the 
mechanism of reflex retrieval is related to the mechanism of emotional state retrieval. 
The mesocorticolimbic DA system is a reward and reinforcement system, directly involved in 
learning and memory (Wise, 1978, 2009; Joseph et al., 2003; Bazyan, & Grigoryan, 2006). The 
nigrostriatal DA system basically controls activity of GABA and glutamatergic receptors of 
middle spiny neurons of dorsal striatum, which regulates a motor function (Greengard, et al., 
1999; Mink, 2003). Also, the DA system is involved in the modification of various epileptiform 
states (Al Tajir & Starr, 1991; Ogren & Pakh, 1993; Amabeoku & Chikuni, 1994). The results 
shown in our work (Bazyan et al., 2000b), allow us to suggest that in the process of learning the 
receptors of the DA system and GABAA receptors of the brain interact and become modified 
and integrated, thus forming a learning-depended emotional state. We suggest that this 
integration is accomplished by the mechanism of intracellular integration of glutamate, 
GABAA and DA receptors by means of transduction signal. The intracellular integration by 
transduction signal of glutamate, GABAA and DA receptors is schematically shown in Fig. 2. 
DA receptors can undergo automodification by the metabotropic feedback loop and then 
modify the activity of glutamate and GABAA receptors by intracellular phosphorylation 
[Greengard et al., 1999]. Via the same reactions of intracellular phosphorylation, glutamate and 
GABAA receptors can control the efficiency of DA receptors. At the second stage, the 
modifications established at the first stage are consolidated through the modification of 
expression of the respective genes. The ability of DA receptors to undergo automodifications 
has been demonstrated both at the level of radioligand binding and at the level of gene 
expression in various brain structures and various experimental procedures (Soghomonian, 
1993; Qin & Weiss, 1994; Richtand et al., 2010). 
Thus, PTZ induced seizures cause amnesia and dissociation state. Low subconvulsive PTZ 
doses restore a memory trace. Low PTZ doses have also anxiogenic effect. As active avoidance 
is based on anxiogenic state it may be restored by induction of the anxiogenic state by PTZ. 
Haloperidol, another anxiogenic compound in low subcataleptic doses is able to restore an 
amnesic memory trace. It seems that DA receptors are also involved in endocellular 
integration together with GABA and glutamatergic receptors and all rules of endocellular 
integration described for GABA and glutamatergic receptors are also applied for DA receptors. 
3. Absence epilepsy of WAG/Rij rat’s strain 
Absence epilepsy in men and in WAG/Rij (Wistar Albino Glaxo, from Rijswijk) rats is a 
genetic animal model of generalized human absence epilepsy (Midzianovskaya et al., 2001; 
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Absence epilepsy in men and in WAG/Rij (Wistar Albino Glaxo, from Rijswijk) rats is a 
genetic animal model of generalized human absence epilepsy (Midzianovskaya et al., 2001; 
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Van Luitelaar & Coenen, 1997; Meeren et al., 2002), which principally differs from 
convulsive forms of epilepsy. For example, a number of widely used anticonvulsants 
enhance absence epilepsy (Coenen et al., 1995; Hosford & Wang, 1997; Bouwman et al., 2003; 
2004; Maris et al., 2006; Tolmacheva & van Luijtelaar, 2007). A series of spontaneous spike-
wave discharges (SWD) induced by hyperpolarization appear on a normal EEG. The SWDs 
in EEG of WAG/Rij rats start at about 2-3 months. At the age of six months, all rats have 
several hundred SWDs per day. The generalized and widespread bilaterally presented 
synchronous SWDs are the result of highly synchronized oscillations in the thalamocortical 
network. SWDs have a local cortical origin in the perioral region of the somatosensory 
cortex (Meeren et al., 2002; 2009; van Luijtelaar & Sitnikova, 2006). Besides, there is another 
strain of rats with absence epilepsy deduced GAERS (Genetic Absence Epilepsy Rats from 
Strasbourg) similar to WAG/Rij rats. 
There are two other features, which make WAG/Rij rats as a valid model of human absence 
epilepsy: 1) The changed expression of genes coding low threshold Ca2+ channel of T – type 
(ICa,T) of WAG/Rij compared to ACI control rats (Broicher, et al., 2008) and mutation of genes 
coding ICa,T by people with absence epilepsy (Vitko et al., 2007; Arias-Olguín, et al., 2008); 2) 
Local variations of GABAA receptors subunit expression in thalamo–cortical systems (Liu, et 
al., 2007) of WAG/Rij rats and mutation of genes coding subunits of GABAA receptors in 
people with absence epilepsy (Bowser, et al., 2002; Kang & Macdonald, 2004). 
Chlorine conductance of the GABAA receptor at absence epilepsy and PTZ kindling 
In the study [Rebrov et al., 2007], we determined the features of the functional activity of the 
GABAA receptor (intensity of chloride current) in WAG/Rij rats with a genetic 
predisposition to absence epilepsy and Wistar rats at an early stage of kindling development 
(absence epilepsy) and after kindling (generalized tonic–clonic seizures). Muscimol was 
found to dramatically increase 36Cl– conductivity in synaptoneurosomes of the brain cortex 
after its addition to the incubation medium as compared to the basal level in all groups of 
animals. We found a fundamental difference between the muscimol-induced 36Cl– 
conductivity of synaptoneurosomes from the brain cortex (frontal and somatosensory areas) 
of the convulsive PTZ-treated Wistar rats and WAG/Rij rats with absence epilepsy. 
Development of the tonic–clonic kindling induced a significant decrease in muscimol-
induced 36Cl– conductivity in neocortical synaptoneurosomes as compared to the control 
rats. The muscimol-induced 36Cl– conductivity of synaptoneurosomes from the 
somatosensory and frontal cortex of the control WAG/Rij rats was considerably higher than 
in the control Wistar rats.  
The high muscimol-induced 36Cl– conductivity in the neocortical synaptoneurosomes of 
the WAG/Rij rats corresponds to the hyperpolarization-induced nature of spike-wave 
discharges in absence epilepsy (Inoue et al., 1993; Midzianovskaya et al., 2001; Meeren et 
al., 2002; 2009; Maris et al., 2006) and the presence of a cortical focus in the somatosensory 
cortex (Meeren et al., 2002; 2009; van Luijtelaar & Sitnikova, 2006). This proposal agrees 
with the pharmacological results that describe regulation of spike-wave discharges by 
activation or inhibition of WAG/Rij rats GABA system (Peeters et al., 1989; 1990; Coenen 
et al., 1995; Hosford & Wang, 1997; Bouwman et al., 2003; 2004; Maris et al., 2006; 
Tolmacheva, van Luijtelaar, 2007). Our results, obtained in animals with nonconvulsive 
kindling, which is an experimental model of absence epilepsy (Caddick & Hosford, 1996; 
Snead 1996; 1998), also point to an increase in the activity of the GABAA receptor via 
intensification of the chlorine current.  
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Thus, two types of generalized seizures are accompanied by opposing changes in the 
GABAA-mediated 36Cl– conductivity inside neocortical synaptoneurosomes. 36Cl– 
conductivity decreased in rats with PTZ-induced convulsive kindling and increased in rats 
with a genetic predisposition to nonconvulsive absence epilepsy. 
Cognitive processes in WAG/Rij rats  
Learning and memory 
It is known that SWDs are controlled by the DA-ergic system of the brain. Antagonists of D2 
DA receptors increase and agonists decrease of SWDs (De Bruin et al., 2000; Deransart et al., 
2000; Midzianovskaya et al., 2001). It is possible the opioid system of brain also controls 
SWDs (Lason et al., 1990; 1992; 1994a; 1994b; 1995; Przewlocka et al., 1995). It is very well 
known that the mesocorticolimbic DA-ergic system is the system of reinforcement; it 
actualizes an emotional positive state and is also involved in processes of learning and 
memory (Wise, 1978, 2009; Joseph et al., 2003; Bazyan, & Grigoryan, 2006). The opioid 
system controls the threshold of pain sensitivity and actualizes the motivation of escape and 
avoidance of pain (Baranauskas, & Nistri, 1998; Bazyan, et al., 2000a;). An infringement of 
WAG/Rij rat's behavior was shown (Bazyan et al., 2000c; Sarkisova and Kulikov, 2000). The 
decrease of memory reproduction, spontaneous catalepsy, low threshold of haloperidol-
induced catalepsy and the actualization of depression were found in WAG/Rij rats. All 
these data can be explained by a DA deficit of WAG/Rij rat brain. The goal of the 
investigation (Getsova et al., 2003; 2004) was to study the possibility of WAG/Rij rat's 
behavior correction by pharmacological activation of DA-ergic system. 
The procedure of passive avoidance is described above. The defensive conditioned reflex of 
two-way avoidance was established in a shuttle-box. There were three series of experiments. 
First series: disulfiram (25 mg/kg i.p.), inhibitor of dopamine–β–hydroxylase, was 
administered to Wistar and WAG/Rij rats 4 hours before the 1st day learning session. 
Second series: L-DOPA (25 mg/kg i.p.) was administered to Wistar and WAG/Rij rats 4 
hours before the 1st learning session. In the 3rd series of experiment disulfiram (25 mg/kg 
i.p.) was administered immediately after 1st learning session in Wistar and WAG/Rij rats. 
Saline was administered i.p. in the same number of control Wistar and WAG/Rij rats. An 
amnesic reaction in control WAG/Rij rats versus control Wistar rats was found in day 2 of 
the passive avoidance conditioning procedure. The administration of disulfiram before as 
well as after passive avoidance conditioning increased the reflex reproduction on the next 
day after learning both in Wistar and WAG/Rij rats. The reproduction of passive avoidance 
memory was increased 1,34 and 1,41 times in Wistar rats and 4,21 and 4,89 times in 
WAG/Rij rats accordingly. 
The administration of disulfiram 4 hours before establishment of active avoidance 
conditioning changed the learning processes in the first day. It was shown that control 
WAG/Rij rats realized 2,23 times more avoidance reactions than control Wistar rats in the 
first day of learning. Disulfiram administration before learning decreased the number of 
avoidance responses in the first day: in Wistar rats 1,47 times and in WAG/Rij rats 6,45 
times. In the second day of learning an amnestic effect in control WAG/Rij rats versus 
control Wistar rats was found. The index of memory trace storage of WAG/Rij rats was 2,11 
times lower than in Wistar rats. The administration of disulfiram increased the memory 
trace storage of Wistar rats in 1,44 times and in WAG/Rij rats 7,33 times. The other inductor 
of DA system activation, L-DOPA, a precursor of DA synthesis, was used for comparison. 
Synergic effects of disulfiram and L-DOPA administered 4 hours before learning were 
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found. The administration of L-DOPA 4 hours before learning decreased the number of 
avoidances in the first day of learning in Wistar rats 1,76 times and in WAG/Rij rats 7,65 
times. Herewith, the index of memory trace storage was increased in Wistar rats 1,82 times 
and in WAG/Rij rats 7,70 times. The high number of avoidances in WAG/Rij rats on the 
first day of active avoidance conditioning was found earlier (Bazyan et al., 2000c; 2001). We 
explain this reaction by the low efficiency of opioid system in WAG/Rij strain (Lason et al., 
1990; 1992; 1994a; 1994b; 1995; Przewlocka et al., 1995) and as a consequence a low pain 
threshold and a high level of escape and avoidance motivation. It is shown (Altier & 
Stewart, 1998; 1999; Calabrese 2001) that activation of the DA-ergic system evokes analgesic 
reaction including activation of the opioid system (Suaudeau & Costentin, 1995; Cook et al., 
2000; Magnusson & Fisher, 2000; Gao et al., 2001; Trekova et al., 2001). It was suggested that 
a deficit of dopaminergic system in WAG/Rij rats is the biological correlate of these 
behavioural deficits and that an enhanced sensitivity to DA-ergic agents is the consequence 
of this deficit. 
DA activity in WAG/Rij rats 
Further we studied some parameters of DA activity in WAG/Rij rats in attempt to find their 
deficiency. The goal of our first experiment (Midzianovskaya et al., 2004) was to investigate 
DA and its metabolites, DOPAC and HVA concentration in the following brain structures of 
Wistar and WAG/Rij rats: frontal cortex, parietal cortex, medulla, striatum, thalamus and 
cerebelum. Concentrations of DA and its metabolites have been defined by method of high 
performer’s liquid chromatography. There was no difference in dopamine concentration in 
WAG/Rij versus to Wistar rats. But the changes of dopamine metabolites concentration and 
relation HVA/DA in some structures were substantially different for WAG/Rij and Wistar 
rats. There was a significant reduction of DOPAC concentration in striatum, and of HVA 
concentration in thalamus in SWDs rats. Reduction of metabolites concentration in the 
thalamus and striatum is related to enhancement of DA activity in these structures. The 
strengthening of DA activity may occur as compensation for DA deficiency at behavioural 
level. The deficiency of dopaminergic activity is likely to be linked with changes of DA 
receptors. In order to test such probability we compared (Birioukova et al., 2006) D1 and 
D2/D3 DA receptors binding sites in some brain areas of WAG/Rij rats. DA receptors-
binding sites were analysed using in vitro autoradiography. 
A significant reduction of [3H] SCH 23390 binding sites density with D1 DA receptors of 
WAG/Rij rats compared to ACI rats in the shell of nucleus accumbens and in the head of 
caudate nucleus is seen. In other structures the significant changes are not observed. A 
significant increase of [3H] spiperone binding sites density with D2/D3 DA receptors of 
WAG/Rij rats compared to ACI in motor, somatosensory and parietal cortex is seen. In the 
head of caudate nucleus and in the hippocampal CA3 area of WAG/Rij rats the [3H] 
spiperone binding sites density with D2/D3 DA receptors is substantially lower than in the 
same structures of ACI rats. In the other structures there are no signifint differences on these 
measures. Our results show a deficiency of mesolimbic (NAcb shell) and mesocortical 
(motor, somatosensory and parietal cortex) DAergic activity at the level of somatodentritic 
D1– up-regulated and D2–like down-regulated DA receptors in WAG/Rij versus to ACI 
rats. At the same time a deficiency of nigrostriatal DAergic system in the head of caudate 
nucleus caused by reduction of D1-like DA receptors density is compensated by reduction 
of D2-like DA receptors density. The deficiency of mesocorticolimbic DA systems 
corresponds to behavioral features of WAG/Rij rats. During active and passive avoidance a 
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deficit of reinforcement in WAG/Rij rats has been revealed (Getsova et al., 2003; Getsova et 
al., 2004) which was eliminated by administration of the DA precursor, or a low doze of 
disulfiram, inhibitor of dopamine–β–hydroxylase, by increase of DA concentration in 
brain. Besides, there was shown that WAG/Rij rats have a higher level of depression than 
control Wistar rats without of absence epilepsy (Sarkisova et al., 2003; Sarkisova & 
Kulikov 2006). Depression of WAG/Rij rats has a DA-ergic nature (Sarkisova et al., 2008). 
The high depression of WAG/Rij rats may be explained by deficiency of the DA 
mesocorticolimbic system. 
The question arises then. If the absence epilepsy is related with disturbance or mutation of 
GABAA receptor and low-threshold Ca2+ channel of T-type then what is a role of DA receptors 
in it. Why there is a functional deficiency of these receptors seen? We suggest that diminished 
activity of DA receptors and DA system deficit occur due to disruption of intracellular 
integration triggered by transductional signal (Fig. 2). The initial disruption of GABAA 
receptor activity disrupts transductional signal on the first stage induced by this receptor. 
Disruption of transductional signal changes modification of other receptors and their activity. 
On the second stage the disrupted activity of receptors is consolidated and stored by 
expression of genes. It should be noted that we did not practically see the changes of DA 
concentrations in structures investigated but could see the changes of receptors activity. So, a 
process of intracellular integration may disrupt activity of other neurotransmitter and 
neuromodulatory systems, for instance activity of opioide system disrupted in WAG/Rij rats 
(Lason et al., 1990; 1992: 1994a; 1994b; 1995; Przewlocka et al., 1995). 
Our results (Birioukova et al., 2006; Rebrov et al., 2007) confirm the idea that absence 
epilepsy is connected with function of the hyperpolarization–induced cyclic nucleotide–
gated pacemaker Ih channel, which subunits are expressed in thalamic neurons (Clapham, 
1998). Recent studies have shown (Strauss, 2004) that subunits of Ih channel are expressed in 
neurons of the somatosensory cortex of WAG/Rij rats. 
Hyperpolarization–activated Ih pacemaker channel during absence epilepsy 
Hyperpolarization–activated cyclic nucleotide–gated cationic Ih pacemaker channels 
maintain spontaneous periodic activation, which was discovered in the brain. In all, four 
isoforms of this channel are known (HCN1–HCN4, hyperpolarization–activated and cyclic 
nucleotide–gated) (Bazyan & Segal, 2010). The HCN channel is open at an average 
membrane potential of –80 mV. However, different subunits of the HCN channel possess 
different functional properties. For example, HCN1 channels become activated five to ten 
times faster than HCN2 channels. Also, HCN1 channels become activated at a membrane 
potential that is 20 mV more positive than the potential required for HCN2 activation. The 
HCN1 channel demonstrates minimal response to cAMP binding (+4 mV) to the cAMP–
binding domain on the C–terminus (see Bazyan & Segal, 2010), whereas the HCN2 channel 
demonstrates a clear response (+17 mV). Coexpressed heteromultimeric channels 
demonstrate a relatively larger shift in response to cAMP (+14 mV). 
The literature reviewed suggests that the Ih channel and low–threshold T–type Ca2+ channel 
(ICa2+, T) work in tandem (Bazyan, Segal, 2010). Hyperpolarization opens the Ih channel, and 
cationic current depolarizes the membrane to the threshold and induces a spike. 
Hyperpolarization also opens the ICa2+, T channels. The entrance of Ca2+ ions into the cell 
induce Ca2+–dependent cAMP synthesis, and cAMP dramatically increases channel activity 
through binding to the CNBD locus of HCN subunits. The HCN1 subunit responds weakly 
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rats. At the same time a deficiency of nigrostriatal DAergic system in the head of caudate 
nucleus caused by reduction of D1-like DA receptors density is compensated by reduction 
of D2-like DA receptors density. The deficiency of mesocorticolimbic DA systems 
corresponds to behavioral features of WAG/Rij rats. During active and passive avoidance a 
Two Types of Epilepsy Models and Processes of Cognition:  
Pentylenetetrazole Kindling and Absence Epilepsy of WAG/Rij Rats Strain 
 
293 
deficit of reinforcement in WAG/Rij rats has been revealed (Getsova et al., 2003; Getsova et 
al., 2004) which was eliminated by administration of the DA precursor, or a low doze of 
disulfiram, inhibitor of dopamine–β–hydroxylase, by increase of DA concentration in 
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isoforms of this channel are known (HCN1–HCN4, hyperpolarization–activated and cyclic 
nucleotide–gated) (Bazyan & Segal, 2010). The HCN channel is open at an average 
membrane potential of –80 mV. However, different subunits of the HCN channel possess 
different functional properties. For example, HCN1 channels become activated five to ten 
times faster than HCN2 channels. Also, HCN1 channels become activated at a membrane 
potential that is 20 mV more positive than the potential required for HCN2 activation. The 
HCN1 channel demonstrates minimal response to cAMP binding (+4 mV) to the cAMP–
binding domain on the C–terminus (see Bazyan & Segal, 2010), whereas the HCN2 channel 
demonstrates a clear response (+17 mV). Coexpressed heteromultimeric channels 
demonstrate a relatively larger shift in response to cAMP (+14 mV). 
The literature reviewed suggests that the Ih channel and low–threshold T–type Ca2+ channel 
(ICa2+, T) work in tandem (Bazyan, Segal, 2010). Hyperpolarization opens the Ih channel, and 
cationic current depolarizes the membrane to the threshold and induces a spike. 
Hyperpolarization also opens the ICa2+, T channels. The entrance of Ca2+ ions into the cell 
induce Ca2+–dependent cAMP synthesis, and cAMP dramatically increases channel activity 
through binding to the CNBD locus of HCN subunits. The HCN1 subunit responds weakly 
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to cAMP binding, therefore, a decrease in the proportion of HCN1 subunits in the channel 
increases pacemaker activity and an increase in the proportion of HCN1 subunits in the 
channel decreases pacemaker activity. 
Several studies have focused on Ih channel activity during absence epilepsy. The fast 
component of Ih activation in neurons of WAG/Rij rats was significantly reduced (a 50% 
decrease in the current density), and was four time slower than in the neurons of 
nonepileptic Wistar or ACI rats (Strauss et al., 2004). The results of Western blot and PCR 
analysis corresponded to a decreased Ih current. A decrease by 34% was found in the level 
of the HCN1 subunit protein in the cerebral cortex of WAG/Rij rats as compared to 
Wistar rats but HCN1 mRNA had stable expression. The protein and mRNA levels of the 
other three Ih channel subunits (HCN2–HCN4) were not altered (Strauss et al., 2004). 
These results suggest that there are substantially fewer HCN1 subunits in the combined 
complex of the Ih channel in WAG/Rij rats than in rats of the control strains. This fact 
allows one to make the assumption that these channels work substantially more slowly 
but possess higher activity than the Ih channels of Wistar and ACI rats. High activity is 
defined, for example, by insignificant modification of the HCN1 subunit after cAMP 
binding, whereas modification of the HCN2 subunit is stronger. This means that the 
increase in the proportion of the HCN1 subunit in the channel complex decreases its 
response to cAMP binding, and, in contrast, the channel with more HCN2 subunits and 
less HCN1 subunits in its composition functions better. 
It has been already shown that neonatal handling and mother deprivation in the early 
childhood of WAG/Rij rats (during postnatal 1-21days) result in reduced seizures and 
decreased interspike interval and frequency spectrum power of spike–wave discharges of 
adult WAG/Rij rats (Schridde & van Luijtelaar, 2005). Whole cell patch–clamp recordings 
from the cells of the fifth pyramidal layer, in situ hybridization, and Western blot analysis of 
the cortex of adult WAG/Rij rats (Schridde et al., 2006) showed an increase in the HCN1 
protein level in the somatosensory cortex of handled and mother–deprived rats as compared 
to control rats. This increase was selective for the HCN1 subunit and did not affect the 
expression of HCN2–HCN4 subunit proteins, neither did expression of the mRNA of any 
subunit (HCN2, HCN3, HCN4). These results indicate that relatively mild changes in the 
environment of neonatal rats have long–lasting consequences for paroxysm activity and 
suggest that increased concentration of the HCN1 subunit in Ih channel composition is 
related to reduced absence epileptic activity. It was demonstrated that genetic absence 
epilepsy is highly susceptible to early interventions that lead to increased Ih current and 
higher concentrations of the HCN1 subunit as compared to control rats. However, the level 
of mRNA and protein of HCN2, HCN3 and HCN4 subunits did not differ in control and 
WAG/Rij rats (Schridde et al., 2006). These results indicate that the Ih channel plays an 
important role in the generation of seizures in a specific small area of the somatosensory 
cortex, and may be simply explained by alterations in the subunit composition of Ih channel, 
namely, an increased proportion of HCN1 subunits. 
4. Conclusion 
We have described that efficiency of allosteric regulation depends on subunits structure of 
GABAA receptor. We came to conclusion that the subunits composition of GABAA receptor 
in sensitive and resistant rats is different. The results assume that allosteric plasticity of 
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GABAA receptor and its consolidation are related with modification of subunits expression 
which finally lead to modification of GABAA receptor subunits structure. PTZ induced 
seizures cause amnesia and dissociation state. Low subconvulsive PTZ doses restore a 
memory trace. Low PTZ doses have also anxiogenic effect. Haloperidol, another anxiogenic 
compound in low subcataleptic doses is able to restore an amnesic memory trace. The 
process of plasticity represents a cooperation and integration of GABA, glutamate and DA 
receptors into interdependent systems. Its integration includes automodification of receptors 
activity. On the second stage, a new level of activity, by means of secondary intranuclear 
signals induce modification of genes expression, which consolidates a newly developed 
activity of receptors. 
Two types of generalized seizures are accompanied by opposing changes in the muscimol-
indused GABAA-mediated 36Cl– conductivity. GABA reaction decreased in rats with PTZ-
induced convulsive kindling and increased in WAG/Rij rats with a genetic predisposition to 
nonconvulsive absence epilepsy. In the shell of nucleus accumbens the lower density of D1-
like DA receptors was found. The results specify deficiency of mesolimbic dopaminergic 
system activity of WAG/Rij rat brain that corresponds to specific behavioral characteristics 
of WAG/Rij rats and to pharmacological experimental data. It has been assumed that the 
source of spike–wave discharges was the Ih pacemaker channel that is localized in the 
thalamic reticular nucleus and in the pyramidal neurons of the somatosensory cortex layers 
three, four, and five. The analysis of the experimental data shows that one of the basic 
mechanisms for the long–term regulation of Ih pacemaker activity is the modification of the 
number of HCN1 subunits in the pacemaker channel of WAG/Rij rats strain. 
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These results suggest that there are substantially fewer HCN1 subunits in the combined 
complex of the Ih channel in WAG/Rij rats than in rats of the control strains. This fact 
allows one to make the assumption that these channels work substantially more slowly 
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1. Introduction 
Oxcarbazepine (OXC) is a second generation antiepileptic drug (AED) whose chemical 
structure resembles carbamazepine but has a different metabolism. OXC is rapidly reduced 
to 10, 11-dihiydro-10-hydroxy-carbamazepine (monohydroxy derivative, MHD), the 
clinically relevant metabolite of OXC (Kalis & Huff, 2001). 
OXC is used for the treatment of partial seizures as a monotherapy or as an adjunctive 
therapy in adults and children aged 4 to 16 years. OXC Is also sometimes used to treat acute 
mania in adults, as well as bipolar disorder, a disease that causes episodes of depression, 
episodes of frenzied, abnormal excitement, and neuropathic pain (Landmark, 2007, Tidwell 
& Swims; 2003). The mechanism of action for OXC is not completely understood. 
Electrophysiological studies suggest that the presence of the active MHD metabolite results 
in the blockage of voltage-sensitive sodium channels, possibly through the modulation of 
high-voltage calcium channels and an increase in K+ channel conductance (Mclean et al., 
1994). The ability of OXC and MHD to limit repetitive high-frequency firing of sodium-
dependent action potentials on neurons can contribute to inhibition of the spread of seizure 
activity from a focal point (Kalis & Huff; 2001, Landmark; 2007). 
On the other hand, Clinckers (2005) showed that hippocampal DA and 5-HT levels are 
critically involved in the anticonvulsant activity of OXC. These anticonvulsant effects were 
restricted to a well-defined anticonvulsant concentration range and were proven to be 
mediated by D2 and 5-HT1A receptor stimulation (Clinckers et al., 2004). The lack of effect 
after systemic administration might originate from pharmacodynamic interactions with 
other brain areas suppressing increases in hippocampal monoamines. 
The neurobiological relationships between epilepsy and sleep are receiving increased 
experimental attention. A key role for limbic monoamines in epilepsy has been established, 
and recently some studies showed the importance of hippocampal monoamines in limbic 
seizure control (Wójtowicz, et al. 2009). 
Epileptic phenomena may provoke sleep modifications, such as those that have been 
observed in idiopathic generalized epilepsies, in partial epilepsy with or without seizures, 
and in secondarily generalized seizures, as well as in animal models of temporal lobe 
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1. Introduction 
Oxcarbazepine (OXC) is a second generation antiepileptic drug (AED) whose chemical 
structure resembles carbamazepine but has a different metabolism. OXC is rapidly reduced 
to 10, 11-dihiydro-10-hydroxy-carbamazepine (monohydroxy derivative, MHD), the 
clinically relevant metabolite of OXC (Kalis & Huff, 2001). 
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mania in adults, as well as bipolar disorder, a disease that causes episodes of depression, 
episodes of frenzied, abnormal excitement, and neuropathic pain (Landmark, 2007, Tidwell 
& Swims; 2003). The mechanism of action for OXC is not completely understood. 
Electrophysiological studies suggest that the presence of the active MHD metabolite results 
in the blockage of voltage-sensitive sodium channels, possibly through the modulation of 
high-voltage calcium channels and an increase in K+ channel conductance (Mclean et al., 
1994). The ability of OXC and MHD to limit repetitive high-frequency firing of sodium-
dependent action potentials on neurons can contribute to inhibition of the spread of seizure 
activity from a focal point (Kalis & Huff; 2001, Landmark; 2007). 
On the other hand, Clinckers (2005) showed that hippocampal DA and 5-HT levels are 
critically involved in the anticonvulsant activity of OXC. These anticonvulsant effects were 
restricted to a well-defined anticonvulsant concentration range and were proven to be 
mediated by D2 and 5-HT1A receptor stimulation (Clinckers et al., 2004). The lack of effect 
after systemic administration might originate from pharmacodynamic interactions with 
other brain areas suppressing increases in hippocampal monoamines. 
The neurobiological relationships between epilepsy and sleep are receiving increased 
experimental attention. A key role for limbic monoamines in epilepsy has been established, 
and recently some studies showed the importance of hippocampal monoamines in limbic 
seizure control (Wójtowicz, et al. 2009). 
Epileptic phenomena may provoke sleep modifications, such as those that have been 
observed in idiopathic generalized epilepsies, in partial epilepsy with or without seizures, 
and in secondarily generalized seizures, as well as in animal models of temporal lobe 
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epilepsy that is induced by kainic acid (KA) (Ben-Ari, 1985; Sperk, 1994). Because seizures 
that are induced by systemic administration of KA arise in the limbic system and remain 
largely confined therein, they may serve as a model for complex partial seizures in humans. 
One of the uses of such a model would be as a test system for analyzing the effects of limbic 
seizures on sleep pattern organization. 
However, after kainic acid (KA) administration, animals currently display a complex pattern 
of behavior known as “head and body shakes”, which has been related to the serotoninergic 
system. Serotonin (5-HT) plays an important role in the central nervous system by 
controlling posture and movements, as well as behavior (Ben-Ari, et al. 1981; Osorio-Rico, 
2003). The normothymic effects of OXC may be related to its impact on neurotransmitter 
systems because the GABA-ergic, serotoninergic and dopaminergic systems are all related to 
sleep functions (Ben-Ari, et al. 1981). 
OXC may also exert effects on the brain’s neurotransmitter systems and on structures 
related to the sleep cycle at both the cellular and molecular levels. 
Therefore, the aim of this work was to analyze the effects of OXC on sleep patterns, “head 
and body shakes”, and the participation of 5-HT and DA in the hippocampus in a model of 
kainic-induced seizures. 
2. Materials and methods 
2.1 Animals 
Sixty male Wistar rats weighing 280-300 g were used. They were fed with a standard chow 
diet (Purina, México City) and drank water ad libitum. Animals were maintained under 
controlled conditions, with a temperature of 25°C, a relative humidity of 40% and a 12 h:12h 
light-dark cycle, with lights on at 08:00 h. 
The rats were separated into acrylic box cages, with five animals per cage, until they were 
treated with each experimental condition. All experimental protocols were approved by 
the Research Committee of the National Institute of Rehabilitation, SSA México. The rats 
were treated according to the Guide for the Care and Use of Experimental Animals (Olfert 
et al. 1993). 
2.2 Surgeries 
To perform sleep recordings, animals were implanted with electrodes. To this end, 
animals were anesthetized with sodium pentobarbital (40 mg/kg i.p.) and mounted in a 
stereotaxic frame (David Kopff Instruments, Munich, Germany). The rats were implanted 
with bipolar stainless steel electrodes (Bore 0.010 in., Coated 0.013 in., A-M Systems, Inc., 
Carlsborg, WA) in the right sensorimotor cortex (2 mm length) for 
electroencephalographic recording (EEG) and in the neck muscles (50 mm length) for 
electromyographic recording (EMG). A screw was implanted on the skull to serve as a 
reference. Electrodes were then soldered to miniconnectors and secured to the skull with 
dental acrylic. After seven days of postoperative recovery, the rats were placed in a 
soundproofed recording cage and given free access to food and water under controlled 
light-dark conditions (08:00-20:00 h light, 20:00-08:00 h dark) without any movement 
restrictions. 7 days after the surgery, a basal polysomnographic study for 10 h (8:00-18:00 
h) was performed and later used as a control. Subsequently, rats were allocated to one of 
three experimental groups: the KA group (n=10), which was administered KA (10 mg/kg, 
i.p.); the Oxcarbazepine group (n=10), which was administered OXC (50 mg/kg, i.p, 
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dissolved in ethanol (5%) and carboxymethylcellulose ); and the OXC+KA group (n=10), 
which was administered KA 30 minutes after OXC-treatment. A new session of 
polygraphic recordings were performed for 10 h over 3 days. The rats were then returned 
to the animal facility, where the veterinarians would care for them. 
2.3 Behavioral assessment 
Three additional groups of rats that were administered either saline solution (n=7), KA 
(n=11) or OXC+KA (n=12) were used to assess the frequency of head and body shakes in 
each condition. There was no need for an OXC group since it is widely known that this 
substance does not elicit seizures. Head and body shakes were visually recorded for a total 
period of two hours (8:30-12:30 h) by an observer who was unaware of the drug treatment, 
according to the protocol of Altagracia et al. (1994). 
2.4 Analysis of serotonin (5-HT), 5-hydroxy-indol-acetic acid (5-HIAA), dopamine (DA), 
noradrenaline (NA) and Homovanilic acid (HVA) 
The levels of serotonin and its metabolite were studied, because KA induces seizures that 
are promoted by elevated levels of serotonin. It was found that pretreatment with OXC 
increased the levels of serotonin and its metabolite in the brain, which was consistent with 
the finding that OXC reduced the frequency of head and body shakes. After 4 hours of 
behavioral assessment, rats from all three groups were sacrificed by decapitation. The 
hippocampus was dissected out according to the techniques of Glowinski and Iversen 
(Glowinski & Iversen 1996). The tissues were immediately placed into Teflon tubes that 
were kept on ice, sonicated in 0.4 N of percloric acid with 0.1% (w/v) of sodium 
metabisulfite followed by 10 min of centrifugation at 15,000 rpm at 4°C. The supernatants 
were kept frozen at 70°C until chromatographic analysis. The contents of 5-HT, its 
metabolite 5-HIAA, and catecholamines (DA, NA and HVA), were analyzed by high-
performance liquid chromatography (HPLC) with an electrochemical detector according 
to the protocol of Alfaro-Rodríguez et al. (2006). A Perkin-Elmer LC-250 liquid 
chromatograph with a metrohm electrochemical detector was used. Calibration curves for 
monoamines were constructed using known concentrations of standards prepared in 
percloric metabisulfite solution that were injected into the 20 µl loop of chromatograph. 
Peaks were integrated with the Perkin Elmer LC 1020 program. The concentration of 
indolamine in the samples was obtained by interpolation of their respective standard 
curves. 
We used an Alltech adsorbosphere catecholamine 3U analytical column (particle size= 3 
µm). The mobile phase consisted of an aqueous phosphate buffer solution (0.1 M, pH 3.2) 
that contained 0.2 mM sodium octyl sulfate, 0.1mM of EDTA and 14% v/v methanol. The 
flow rate was 1.2 ml/min, and the potential was fixed at 0.80 V against an Ag/AgCl 
reference electrode. 
2.5 Analysis of sleep and statistical analysis of results 
Each of the printed polygraphic recordings was analyzed visually, according to Alfaro-
Rodríguez and Gonzalez-Pina (2005). Briefly, they were classified as follows: Wakefulness 
(W), which was characterized by the desynchronization of the EEG and the presence of 
muscle tone (EMG) that was accentuated during movements; Slow Wave Sleep (SWS), 
which was characterized by the presence of sleep spindles, slow waves with voltage higher 
than 75 µV, and a decrease in EMG voltage; and Paradoxical Sleep (PS), which was 
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characterized by the desynchronization of the EEG and an absence of EMG voltage. Mean 
duration values (mean ± S.E.M.) of each EEG state were statistically compared by a one-way 
analysis of variance (ANOVA), and subsequent comparisons within groups were performed 
using a Tukey test, with p≤ 0.01. 
Results from the counting of the head and body shakes were analyzed by ANOVA followed 
by Dunnett’s test. Values of P<0.01 were considered to be significant. 
Monoamine concentration and metabolite/neurotransmitter rate values were analyzed 
statistically by ANOVA, and subsequent comparison within groups were carried out by a 
Tukey test. 
3. Results 
3.1 Effects of kainic acid on sleep 
Table 1 shows the results that were obtained from the sleep recordings. A single dose of KA 
(10 mg/kg) affected the organization of the sleep patterns. Kainic acid induced animals to 
stay awake for the whole initial 10 hours of electroencephalographic recording. During the 
follow-up on the next day, the W increased its total duration, and therefore, the SWS and PS 
decreased their respective total durations. The mean duration of the SWS and PS did not 
show any significant changes. On the second day, all parameters returned to control levels, 
suggesting that the rats did recovered from the effects of KA on the sleep-wake cycle 48hrs 
after treatment. 
3.2 Effect of oxcarbazepine on sleep 
OXC had a strong and immediate effect on the sleep-wake cycle. On the treatment day, the 
animals in the OXC group increased their sleep behavior throughout the recording period, 
remaining in sleep posture most of the time, only moving to eat or drink. OXC induced a 
significant decrease in W (21.5%), with a concomitant increase in total sleep time (SWS: 
12.56% and PS: 28.7%). The sleep-wake cycle returned to their control values by day 1, and 
remained unchanged on day 2 (table 1). 
3.3 Effect of oxcarbazepine + kainic acid on sleep 
The animals treated with OXC 30 min before KA injection showed significant changes in 
almost all the sleep-wake parameters that were measured. The latency of SWS increased 
to 289.98 min (p<0.001) and that of PS to 304.45 min (p<0.01). There was also a significant 
increase in total time of W (p<0.05). However, these changes were much less dramatic 
than those observed under treatment with kainic acid alone. The present results suggested 
that there was an anticonvulsive effect of OXC on the KA-induced changes in the sleep 
patterns and a protective activity on seizures. During the following days of recordings, 
the amount of wakefulness progressively decreased, returning to control values by day 1 
(Table 1). 
3.4 Effects of KA and OXC+KA on the head and body shakes 
KA administration produced a significant increase in the frequencies of the head and body 
shakes during the first two hours following drug administration (Table 2). Administration 
of OXC 30 min prior to kainic acid treatment reduced the frequency of head and body 
shakes to 42% of those of the KA group. The increase in head and body shakes observed 
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seemed to be related to sleep behavior. The frequency of head and body shakes in animals 
began to decrease after the second hour (Table 2). 
3.5 Total 5-HT and 5-HIAA content in hippocampus 
When the average concentration of monoamines (µg/g of tissue) was analyzed, the contents 
of 5-HT increased in KA group (p<0.05), but there was a more significant increase in the 
KA+OXC group (p<0.001; Fig. 1). In addition, there was a significant increase in the 5-HIAA 
content in the same group (p<0.01). The increase in serotonin and its metabolite levels was 




Table 1. Sleep parameters (mean ± S.E.M.) recorded over 10 h in rats treated with kainic acid 
(KA; 10 mg/Kg; n=10), with oxcarbazepine (OXC; 50 mg/kg, n=10) and with OXC+KA 
(n=10) for the treatment day and the two subsequent days. Data of the control group were 
obtained from the basal recordings in all the rats (n= 30). It is observed that animals treated 
with KA remained awake over the 10 hours of initial recording, immediately following drug 
administration. Abbreviations: W, total time spent in waking state; SWS, total time spent in 
slow wave sleep; PS, total time spent in paradoxical sleep. Statistical analysis was performed 
with one way ANOVA followed by Tukey´s test. Statistically different from control; *p≤0.01, 
** p≤0.001. 
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Table 2. Effects of oxcarbazepine + kainic acid on the frequency of head and body shakes 
induced by kainic acid. Behavioral results are expressed as mean ± S.E.M. of n=7-12 
independent experiments. *P<0.05, **p<0.01, statistically different from the kainic acid 
group. ANOVA followed by Dunnet´s test. 
 
 
Fig. 1. Total content of serotonin (5-HT) and its metabolite 5-hydroxy-indol-acetic acid (5-
HIAA) in the hippocampus. There was a significant increase in the concentrations of both 5-
HT and 5-HIAA in the kainic acid (KA) and oxcarbazepine /KA-treated (OXC/CA) rats, in 
comparison with control (C). One-way ANOVA and pos hoc Tukey test *p≤0.05 **p≤0.01. 
The 5-HIAA/5-HT ratio revealed that the metabolite 5-HIAA increased more than its 
precursor in both, the KA alone and the OXC+KA conditions (Fig 2). 
 




Fig. 2. 5-HIAA/5-HT ratio estimated in the hippocampus. The 5-HIAA/5-HT ratio was 
significantly increased in the kainic acid (KA) and oxcarbazepine /KA-treated (OXC/CA) 
rats compared to control (C). One-way ANOVA and pos hoc Tukey test *p≤0.05. 
3.6 Total DA, NA and HVA content in hippocampus 
When the average concentration of monoamines (µg/g of tissue) was examined, a 
significant increase in DA and HVA was observed for both the KA (DA, HVA: p<0.05) and 
the KA+OXC groups (DA: p<0.01, HVA: p<0.05). Moreover, this increase in catecholamine 
levels is related to sleep behavior. By contrast, the metabolite NA decreased significantly in 
both the KA and KA+ OXC groups (p<0.05) (Fig. 3). 
4. Discussion 
4.1 Effects on sleep 
As described previously in the rat model of temporal lobe epilepsy, we observed a 
significant KA-induced disorganization of the sleep-wakefulness cycle that involved both 
the SWS and PS phases (Alfaro et al. 2009). This suggests that such sleep inhibition and 
longtime insomnia is not only due to a physical effect of the immediate pharmacological 
action of KA, but also to an action that is exercised on the neurophysiological mechanisms 
that regulate the sleep-wakefulness cycle. It is also interesting, from a pathophysiological 
point of view, that the reduction of sleep that is induced by epileptic seizures did not 
produce a compensatory increase, as is normally observed with sleep inhibition that is 
produced by other means (Frank et al. 1997). Whereas our findings showed that OXC 
induces an increase in both sleep phases, CBZ has an inhibitory effect on PS (Alfaro-
Rodríguez et al. 2002; Alfaro et al. 2009, Ayala-Guerrero et al. 2002). 
In contrast to CBZ, which had no effects on the sleep-wake cycle (Alfaro et al. 2009), animals 
treated with OXC adopted a sleep behavior through the observation period. Time sleep 
initiation (latency) decreased and mean duration and frequency are increased significantly 
in OXC treated animals. On the other hand, in OXC-pretreated animals, the frequency and 
duration of behavioral and electrophysiological manifestations of KA-evoked seizures 
decreased. 
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precursor in both, the KA alone and the OXC+KA conditions (Fig 2). 
 




Fig. 2. 5-HIAA/5-HT ratio estimated in the hippocampus. The 5-HIAA/5-HT ratio was 
significantly increased in the kainic acid (KA) and oxcarbazepine /KA-treated (OXC/CA) 
rats compared to control (C). One-way ANOVA and pos hoc Tukey test *p≤0.05. 
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4. Discussion 
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significant KA-induced disorganization of the sleep-wakefulness cycle that involved both 
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initiation (latency) decreased and mean duration and frequency are increased significantly 
in OXC treated animals. On the other hand, in OXC-pretreated animals, the frequency and 
duration of behavioral and electrophysiological manifestations of KA-evoked seizures 
decreased. 
 




Fig. 3. Total content of dopamine (DA), noradrenaline and the dopamine metabolite, 
homovanilic acid (HVA) in the hippocampus. An increase in both the DA and HVA 
concentration was observed in the kainic acid (KA) and oxcarbazepine /KA-treated 
(OXC/CA) rats, when these groups were compared with Control (C). In contrast, NA was 
significantly decreased in both experimental groups. One-way ANOVA and pos hoc Tukey 
test *p≤0.05 **p≤0.01. 
The neurochemical mechanisms of OXC might be mediated by promoting the activation of 
the monoaminergic systems, which contribute to the anticonvulsant activity of OXC. OXC 
activates endogenous DA and 5-HT leading to the activation of D1 and 5-HT1A receptors in 
the hippocampal region (Clinckers et al. 2005). This information is important because sleep 
is believed to contribute preferentially to the consolidation of explicit memories, which are 
thought to be encoded within the prefrontal-hippocampal circuit. Hippocampus-dependent 
declarative memory beneficiates particularly from SWS, whereas PS seems to benefit 
procedural aspects of memory (Kalia; 2006).} 
Several researchers are currently trying to unravel the neurobiological relationships between 
epilepsy and sleep. After all, these phenomena often develop in the same vulnerable brain 
regions, and the importance of comorbid of sleep- wake cycle and epilepsy is an active area 
of research. Facilitation of central serotonin, dopamine and noradrenaline release seems to 
be associated with both anticonvulsant and sleep disorders effects (Shouse et al. 2001). 
4.2 Effects of kainic acid on the hippocampus 
The hippocampal formation is one of the most seizures-prone structures in the brain due to 
its defining characteristic; the presence of a tri-synaptic circuit of fibers. The reverberation of 
impulse activity in the hippocampal loop is suggested to cause and maintain epileptiform-
like activity patterns (Stringer and Lothman, 1992). Hippocampal cells are endowed with 
several voltage and ligand-gated conductances, which play a major role in the cells´ 
excitability. Blockage of GABAergic transmission has been consistently proven to precipitate 
seizures. It has thus been assumed that abnormal GABAergic neurotransmission may be 
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related to epilepsy (Prince, 1978). However, in vivo epilepsy can also be induced with 
exposure to an agonist of glutamate receptors, in a manner that may not be directly related 
to GABAergic mechanisms. One such agent is kainic acid, whose induced seizures are a 
well-established model of temporal lobe epilepsy, and KA-induced epileptic seizures 
reliably occur at the systemic dose of 10mg/kg used in this study. Khazipov & Holmes 
(2003) implicate GABA inhibitory mechanisms in the KA- induced emergence of 
synchronized epileptiform-like activity patterns in the hippocampus. 
4.3 Relationship between monoamines and OXC and their effects  
on sleep and seizures 
Clinckers (2005) provided evidence that OXC and MHD led to an increase in the release of 
monoamines to the extracellular space. Thus, their anticonvulsant effects seem to depend upon 
the enhancement of endogenous DA and 5-HT transmission and the subsequent activation of 
D2 and 5HT1A receptors. In recent studies, OXC and its active metabolite (MHD) have been 
shown to exert important dopamine- and serotonin-promoting effects in the limbic area 
(Kovacs, 2008). Therefore, in our study, we assumed that the OXC-induced decrease in 
seizures and increase in sleep was mediated by serotonergic and dopaminergic system. 
In a previous study (Clinckers, et al. 2005), it was shown that hippocampal DA and 5-HT 
levels are critically involved in the anticonvulsant activity of OXC. Furthermore, this study 
suggested that the lack of effect after systemic administration might originate from the 
pharmacodynamic interactions with other brain areas which result in the suppression of 
hippocampal monoamine increases. In addition, it was also shown that the selective block of 
either the D2 receptor or the 5-HT1 receptor was able to completely abolish the 
anticonvulsant effects of OXC and MHD. These results indicate that activation of both 
receptor types is necessary for the anticonvulsant effects of OXC and MHD. 
We also found that 5-HT, 5-HIAA and DA were also increased, an effect possibly exerted by 
the alteration of the excitation-inhibition balance. In our results the increase of 5-HIAA 
suggests the active participation of 5-HT metabolism in the pattern of changes by KA and 
KA+OXC. Excitatory and inhibitory actions of DA have been reported in hippocampus 
(Barone, et al. 1991 Starr, 1996). High DA concentrations enhance glutamate release via 
D1/D5 receptor stimulation, while low concentrations reduce excitatory responses via D2 
receptors. Both excitatory and inhibitory hippocampal transmission can be reduced via 
receptor 5-HT3 activation (Dorostkar & Boehm, 2007 ). Additionally, hippocampal 5-HT 
reduces glutamate release by acting on presynaptic 5-HT1A receptors (Mauler et al. 2001). 
During selective 5-HT1A blockade, 5-HT produces fast excitation probably mediated by 5-
HT2C receptors (Beck 1992). Moreover, 5-HT inhibits GABA-ergic hippocampal interneurons 
via presynaptic 5-HT1A receptors (Schmitz et al.1995a). The inhibitory effect of 5-HT on 
glutamatergic transmission may therefore be partially counterbalanced by a 5-HT-mediated 
disinhibition of the principal hippocampal output cells (Schmitz et al.1998).  
However, in our results we found that the levels of catecholamines such as NA were 
decreased from the control values in both KA and KA+OXC groups. In contrast, HVA was a 
significantly increased in both groups. These results suggested an effect of OXC on the 
metabolism of catecholamines. 
4.4 Effects of KA and KA/OXC on limbic seizures 
It’s known that KA produces neurochemical changes in monoamines (Bourne et al. 2001). 
KA also produces alterations in the complex behavioral pattern known as “limbic seizures”. 
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(Kovacs, 2008). Therefore, in our study, we assumed that the OXC-induced decrease in 
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suggested that the lack of effect after systemic administration might originate from the 
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decreased from the control values in both KA and KA+OXC groups. In contrast, HVA was a 
significantly increased in both groups. These results suggested an effect of OXC on the 
metabolism of catecholamines. 
4.4 Effects of KA and KA/OXC on limbic seizures 
It’s known that KA produces neurochemical changes in monoamines (Bourne et al. 2001). 
KA also produces alterations in the complex behavioral pattern known as “limbic seizures”. 
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One of the components of this pattern, the head and body shakes, is frequently associated 
with the intensity of seizures (Sperk 1994), increased levels of amine metabolites for both 5-
HT and DA and the NA content after KA administration (Ben-Ari, 1981). Other studies have 
demonstrated that 5HT is involved in the development of the wet dog-shakes, which is a 
response in rats and some other models that involves central 5HT activity (Osorio-Rico, 
2003). In these cases, the participation of 5HT that is induced by KA may cause toxic effects. 
Another report has shown the participation of D2 dopamine receptors in the susceptibility of 
mice to kainic acid-evoked hippocampal cell death (Bozzi et al. 2000). 
In our results we found that neurochemical changes produced as a consequence of KA 
administration involved increases in the levels of 5-HT, 5-HIAA and DA, HVA, and a 
decrease in the levels of NA. With the addition of OXC (KA/OXC group), there was an ever 
larger increase in all these systems, except for NA, which remained decreased. The 
increment in 5-HT and its metabolite together with the DA increment in the KA/OXC 
treatment mediate disinhibition of the principal hippocampal output cells probably induced 
by MHD, the active metabolite of OXC. The anti-convulsive effects of OXC are achieved by 
5HT and other neurotransmitters, such as NA and DA, which generate SWS and the first 
minutes of PS. OXC significantly reduced motor seizures. The 50 mg/kg dose of OXC was 
also able to diminish the kainic acid-evoked body and head shakes (47%), as has been 
previously shown in studies (Landmark, 2007; Mclean et al. 1994). 
These results explain why, KA-induced seizures disappear within the third hour of OXC 
treatment, while in previous study using CBZ (Alfaro, et al. 2009) the seizures disappeared 
six hours after administration of treatment. 
Several anti-epileptic drugs such as OXC increase extracellular levels of DA and/or 5-HT in 
brain areas involved in epileptogenesis (Biggs et al. 1995; Southam et al.1998; Murakami et 
al. 2001). It is not clear whether these increases in monoamine levels have a direct 
anticonvulsant effect, contribute to the total anticonvulsant effect, or are just a drug side-
effect. 
4.5 Mechanisms of action of OXC on ionic channels 
Like CBZ, OXC and MHD are considered to exert their pharmacological effects by 
stabilization of Na+ channels in a voltage-, frequency-, and time-dependent manner (Mclean 
et al. 1994; Malow et al. 1998). They also block high-threshold Ca2+ current (Akaike et al. 
2001) and increase K+ channel conductance (Malow et al. 1998). The mechanism of action of 
OXC has been proposed to differ that of CBZ by the modulation of the Ca2+ channels 
(Calabresi, 1995; Wellinton & Goa, 2001), although the study by Sitges, et al. (2007) does not 
show remarkable differences between the inhibition exerted by the older and newer 
anticonvulsants on channel-mediated release of glutamate evoked by high K+. 
The effect of OXC appears to be related to the dose and to the serum concentrations of MHD. 
In general, daily fluctuations in MHD concentration are relatively slight, smaller than would 
be expected from the elimination half-life of the compound. Therapeutic monitoring may help 
to decide whether adverse effects are dependent on MHD concentrations (May, et al., 2003). 
5. Conclusions 
We, therefore, believe that the effects of OXC and MHD on hippocampal monoaminergic 
transmission are contributors to the anticonvulsive effects of these compounds. 
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These results are clinically relevant as hippocampus plays a significant role in seizures in 
many diseases. These results also offer a better understanding of the mechanisms by which 
anticonvulsants affect the seizures along with the origin of seizures. 
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1. Introduction 
Epilepsy is one of the most serious neurological disorders affecting about 0.5-1% of the 
world population. There is no definite radical therapy against epilepsy; however, actual 
therapy includes simple inhibition of epileptic activity. Apart from effective drugs against 
epilepsy, plant extracts as well as essential oils, which have been used for generations by 
humans to treat the disease, are considered nowadays as potential bioactive agents that can 
interfere and alter cellular physiological processes involved in epileptogenesis. However, 
the exact underlying mechanisms and the electrophysiological consequences of action of 
most medicinal herbs are still not known.  
Recently, we have reported that the essential oil of Anise, Pimpinella anisum L. (Apiaceae), 
which is one of the oldest known and highly used spice plants in the folk medicine, causes 
hyperexcitability at the cellular level and changes the neuronal firing pattern from a regular 
tonic discharge to an irregular and then to bursting mode in normal cells or potentiates the 
burst firing and the steepness of the paroxysmal shift induced by PTZ treatment (Janahmadi 
et al., 2008). However, we have also shown that some herbs, including Cuminum cyminum 
(Janahmadi et al, 2006) and Artemisia drancunculus (Farajnia et al., 2011), can inhibit the 
epileptiform activity induced by PTZ, a well known convulsant agent. This sort of 
contradictory effect of herbal essential oils and extracts is one reason why a certain caution is 
needed when medicinal herbs are used to treat patients suffering from epilepsy. The present 
work is focused on comparison of the electrophysiological consequences of essential oil and 
extract of Tarragon on PTZ-induced neuronal hyperexcitability in snail for the first time. In 
addition, the effect of anethole, the chief ingredient of many aromatic herbs, including anise 
and tarragon, on normal neuronal excitability is also tested.  
Tarragon or dragon's-wort (Artemisia dracunculus) is a perennial herb in the family 
Asteraceae related to wormwood that exerts radical-scavenging activities (Parejo et al., 
2002), antifungal and antitumor effects (Zani et al., 1991; Meepagala et al., 2002) and 
antiepileptic activities (Sayyah et al., 2004; Farajnia et al., 2011). In Iranian traditional 
medicine, the dried aerial parts of this plant were mentioned as a treatment for epilepsy 
(Aqili Khorasani, 1992). The composition of the essential oil of Iranian A. dracunculus was 
reported to include trans-anethole and α-trans-ocimene as the major constituents (21.1% and 
20.6%, respectively). More recently, we demonstrated the dual effects of anethole on Ca2+-
dependent excitability in snail neurons: at low concentration anethole caused a significant 
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(Janahmadi et al, 2006) and Artemisia drancunculus (Farajnia et al., 2011), can inhibit the 
epileptiform activity induced by PTZ, a well known convulsant agent. This sort of 
contradictory effect of herbal essential oils and extracts is one reason why a certain caution is 
needed when medicinal herbs are used to treat patients suffering from epilepsy. The present 
work is focused on comparison of the electrophysiological consequences of essential oil and 
extract of Tarragon on PTZ-induced neuronal hyperexcitability in snail for the first time. In 
addition, the effect of anethole, the chief ingredient of many aromatic herbs, including anise 
and tarragon, on normal neuronal excitability is also tested.  
Tarragon or dragon's-wort (Artemisia dracunculus) is a perennial herb in the family 
Asteraceae related to wormwood that exerts radical-scavenging activities (Parejo et al., 
2002), antifungal and antitumor effects (Zani et al., 1991; Meepagala et al., 2002) and 
antiepileptic activities (Sayyah et al., 2004; Farajnia et al., 2011). In Iranian traditional 
medicine, the dried aerial parts of this plant were mentioned as a treatment for epilepsy 
(Aqili Khorasani, 1992). The composition of the essential oil of Iranian A. dracunculus was 
reported to include trans-anethole and α-trans-ocimene as the major constituents (21.1% and 
20.6%, respectively). More recently, we demonstrated the dual effects of anethole on Ca2+-
dependent excitability in snail neurons: at low concentration anethole caused a significant 
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reduction in the firing frequency and enhancement of AHP amplitude, but at high 
concentration it significantly increased the firing frequency and also decreased the AHP 
amplitude (Ghasemi et al., 2011). Anethole (1-methoxy-4-(1-propenyl)-benzene), which is 
largely used in industry as a flavor or as a odorant, possess several potential 
pharmacological activities such as depressive action on motor system (Boissier et al., 1967), 
anticarcinogenic (Al-Harbi et al., 1995), antioxidant (Freire et al., 2005), anti-inflammatory, 
(Chainy et al., 2000) and anesthetics activity (Ghelardini et al., 2001). It was suggested that 
some of the essential oils (e.g. anise) containing monoterpenoids especially trans-anethole 
exert anticonvulsant activity (Sayyah et al., 2004). Pimpinella anisum is another aromatic herb 
which contains anethole as its main constituent. Anise is native to the eastern Mediterranean 
and is a plant rich in volatile oils, which are employed in traditional Asian folk medicine. 
Water and ethanol extracts of Pimpinella anisum seed have several potent therapeutic effects 
including antioxidant and antimicrobial activities (Gülçin et al., 2003). The essential oil of 
anise has also been reported to exert both fungicidal and antibacterial actions (Soliman and 
Badeaa, 2002; Singh et al., 2002) and anticonvulsant activity (Pourgholami et al., 1999). In 
contrast, we have recently shown that the essential oil of anise produces neuronal 
hyperexcitability and potentiates PTZ-induced epileptiform activity in snail by enhancing 
the Ca2+ channels activity or inhibition of voltage and /or Ca2+ dependent K+ channels 
function (Janahmadi et al., 2008). We believe that this effect might be due to anethole, the 
chief constituent of the essential oil of anise. Thus, the main aims of this study are: (1) to 
compare the electrophysiological effect of Tarragon extract with that of its essential oil, (2) to 
test the cellular effect of anethol on neuronal excitability, using intracellular recording 
method under current clamp condition.  
2. Materials and methods 
Electrophysiological recording was performed on the soma membrane of neurons from sub-
oesophageal ganglia of Helix aspersa (Iranian garden snail). The snail brain consists of a 
circum-oesophageal ring of nine ganglia. Two are dorsal supra-esophageal (the cerebral 
ganglia) and the remaining seven constitute the suboesophageal ganglia (Kerkut et al., 
1975). Snail neurons are often large and located peripherally. It is therefore possible to work 
on a specific neuron from on preparation to another because they can be consistently 
identified on the basis of their size and location. In the present study, we will focus on F1, 
the largest neuron located in right parietal ganglion (Fig.1).  
Adult Iranian garden snails were collected from north of Iran and were kept in a dormant 
state until they were used. The day before experimentation, animals were activated by 
wetting and then they were anaesthetized by injecting them with 2 ml of 50 mM MgCl2. The 
shell was removed with bone forceps and the snail with its head extended was pinned out 
on a cork board. Next, the circum-oesophageal ganglia were removed from the animal, 
keeping the nerves and aorta attached to the ganglia as long as possible. Then, the 
ganglionic mass with its main peripheral nerves and aorta was placed in a recording 
chamber, lined with Sylgard 170 (Dow corning Midland, MI, USA) containing normal snail 
Ringer solution (in mM): NaCl 80, KCl 4, CaCl2 10, MgCl2 5, Glucose 10, Hepes 5 (Taylor, 
1987). In order to expose F1 neuron, the connective tissue overlying the ganglia were gently 
torn using two pairs of fine forceps without any pre-treatment with proteolytic enzymes. F1 
cell was visually identified by its size, color and location within the right parietal ganglion 
(Kerkut et al., 1975). These procedures were in accordance with the guidelines of the 
Institutional Animal Ethics Committee at Shahid Beheshti University of Medical Sciences. 
 




Fig. 1. (A) Scheme redrawn from Kerkut et al. (1975) showing the nine ganglia of the H. 
aspersa circum-oesophogeal ganglia and the four main peripheral nerves. The cell body of F1 
(in grey colour) is located in the RPG (A left cerebral ganglion, B right cerebral ganglion, C 
LPlG, D LPG, E VG, F RPG, G RPlG, H left pedal ganglion, I right pedal ganglion, LPN left 
pallial nerve, RP right pallial nerve, VN visceral nerve, AN anal nerve). (B) F1 neuron was 
stained intracellularly by the injection of Lucifer Yellow (5nA hyperpolarizing current pulses 
of 500ms duration).  
2.1 Intracellular electrophysiological recording 
Sharp intracellular recording was done using Axoclamp 2B amplier (Axon instrument, 
Foster City, CA, USA) at room temperature (22-250C) in snail Ringer. Each cell was impaled 
with single electrode (5-7MΩ). Electrode was filled with 3MKCl and in some cases with 
Lucifer Yellow. The reference electrode in all experiments was a silver-silver chloride wire 
within an agar bridge (%4 agar in snail Ringer). The above set-up and recording equipment 
were kept in a Faraday’s cage.  
Intrinsic spontaneous neuronal activity was recorded under conventional current clamp in 
real time by testing, before (control), and after application of drugs. Five sets of experiments 
were done. The first and second sets of experiments were conducted in order to examine the 
cellular and antiepileptic effects of essential oil of Tarragon alone or on the PTZ-induced 
epileptiform activity, respectively. In the third and fourth sets of experiments, the cellular 
and antiepileptic actions of Tarragon extract alone or against the epileptogesis induced by 
PTZ were assessed, respectively. The sixth set of experiment was performed to evaluate the 
electrophysiological effect of anethole on normal neuronal excitability in snail. Data were 
filtered at 30 kHz, voltage records were sampled at 20 kHz and digitized online using a 16 
bit A/D converter (ADInstrument Pty Ltd., Sydney, Australia) and stored for further 
analysis using Chart 5 and MATLAB softwares. The following electrophysiological 
parameters of spikes were considered in particular: The firing pattern, the firing frequency, 
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the resting membrane potential (RMP), the half-width of action potential (AP), The AHP 
amplitude, the AP amplitude. AP amplitude was defined as the change in voltage from the 
RMP to the peak of AP and its duration was measured at mid amplitude. The AHP 
amplitude was measured from the RMP to the peak negativity after an AP and the duration 
was measured as the time required declining to 80% of its peak value. The firing regularity 
was assessed using the coefficient of variation (CV) of interspike intervals (ISI) of 
spontaneous activity (CV=ISI S.D / mean ISI). 
2.2 Plant material and drugs  
The aerial parts of Artemisia dracunculus were collected from the north of Iran in April 
(2006). A. dracunculus was authenticated by M. Kamalinejad and a voucher specimen (no. 
861) was deposited in the herbarium of Faculty of Pharmacy, Shahid Beheshti University of 
Medical Sciences, Tehran. The plant materials were dried, far from direct sunlight. Then 
1000ml of ethanol (96%) was added to the dried leaves and kept at room temperature for 
48h. Thereafter, it was filtered and the alcohol was evaporated using rotary evaporator and 
dried extract was obtained.  
2.3 Isolation of the essential oil 
The aerial parts of A. dracunculus were subjected to hydrodistillation for 3 h using a 
clevenger apparatus. The plant yielded 4% (v/w) essential oil. The essential oil was kept 
protected from light at 4°C (Sayyah et al., 2004). The final concentrations of 0.1% and 
0.005%, required to influence the neuronal excitability for Tarragon extract and its essential 
oil, respectively, were chosen on the basis of the preliminary experiments. 
Anethole (0.99%) was purchased from Sigma (St. Louis, MO, USA), dissolved in Ringer 
solution and was applied at final concentrations of 0.5% and 2%. Then the diluted anethole 
solution prepared in normal Ringer was perfused into the experimental chamber at a rate of 
approximately 2.5ml/min.  
Pentylenetetrazol (PTZ, Sigma) was applied (25mM) into the bathing solution. Extract of 
Artemisia dracunculus was dissolved in absolute ethanol at a final concentration of 1% and 3% 
(the final concentration of vehicle in the perfusion solutions was 0.3% (v/v). The same 
concentration of vehicle had no effect on bioelectrical activity of neurons. The pH of 
solutions was adjusted to 7.8 with either Trizma hydrochloride or Trizma base (Sigma). Each 
solution was superfused into the experimental chamber at a rate of approximately 2.5 
ml/min. 
2.4 Statistical analysis 
Numerical results are given as mean ± S.E.M., with n being the number of cells on which the 
measurement was done. Significant differences between the groups were evaluated using a 
student t-test or one way ANOVA and P < 0.05 was considered to be significant.  
3. Results 
3.1 Tarragon essential oil altered the neuronal excitability more robust than  
its extract 
In normal Ringer, neurons showed spontaneous regularly spaced action potentials (Fig. 2) 
with a frequency of 0.9 ± 0.05 Hz and a mean duration of 8.02 ± 0.05 ms (n=6, Fig.3).  
 




Fig. 2. Tarragon essential oil and its extract affect differentially F1 neuronal firing activity. 
(A) Spontaneous regular tonic firing activity in control condition. Application of Tarragon 
extract (0.1%) caused an increase in the firing rate associated with an irregular discharge 
activity after 10 min (B). However, Tarragon essential oil alone led to a neuronal 
hyperexcitability after 5min (C) followed by a distinct PDS (asterisk) after 10min of 
application (D). The inset shows superimposed action potentials recorded in control and 
after treatment with either Tarragon essential oil or its extract alone. 
 
 
Fig. 3. Electrophysiological consequences of Tarragon application on action potential 
parameters in F1 neurons. Tarragon essential oil and its extract altered the AP configuration, 
as the essential oil profoundly increased the firing frequency and AP duration, but 
decreased the AHP amplitude. Tarragon extract also increased the firing rate and decreased 
the AHP, but to a lesser extent than did its essential oil. **, ***, significantly differences 
(P<0.01, P<0.001) from controls and ‡‡‡, significant difference (p<0.001) from Tarragon 
extract treated group.  
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Single action potentials were followed by AHP with mean amplitude of -14.75 ± 0.21mV 
(Fig. 3). When Tarragon essential oil was applied alone in the normal recording solution, 
within 10min caused a significant increase in the firing frequency (2.24±0.58Hz) compared 
to control and Tarragon extract (1.28±0.3 Hz, P<0.001), although exposure to the extract 
alone also produced a significant (P<0.01) increase in the excitability when compared to the 
normal excitability (Fig.3). Following addition of essential oil to normal Ringer solution, F1 
neurons displayed a clear paroxysmal depolarization shift (PDS; Fig.2).Treatment with 
essential oil, furthermore, significantly resulted in a prolongation of action potentials 
(16.61±0.11ms, P<0.001) both compared to control and extract alone (8.35±0.14ms). However, 
there was no significant difference between the AP duration measured in control condition 
and after application of Tarragon extract (Fig. 3). Exposure to both Tarragon extract and 
essential oil caused a significant reduction in the AHP amplitude; however, this inhibitory 
effect was more profound in essential oil-treated neurons (Fig.3). Neither essential oil nor 
extract affected significantly the resting membrane potential of F1 cells (-43.63±0.6mV in 
control; -42.99±0.56mV and -42.16±1.88mV in the presence of essential oil and extract, 
respectively). 
3.2 Tarragon extract, but not essential oil, attenuated the PTZ-induced 
hyperexcitability 
In order to investigate and compare the potential antiepileptic effects of Tarragon essential 
oil and its extract, PTZ (25mM) was added to the normal Ringer solution. Neuronal 
exposure to PTZ resulted in a significant increase in the spontaneous firing activity 
associated with a paroxysmal depolarization shift and bursting (Figs.4&5A-A’). In addition, 
PTZ significantly increased the AP duration and decreased the AHP amplitude (Figs. 5B-B’ 
and 5C-C’). When, the essential oil of Tarragon was added to the Ringer solution containing 
PTZ , the firing frequency remained almost unchanged and even worsen the bursting 
activity, however the duration of AP and the amplitude of AHP were further significantly 
increased and decreased, respectively (Figs.4&5A).  
In contrast to these effects, treatment with Tarragon extract following PTZ application did 
not significantly affect the AP half-width (Fig. 5B’), but significantly decreased the firing 
frequency and the AHP amplitude (Figs.5A’ &C’). Tarragon extract also caused the PTZ-
induced PDS to be disappeared and changed the burst activity into almost regular firing 
interrupted occasionally by a silent period associated with inhibitory postsynaptic potentials 
(IPSPs) (Fig.4). 
3.3 Anethole, one of the major components of the essential oil of Iranian  
A. dracunculus, had differential effects on normal neuronal firing excitability 
To characterize the electrophysiological consequences of neuronal exposure to anethole on 
normal excitability, a low (0.5%) and a high (2%) concentrations were chosen on the basis of 
our previous work (Ghasemi et al., 2011).  
Application of 0.5% anethole did not significantly change the RMP, but at its higher 
concentration (2%) hyperpolarized the cell resting membrane potential (data not shown) 
and altered the neuronal firing pattern from a regular spiking observed in control or  
in the presence of extract to an irregular hyperexcitable pattern often followed by a  
PDS (Fig.6).  
 









Fig. 4. Effects of Tarragon extract and essential oil on PTZ-induced epileptiform activity. (A) 
Spontaneous regular activity of a representative neuron under control condition. Following 
PTZ application, the cell became hyperexcitable and a PDS (asterisk) was appeared (B, left 
trace) and later the firing pattern was changed from tonic spiking to burst firing (B, right 
trace). Addition of Tarragon essential oil (0.005%) in the presence of PTZ worsened the PTZ-
induced hyperexcitability and in this condition cell continued to exhibit burst firing (C). 
Tarragon extract at concentration of 0.1%, however, decreased the PTZ-induced epileptiform activity 
and caused disappearance of PDS observed in the presence of PTZ alone. Neuronal firing 
was interrupted by IPSPs when normal Ringer containing PTZ+Tarragon extract was 
perfused.  
Anethole at both concentrations resulted in a significant increase in the firing frequency, but 
to a much greater extent after 2% anethole (from 0.8±0.03Hz in control condition to 
3.11±0.09Hz and 4.13±0.03Hz after exposure to 0.5% and 2% anethole, respectively, Fig.7A). 
However, anethole at concentrations of 0.5% and 2% affected differently the discharge 
regularity, as evidenced by coefficient of variations (CV) measured in different condition. 
Perfusion of normal Ringer containing anethole 0.5% slightly increased the firing 
irregularity (CV= 0.22 after anthole 0.5% versus 0.19 in control condition), whereas 2%  
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PTZ application, the cell became hyperexcitable and a PDS (asterisk) was appeared (B, left 
trace) and later the firing pattern was changed from tonic spiking to burst firing (B, right 
trace). Addition of Tarragon essential oil (0.005%) in the presence of PTZ worsened the PTZ-
induced hyperexcitability and in this condition cell continued to exhibit burst firing (C). 
Tarragon extract at concentration of 0.1%, however, decreased the PTZ-induced epileptiform activity 
and caused disappearance of PDS observed in the presence of PTZ alone. Neuronal firing 
was interrupted by IPSPs when normal Ringer containing PTZ+Tarragon extract was 
perfused.  
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Fig. 5. The effect of anethole, the main constituent of Iranian A. Dracunculus, on firing 
activity of F1 neurons. Somatic conventional intracellular recording of spontaneous intrinsic 
firing F1 neuron in normal Ringer (A),after application of anethole at concentration of 0.5% 
(B) and following treatment with anethole 2% (C). Application of anethole at higher 
concentration clearly caused a neuronal excitability and elicited a PDS (asterisk).  
anethole increased the firing precision as defined by smaller CV (0.03). Furthermore, 
anethole induced differential effect on the AHP that followed AP. At concentration of 0.5% 
it caused a significant reduction in the AHP amplitude, but at 2% produced a significant 
increase in the AHP, both compared to control and anethole 0.5% (Fig. 7C). Both high and 
low concentrations of anethole caused also a significant shortening of AP compared to 
control group, although this effect was more potent in 2% anethole-treated group when 
compared with 0.5% anethole (Fig.7B). 
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Fig. 7. Effects of anethole treatment on action potential characteristics. Effects of anethole 
treatment on (A) firing frequency, AHP amplitude (B) and on the AP duration (C). ***, 
significantly different (P<0.001) from control; ‡‡‡, significant different (P<0.001) from the 
0.5% anethole- treated group. 
 




Invertebrates have often been used as an experimental model for investigating the cellular 
mechanisms of the effect of many convulsant and anticonvulsant agents. It has been 
reported that convulsant drugs such as PTZ induces a potential pattern in molluscan 
neurons which closely resembles the epileptic activity of mammalian neurons, called PDS 
(Goldensohn and Pupura, 1963; Matsumoto and Ajmone Marsan, 1964; Sugaya et al., 1973). 
In invertebrate neurons, following application of PTZ, the endogenous mechanisms are so 
pronounced that PDS may still be recorded even after complete inhibition of synaptic inputs 
(Faugier-Grimaud, 1974; Speckmann and Caspers, 1973). Ion channel currents underlying 
action potentials have been shown to participate in the generation of epileptic discharges as 
well as in the actions of antiepileptic drugs. Among these channels, calcium and voltage-
dependent K+ channels play a crucial in the repolarization and hyperpolarization that 
follows PDSs. The knowledge of the cellular mechanisms of action of the medicinal plants 
with antiepileptic potential is allowing the design of new therapeutic approaches possibly 
with fewer side effects. Aromatic spice plants have been used traditionally as food and for 
medicinal purposes in the therapy of some diseases for a long time in the world. Essential 
oils and extracts in these plants are used extensively in medicine and in the food and 
cosmetic industries. Although, there is a distinct difference between pure essential oils and 
simple plant extracts, the mechanisms of these at the cellular level have not been completely 
elucidated yet. As an aromatic plant, Tarragon (A. dracunculus anisum L.) is a perennial herb 
in the family Asteraceae that exerts several therapeutic effects.  
In traditional medicine, the fruit and dried aerial parts of Tarragon were used as a 
treatment for epilepsy, toothache and diarrhea (Zargari, 1989). The plant is mildly 
sedative (Sayyah et al., 2004) and has been taken to aid sleep (Chevallier, 1996). Recently, 
the anticonvulsive activity of essential oil of Artemisia dracunculus in a rat model of 
epilepsy has been shown. It is reported that the monoterpenoids especially trans-anethole, 
pinene and methyl eugenol present in the essential oil, mediates its anticonvulsant 
activity (Sayyah et al., 2004). 
 The present study compared the electrophysiological consequences of Tarragon essential oil 
and its extract alone and on the PTZ-induced epileptiform activity. Moreover, alterations in 
the parameters of the action potentials upon application of anethole as a major component 
of Iranian Tarragon on neuronal cells were also investigated. In our previous work we 
reported that the fruit essential oil of Pimpinella anisum L. (Umblliferae), which contains 
anethole, not only did not show antiepileptic activity but also induced neuronal 
hyperexcitability (Janahmadi et al., 2008). On the other hand, we have also showed that both 
the essential oil of cuminum cyminum and low concentration (0.05%) of Tarragon extract 
exhibit antiepileptic activity (Janahmadi et al., 2006; Farajnia et al., 2011).  
The results obtained here showed that the essential oil of Tarragon not only does not 
show any antiepileptic activity at concentration of 0.005%, but also worsened the 
epileptiform activity induced by PTZ. Whereas, Tarragon extract, at even higher 
concentration (0.1%) than that we have reported more recently, can reduce and modulate 
PTZ-induced neuronal hyperexcitability. Furthermore, the finding showed that anethole 
affects the normal neuronal excitability in a concentration manner. The neuronal 
excitability and the firing patterns are balanced by the activity of many ion channels, 
including voltage and Ca2+-activated K+ (SK and BK) channels (Faber et al., 2005; Crest 
and Gola, 1993; Arai et al., 2004).  
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Here, it was found that both essential oil and extract of A. dracunculus led to a decrease in 
the amplitude of AHPs and the essential oil, but not extract prolonged the AP duration. In 
snail neurons, spike duration and AHP amplitude are determined by a set of potassium 
channels which underlie fast and delayed outward K+ currents (Bal et al. 2000; Sakakibara 
et al. 2005; Solntseva 1995; Thompson 1977). There are also two classes of Ca2+ activated 
K+ channels (KCa); the large conductance Ca2+ activated K+ channels (BK channels) and the 
small conductance Ca2+ activated K+ channels (SK) (Crest and Gola 1993; Hermann and 
Erxleben 1987). SK channels mediate a Ca2+-activated afterhyperpolarizing current, IAHP, 
in most nerve cells, whereas large conductance Ca2+-activated K+ (BK) channels are 
responsible for the fast afterhyperpolarization (fAHP). Both types of channels are 
activated during the action potential causing a transient hyperpolization of the cell 
membrane. This produces the AHP which in turn inhabits further AP firings. Therefore, 
the decrease in AHP and the increase in the firing rate particularly in the presence of 
Tarragon essential oil could be partly related to the possible inhibition of KCa channels. 
However, the increase in the duration of AP following Tarragon oil treatment might be 
due to the inhibition of Na+ and/or voltage-gated K+ channels. It has now been reported 
that very small influxes of Na+ through voltage-gated Na+ channels activate a K+ 
conductance which play an important role in determining AP duration in both vertebrate 
and invertebrate neurons (Bader et al.,1985; Hartung, 1985; Dryer et al., 1989; Budelli et 
al., 2009).  
On the other hand, the results of the second sets of the experiments suggest that Tarragon 
extract has a potential antiepileptic effect. The decrease in the PTZ-induced 
hyperexcitability, the unchanged AP duration and the pause between active periods clearly 
indicate that the crude extract of Tarragon can alleviate the epileptiform activity partly 
through the activation of K+ channels or receptor dependent ion channels. 
It has been reported that epileptic activity can be suppressed by drugs that enhance gamma 
amino butyric acid-type A (GABAA) receptor-mediated inhibitory neurotransmission, such 
as benzodiazepines and phenobarbital (Macdonald and Kelly, 1995). The presence of 
anticonvulsant benzodiazepines in alcoholic extract of A. dracunculus supports the 
antiepileptic potential of extract (Kavvadias et al., 2000). The appearance of IPSPs during 
quiescence period recorded between firing activity in the presence of Tarragon extract, 
therefore, could be due to the activation of GABAA receptors. However, Tarragon essential 
oil worsened the PTZ-induced profound hyperexcitability, as evidenced by a significant 
increase in the firing frequency and reduction in the AHP amplitude. The stronger 
antiepileptic activity of Tarragon alcoholic extract than its own essential oil could be 
attributed to the benzodiazepine in the extract (Kavvadias et al., 2000), as we have more 
recently reported that picrotoxin, a GABA antagonis, eliminates the IPSPs-induced by 
Tarragon extract at concentration of 0.05% (Farajnia et al., 2011). However, potentiation of 
PTZ-induced epileptiform activity possibly could be due, in part, to the existence of some 
active component, such as anethole. In the present study, we found that anethole at higher 
concentration (2%), but not at lower concentration (0.5%) produces hyperexcitability and 
paroxysmal depolarization shift very similar to that of induced by PTZ in Na+ Ringer 
solution. We have more recently demonstrated that anethole affects the Ca2+-dependent 
excitability and Ca2+ spike characteristics in a concentration manner (Ghasemi et al., 2011). 
Therefore, it can be speculated that anethole 2% increases the neuronal hyperexcitability 
directly or in directly through activation of outward K+ channels, including KCa, as 
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evidenced by a significant increase and decrease in the AP duration and AHP amplitude, 
respectively.  
The stronger antiepileptic activity of alcoholic extract of Tarragon than its own essential oil 
could be attributed to the benzodiazepine in the extract (Kavvadias et al., 2000), as we have 
more recently reported that picrotoxin, a GABA antagonist, eliminates the IPSPs-induced by 
0.05% Tarragon extract (Farajnia et al., 2011). However, potentiation of PTZ-induced 
epileptiform activity by essential oil possibly could be due to the existence of some active 
component, such as anethole. In the present study, we found that anethole at higher 
concentration (2%), but not at lower concentration (0.5%) produces hyperexcitability and 
paroxysmal depolarization shift very similar to that of induced by PTZ in Na+ Ringer 
solution. Anethole treatment at concentration of 2% enhances the AHP amplitude which in 
turn hyperpolarizes the cell membrane and thereby removes sodium channels inactivation 
and increases the availability of these channels. The availability of Na+ channel, which is 
strongly regulated by AHP-induced hyperpolarization, is known to regulate the firing 
regularity and increases the firing excitability (Patlak, 1991; Vervaeke et al., 2006; Mecer et 
al., 2007). 
It is likely the augmentation of the amplitude of AHP following treatment with anethole 2% 
could be caused by activation of voltage and/or particularly calcium dependent potassium 
channels, which play an important role in neuronal discharge regularity. it is generally 
accepted that AHP amplitude is reversely correlated with the firing frequency (Madison and 
Nicoll, 1984; Hallworth et al., 2003; Vatanparast and Janahmadi, 2009) and blockade of these 
channels disrupts the precision of firing and produces less regularity in firing (Haghdoust et 
al., 2007; Hallworth et al., 2003; Sausbier et al., 2004; Walter et al., 2006). Therefore, 
increasing the firing precision and regularity, as evidenced by a significant increase in the 
AHP amplitude and a decrease in CV following exposure to 2% anethole here in F1 cells, 
could be possibly attributed to the opening of KCa channels. 
We have more recently demonstrated that anethole affects the Ca2+-dependent excitability 
and Ca2+ spike characteristics in a concentration manner (Ghasemi et al., 2011).  
In conclusion, findings of the study suggest that herbal medicine may be considered a s a 
two-edged sword since some of the medicinal essential oils (such as anise and Tarragon oils) 
and the compounds isolated from them (e.g. anehole) have potential capacity to induce 
neuronal hyperexcitability and epileptiform activity or alternatively their own crude 
extracts may possess antiepileptic activity. Therefore, when they are used for treating 
patients suffer from epilepsy, a certain caution is needed. 
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The interest to ’in situ’ drug delivery systems has been sparked by the advantages of
these systems, such as ease of application, localized delivery for a site-specific action,
prolonged delivery periods, decreased body drug dosage with concurrent reduction in
possible undesirable side effects common to most forms of systemic delivery, and improved
patient compliance and comfort. There are different materials that can be potentially used
as the implants, each of which has its advantages and disadvantages. Emulsion, liposomes,
microcapsules and micells may be potentially used for certain applications Collins-Gold et al.
(1990); Sharma (1997); Chen et al. (1997); Zhang et al. (1996), however, they still have some
room for improvement. They are not the best systems for long-time delivery because of the
stability, sterilization and low drug entrapment problems, as well as, in some cases, difficulty
of manufacturing procedure or in control of the properties Hatfia & Amsdena (2002). As
alternative, ’in situ’ setting semi-solid drug depots are being developed. These implants are
made of biodegradable polymers that solidify once injected into the site. Together with all the
advantages, the main minus of these systems is the initial burst in the drug release connected
with the release of the drug during the solidification time of the matrix. Also, some of the
polymers require high temperature for injection or usage of organic solvents, which may result
in necrosis or toxicity. Another polymer matrix (ethylene-vinyl acetate) was successfully used
as an implant to deliver phenytoin into the brain Tamargo et al. (2002), however, the material
manufacturing time is quite long, more than one month, which makes it difficult to apply
routinely.
The recently developed sol-gel technology offers new possibilities for incorporating
biologically active agents within inorganic titania or silica xerogels at room temperature, and
for controlling their release kinetics from the gel matrix Chiriac et al. (2010); Quintar-Guerrero
et al. (2010); Lopez et al. (2006); Lopez & Quintana et al. (2007); Lopez et al. (2007). This
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sol-gel technique is inexpensive, versatile and simple and provides easily reproducible xerogel
properties. Thus, such materials are good candidates to create ’in situ’ delivery systems.
2. State of the art
Phenytoin (5,5-diphenyl hydantoin) is one of the major first-line antiepileptic drugs used in
the treatment of generalized and partial (with or without secondary generalization) seizures.
Also, it is used acutely in the management of life threatening status epilepticus and in
the treatment of serial seizures. The mechanism of action is not definitely known but
extensive research strongly suggests that its main mechanism is to block frequency-, use-
and voltage-dependent neuronal sodium channels and, therefore, limit repetitive firing of
action potentials. In chemical structure, phenytoin is related to the barbiturates. However,
the use of phenytoin clinically is problematic for several reasons. Firstly, phenytoin has a
low therapeutic index so that therapeutic and toxic doses are close to each other. Secondly,
because of its saturable metabolism, the relationship between plasma concentration and dose
is non-linear and difficult to predict Richens & Dunlop (1975). Thirdly, it has a long term
toxicity profile, including adverse cosmetic effects Reynolds (1989), which is undesirable.
Also, chronic drug administration can lead to many side effects, among which language and
memory problems, intellectual decline and psychiatric illness. This occurs because only a
certain amount of the drug overcomes the hematoencephalic barrier, which requires its higher
dosage Lolin et al. (1994). Considering this, ’in situ’ prolonged drug delivery represents an
alternative that has excellent therapeutic benefits.
3. Sol-gel derived materials
The encapsulation of a drug inside an inorganic nanostructured matrix is a promising way to
deliver the drug. The matrix is usually some metal oxide such as Titanium or Silicon dioxides
or aluminosilicates of different structures. The structure may vary from highly organized
(crystals, microtubes) to an amorphous one. Such a matrix has a high surface area and porosity
allowing to accommodate rather large amounts of the drug. The drug may be incorporated
either by adsorption into already existing structure or during the structure formation, namely
the synthesis of the matrix. The latter method is more efficient because it allows encapsulation
of larger amounts of the drug and its release during a longer period. The synthesis conditions
of conventional chemical processes do not always allow addition of the drug during the
synthesis, since many drugs are quite sensitive to the change of the synthesis parameters
such as temperature, pH, etc. Also, the solubility of the drug influences the possibility of its
encapsulation. However, in this case, the sol-gel method may overcome these difficulties and
become a good option, since it allows the drug encapsulation under the mild conditions. In
the typical sol-gel process the synthesis starts with a solution containing metal precursors,
such as metal alkoxides, water as a hydrolysis agent, and alcohol as a solvent. The reacting
mixture may also include acid or base as a catalyst. Metal alkoxides undergo hydrolysis and
polycondensation at near room temperature forming a sol, in which polymers or fine particles
are dispersed without precipitation. Further reaction connects the particles solidifying the
sol into a wet gel, which still contains water and solvents. Vaporization of the solvent and
water produces a dry gel, which is a porous material. Since the sol-gel process starts with
a well mixed solution, the reaction may take place at lower temperatures as compared to
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conventional mixtures. This enables incorporation of otherwise decomposing compounds
such as many drugs. The drug is usually added to the initial mixture and during the process
accommodates within the pores. Usually amorphous material has a distribution of the pore
sizes. Thus, on release, firs, the drug situated inside the large pores comes out, then the one
inside the mesopores, and, finally, the one inside the micropores. This permits reaching a
desired level of the drug and then to have its prolonged liberation.
The release profile of the drug incorporated into titania matrix is expected to depend on
the following factors: the reservoir surface properties affecting drug-matrix interactions, the
morphology of the matrix, the degree of crystallinity, drug dissolution and diffusion, and the
method of incorporation of the drug into the matrix. Since the majority of these factors may
be controlled by the parameters of the sol-gel synthesis, the drug release kinetics, therefore,
may be tuned by tailoring the processing parameters during the sol-gel reaction. Thus, one
specific parameter of the synthesis can be varied in order to change the drug release profile.
In the following sections we will discuss what are the main parameters influencing the release
profile and how they affect the release kinetics ’in vitro’.
4. Phenytoin-titania reservoirs
In the particular case of the drug incorporated into the sol-gel titania, there are two principal
questions that one should address: (i) does the synthesis process affect the structure-activity
relation and the stability of the drug and (ii) what functional groups of the matrix and the drug
participate in the interaction? There are different types of interactions that can be found in the
modern drug delivery systems: electrostatic (Coulombic), hydrophobic, or hydrogen-type.
Sol-gel titania, if it is not calcinated, has a surface covered with hydroxyl groups with the
average density of 5 OH/nm2. These terminal hydroxyls can interact with a heteroatom of
the drug molecule serving as adsorption sites favoring the drug distribution inside the matrix.
Naturally, the number of OH groups capable of binding the drug would define the amount
of the drug that can be carried by the matrix, whereas the strength of the interaction would
influence the drug diffusion out of the reservoir. The two parameters together will influence
the release profile. Thus, the surface coverage by OH groups determines the adsorption
behavior and the surface reactivity.
4.1 Phenytoin-titania interactions
The solid state 13C NMR study allowed us to determine that phenytoin is attached to the
matrix without any changes in the structure and to establish what part of the molecule couples
to the titania hydroxyl groups Lopez et al. (2010). The comparison of the two spectra for pure
phenytoin and the one encapsulated into the titania matrix (Figs. 1) revealed that the same
signals are present in both cases with the only difference of the peaks in the aliphatic region
of the spectrum for phenytoin within titania. These peaks correspond to the nonhydrolyzed
butyl radicals attached to titania. The slight shift of the signals for encapsulated phenytoin
as compared to pure phenytoin implies that the structure of the phenytoin molecule in the
matrix is more rigid than ’free’ phenytoin. Due to the largest shifts for the two carbons of
the hydantoin ring it becomes clear that the hydantoin ring in the phenytoin molecule is the
system that interacts with OH groups of the titania matrix. To answer the question how exactly
the interaction takes place, we suggested the possible complexes between the hydantoin ring
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Also, it is used acutely in the management of life threatening status epilepticus and in
the treatment of serial seizures. The mechanism of action is not definitely known but
extensive research strongly suggests that its main mechanism is to block frequency-, use-
and voltage-dependent neuronal sodium channels and, therefore, limit repetitive firing of
action potentials. In chemical structure, phenytoin is related to the barbiturates. However,
the use of phenytoin clinically is problematic for several reasons. Firstly, phenytoin has a
low therapeutic index so that therapeutic and toxic doses are close to each other. Secondly,
because of its saturable metabolism, the relationship between plasma concentration and dose
is non-linear and difficult to predict Richens & Dunlop (1975). Thirdly, it has a long term
toxicity profile, including adverse cosmetic effects Reynolds (1989), which is undesirable.
Also, chronic drug administration can lead to many side effects, among which language and
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certain amount of the drug overcomes the hematoencephalic barrier, which requires its higher
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synthesis, since many drugs are quite sensitive to the change of the synthesis parameters
such as temperature, pH, etc. Also, the solubility of the drug influences the possibility of its
encapsulation. However, in this case, the sol-gel method may overcome these difficulties and
become a good option, since it allows the drug encapsulation under the mild conditions. In
the typical sol-gel process the synthesis starts with a solution containing metal precursors,
such as metal alkoxides, water as a hydrolysis agent, and alcohol as a solvent. The reacting
mixture may also include acid or base as a catalyst. Metal alkoxides undergo hydrolysis and
polycondensation at near room temperature forming a sol, in which polymers or fine particles
are dispersed without precipitation. Further reaction connects the particles solidifying the
sol into a wet gel, which still contains water and solvents. Vaporization of the solvent and
water produces a dry gel, which is a porous material. Since the sol-gel process starts with
a well mixed solution, the reaction may take place at lower temperatures as compared to
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conventional mixtures. This enables incorporation of otherwise decomposing compounds
such as many drugs. The drug is usually added to the initial mixture and during the process
accommodates within the pores. Usually amorphous material has a distribution of the pore
sizes. Thus, on release, firs, the drug situated inside the large pores comes out, then the one
inside the mesopores, and, finally, the one inside the micropores. This permits reaching a
desired level of the drug and then to have its prolonged liberation.
The release profile of the drug incorporated into titania matrix is expected to depend on
the following factors: the reservoir surface properties affecting drug-matrix interactions, the
morphology of the matrix, the degree of crystallinity, drug dissolution and diffusion, and the
method of incorporation of the drug into the matrix. Since the majority of these factors may
be controlled by the parameters of the sol-gel synthesis, the drug release kinetics, therefore,
may be tuned by tailoring the processing parameters during the sol-gel reaction. Thus, one
specific parameter of the synthesis can be varied in order to change the drug release profile.
In the following sections we will discuss what are the main parameters influencing the release
profile and how they affect the release kinetics ’in vitro’.
4. Phenytoin-titania reservoirs
In the particular case of the drug incorporated into the sol-gel titania, there are two principal
questions that one should address: (i) does the synthesis process affect the structure-activity
relation and the stability of the drug and (ii) what functional groups of the matrix and the drug
participate in the interaction? There are different types of interactions that can be found in the
modern drug delivery systems: electrostatic (Coulombic), hydrophobic, or hydrogen-type.
Sol-gel titania, if it is not calcinated, has a surface covered with hydroxyl groups with the
average density of 5 OH/nm2. These terminal hydroxyls can interact with a heteroatom of
the drug molecule serving as adsorption sites favoring the drug distribution inside the matrix.
Naturally, the number of OH groups capable of binding the drug would define the amount
of the drug that can be carried by the matrix, whereas the strength of the interaction would
influence the drug diffusion out of the reservoir. The two parameters together will influence
the release profile. Thus, the surface coverage by OH groups determines the adsorption
behavior and the surface reactivity.
4.1 Phenytoin-titania interactions
The solid state 13C NMR study allowed us to determine that phenytoin is attached to the
matrix without any changes in the structure and to establish what part of the molecule couples
to the titania hydroxyl groups Lopez et al. (2010). The comparison of the two spectra for pure
phenytoin and the one encapsulated into the titania matrix (Figs. 1) revealed that the same
signals are present in both cases with the only difference of the peaks in the aliphatic region
of the spectrum for phenytoin within titania. These peaks correspond to the nonhydrolyzed
butyl radicals attached to titania. The slight shift of the signals for encapsulated phenytoin
as compared to pure phenytoin implies that the structure of the phenytoin molecule in the
matrix is more rigid than ’free’ phenytoin. Due to the largest shifts for the two carbons of
the hydantoin ring it becomes clear that the hydantoin ring in the phenytoin molecule is the
system that interacts with OH groups of the titania matrix. To answer the question how exactly
the interaction takes place, we suggested the possible complexes between the hydantoin ring
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Fig. 1. Solid state 13C NMR spectra of (a) pure and (b) titania encapsulated phenytoin. The











Fig. 2. Optimized geometries of phenytoin-titania complexes: C − I and C − I I are
monodentate complexes, and C − I I I is the tridentate complex. The corresponding corrected
free Gibbs energies on formation of each complex are given below.
and titania hydroxyl groups, calculated using the Gaussian 03 Frisch et al. (2004) package of
programs within the Density Functional Theory (DFT) formalism, and shown in Fig. 2.
The last complex proposed (tridentate C-III) has three simultaneous weak hydrogen-type
interactions: two hydroxyl groups of titania interact with two oxygen atoms (of carbonyl
groups) of phenytoin and there is an oxygen bridge from titania to a proton of the amine
group of phenytoin. The calculated Gibbs energies show that C-III is more favorable in
comparison to C-I and C-II. Since hydroxyl groups of titania participate in the complex
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formation, phenytoin adsorption on titania should significantly depend on the hydroxylation
degree of titania. The experimental evidence of the presence of C-III complex was obtained
by comparison of carbonyl region of IR-spectra calculated for different complexes with
the experimental IR-spectrum. Even though the carbonyl group signals do not disappear
completely, as suggested in an ’ideal’ theoretical system, a significant reduction of the signals
suggests the presence of rather large amounts of C-III, though it is hard to conclude in what
proportion to C-II and unbound phenytoin it is formed. Since the amount of hydroxyl groups
on the titania surface is crucial for the phenytoin load in titania reservoirs, the hydroxylation
degree was analyzed by IR and TGA/DSC analyses. It was found that with increase of
water/alkoxide ratio rw, the hydroxylation degree increases up to rw = 16 and then decreases
for rw = 24. Water/alkoxide ratio rw = 16 was concluded to be the most favorable to bind the
largest amount of the drug because of the highest hydroxyl group coverage. The next step in
the research was to study how different rw would affect the phenytoin release ’in vitro’.
4.2 Water-alkoxide ratio
As it was mentioned above, titania reservoirs were synthesized by the sol-gel method.
Titanium(IV) tetrabutoxide was continuously added to the mixture of deionized Millipore
filtered water, filtered ethanol and sodium phenytoin at 25◦C under constant stirring.
The molar ethanol/alkoxide ratio was kept constant and equal to 8. The sodium
phenytoin/alkoxide ratio was fixed to 7.5 mg per 1 g of alkoxide. The molar ratio of
water/alkoxide rw was taken as 4, 8, and 16. The resulting homogeneous sol was then left
to gelate for 24 h under constant stirring and after that was dried at room temperature. The
white powder was then dried at 40◦C in a vacuum for 24 h. The surface properties were
characterized by the Brunauer-Emmett-Teller (BET) method, crystallinity - by High Resolution
Transmission Electron Microscopy (HRTEM), hydroxyl group coverage - by IR spectroscopy
combined with a homemade vacuum heating cell under nitrogen atmosphere Lopez et al.
(2011). These parameters were considered in the connection with the drug release ’in vitro’.
To give an idea about the structure and morphology of the prepared materials, it is important
to notice that the structure of the reservoirs is rather complex. The primary particles formed
during the polycondensation are of the size of about 3 - 5 nm (Fig. 3a). The primary particles
almost immediately aggregate, forming the primary aggregates of about 50 nm size Heredia
et al. (2009). Slitlike micropores of 2.5 nm are formed as a result of aggregation of the primary
aggregates with the formation of the secondary aggregates. The secondary aggregates are
much larger but they also can aggregate between them during the sample drying, forming
the structure shown in Fig. 3b with macropores comparable to the aggregate sizes. The
agglomerates have different sizes ranging from 0.1 up to 0.8 μm, building up a porous
structure with large distribution of pore sizes.
Interestingly, it was found that the specific surface area increases with the addition of
phenytoin to the reaction due to difference in the particle growth at larger pH (pH=10 for the
solution of phenytoin sodium in water). In the case of different rw, it was observed that the
surface area first increases and then decreases, while crystallization degree decreases with the
increase of water content in the reaction. Titania synthesized in this way is mainly amorphous,
however, when the samples were observed under a high resolution electron microscope
(HRTEM), the regions with the crystalline structures corresponding to anatase titania were
observed (Fig. 4). Thus, there is an indication of a small degree of crystallinity on the nano
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Fig. 4. HRTEM micrographs with corresponding diffraction patterns of phenytoin-titania
reservoirs synthesized with different water/alkoxide ratios rw: (a) rw = 4, (b) rw = 8, (c)
rw = 16, and (d) rw = 16 titania reference (without phenytoin).
scale in the material. Moreover, the degree of crystallinity depends on the water/alkoxide
ratio rw and decreases with the increase of rw Lopez et al. (2011).
It was possible to characterize the OH group coverage in an accurate way, excluding the
contribution of the sample humidity and physically adsorbed water. The results showed that
the hydroxyl group coverage increases with increase of rw from 4 to 16. Fig. 5 shows the drug
release kinetics of phenytoin from the reservoirs synthesized with different water/alkoxide
ratios rw.
For all three samples the release profiles are similar in shape and characterized by the two
regimes: the initial fast release described by the short-time (ST) release rate followed by the
long-time sustained release with lower release rate (LT). The initial release rate increases with
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Fig. 5. Release kinetics of phenytoin to buffer from 50 mg of titania reservoirs synthesized
with different water/alkoxide ratios rw: squares rw = 4, circles rw = 8 and diamonds
rw = 16. The lines indicate the Fick’s second law fits: solid for rw = 4, dashed for rw = 8 and
dash-dotted for rw = 16. The inset shows closer look to the initial release stage.
the increase of water content in the reaction. It is correlated with the size of macropores
formed between the secondary aggregates of titania nanoparticles. The size of the secondary
aggregates grows with increase of rw, thus, during the initial release period, there is a drug
discharge with the highest release rate and drug amount for rw = 16. Then, the initial
discharge slows down with the decrease of rw.
The constant long-time release rate is affected mainly by the following factors: reservoir
morphology on the surface (surface area, porosity and pore size) and in bulk (crystalline or
amorphous), interactions between the matrix and the drug, and the diffusion of the molecules
within the matrix. These parameters interplay in such a way that LT release rate first slightly
increases with increase of water content from 4 to 8 and then decreases for rw = 16. The
combination of morphology, degree of hydroxylation, and crystallinity allows sample rw = 8
to liberate faster than other samples during the long-term stage.
There are different empirical and semiempirical approaches that have been developed to
interpret the release mechanisms. One of the simplest empirical equation is the so-called
power law equation based on Fick’s second law of diffusion:
Mt/M∞ = ktn, (1)
where M is the amount of drug released after an instant t and infinite times, k is the constant
that correlates with the diffusion coefficient and n is the exponent characterizing the release
mechanism. If the Fickian diffusion takes place, n is equal to 0.5, 0.45 and 0.43 for a thin film,
a cylinder and a sphere, respectively. For porous matrix n is expected to take lower values
Peppas (1985); Peppas & Korsmeyer (1986). However, given the simplifications introduced
for this model, the analysis based on the power law should be taken with precaution. The
values of parameter n are very low (n < 0.45 for all the samples) and vary from 0.2 to 0.3. This
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Fig. 6. (Schematic illustration of the morphology of the titania reservoirs, consisting of
nanoparticles, aggregates, and macro- and mesopores. The green and purple encircled
regions show phenytoin present in macropores and mesopores, respectively.
suggests that the release process is controlled by non-Fickian diffusion. The titania matrix has
the pores quite heterogeneous in length, surface roughness and fractality, which may be the
reason for the complex transport behavior.
4.3 Thermal treatment
With the purpose to determine the influence of the surface characteristics such as the effective
surface area, porosity, and the average pore size of titania on the release kinetics of phenytoin,
various titania-phenytoin reservoirs were prepared by the sol-gel method combined with the
hydrothermal treatment of titanium (IV) isopropoxide in 1 M acetic acid. Control over the
particle size was achieved by using the hydrothermal treatment at 220◦C for different times:
1, 3, 8, 20 and 42 hours. The reservoirs were loaded with 5 wt% of phenytoin Heredia et al.
(2009).
The obtained material consisted of pure anatase crystal phase independent of the heat
treatment time. It was found that the average particle size defined from XRD measurements
grows with the increasing treatment time. As it was previously mentioned, most nanoparticles
are clustered in aggregates. The average aggregate size determined by dynamic light
scattering was found to be in the range between 20 and 60 nm for the shortest and longest
treatment time, respectively. The average number of nanoparticles per aggregate was found
to be about 15-40 suggesting the development of porosity as shown in Fig.6.
The drug release kinetics were determined by measuring the UV-vis spectra of the buffer
solution with the immersed reservoir as a function of time for a period of up to two months
in a closed glass bottle. Fig. 7 shows the results of the release studies of five materials
hydrothermally treated for different periods of time. It was found that the reservoirs are
able to release phenytoin for more than 45 days, and the release kinetics are characterized by
two regimes: an initial fast release and a subsequent slow release, similar to that observed in
Fig.5. The duration of the initial fast release regime was found to depend on the hydrothermal
treatment time, and decreases with nanoparticle and aggregate size. Unfortunately, the initial
release rate was not quantified due to a generally non-linear behavior and insufficient data
points. The slow release rate is independent of time and showed a weak dependence on
the morphology of the nanomaterial. The phenytoin constant release rate was found to be




















Fig. 7. Release kinetics for the titania reservoirs with different morphological properties. The
released phenytoin is shown as a percentage of the initially incorporated amount of
phenytoin. The kinetics were determined for three samples of each hydrothermal treatment
duration. The straight lines correspond to linear fits after allowing for the initial fast release
period to end.
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Fig. 8. (a) Stereotactic surgery is used to introduce the implant; (b) Cannula used for
compressing the material to a cylinder and 1x1.5 mm titania cylinder implant.
between 0.017 mg/day and 0.030 mg/day, depending on the properties of reservoirs. One
could distinguish between two main release rates: for the two smallest particles (1 and 3 h
of thermal treatment) the rate is about 0.017 mg/day, while for the three largest particles (8,
20 and 42 h), the rate is about 0.030 mg/day. This trend follows the size of the mesopores,
however, the dependence is remarkably weak. Taking into account that the pore size is at
least a factor of two larger than the phenytoin molecules (varies from 4.3 to 12.6 nm for 1
and 42 h of treatment, respectively), the release rate is expected to be mainly related to the
phenytoin-titania surface interaction. For strong interactions, the difference in specific surface
area for the smaller mesopore and the larger mesopore nanomaterials would be expected to
result in significantly different release rates. However, as it was shown, the release rate can
be tuned to between 0.017 mg/day and 0.030 mg/day by control over the properties of the
materials.
5. In vivo tests
Male Wistar rats (180-250 g) were used to study biocompatibility and effectiveness of the
materials Lopez et al. (2006; 2007; 2009). All rats were induced epileptic convulsions following
the Kindling model, where the rats were intraperitoneally injected with an aqueous solution of
a subconvulsive dose of Pentilentetrazole (PTZ) (35 mg/kg). After each injection, observations
were made for 20 min and the resulting seizures classified based on Racine’s description for
motor seizure activity in rats Racine (1972) as follows: 0 - normal activity; 1 - mouth and
facial movements; 2 - head nodding; 3 - forelimb clonus; 4 - rearing; 5 - rearing and falling,
loss of postural control, or full motor seizure activity. The animals were considered epileptics
after exhibiting at least three consecutive phase 4 or 5 seizures. The material with or without
phenytoin was then compressed to the form of a small cylinder with 1 mm diameter and 1.2
mm of height and stereotactically implanted into the temporal lobe of the rats (Fig. 8).
After the surgery, the animals were allowed to recover in their home cages with food and
water. The effect of the implants were evaluated by further initiation of the seizure with
PTZ on the rats with the reference and drug loaded reservoirs (six for each group). For the
reference group of rats with a drugless TiO2 reservoir, all six rats kept on having epileptic
events (Crisis-Tonic-Clonic-Generalized CTCG), thus, no curative effect was observed for
these implants. The group of rats with implants showed a reduction of the intensity and
frequency of the seizures, however, only about 45% of effectiveness of shielding was observed.
One of the possible reasons for that may be a very small size of the implant, which results in
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Fig. 9. Comparative histological study: (a) overall view of an histological section with the
reservoir (20X); (b) The same as (a) at 100X; (c) Glial response to inflammation of the tissue in
the neighborhood of the reservoir (20X); (d) Amplified limiting zone in (c) at 100X.
the release of phenytoin with the concentration lower than its terapeutic threshold. Another
reason is that the release ’in vivo’ may differ from ’in vitro’, which requiers additional
information to be able to really design the material. Our next steps would be to change the
parameters of the matrix in order to find the best conditions for the reservoir to work ’in vivo’.
Also, the size of the implant may be varied up to 4-5 mm in diameter Tamargo et al. (2002),
which also may result in better protection.
A group of rats was sacrificed using an overdose of sodium phenobarbital administered by an
intraperitoneal injection after 6 months following the implant. After that, they were perfused
using a saline solution of 3.7% formaldehyde. The brains were extracted and conserved in
3.7% formaldehyde solution. The brain specimens were microtomed and conserved in a 4%
formaldehyde solution for a period of 15 days. Sections (10 μm) were embedded in paraffin
and viewed using an optical microscope. The sections were dyed using the Bielchowsky
technique, which enables examination of the neuronal microfibrils and cell soma integrity.
Implant position did not vary after 6 months in the basolateral amygdala, meaning that the
reservoir was highly compatible with the nervous tissue. To confirm the lack of glial response
to the implant, sections were taken of the implant zone for histological analysis and neuronal
damage evaluation.
A comparative histological study Fig. 9 shows that the nerve cells are not adversely affected
by the presence of the reservoir. The interfacial area between the implant and the surrounding
tissue is devoid of inflammatory areas. This observation suggests that these ceramic implants
can safely be used to deliver drugs to the damaged areas of the brain.
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area for the smaller mesopore and the larger mesopore nanomaterials would be expected to
result in significantly different release rates. However, as it was shown, the release rate can
be tuned to between 0.017 mg/day and 0.030 mg/day by control over the properties of the
materials.
5. In vivo tests
Male Wistar rats (180-250 g) were used to study biocompatibility and effectiveness of the
materials Lopez et al. (2006; 2007; 2009). All rats were induced epileptic convulsions following
the Kindling model, where the rats were intraperitoneally injected with an aqueous solution of
a subconvulsive dose of Pentilentetrazole (PTZ) (35 mg/kg). After each injection, observations
were made for 20 min and the resulting seizures classified based on Racine’s description for
motor seizure activity in rats Racine (1972) as follows: 0 - normal activity; 1 - mouth and
facial movements; 2 - head nodding; 3 - forelimb clonus; 4 - rearing; 5 - rearing and falling,
loss of postural control, or full motor seizure activity. The animals were considered epileptics
after exhibiting at least three consecutive phase 4 or 5 seizures. The material with or without
phenytoin was then compressed to the form of a small cylinder with 1 mm diameter and 1.2
mm of height and stereotactically implanted into the temporal lobe of the rats (Fig. 8).
After the surgery, the animals were allowed to recover in their home cages with food and
water. The effect of the implants were evaluated by further initiation of the seizure with
PTZ on the rats with the reference and drug loaded reservoirs (six for each group). For the
reference group of rats with a drugless TiO2 reservoir, all six rats kept on having epileptic
events (Crisis-Tonic-Clonic-Generalized CTCG), thus, no curative effect was observed for
these implants. The group of rats with implants showed a reduction of the intensity and
frequency of the seizures, however, only about 45% of effectiveness of shielding was observed.
One of the possible reasons for that may be a very small size of the implant, which results in
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Fig. 9. Comparative histological study: (a) overall view of an histological section with the
reservoir (20X); (b) The same as (a) at 100X; (c) Glial response to inflammation of the tissue in
the neighborhood of the reservoir (20X); (d) Amplified limiting zone in (c) at 100X.
the release of phenytoin with the concentration lower than its terapeutic threshold. Another
reason is that the release ’in vivo’ may differ from ’in vitro’, which requiers additional
information to be able to really design the material. Our next steps would be to change the
parameters of the matrix in order to find the best conditions for the reservoir to work ’in vivo’.
Also, the size of the implant may be varied up to 4-5 mm in diameter Tamargo et al. (2002),
which also may result in better protection.
A group of rats was sacrificed using an overdose of sodium phenobarbital administered by an
intraperitoneal injection after 6 months following the implant. After that, they were perfused
using a saline solution of 3.7% formaldehyde. The brains were extracted and conserved in
3.7% formaldehyde solution. The brain specimens were microtomed and conserved in a 4%
formaldehyde solution for a period of 15 days. Sections (10 μm) were embedded in paraffin
and viewed using an optical microscope. The sections were dyed using the Bielchowsky
technique, which enables examination of the neuronal microfibrils and cell soma integrity.
Implant position did not vary after 6 months in the basolateral amygdala, meaning that the
reservoir was highly compatible with the nervous tissue. To confirm the lack of glial response
to the implant, sections were taken of the implant zone for histological analysis and neuronal
damage evaluation.
A comparative histological study Fig. 9 shows that the nerve cells are not adversely affected
by the presence of the reservoir. The interfacial area between the implant and the surrounding
tissue is devoid of inflammatory areas. This observation suggests that these ceramic implants
can safely be used to deliver drugs to the damaged areas of the brain.
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6. Outlook and prospects
An anticonvulsant drug phenytoin can be encapsulated into the sol-gel biocompatible titania
and can be successfully implanted into the temporal lobe of the brain by low invasion
stereotactic surgery. The implantation process is such that the damage of the surrounding
tissue is minimal. The drug release from the implants is controlled by the parameters of
the matrix such as its morphology, drug-matrix interaction strength, etc. Depending on the
parameters of the synthesis, the release profile may be designed according to the necessities
in terms of release rate and the amount of the released drug.
The first experiments ’in vivo’ indicate that there is a certain degree of protection on the
epileptic rats, even though no sharp fall of the seizure type was observed. Also, the
biocompatibility tests revealed a good affinity between the material and the brain tissue. Thus,
the first results are quite promising for the future application of the reservoirs.
One of the main prospects of the study is to achieve better protection ’in vivo’ for longer
time. Also, one needs to find a correlation between the drug release ’in vitro’ and its effect
and release profile ’in vivo’. This would allow generalization of design of the materials for
different types of epilepsy patients and their needs. A very firm clinical stage is required
before any commercialization of the materials.
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1. Introduction 
Epilepsy is a chronic disorder characterized by a spontaneous tendency for recurrent 
seizures which affects major aspects of a patient’s life, including cognitive, behavioral, 
psychological and social functioning (Foldwary & Wyllie, 1999). It has been reported that 
cumulative lifetime risks for epilepsy and for any unprovoked seizure are 3.1% and 4.1% 
respectively in industrialized countries. Estimates of annual incidence of epilepsy are 
reported as high as 43 cases per 100,000 of the population in so-called developed countries, 
and are almost double this figure in the developing world (McHugh & Delanty, 2008). 
Another estimation points out that there are 50 million people who have epilepsy in the 
world (WHO 2001,  Leonardi & Ustun, 2002). It was suggested that more than 80% of people 
with epilepsy live in developing countries, where the condition remains largely untreated 
(ILAE/IBE/WHO Annual Report, 1999; Meinardi et al., 2001).  
2. Quality of life and psychiatric aspects in epilepsy 
The science of health related quality of life (HRQOL) measurement rapidly evolved during 
the 1980s and 1990s within general health and in all medicine disciplines. (Tulsky & 
Rosenthal 2002). Despite a substantial increase in the number of published articles in recent 
years, research in the literature regarding the quality of lives of epileptic patients is 
relatively limited (Aydemir et al., 2004; Birbeck 2002). One of the most important reasons 
why HRQOL has become so important for those who engaged in epilepsy is related with 
well known characteristics of this disorder. Its chronic nature, presence of unexpected, 
intractable and/or frequent seizures, stigma and side effects of the antiepileptic drugs are 
some of these characteristics among others.   
Epileptic patients experience various problems due to this disorder which will result in a 
lower quality of life. Seizure frequency, side effects of the antiepileptic drugs, psychological 
comorbidity and stigma are the factors which are associated with the severity of the disease 
and these factors may cause an important impact on life quality of epileptic patients. 
Previous researches regarding quality of life (QOL) in epilepsy yielded contradictory results 
(Jacoby 1994; Leidy et al., 1999).  Although most reports in this field share a common message 
emphasizing the negative effects of epilepsy on patients’ HRQOL, there are still some other 
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studies which reported that this disease has little or no effect on epileptic patients’ QOL 
(Jacoby 1994; Leidy et al., 1999). Some authors suggested that the impact of epilepsy might be 
minimal if the disease is well controlled and HRQOL of patients in this condition would be 
nearly the same as those of healthy controls (Jacoby 1994; Leidy et al.,1999). On the other hand, 
epileptic patients living in Europe and North America were reported to have significant 
impairment in HRQOL(Stavem et al., 2000; Buck et al., 1999). This discrepancy in reported 
results may well be related to methodological issues and/or cultural differences. However, 
one can easily notice that especially in studies conducted with larger samples it was found that 
HRQOL is decreased in patients with epilepsy  (Baker et al., 2005; Baker et al., 1997). 
Baker et al. reported that epilepsy has the potential to negatively affect different aspects of 
what is called “quality of life” (Baker et al., 2005). The authors collected data from 3889 
patients with epilepsy from 10 different countries. In this multicenter survey it was 
concluded that the most commonly reported complaints interfering with daily living 
activities were nervousness, headaches and tiredness. Respondents in this study reported 
that their disease and its treatment had a significant impact on their HRQOL. Short Form-36 
(SF-36) was used in Baker et al.’s study and patients scored significantly lower in domains 
such as physical and social functioning, energy and vitality (Baker et al., 2005). 
In another multicenter (European) study again conducted by Baker et al. in 15 countries in 
Europe, data from more than 5000 patients were investigated and it was concluded that 
epilepsy had a negative effect on patients’ social and psychological well-being (Baker et al., 
1997). Argyriou et al. studied the impact of epilepsy on the psychological health and HRQOL 
of patients suffering from mild epilepsy in a rural area of southeastern Greece and reported 
that HRQOL of their patient sample was obviously affected while their psychological health 
remained nearly unaffected (Argyriou et al., 2004). Kutlu et al, investigated the HRQOL, 
anxiety and depression states of patients with epilepsy (PWE) (Kutlu et al., 2010). The SF-36 
health survey scores were significantly lower in all subscales in PWE compared with the 
control group. Total scores for Beck Depression Inventory (BDI) were significantly higher in 
epilepsy patients. Hamilton anxiety scale were also found to be significantly increased in the 
epilepsy group. It was concluded that epilepsy significantly interferes with QOL and 
psychologic health of patients. In the patient group relationship between the seizure frequency 
and vitality was found to be statistically significant (Kutlu et al., 2010). 
Women with epilepsy of childbearing age were reported to be at high risk of depression. 
Factors associated with depression include lack of occupation, the presence of an underlying 
disabling condition (with treatment), and the severity of epilepsy. Compared with the general 
population depressed women have greater impairment of HRQOL with epilepsy, which 
reflects the physical, social and emotional implications of the disease (Beghi et al., 2004). 
Several comorbid psychiatric problems accompany the clinical picture in epilepsy. According 
to Kanner depression is the most common comorbid psychiatric disorder in patients with 
epilepsy though it remains underrecognized and undertreated (Kanner, 2003). According to 
Devinsky, seizures by definition change behaviour (Devinsky, 2004). Behavioural disorders are 
perhaps the most common and serious complications in epilepsy. For patients with difficult to 
control epilepsy, depression makes a greater contribution to impaired quality of life than 
seizure frequency (Devinsky, 2004). In an extended review reported by Gaitatzias et al. it was 
pointed out that 6% of people with epilepsy in the general population appears to suffer from a 
psychiatric disorder while this rate increases to 10-20% in patients with temporal lobe and/or 
refractory epilepsy (Gaitatzis et al., 2004). In general 30% of PWE suffer from depression, 10-
20% from anxiety, 2-7% psychosis, 1-2% from personality disorders (Gaitatzis et al., 2004). On 
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the other hand, fear of seizures seems to play a very important role in psychiatric aspects of 
this disease. Newsom-Davis et al, stated that after an experience of a generalized epileptic 
seizure, a subsequent and anticipatory fear may well be seen in the sufferer (Newsom-Davis et 
al.,1998). Authors also underlined that there is a sufficient evidence in the literature suggesting 
that epileptic patients commonly fear death and or brain damage resulting from their seizures 
(Newsom-Davs et al.,1998). Furthermore there is a strong association between the degree of 
psychopathology and the intensity of patients fears. 
To qualify as a specific phobia, the Diagnostic and Statistical Manual IV requires that the 
following criteria are met: (a) a marked and persistent fear is excessive or unreasonable and 
cued by the presence or anticipation of a specific object or situation; (b) exposure to the 
phobic stimulus provokes an immediate anxiety response; (c) the person recognizes that the 
fear is excessive or unreasonable; (d) the phobic situation is avoided or endured with intense 
anxiety or distress; and (e) avoidance, anxious anticipation, or distress in the feared situation 
interferes significantly with the person's normal routine, occupational functioning or social 
activities or relationships (Newsom-Davs et al.,1998; DSM-IV, 1994). 
It is very well known that one of the most important features of epilepsy is stigma.  De Boer 
et al. reviewed the global burden and stigma of epilepsy (De Boer et al., 2008). The authors 
stated that people with disabilities are among the most vulnerable in any society. Hidden 
disabilities such as epilepsy leads to even a greater vulnerability. Epileptic people may fear 
going outside their homes unaccompanied and they also fear what people might think of 
them if they were to have a seizure in public. Inevitably this leads to social isolation and 
participation restriction in the community. 
In a recent study reported by Kanner et al. it was demonstrated that patients with 
subsyndromic depressive episodes (SSDEs), major depressive episodes (MDEs), anxiety 
disorders, and mixed MDEs (or SSDEs) with anxiety disorder(s) have a significantly worse 
quality of life than asymptomatic patients (Kanner et al., 2010). Authors also suggested that the 
comorbid occurrence of mixed MDE/anxiety disorders (particularly in the presence of more 
than one type of anxiety disorder) and SSDE/anxiety disorder yielded a worse impact on 
HRQOL than the occurrence of anxiety disorders alone. Another important finding of this 
study was that the comorbid occurrence of depressive and anxiety disorders have been found 
to have significant clinical implications beyond their impact on HRQOL which include: 
1. An increased suicidal risk.  
2. A worse course and poorer response to treatment of a depressive disorder  
3. An increased risk of MDE recurrence. types of anxiety increased the probability of a 
new depressive episode.  
4. An increased risk of failure to achieve a seizure-free state following an anterotemporal 
lobectomy in patients with pharmacoresistant temporal lobe epilepsy (Kanner et al., 
2010). 
Literature survey reveals enough evidence regarding the negative impact of mood disorders  
and anxiety symptoms on the quality of life of patients with epilepsy (PWEs) (Perrine et al., 
1995; Gilliam, 2002; Cramer et al., 2003; Boylan et al., 2004; Johnson et al., 2004; Loring et al., 
2004;  Tracy et al., 2007). Symptoms of depression and anxiety are independently associated 
with reduced HRQOL; psychiatric comorbidity explains more variance in HRQOL than the 
combined groups of clinical seizure or demographic variables (Johnson et al., 2004). A study 
with a large sample included 435 PWEs aiming to investigate the relative impact of mood 
and anxiety symptoms as well as social and seizure related variables on HRQOL (Tracy et 
al., 2007); the presence of depressive symptoms was the strongest predictor of the composite 
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and subscales of the Quality of Life in Epilepsy instrument used (QOLIE-31). In none of the 
cases did the severity of symptoms of depression interact significantly with the other 
variables, suggesting that its effect on HRQOL was direct and not mediated by other factors. 
In other studies conducted on patients with pharmacoresistant temporal lobe epilepsy 
(TLE), symptoms of depression were found to be the strongest independent predictors of 
poor quality of life but (unexpectedly) not the seizure frequency or severity (Perrine et al., 
1995; Gilliam, 2002; Boylan et al., 2004). All of the mentioned studies relied on screening 
instruments identifying symptoms of depression and anxiety, but did not generate 
psychiatric diagnoses of mood or anxiety disorders, based on predetermined diagnostic 
criteria, such as those suggested by the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM-IV-TR, 2000). The lack of a DSM-IV-TR diagnosis does not 
invalidate the significance of the data cited earlier. Studies on primary mood disorders 
emphasised the relatively high prevalence and significant clinical impact of subsyndromic 
forms of depressive disorders (Van Praag et al.,2004). Whether subsyndromic depressive 
episodes (SSDEs) differ from major depressive episodes (MDEs) or anxiety disorders in their 
impact on HRQOL of PWEs is yet to be established. The purpose of van Praag et al.’s  study 
was to test the following four hypotheses:  
1. Patients with SSDEs, MDEs, and anxiety disorders have worse HRQOL than 
asymptomatic patients, 
2. The more severe forms of depressive episodes (e.g., MDEs) have a greater negative 
impact on HRQOL measures than SSDEs, 
3. Depressive and anxiety disorders do not differ in their impact on HRQOL, 
4. Comorbidity of MDEs and anxiety disorders, but not of SSDEs and anxiety disorders, 
has a worse impact on HRQOL than MDEs and anxiety disorders alone (Van Praag et 
al.,2004). 
According to Winter, self-esteem is the most important part of the ego, which is also the 
most important factor contributing to psychosocial well-being (35). The most important 
determinants of self-esteem are (1) what we think of ourselves, as a reflection of what the 
people we care about think of us; (2) how we evaluate ourselves in comparison to other 
people; and (3) our ability to reach a positive outcome concerning issues that are important 
to us (Winter, 1996). Literature survey reveals contradictory data regarding the correlation 
between epilepsy and self-esteem (Winter, 1996; Reeve & Lincoln, 2002; Lee et al., 2008). 
Gauffin et al. studied self-esteem, and sense of coherence in a group of young adults wtih 
epilepsy and compared the results with those obtained five years earlier (Gauffin et al., 
2010). The authors found that there was a decline in both sense of coherence and self-esteem 
overtime in young adults with epilepsy. On the other hand Lee et al. reported that epilepsy 
in general has little impact on overall self-esteem in adolescents (Gauffin et al., 2010). 
As it was mentioned above several comorbid psychiatric problems such as depression, 
anxiety, psychosis and personality disorders accompany the clinical picture in epilepsy. One 
should also bear in mind the important role of antiepileptic drugs (AEDs) in 
psychopathology of epilepsy (Mula & Monaco, 2009). Mula and Monaco have drawn 
attention to the risk benefit ratio of AED usage in epilepsy. Possible adverse effects of AEDs 
include behavioural problems and psychiatric disorders. According to the authors it is often 
difficult to determine which pyshopathological manifestations are due to the drug therapy 
and which may be due to the characteristics of epilepsy disease itself. Mula and Monaco 
concluded that the most commonly reported psychiatric adverse effects of AEDs are non-
specific behavioral problems (Mula & Monaco, 2009). Among specific psychiatric diagnoses, 
depression is the most commonly reported. Psychosis is much less frequent. 
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In a study which investigated the sociodemographic and clinical factors associated with 
depression in epilepsy it was reported that, depressed subjects with epilepsy were 
significantly less likely to be married or employed and more likely to report comorbid 
medical problems and active seizures in the past 6 months (Thompson et al., 2009). Another 
important conclusion of this study was, when adjusted for all other variables, subjects with 
epilepsy reporting lamotrigine use were significantly less likely to be depressed compared 
to those not reporting lamotrigine use (Thompson et al., 2009). 
In a review covering 35 years of research specifically devoted to QOL in adult epilepsy, Leone 
et al. classified the questionnaires used in epilepsy according to validation, diffusion of use 
and spesificity of domains characteristics (Leone et al., 2005). The authors concluded that 
questionnaires covering all three aspects (Washington Psychosocial Seizure Inventory (WPSI), 
Epilepsy Surgery Inventory 55 Survey (ESI-55), Quality of Life in Epilepsy Inventory (QOLIE-
89), QOLIE-31, QOLIE-10, Liverpool Batteries) should be preferred when planning a QOL 
study in epilepsy. However those covering only two aspects (SF-36, The Side Effect and Life 
Satisfaction (SEALS) inventory, Epilepsy Psychosocial Effects Scale (EPSES), Performance, 
Sociodemographic aspects, Subjective evaluation/estimation questionnaire (PESOS), Quality 
of Life Assessment Schedule (QOLAS) could also be useful in selected situations or may 
become a first-choice instrument in the future, after more widespread use or complete 
validation (Leone et al., 2005).  On the other hand Wiebe et al. aimed to determine the 
minimum clinically important change, and small medium, and large changes in broadly used 
epilepsy specific and generic HRQOL instruments and found that QOLIE-89, QOLIE-31, SF-36, 
SF-36 physical composite score and HUI-III (health utility ndex mark III) differentiated 
between no change and minimum important change with precision (Wiebe et al., 2002). 
Birbeck et al. in their study evaluating ability of HRQOL measures to detect change overtime 
in people with epilepsy, suggested that SF-36 yielded responsiveness indices comparable to 
those of the epilepsy targeted (specific) measures (Birbeck et al., 2000). 
In a randomized controlled study May and Pfäfflin emphasized the efficacy of an educational 
treatment program for PWE. Modular service package epilepsy (MOSES) which was 
developed to improve patients’ knowledge and understanding about their epilepsy, its 
treatment and psychosocial consequences, was used in the study. The study clearly indicated 
the need for patient education. Even patients with a long history of epilepsy and with 
additional handicaps or diseases benefitted from the MOSES program (May & Pfäfflin 2002). 
Psychologically, persons with epilepsy may have feelings of worthlessness, fear, stigma, anger, 
and hopelessness, and may exhibit passive behavior (Chen et al., 2010). Stigmatization leads to 
discrimination, and people with epilepsy have been the target of prejudicial behavior in many 
aspects of life, over many centuries and in many cultures (De Boer et al., 2008; Pahl & De Boer, 
2005). These factors decrease their psychosocial function, self efficacy, and quality of life (Chen 
& Tsai , 2003; Pramuka et al., 2007) and even increase the suicide rate (Bell et al., 2009).  
Evidence shows that there is a spectrum of cognitive, behavioural and psychiatric disorders 
that accompany many forms of epilepsy. New discoveries may contribute to the 
development of therapies and management techniques that will better enable physicians to 
treat the full spectrum of disorders that epilepsy and tails (Berg , 2011). 
ILAE recently recommended that the term “benign” no longer be used to describe epilepsy, 
precisely because of the large number of disorders often seen in association with even 
relatively uncomplicated epilepsy (Berg et al., 2010). Berg suggested that any patient with 
epilepsy should be viewed as someone who is at risk of encountering a variety of 
consequences including cognitive problems, behavioural disorders, depression, suicide and 
also sudden death (Berg , 2011). 
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Epilepsy, with its rich clinical features, is particularly important for HRQOL research. 
Despite a substantial increase in the number of published articles in recent years, research in 
the literature regarding the quality of lives of epileptic patients is relatively limited 
(Aydemir  et al., 2008; Birbeck et al., 2002). Most of the current reports in this field share a 
common message emphasizing the negative effects of epilepsy on patients’ HRQOL. 
Epileptic patients may experience various problems which will result in a lower quality of 
life. Seizure frequency, side effects of the antiepileptic drugs, psychological comorbidity and 
stigma are important factors associated with the severity of the disease and these factors 
may cause an important impact on life quality of epileptic patients. Stemming from a 
thorough review of the current literature, we can conclude that there is still a need for 
further scientific research with further validated instruments to find out more clear relation 
between epilepsy and HRQOL. 
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Epilepsy, with its rich clinical features, is particularly important for HRQOL research. 
Despite a substantial increase in the number of published articles in recent years, research in 
the literature regarding the quality of lives of epileptic patients is relatively limited 
(Aydemir  et al., 2008; Birbeck et al., 2002). Most of the current reports in this field share a 
common message emphasizing the negative effects of epilepsy on patients’ HRQOL. 
Epileptic patients may experience various problems which will result in a lower quality of 
life. Seizure frequency, side effects of the antiepileptic drugs, psychological comorbidity and 
stigma are important factors associated with the severity of the disease and these factors 
may cause an important impact on life quality of epileptic patients. Stemming from a 
thorough review of the current literature, we can conclude that there is still a need for 
further scientific research with further validated instruments to find out more clear relation 
between epilepsy and HRQOL. 
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